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Generalized hypermobility has been known since ancient times, and a 
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been recorded by Hippocrates in 400 BC. Hypermobility syndromes occur 
frequently, but the wide spectrum of possible symptoms, coupled with a 
relative lack of awareness and recognition, are the reason that they are 
frequently not recognized, or remain undiagnosed.
This book is an international, multidisciplinary guide to hypermobility 
syndromes, and EDS in particular. It aims to create better awareness of 
hypermobility syndromes among health professionals, including medical 
specialists, and to be a guide to the management of such syndromes for 
patients and practitioners. It is intended for use in daily clinical practice 
rather than as a reference book for research or the latest developments, 
and has been written to be understandable for any healthcare worker 
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followed by chapters on individual types, organ (system) manifestations 
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appendix on surgery and the precautions which should attend it. A special 
effort has been made to take account of the perspective of the patient; two 
of the editors have EDS.
The book will be of interest to patients with hypermobility syndromes 
and their families, as well as to all those healthcare practitioners who may 
encounter such syndromes in the course of their work.
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Preface 
 
 
We are a team of Dutch authors and editors, two of whom are Ehlers-Danlos syndrome (EDS) 
patients. In 2005, along with several co-authors and with financial support from the Dutch 
EDS support group “VED”, we published a book entitled: “Ehlers-Danlos syndroom. Een 
multidisciplinaire benadering” (Ehlers-Danlos syndrome. A multidisciplinary approach). The 
aim of this multidisciplinary, practical book was to create more awareness for and increase the 
knowledge of hypermobility syndromes, especially EDS and benign joint hypermobility 
syndrome, among health professionals, including medical specialists, and to be a guide for 
patients. Hypermobility syndromes often are characterised by extra-articular signs and 
symptoms that often go unrecognised or are only recognized at a late stage. The ultimate goal 
was to improve care for patients with hypermobility syndromes, and this proved to be a great 
success.  
Realising that this book indeed filled a gap in the health care system, some years ago the idea 
arose to publish an international multidisciplinary book on hypermobility syndromes with the 
help of international authors, with the same aims as those for the Dutch book. This has proven 
not to be a simple endeavour, but we think we eventually have succeeded. We hope it will 
meet our aims, described above, and your hopes and expectations. To make this book easily 
accessible to patients and health care workers, we decided to publish it as a freely available e-
book. Financial support was given by many organisations (see the acknowledgements on the 
next page), for which we are very grateful.  
JWG Jacobs, editor-in-chief, Associate Professor in Rheumatology 
BCJ Hamel, editor, Professor Emeritus of Clinical Genetics 
MC Veenhuizen, editor, Nurse Tutor, hypermobile EDS (hEDS) patient 
LJM Cornelissens, editor, Psychotherapist and Medical Ethicist, hEDS patient 
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Chapter 1. History and introduction 
 
 
Generalised hypermobility has been known since ancient history; for instance Peruvian 
ceramic figures of 1200–200 B.C. visualize hypermobile individuals. The clinical picture of 
Ehlers-Danlos syndrome (EDS) is said to be first described by Hippocrates in 400 B.C. The 
Dutch surgeon Job Janszoon van Meek'ren in 1657 and the Russian dermatologist 
Tschernogobow in 1892 described the clinical picture of EDS, but EDS was named after the 
Danish dermatologist Edvard Lauritz Ehlers (1863–1937), who recognized the condition as a 
distinct entity in 1901 and after Henri-Alexandre Danlos, a French physician (1844–1912), 
who suggested in 1908 that skin extensibility and fragility are cardinal features of EDS.
1
 
Since about the first half of last century, several case reports of EDS and other hypermobility 
syndromes were published. In the earliest publications, several signs and symptoms have been 
described as associated with EDS, which later proved to be not to be related with EDS, such 
as mental retardation, bleeding disorders and anatomical cardiac anomalies. 
In the second half of last century, also classifications were formulated,
2,3
 based on patterns of 
inheritance and clinical features. With the development of genetic techniques and more 
systematic research, new genetic defects and subsequently several new types of EDS and 
other hypermobility syndromes have been recognised and very likely more will be 
distinguished in the future, necessitating continued updating of existing classification systems. 
This will probably take place during international congresses, such as that in New York City 
May 2016. Laboratory testing for most of the hypermobility syndromes has become possible. 
However, there is no curative treatment for these syndromes, though in vascular EDS 
celiprolol and in Marfan syndrome losartan have been proven to diminish the risk of vascular 
complications, likely due to mechanisms beyond that of lowering blood pressure.
4,5
 
In contrast with these developments and the relatively frequent occurrence of hypermobility 
syndromes is the relative lack of awareness and recognition of these syndromes in daily 
clinical practice with underdiagnosis as result. This could be due to the wide spectrum of 
possible signs and symptoms. Although - as said - therapeutic options are meagre, recognition 
and diagnosis of a hypermobility syndrome in a patient are beneficial, ending an often year-
long quest for the cause of signs and symptoms and guiding management. When the quest 
ends, finding a way of coping for patient and because of the genetic nature of these syndromes 
also for his/her family can start. For hypermobility syndromes with the risk of life-threatening 
complications, recognition and diagnosis might even be life-saving. 
The aim of this book is creating more awareness for hypermobility syndromes, especially 
EDS, among health professionals, including medical specialists, and being a guide for 
patients, in order to improve the care for patients with hypermobility syndromes. This book is 
not meant as a reference book for basic research or the newest developments; it is meant for 
usage in daily clinical practice, with a practical, clinical scope, as much as possible in a 
reading level of text, health care worker or educated patient can understand, without 
compromise to the scientific content. Bearing our purpose in mind, we believe this book 
should be widely available, which we have attempted to achieve by publishing it as an E-
book. 
Patients with hypermobility syndromes, having a wide spectrum of signs, symptoms, 
manifestations and complications, often get to deal with a wide array of medical specialists 
and other health care providers, who each have a special interest in and knowledge about a 
specific organ or physical system. The description of these symptoms by only one person with 
one specialism is bound to be a bit one-dimensional (see figure). 
1
 
 
 
A generalist with extensive knowledge of virtually all organ systems possibly affected or 
influenced by hypermobility syndromes does not exist. Next best for an individual patient 
would be a clinician acting as case manager. We would welcome development of 
multidisciplinary outpatient clinics for patients with hypermobility syndromes.  
Both a case manager and a multidisciplinary outpatient clinic should take the whole spectrum 
of possible manifestations into account. This is the reason we chose for our book the scope 
and vision from different specialisms on the subject, trying to describe the whole spectrum of 
manifestations, as much as possible at the persons level, rather than at the organ level. The 
drawback of this choice is some heterogeneity in the medical level and length of chapters, and 
some overlap between chapters, which we accepted. The outline of the book is as follows: 
first there are chapters on classifications and genetics, then chapters on individual types, organ 
(system) manifestations and complications, and at the end ethics and therapeutic strategies, 
with an appendix on (precautions at) surgery. With the efforts of two of our editors, who 
suffer from EDS, we tried to incorporate also the patient’s perspective. 
 
In May 2016 in New York an international symposium of the Ehlers-Danlos Society took 
place, with propositions of changes regarding classification and nosology.
6
 We incorporated 
these changes into this book. Given the fast developments in research, particularly in genetic 
testing through the widespread introduction of next generation sequencing, it might be that 
criteria sets, classifications and genetic tests, will be further updated in the near future. 
However, we feel that for the purpose of the book this is not a major obstacle, and can update 
the text, given this is an e-publication. So, if our book leads to earlier recognition of patients 
with hypermobility syndromes and better management, and functions as a practical guide for 
patients and their families and friends in daily practice, we feel we have met our aim. We 
hope you will enjoy reading it. 
 
JWG Jacobs, editor-in-chief 
BCJ Hamel, editor 
MC Veenhuizen, editor 
LJM Cornelissens, editor  
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1. Introduction  
Ehlers-Danlos syndrome (EDS) comprises a clinically and genetically heterogeneous group of 
heritable connective tissue disorders (HCTD), mainly characterized by a variable degree of 
generalized joint hypermobility, skin hyperextensibility, easy bruising and skin fragility. 
When in 1956 the first edition of McKusick’s book entitled “Heritable disorders of connective 
tissue” was published, less than 100 papers had been devoted to EDS, mainly case reports.
1
 At 
about the same time it became clear that EDS basically was an autosomal dominant, clinically 
and probably also genetically heterogeneous disorder. In his classical monograph on EDS, 
published in 1970, Beighton described 5 EDS types: I = gravis (severe), II = mitis (mild), III = 
hypermobility, IV = ecchymotic, and V = X-linked.
2
 The Berlin classification listed 11 EDS 
types.
3
 Revision became necessary because of new biochemical, molecular and clinical data, 
leading to the Villefranche nosology of 1997, in which 6 EDS types were recognized.
4
 New 
clinical and molecular data required another revision, which was initiated during the Ehlers-
Danlos Society International Symposium in New York, May 2016, the results of which have 
been published in the March 2017 issue of the American Journal of Medical Genetics Part C, 
Seminars in Medical Genetics. The most striking changes were: 
- incorporating EDS types which were published since the Villefranche nosology, leading 
to a total number of 13 types.
5
 
- deciding - not unexpectedly though - that EDS hypermobility type and benign joint 
hypermobility syndrome (BJHS; also called joint hypermobility syndrome or 
hypermobility syndrome) are in fact part of one and the same clinical spectrum ranging 
from apparently symptomatic generalized joint hypermobility to the most disabled 
individuals fitting the new diagnostic criteria. These new criteria are more strict than the 
Villefranche criteria and the Brighton criteria for BJHS in order to define a homogeneous 
phenotype for management and scientific purposes. Its name is hypermobile EDS. 
 
It always has been, and still is, a challenge to classify individual patients in one of the existing 
EDS types. Often this is not possible. This is, among other things, due to: 
- the clinical overlap between many of these EDS types 
- absence of a pathogenic variant in any of the known EDS associated genes in an 
important proportion of EDS patients. 
- the presence of associated features which do not fit into one of the existing types. 
- the absence of a laboratory test for hypermobile EDS. 
 
EDS is not a rare disorder; the prevalence is estimated to be about 1:5000. The hypermobile 
type - by far the most common - and the classical type comprise more than 90% of all cases.
6 
 
2. Classification and nosology  
The New York classification is based on clinical, biochemical and molecular data.
5
 Table 2-1 
shows the New York nosology alongside the previous nosologies with inheritance patterns, 
genetic bases and proteins, while in table 2-2 EDS types are grouped according to underlying 
genetic and pathogenetic mechanisms; OMIM numbers (see glossary) are added.  
In clinical practice, the clinical manifestations guide the choice for further investigations. The 
major clinical manifestations of EDS need some clarification, however.  
Skin hyperextensibility should be tested at specific sites, e.g. the volar side of the non-
dominant forearm or the dorsum of the hand by pulling up the skin until resistance is felt. In 
contrast to cutis laxa, a group of clinically and genetically heterogeneous disorders 
characterised by redundant, sagging and inelastic skin, with or without joint hypermobility, in 
EDS the skin snaps back after release.
7
 The upper limit of normal for the forearm and dorsum 
of the hand is about 1 ½ cm.
8
 In young children it is difficult to assess hyperextensibility due 
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to the abundance of subcutaneous fat. Skin hyperextensibility can also be assessed at the 
dorsal aspect of the elbow in 90
0
 flection, where the upper limit of normal is 3 cm.  
Joint hypermobility is scored using the Beighton mobility scale (table 2-3). In the New York 
nosology, a score of 5/9 or more defines generalized hypermobility in both sexes, though it is 
known that joint mobility depends, apart from age, family and ethnic background, also on 
gender. Since laxity decreases with age, patients with a Beighton score <5/9 may be 
considered positive based on their historical observations (five-point questionnaire = 5PQ; see 
footnote with table 2-4). For the diagnosis of hypermobile EDS different age and sex specific 
cut-off points were proposed (see table 2-4). In children under the age of about 5 years, the 
Beighton scale is less useful. Not infrequently, the Bulbena mobility score is also used (table 
2-4), in which a score of 5/10 or more defines generalized hypermobility in females and 4/10 
or more in males. It is more easily applicable in children. Generalised hypermobility is not 
rare: 5-10% of – mainly female – secondary school age Caucasian children is hypermobile.
8,9
  
Easy bruising is seen as spontaneous ecchymoses, frequently recurring in the same bodily 
regions, of which long-term signs are often visible as brownish discoloration (haemosiderin), 
in particular on knees and shins. If it is the predominant presenting sign, child abuse and 
bleeding disorders need to be considered first.  
Tissue fragility is manifested in the skin as easy bruising and impaired wound healing with 
dystrophic scars, which are usually found over pressure points like forehead, chin, elbow, 
knee and shin and which may have a wide and papyraceous appearance. Internal organs like 
arteries, lungs, intestines, liver, spleen and uterus may also show fragility, predominantly in 
the vascular type. 
Some features are regularly observed, but are not criteria of generalised hypermobility 
syndromes. One example is the ineffectiveness of local anaesthetics in hypermobile EDS.
10 
In table 2-5 the major and minor diagnostic criteria are shown, minimal criteria for diagnosis 
and how to verify the diagnosis. 
A major diagnostic criterion predominantly has high diagnostic specificity, which means that 
it is present in the vast majority of the affected individuals and/or it is characteristic for the 
disorder and allows differentiation from other EDS types and/or other HCTD. A minor 
criterion is a sign of lesser diagnostic specificity, but its presence supports the diagnosis. 
However, in the absence of major criteria, minor criteria are not sufficient for a given 
diagnosis. Because of the vast genetic heterogeneity and phenotypic variability of the EDS 
types and the clinical overlap between many of these, the definite diagnosis relies for all 
types, except the hypermobile type, on molecular confirmation. 
In older publications features like facial dysmorphisms and mental retardation/intellectual 
disability were attributed to EDS, whereas nowadays these features are not any longer 
considered characteristics of EDS, except for facial dysmorphisms in vascular, 
dermatosparaxis, spondylodysplastic and musculocontractural EDS and intellectual disability 
in spondylodysplastic EDS (see table 2-5). Explanation for this could be that other syndromes 
associated with these features were erroneously diagnosed as EDS because of overlapping 
features with EDS. Another explanation is that these other features are not rare and 
consequently are found associated with EDS in a low percentage of cases. 
 
The classical EDS has all the skin and joint characteristics of EDS, though in variable range 
of severity. Minimal diagnostic criteria are the presence of skin hyperextensibility and 
atrophic scars, plus either generalized joint hypermobility and/or 3 minor criteria (see table 2-
5).
11
 A recent paper reviews 62 molecularly confirmed cases from Italy.
12
 It is inherited in an 
autosomal dominant fashion (see glossary), implying that each child (be it a boy or a girl) of 
an affected parent (be it father or mother) has a chance of 50% (= ½) of also having the 
classical type of which the expression (see glossary) cannot be predicted. However, sporadic 
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cases (i.e. without an affected parent) do occur due to a spontaneous mutation. Genetically, it 
is heterogeneous since in over 90% of patients, who fulfil all major criteria, a defect can be 
found in (products of) one of the two genes that are up to now known to be involved, COL5A1 
and COL5A2. An EDS type resembling the classical type but clinically characterized by a 
propensity to arterial rupture and molecularly by a specific mutation in COL1A1 (c.934C>T; 
p.Arg312Cys) is regarded as a variant type of classical EDS.
13,14
 Once the causative mutation 
has been found in a proband (see glossary), mutation analysis in relatives of the proband is 
possible. The major differential diagnosis of the classical type, at least in a sporadic case, is 
the classical-like EDS. Also, in mild cases of the classical type (partial expression), 
differentiation from the hypermobile type might be difficult, if not impossible.  
 
Classical-like EDS resembles the classical type, however with normal wound healing and scar 
formation.
14,15
 Minimal diagnostic criteria are the presence of all 3 major criteria, i.e. skin 
hyperextensibility, generalized joint hypermobility and easy bruisability and a family history 
compatible with autosomal recessive inheritance. It is characterised by generalized 
hypermobility, with a remarkable laxity of finger joints. In contrast with the classical type, its 
inheritance is autosomal recessive, so most cases are sporadic and some occur in sibships. It is 
due to tenascin-X deficiency. In serum, tenascin-X is completely absent and mutation analysis 
(TNX-B) is performed in blood.  
 
The cardiac-valvular EDS is rare.
14,16
 Apart from typical EDS features, it is associated with 
severe aortic and/or mitral valve insufficiency, necessitating valve replacement at relatively 
young age. Minimal diagnostic criteria are the presence of severe progressive cardiac-valvular 
problems, family history compatible with AR inheritance plus either one other major criterion 
and/or at least 2 minor (see table 2-4). The inheritance is autosomal recessive. It is due to 
homozygous or compound heterozygous COL1A2 null mutations (see glossary).  
 
The vascular EDS is the most severe form of EDS.
17
 Minimal diagnostic criteria are the 
presence of of a family history of vascular EDS, arterial rupture/dissection <40 years, 
unexplained sigmoid colon rupture or spontaneous pneumothorax in the presence of other 
features consistent with vascular EDS. These and a combination of minor criteria warrant 
verifying diagnostic tests, i.e. DNA analysis (see table 2-5). Diagnosis in children is difficult, 
particularly in the absence of a family history. The vascular type is inherited in an autosomal 
dominant fashion. Arterial rupture is the most common cause of sudden death and has its peak 
incidence in the 3
rd
 or 4
th
 decade. Acute abdominal and flank pain is a common presentation 
of an arterial or intestinal rupture and needs urgent investigation and treatment. Recently, 
Frank et al. showed that the type of COL3A1 mutation is associated with the phenotype and 
severity: patients with glycine substitutions and splice-site and in-frame insertions–deletions 
have a more severe phenotype, including digestive events, compared to e.g. mutations leading 
to non-glycine missense variants or haplo-insufficiency, due to a null allele. The latter may 
delay onset of complications by almost 2 decades.
17,18 
 
For women with the vascular type, pregnancy and delivery pose specific risks, which warrant 
pre-conceptional counselling with an experienced obstetrician and clinical geneticist.
19 
There is considerable clinical overlap between the vascular type and Loeys-Dietz syndrome 
type 1 and 2 (OMIM 609192 and 610168 respectively; see chapters 5 and 6 for details and 3 
more types), which are due to TGFBR1 (type 1) and TGFBR2 (type 2) mutations.
20
 Also other 
aortic aneurysm syndromes, such as Marfan syndrome, Thoracic Aortic Aneurysm and 
Dissection (TAAD), annulo-aortic ectasia should be included in the differential diagnosis.
21
 
As said above, when extensive bruising is the initial presentation and the only sign/symptom, 
bleeding disorders and child abuse have to be considered. 
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The hypermobile EDS, incorporating BJHS, is dominated by generalized joint hypermobility 
and its possible sequelae, in particular chronic pain, which can be severe and invalidating, and 
possibly early osteoarthritis.
22
 As said, the new diagnostic criteria are more strict than those of 
the Villefranche criteria and the Brighton criteria (see table 2-5 and chapter 5). The clinical 
diagnosis of hypermobile EDS needs the simultaneous presence of 3 criteria: criterion 1 = 
generalized joint hypermobility, criterion 2 = 2 or more of the features A, B and C (A = 
systemic manifestations of a more generalized connective tissue disorder; B = positive family 
history; C = musculoskeletal complications) and criterion 3 = absence of unusual skin 
fragility and exclusion of alternative diagnosis (for details see table 2-5 and chapter 5). 
Recently, also cardiovascular dysautonomia (mainly postural tachycardia syndrome = POTS), 
functional gastro-intestinal manifestations, sleep disturbance, fatigue, depression and anxiety 
disorders have been attributed to hypermobile EDS, but these are at the moment not 
sufficiently sensitive nor specific. Basically, there is no confirmative laboratory test for the 
hypermobility type, meaning that it is a pure clinical diagnosis. Recently, Syx et al. reported 
linkage to chromosome 8p22-8p21.1 in a 3 generation Belgian family with EDS 
hypermobility type, whereby whole exome sequencing revealed a possibly involved gene.
23
 
Up to recently, BJHS was considered a separate entity with its own diagnostic criteria.
24
 It 
was already argued earlier that the hypermobility type and BJHS are in fact one and the same 
disorder with variable expression. Arguments put forward for this were among others the fact 
that haplo-insufficiency of TNX-B, assessed as about half of the normal activity of tenascin-X 
in blood, and/or heterozygosity for a pathogenic TNX-B mutation, is found both in cases with 
EDS hypermobility type and cases in whom BJHS is the more likely diagnosis.
25
 Also, a 
changing phenotype from one diagnosis into the other in one individual and in some pedigrees 
the occurrence of both diagnoses argued for this statement.
26
 
Castori et al. proposed a frame for the classification of joint hypermobility and related 
syndromes, which is worth reading.
27
  
 
The arthrochalasia EDS is also rare, but diagnosable at birth.
14
 Minimal criteria suggestive 
for arthrochalasia EDS are congenital bilateral hip dislocation plus either skin 
hyperextensibility or severe generalized joint hypermobility with multiple 
dislocations/subluxations and at least 2 other minor criteria It is inherited in an autosomal 
dominant fashion. It is due to specific mutations in COL1A1or COL1A2. Larsen syndrome, 
which also features congenital luxations, should be in the differential diagnosis. 
 
The dermatosparaxis EDS derives its name from a similar phenotype and biochemical defect 
in cattle, sheep, and other animals.
14
 It is the EDS type which has the closest resemblance to 
cutis laxa. However, in cutis laxa there is neither fragility nor bruising. Its mode of 
inheritance is autosomal recessive. It is one of the rarest of all types and since only very few 
cases have been described, possibly this type is characterised by other - as yet unrecognised - 
features. Recently, Van Damme et al. expanded the phenotype and suggested new diagnostic 
criteria.
28
 The New York nosology requires for its diagnosis extreme skin fragility with 
congenital or postnatal skin tears AND characteristic craniofacial features plus either 1 other 
major and/or 3 minor criteria (for details see table 2-5). It is due to mutations in ADAMTS2. 
The mode of inheritance is autosomal recessive (see glossary), whereby both parents of a 
patient are healthy carriers and the recurrence risk for siblings is 25% (= ¼). 
 
The kyphoscoliotic EDS is a rare but severe form of EDS, manifesting itself often at or shortly 
after birth.
14,29
 The presence of congenital muscle hypotonia AND congenital or early onset 
kyphoscoliosis plus either generalized joint hypermobility and/or 3 minor criteria (either  
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general or PLOD1 and FKBP14 gene-specific) warrants laboratory testing. Kyphoscoliotic 
EDS is genetically heterogeneous and can be caused by mutations in PLOD1 and FKBP14. 
Laboratory tests should start with measurement of the urinary lysyl and hydroxy-lysyl 
pyridinoline ratio. An increased ratio has a very high degree of sensitivity and specificity for 
PLOD1 mutations, but not for FKBP14 mutations. For molecular tests: see table 2-5. The 
mode of inheritance is autosomal recessive (see glossary), whereby both parents of a patient 
are healthy carriers and the recurrence risk for siblings is 25% (= ¼). Because of severe 
hypotonia, patients very often undergo a full scale neuromuscular work-up, including a 
muscle biopsy before the diagnosis is established. The differential diagnosis comprises all 
other causes of severe hypotonia, including neonatal Marfan syndrome.  
 
The even rarer brittle cornea syndrome (formerly EDS VIB) resembles the kyphoscoliotic 
type, but is generally milder.
14,30
 Minimal diagnostic criteria are thin cornea with or without 
rupture plus either at least one other major criterion and/or 3 minor criteria (see table 2-5). It 
shows a normal urinary lysyl and hydroxy-lysyl pyridinoline ratio, and is characterised by 
mutations in the genes ZNF469 or PRDM5.  
 
Spondylodysplastic EDS is genetically heterogeneous and is due to bi-allelic mutations in 
either B4GALT7 (former name progeroid type 1
31
), B3GALT6 (former name progeroid type 
2
32
) or SLC39A13 (former name spondylocheirodysplastic type
33
).
14
 There is considerable 
overlap with kyphoscoliotic EDS. Minimal diagnostic criteria are short stature AND muscle 
hypotonia plus characteristic radiographic abnormalities and at least 3 other minor criteria 
(general or gene-specific; see table 2-5).
 
The urinary lysysl and hydroxylysyl pyridinoline ratio is moderately increased (to 
approximately 1 compared to normal values of ~ 0.2) with HLPC for SLC39A13 mutations.  
 
The musculocontractural EDS (formerly EDS VIB) is due to bi-allelic mutations in either 
CHST14 gene (type 1) or more rarely DSE gene (type 2) and has also considerable clinical 
overlap with the kyphoscoliotic type.
14,34 
Minimal diagnostic criteria are at birth or in early 
childhood congenital multiple contractures AND characteristic craniofacial features, while in 
adolescence and adulthood these are congenital multiple contractures AND characteristic 
cutaneous features. 
 
Myopathic EDS is caused by heterozygous or bi-allelic mutations in COL12A1.
14,35
 Minimal 
diagnostic criteria are congenital muscle hypotonia and/or muscle atrophy that improves with 
age plus either one other major criterion and/or three minor criteria. The phenotype highly 
overlaps with collagen VI type related myopathies, i.e. Bethlem myopathy and Ullrich 
Congenital Muscular Dystrophy. 
 
The periodontal EDS has some overlap with the classical type, but has progressive and 
aggressive periodontitis as a distinguishing feature.
14
 Minimal diagnostic criteria are severe, 
intractable periodontitis of early onset (childhood or adolescence) OR lack of attached gingiva 
plus at least 2 other major criteria and one minor criterion. Recently, it was found that gain-
of-function mutations in the C1R gene or the C1S gene, encoding serine proteinases, cause 
periodontal EDS.
36
 
 
The former EDS type V (X-linked) has been described in only 2 families and is not any longer 
accepted as belonging to EDS spectrum, the same holds true for the former fibronectin 
deficient type X, familial articular hypermobility EDS XI and Filamin A related EDS with 
heterotopia. The former type IX is an X-linked cutis laxa disorder and is renamed occipital 
Chapter 210
 
 
horn syndrome; it is due to mutations in the gene ATP7A, the same gene as is mutated in 
Menkes syndrome (disorder of copper metabolism)  
 
For further reading, the excellent review by Byers and Murray is highly recommended, 
together with the more recent paper by Malfait et al.
14,37 
In fact, the whole March 2017 issue 
of the American Journal of Medical Genetics Part C, Seminars in Medical Genetics provides a 
very good update not only about EDS nosology and diagnostic criteria, but also about 
management aspects of the various types of EDS.  
 
Joint hypermobility is a symptom of large variety of syndromes.  
A search in the London Medical Databases (suite.face2gene.com/lmd-library-london-medical-
database-dysmorphology/) with “joint laxity or multiple joint dislocations” as key words gives 
more than 290 hits. Among these, one finds - not surprisingly - other heritable connective 
tissue disorders like cutis laxa, osteogenesis imperfecta, Stickler syndrome (see chapter 5), 
Loeys-Dietz syndrome and Marfan syndrome, but also skeletal dysplasias, inborn errors of 
metabolism, neuromuscular disorders, chromosomal abnormalities and syndromes like Larsen 
syndrome, Fragile X syndrome and Langer-Giedion syndrome. 
 
3. How to achieve the diagnosis Ehlers-Danlos syndrome, including correct typing? 
Like always in clinical practice, the results of history taking, including a family history, and 
physical examination are the basis for planning additional investigations and finally reaching 
a diagnosis. As mentioned above, additional investigations are often biochemical as a first 
screen, followed by targeted DNA analysis. However, with the introduction of new DNA 
technologies, like next generation sequencing, rapid search for the disease causing mutation 
by molecular analysis of (all) known EDS genes (“the EDS panel”) at once has become 
possible. This is already standard routine diagnostic practice in some laboratories and will 
become routine in all in the near future (see chapter 3). Copy number variation analysis for 
large deletions and duplications has also a place in the molecular analysis in cases where NGS 
did not reveal a mutation in AD types and only one mutation in AR types. 
As history taking and physical examination in relation to EDS are very important, they will be 
discussed below. 
 
Good history taking starts with identifying the exact symptoms and complaints, which 
compelled the patient to see a physician: when and how did they start and evolve, how were 
they treated (what were the results, what was advised/prescribed and by whom?). Specific 
questions should elucidate the presence or absence of: 
- Hypermobility and/or (sub)luxations. If (sub)luxation occurred: which joint(s) was/were 
involved, how often did it occur, was it spontaneous (also the first time) and painful? Was 
it seen/treated by doctors? If necessary also the Five-Point Questionnaire (5PQ; see 
footnote in table 2-5). Contractures? Congenital hip dislocation? (see chapters 5, 8, 22 
and 24).
38,39
  
- Painful joints.
40
 If so: which ones, when, under which circumstances, exercise related, 
warm and swollen, if so, for how long? Use of analgesics? Sprains? What are the major 
limitations in daily life? (see chapters 20, 21, 22 and 24) 
- Temporomandibular joint problems (see chapter 14).
41
 
- Problems with bursae/tendons. 
- (Spontaneous) fractures. 
- Skin fragility and abnormal wound healing with wide atrophic scars (see chapter 9). 
- Surgery, e.g. for inguinal hernia. If so: complications? 
- Easy bruising and/or abnormal menstrual bleeding (see chapter 11). 
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- Abnormal exercise tolerance and/or fatigue.
42
 Sports performed? Type of work: blue or 
white collar? 
- Pneumothorax? 
- Cardiac problems? Cardiovascular autonomic dysfunction?
43
 (see chapter 12)? 
- Genito-urinary tract problems, e.g. uterine prolapse, voiding dysfunction (see chapter 16).  
- Gastro-intestinal tract problems, e.g. constipation, diverticula, rectal prolapse (see chapter 
10).
44
 
- For female patients with children: pregnancy and delivery problems (see chapter 17).
19
  
- Rupture of internal organs (arteries, lungs, intestines, spleen, uterus). 
- Psychiatric problems, like anxiety, depression, ADHD?
45
 
- Neurological problems?
46,47
 Headache? Migraine? (see chapter 13) 
- Eye problems, e.g. refractive errors, abnormal vision (see chapter 15). 
- Hearing? 
- Growth? 
- Motor and cognitive development? 
- Miscellaneous: Gingivitis? Varicose veins? Abnormal effect of local anaesthesia? 
 
The family history includes drawing a three generation pedigree with specific enquiry 
regarding hypermobility, easy bruising, abnormal scarring, arterial dissections and organ 
ruptures.  
 
The physical examination is focused on signs relevant for connective tissue disorders: 
- Build and biometry: height, weight, span and others when indicated. Marfanoid? 
- Facial features: among others, Gorlin sign (ability to touch the tip of the nose with the tip 
of tongue)? High palate? Absence of subcutaneous fat? Prominent eyes? Thin, “pinched” 
nose? Normal earlobes? Epicanthic folds? Low-set ears? Midfacial hypoplasia? 
Micrognathia? Down-slanting palpebral fissures? Gingival recession? 
- Teeth: dental crowding? Discoloured? Dysplastic? Periodontitis? 
- Thorax: deformity? 
- Back: (kypho)scoliosis? 
- Extremities: Beighton score,; Bulbena score; arachnodactyly (wrist and thumb sign)? 
Brachydactyly? Clinodactyly? Contractures? Flat feet? Joints? Muscle strength? Edema? 
Hallux valgus? 
- Skin: extensibility? Texture? Thickness and venous pattern? Striae distensae? Varicose 
veins? Piezogenic papules? Molluscoid pseudotumors? Spheroids? Scars? Herniae? 
- Eyes: Blue sclerae? Microcornea? Strabismus? Clouded cornea? Glaucoma? 
Scleral/ocular fragility? Keratoconus? 
- Neurological examination: muscle weakness? Reduction in vibration sense? Reduction of 
tendon reflexes? 
 
Then a differential diagnosis will be established, on which basis additional investigations, 
such as biochemical and/or DNA analysis in blood and/or cultured fibroblasts, derived from a 
skin biopsy, are planned, if clinically relevant and available for the suspected type. 
Morphological examination of a skin biopsy is of limited value, except in some types, 
particularly in dermatosparaxis EDS. On indication, the patient will be referred to an 
ophthalmologist, cardiologist, orthopaedic surgeon, neurologist and/or others. 
DNA analyses are available as diagnostic services in most of the developed countries. As 
already indicated, there is no DNA test available for hypermobile EDS. If there is any reason 
to believe the phenotype could be the classical-like, tenascin-X deficient type, then there is an 
indication to perform tenascin-X analysis in serum. If there is suspicion of vascular EDS, the 
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threshold to do DNA analysis should be very low, because of the consequences of that 
diagnosis in terms of management and genetic counselling. For some of the other EDS types 
the same holds true, because of their rareness, overlapping features with other EDS types 
and/or different modes of inheritance. In fact, for definite diagnosis molecular confirmation is 
needed for all types, except the hypermobile type. 
 
4. Genetic counselling (see also chapter 19) 
Since all the disorders which have been discussed have a genetic background, genetic 
counselling is an indispensable part of the management of patients and their families. During 
genetic counselling, information will be given about the mode of inheritance, recurrence risk, 
variability and penetrance of the disorder, the possibilities of prenatal diagnosis and diagnosis 
in relatives at risk and management. Prenatal diagnosis and diagnosis in relatives at risk is 
only possible if the causative DNA defect is known. A social worker should be available to 
assist whenever a need is perceived or requested. When there is a patient/parent support 
group, patients/parents should be informed. In case of a proband (see glossary) of non-EDS 
parents, it is essential to differentiate between an autosomal dominant (e.g. classical type) and 
an autosomal recessive type (e.g. classical-like, tenascin-deficient type): in the classical type 
the recurrence risk for a next child of these non-EDS parents is low (less than 1%) and for a 
child of the affected patient high (50%), while in the tenascin-deficient type the recurrence 
risk for a next child is high (25%) and for a child of the affected patient generally low (1% or 
less).  
 
5. Areas of uncertainties/research agenda 
- An international consensus on methods for measuring joint hypermobility and on more 
accurate tools for classifying patients with hypermobile EDS is needed. 
- Controlled studies are necessary to establish the role of tenascin-X in hypermobile EDS. 
- Controlled studies are needed to establish whether hypermobile EDS is a multisystem 
disorder, including among others cardiovascular dysautonomia (mainly postural 
tachycardia syndrome = POTS), functional gastro-intestinal manifestations, sleep 
disturbance, fatigue, depression and anxiety disorders. If that is the case, diagnostic 
criteria need to be adjusted. 
- Research into the hypothesis: joint mobility is the end result of the contribution of many 
genes with each (probably) having a small effect, and exogeneous factors (multifactorial). 
The degree of joint mobility in a population shows a continuous distribution, comparable 
to body length and IQ. At the one extreme there is severe stiffness, and at the other severe 
hypermobility. At the extremes it is likely to find - rare - monogenic forms, but in 
between the extremes chances are high to find the more common forms of multifactorial 
origin. This could be the reason, that so far little has come out of genetic studies in EDS 
hypermobility type. 
- Is classical-like, tenascin deficient EDS more frequent than thought up till now? 
- Education of the general public and health care providers is needed to increase awareness 
of EDS with early diagnosis and proper management as a consequence. Particularly, it is 
important to understand that hypermobile EDS and benign joint hypermobility syndrome 
are one and the same disorder. 
- International registries need to be established, particularly for the more rare types, in 
order to increase knowledge regarding the natural history, the phenotype and 
management. 
- Provide evidence that management of EDS patients needs to be provided in 
multidisciplinary teams in expertise centres.  
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6. Summary 
EDS comprises a group of heritable connective tissue disorders which has as cardinal features 
varying degrees of skin hyperextensibility, joint hypermobility, easy bruising and skin 
fragility. The 2017 New York nosology distinguishes 13 types of EDS, which all, except 
hypermobile EDS, have a known molecular basis. Hypermobile EDS is recognized as a 
common and often disabling disorder, incorporating benign joint hypermobility syndrome. 
EDS needs to be differentiated from other connective tissue disorders, in particular Marfan 
syndrome, Loeys-Dietz syndrome and cutis laxa. The frequent types of EDS can be diagnosed 
after careful history taking and clinical examination, but for definite diagnosis molecular 
confirmation is needed in all types. Management for EDS patients preferably is provided by 
multidisciplinary teams in expertise centres. After diagnosing EDS genetic counselling is an 
essential part of the management of patients and their family. 
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Table 2-1 Classification of Ehlers-Danlos syndrome (adapted from
5
) 
 
Berlin 
classification 
(1988) 
11 types 
Villefranche 
classification 
(1997) 
6 types 
International 
classification 
(2017) 
13 types 
IP  Genetic basis Protein 
Type I (gravis) 
and type II 
(mitis) 
Classical type Classical EDS 
cEDS  
AD Major: COL5A1, COL5A1  
Rare*: COL1A1  
c.934C>T, p.(Arg312) 
Type V collagen  
Type I collagen 
  Classical-like EDS 
clEDS
AR TNXB  Tenascin XB 
  Cardiac-valvular EDS 
cvEDS  
AR COL1A2 (biallelic mutations 
that lead to COL1A2 NMD 
and absence of pro a2(I) 
collagen chains)
Type I collagen 
 
Type 
IVA,B,C,D 
Vascular type Vascular EDS 
vEDS 
AD Major: COL3A1 
Rare: COL1A1  
c.934C>T, p.(Arg312Cys) 
c.1720C>T, p.(Arg574Cys)  
c.3227C>T, p.(Arg1093Cys) 
Type III collagen 
Type I collagen 
 
Type III Hypermobility 
type 
Hypermobile EDS hEDS AD Unknown                                 Unknown 
Type VIIA and 
B
Arthrochalasia 
type 
Arthrochalasia EDS 
aEDS
AD COL1A1, COL1A2  Type I collagen 
Type VIIC Dermatosparaxis 
type 
Dermatosparaxis EDS 
cEDS
AR ADAMTS2  ADAMTS-2 
Type VIA  Kyphoscoliotic 
type 
Kyphoscoliotic EDS 
kEDS
AR  PLOD1   
FKBP14
LH1 
FKBP22
(continued on next page)  
C
lassification and nosology of E
hlers-D
anlos syndrom
e
15
 
 
Type VIB  Brittle cornea syndrome  
BCS
AR ZNF469   
PRDM5
ZNF469 
PRDM5
  Spondylodysplastic EDS 
spEDS 
AR B4GALT7   
B3GALT6   
SLC39A13
b4GalT7 
b3GalT6 
ZIP13
Type VIB  Musculocontractural 
EDS  
mcEDS
AR CHST14 
DSE   
D4ST1 
DSE 
  Myopathic EDS 
mEDS
AD/ 
AR
COL12A1  Type XII collagen 
EDS VIII  Periodontal EDS 
pEDS
AD C1R  
C1S
C1r   
C1s
EDS V
#   XL Unknown   
EDS IX   
= cutis laxa 
syndrome 
  XL ATP7A  Cu-transporting 
alpha polypeptide 
EDS X
#
 
Fibronectin 
abnormality 
  AR Unknown  
EDS XI
#
 
familial joint 
instability 
  AD Unknown  
IP: inheritance pattern 
NMD: nonsense mediated decay 
* EDS classical type with (propensity to) arterial rupture.
13
 
# 
No longer accepted as separate entities 
C
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Table 2-2 EDS grouping according to underlying genetic and pathogenetic mechanisms 
(adapted from
5
)  
 
Berlin or earlier 
name 
Villefranche 
name 
New York name OMIM Gene  
GROUP A: Disorders of collagen primary structure and collagen processing 
EDS I 
EDS  II 
Classical type Classical EDS (cEDS) 130000 COL5A1 
COL5A2
EDS IV Vascular type Vascular EDS (vEDS) 130010 COL3A1
EDS VIIA 
EDS VIIB 
Arthrochalasia 
type  
Arthrochalasia EDS 
(aEDS)
130060 
130080 
Type I 
collagen
EDS VIIC Dermatosparaxis 
type 
Dermatosparaxis EDS 
(dEDS)
225410 ADAMTS2 
Cardiac-valvular EDS ----- Cardiac-valvular EDS 
(cvEDS)
225320 Type 1 
collagen
GROUP B: Disorders of collagen folding and collagen cross-linking 
Ocular-scoliotic EDS 
EDS VI/VIA 
Kyphoscoliotic 
type 
Kyphoscoliotic EDS 
(kEDS-PLOD1)
225400 PLOD1 
---- ---- Kyphoscoliotic EDS 
(kEDS-FKBP14)
614557 FKBP14 
GROUP C: Disorders of structure and function of myomatrix, the interface between 
muscle and ExtraCellular Matrix 
---- ---- Classical-like EDS 
(clEDS)
606408 TNXB 
---- ---- Myopathic EDS (mEDS) 616471 COL12A1
GROUP D: Disorders of glycosaminoglycan biosynthesis 
EDS progeroid type 1 ---- Spondylodysplastic EDS 
(spEDS-B4GALT7)
130070 B4GALT7 
EDS progeroid type 2 ---- Spondylodysplastic EDS 
(spEDS-B3GALT6)
615349 B3GALT6 
Adducted thumb-
clubfoot syndrome 
Musculocontractural 
type 
EDS Kosho type 
D4ST1 deficient EDS
---- Musculocontractural EDS 
(mcEDS-CHST14) 
601776 CHST14 
---- ---- Musculocontractural EDS 
(mcEDS-DSE)
615539 DSE 
GROUP E: Disorders of complement pathway  
EDS VIII Periodontitis 
type 
Periodontal EDS (pEDS) 130080 C1R, C1S 
GROUP F: Disorders of intracellular processes (provisional) 
Spondylocheirodyspl
astic EDS 
---- Spondylodysplastic EDS  
(spEDS-SLC39A13)
612350 SLC39A13 
Brittle cornea 
syndrome 
---- Brittle cornea syndrome 
(BCS)
229200 
614170 
ZNF469 
PRDM5
Unresolved form of EDS 
EDS III Hypermobility 
type 
Hypermobile EDS 
(hEDS)
130020 ?? 
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Table 2-3 Beighton mobility scoring scale* 
Joint  Negative Unilateral Bilateral 
Passive dorsiflexion of 
the 5
th
 finger > 90
o
 
0 1 2 
Passive flexion of thumbs 
to the forearm 
0 1 2 
Hyperextension of the 
elbows > 10
o 
0 1 2 
Hyperextension of the 
knees > 10
o 
0 1 2 
Forward flexion of the 
trunk with knees fully 
extended and palms 
resting on the floor 
 
0 
 
1 
 Total score (maximum=9):  
* a score of 5/9 or more defines generalized joint hypermobility for both sexes (for 
hypermobile EDS, age and sex related cut-off points are used; see table 2-5) 
  
Chapter 218
 
 
Table 2-4 Bulbena mobility scoring scale* 
Joint  Negative Positive 
Passive exorotation of shoulder > 85
o 
0 1 
Hyperextension of the elbow > 10
o
 0 1 
Passive flexion of thumb to the forearm < 21 
mm 
0 1 
Passive dorsiflexion of the 5
th
 finger > 90
o
 0 1 
Passive abduction of both hips > 85
o
 0 1 
Heel touches nates on passive flexion of knee 
while lying on the abdomen 
0 1 
On passive movement of patella laterally it 
crosses the line between the anterior superior 
iliac spine and the medial malleolus  
0 1 
Passive dorsiflexion of ankle joint > 20
o 
0 1 
Passive dorsiflexion of first 
metatarsophalangeal joint > 90
o 
0 1 
Visible ecchymoses (on minimal trauma) 0 1 
Total score (maximum=10):  
* a score of 5/10 or more defines generalized hypermobility in females and 4/10 or more in 
males.
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Table 2-5 Diagnostic criteria, minimal criteria and verification of Ehlers-Danlos syndromes (data extracted from
5
) 
Types of EDS Major diagnostic criteria Minor diagnostic criteria Suggestive minimal criteria 
for diagnosis 
Verification of clinical 
diagnosis 
Classical EDS Skin hyperextensibility and  
atrophic scars 
Generalized joint hypermobility 
Easy bruising 
Smooth, velvety skin 
Skin fragility (or traumatic splitting) 
Molluscoid pseudotumors 
Subcutaneous spheroids 
Hernia (or history thereof) 
Epicanthic folds 
Complications of joint hypermobility e.g. 
sprains, (sub)luxations, pain, pes planus 
First degree relative fulfilling clinical criteria 
Skin hyperextensibility and  
atrophic scars, plus 
either generalized joint 
hypermobility and/or 3 minor 
criteria 
 
Molecular screening of a 
targeted EDS gene panel, 
including at least COL5A1, 
COL5A2, COL1A1 and 
COL1A2. 
When not available 
transmission electron 
microscopy (TEM) of skin 
biopsy (collagen flowers) 
might be supportive
Classical-like EDS Skin hyperextensibility with velvety 
skin texture and absence of 
atrophic scarring 
Generalized joint hypermobility with 
or without recurrent dislocations 
Easy bruisable skin/spontaneous 
ecchymoses 
Foot deformities: broad/plump forefoot, 
brachydactyly, pes planus, hallux valgus, 
piezogenic papules 
Edema of legs 
Mild proximal and distal muscle weakness 
Axonal polyneuropathy 
Atrophy of hand and foot muscles 
Acrogeric hands, mallet finger(s), 
clinodactyly, brachydactyly 
Vaginal/uterus/rectal prolapse
All 3 major criteria and a family 
history compatible with autosomal 
recessive inheritance 
Molecular analysis of TNXB 
gene. If necessary CNV 
analysis for deletions. 
Complete absence of TNX in 
serum. 
Cardiac-valvular EDS Severe progressive cardiac-
valvular problems 
Skin hyperextensibility, atrophic 
scars, thin skin, easy bruising 
Generalized or small joints 
hypermobility 
Inguinal hernia 
Pectus deformity (mostly excavatum) 
Joint dislocations 
Foot deformities: pes (plano)valgus, hallux 
valgus 
Severe progressive cardiac-valvular 
problems AND family history 
compatible with AR inheritance  
plus either one other major  
criterion and/or at least 2 minor  
Molecular screening by 
Sanger sequencing of 
COL1A2 or targeted 
resequencing of a EDS gene 
panel. If necessary CNV 
analysis for deletions and 
duplications. 
Total absence of (pro)α2(I) 
with SDS PAGE 
Vascular EDS 
(continued on 
next page) 
Family history of vEDS with 
molecular confirmation 
Arterial rupture at young age 
Bruising without trauma and/or in unusual 
sites (cheeks, back) 
Thin, translucent skin with increased venous 
A family history of vEDS, 
rupture/dissection <40 years, 
unexplained sigmoid colon rupture 
Molecular screening by 
Sanger sequencing of 
COL3A1 or targeted 
C
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Spontaneous sigmoid colon 
perforation 
3
rd
 Trimester uterine rupture 
Carotid-cavernous sinus fistula 
(Last 3: in the absence of other 
explanations) 
visibility 
Characteristic facial appearance 
Spontaneous pneumothorax 
Acrogeria 
Talipes equinovarus 
Congenital hip dislocation 
Hypermobility of small joints 
Tendon and muscle rupture 
Keratoconus  
Gingival recession and fragility 
Early onset varicose veins (<30 years and  
nulliparous if female) 
or spontaneous pneumothorax in 
the presence of other features 
consistent with vEDS, a 
combination of other minor criteria 
should all lead to verifying 
diagnostic tests. 
resequencing of a EDS gene 
panel, including COL3A1 
and COL1A1.   
If necessary CNV analysis 
for deletions and 
duplications. 
 
 
Hypermobile EDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(continued on 
next page) 
Generalized joint hypermobility 
(GHJ) assessed by Beighton score 
≥ 6 for prepubertal children and 
adolescents 
≥ 5 for pubertal men and women 
up to the age of 50 
≥ 4 for those > 50 years of age 
If the Beighton score is 1 point 
below the age- and sex-specific 
cut-off AND the 5-point 
questionnaire (5PQ)
* 
is positive 
then a diagnosis of GJH can be 
made 
A: systemic manifestations of a more 
generalized connective tissue disorder: 
1. unusually soft or velvety skin 
2. mild skin hyperextensibility 
3. unexplained striae distensae 
4. bilateral piezogenic papules (heel) 
5. recurrent or multiple abdominal hernias 
6. atrophic scarring at 2 or more sites without 
truly papyraceous and/or hemosideric scars 
7. pelvic floor, rectal and/or uterine prolapse 
in children, men or nulliparous women 
without obesity or other explanation 
8. dental crowding and high/narrow palate 
9. arachnodactyly (bilateral positive wrist or 
thumb sign) 
10. arm span-to-height ≥ 1.05 
11. mitral valve prolapse (echocardiographic 
criterion) 
12. aortic root dilatation with Z-score > +2 
B: one or more first degree relatives 
independently meeting the criteria for hEDS 
C: musculoskeletal complications: 
1. Generalized joint hypermobility 
AND 
2. Two or more among features A-
C (A+B, A+C, B+C, A+B+C) must 
be present 
A: total of 5 must be present 
B: must be present 
C: 1 or more must be present 
AND 
3. absence of unusual skin fragility 
AND exclusion of other heritable 
and acquired connective tissue 
disorders, including autoimmune 
rheumatologic disorders
#
 AND 
exclusion of alternative diagnoses 
e.g. neuromuscular disorders, other 
Heritable Connective Tissue 
Disorders, and skeletal dysplasias 
 
Not possible; hEDS is a 
clinical diagnosis. 
Sleep disturbance, fatigue, 
postural orthostatic 
tachycardia, functional 
gastro-intestinal disorders, 
dysautonomia, anxiety and 
depression are not part of 
the diagnostic criteria, but its 
presence may prompt 
consideration of hEDS in the 
differential diagnosis. 
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1. pain in 2 or more limbs, recurring daily for 
at least 3 months 
2. chronic widespread pain for ≥ 3 months 
3. recurrent joint dislocations or frank joint 
instability in the absence of trauma (a or b) 
a. 3 or more dislocations in the same joint or 
2 or more dislocations in 2 different joints 
occurring at different times 
b. medical confirmation of joint instability at 2 
or more sites 
Arthrochalasia EDS Congenital bilateral hip dislocation 
Severe generalized joint 
hypermobility with multiple 
dislocations/ subluxations 
Skin hyperextensibility 
Muscle hypotonia 
Kyphoscoliosis 
Mild osteopenia (X-ray) 
Tissue fragility, including atrophic scars 
Easy bruisable skin 
 
Congenital bilateral hip dislocation 
plus either skin hyperextensibility 
or severe generalized joint 
hypermobility with multiple 
dislocations/ subluxations and at 
least 2 other minor criteria 
Molecular screening by 
Sanger sequencing of 
COL1A1/A2 or targeted 
resequencing of a EDS gene 
panel, including COL1A1/A2.  
If necessary CNV analysis 
for deletions and 
duplications.  
Supportive might be SDS 
PAGE analysis of cultured 
skin fibroblasts and TEM of 
skin biopsies 
Dermatosparaxis 
EDS 
 
 
 
 
 
 
 
 
(continued on 
next page) 
Extreme skin fragility with 
congenital or postnatal skin tears 
Characteristic craniofacial features 
Redundant, almost lax skin, 
Increased palmar wrinkling 
Severe bruisability 
Umbilical hernia 
Postnatal growth retardation 
Short limbs, hands and feet 
Perinatal complications due to 
connective tissue fragility 
Soft and doughy skin texture 
Skin hyperextensibility 
Atrophic scars 
Generalized joint hypermobility 
Complications of visceral fragility 
(bladder/diaphragmatic rupture, rectal 
prolapse) 
Delayed motor development 
Osteopenia 
Hirsutism  
Tooth abnormalities 
Refractive errors (myopia, astigmatism) 
Strabismus 
Extreme skin fragility with 
congenital or postnatal skin tears 
AND characteristic craniofacial 
features plus either 1 other major 
and/or 3 minor criteria 
Molecular screening by 
Sanger sequencing of 
ADAMTS2 or targeted 
resequencing of a EDS gene 
panel, including ADAMTS2.    
If necessary CNV analysis 
for deletions and 
duplications.  
Supportive might be SDS 
PAGE analysis of cultured 
skin fibroblasts and TEM of 
skin biopsies 
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Kyphoscoliotic EDS Congenital muscle hypotonia 
Congenital or early onset  
kyphoscoliosis  
Generalized joint hypermobility with 
multiple dislocations/ subluxations 
 
Skin hyperextensibility 
Easy bruisable skin 
Rupture/aneurysm of a medium-sized artery 
Osteopenia/osteoporosis 
Blue sclerae 
Hernia (umbilical or inguinal) 
Pectus deformity 
Marfanoid habitus 
Talipes equinovarus 
Refractive errors (myopia, hypermetropia) 
PLOD1 specific minor criteria 
Skin fragility (e.g. atrophic scarring, friable 
skin) 
Scleral/ocular fragility/rupture 
Microcornea  
Facial dysmorphology (e.g. low-set ears, 
epicanthal folds, down-slanting fissures, 
synophrys, high palate) 
FKBP14 specific minor criteria 
Congenital sensorineural, conductive or 
mixed hearing impairment  
Follicular hyperkeratosis 
Muscle atrophy 
Bladder diverticula 
Congenital muscle hypotonia AND 
congenital or early onset  
kyphoscoliosis plus either 
generalized joint hypermobility 
and/or 3 minor criteria (general or 
gene-specific) 
Increased Dpyr/pyr (= 
LP/HP) ratio in urine by 
HPLC is highly sensitive for 
PLOD1 kEDS.  Molecular 
analysis: MLPA of PLOD1 
(duplication); if negative 
MLPA, targeted 
resequencing of a EDS gene 
panel, including PLOD1 and 
FKBP14, but also ZNF469, 
PRDM5, B4GALT7, 
B3GALT6, SLC39A13, 
CHST14 and DSE, because 
of overlapping phenotypes.    
If necessary CNV analysis 
for deletions and 
duplications.  
Supportive might be TEM of 
skin biopsies 
Brittle Cornea 
syndrome 
 
 
 
 
 
 
(continued on 
next page) 
Thin cornea with or without rupture 
Early onset progressive 
keratoconus 
Early onset progressive 
keratoglobus 
Blue sclerae 
Enucleation or corneal scarring 
Progressive loss of corneal stroma depth 
High myopia 
Retinal detachment 
Progressive high frequency often mixed 
deafness 
Hypercompliant tympanic membranes 
Developmental hip dysplasia 
Mild hypotonia in infancy 
Scoliosis 
Arachnodactyly
Thin cornea with or without rupture 
plus either at least one other major 
criterion and/or 3 minor criteria 
Molecular screening by 
targeted resequencing of a 
EDS gene panel, including 
ZNF469 and PRDM5, but 
also PLOD1, FKBP14, 
B4GALT7, B3GALT6, 
SLC39A13, CHST14 and 
DSE, because of overlapping 
phenotypes. 
If necessary CNV analysis 
for deletions and 
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Hypermobility of distal joints 
Pes planus, hallux valgus 
Mild finger contractures (esp. 5
th
) 
duplications.     
 
Spondylodysplastic 
EDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(continued on 
next page) 
Progressive short stature 
Muscle hypotonia (ranging severe 
congenital to mild later-onset) 
Bowing of limbs 
Skin hyperextensibility, soft doughy, thin 
translucent skin 
Pes planus 
Delayed motor development 
Osteopenia 
Delayed cognitive development 
B4GALT7 specific minor criteria 
Radioulnar synostosis 
Bilateral elbow contractures or limited 
elbow movement 
Generalized joint hypermobility 
Single transverse palmar crease 
Characteristic facial features 
Characteristic radiographic findings 
Severe hypermetropia 
Clouded cornea 
B3GALT6 specific minor criteria 
Kyphoscoliosis 
Joint hypermobility, generalized or 
restricted to distal joints 
Joint contractures (esp. hands) 
Peculiar fingers (e.g. slender, tapered, 
spatulate, broad distal phalanges) 
Talipes equinovarus 
Characteristic facial features 
Tooth discoloration, dysplastic teeth 
Characteristic radiographic findings 
Osteoporosis (spontaneous fractures) 
Ascending aortic aneurysm 
Lung hypoplasia, restrictive lung disease 
SLC39A13 specific minor criteria 
Protuberant eyes with bluish sclerae 
Short stature AND muscle 
hypotonia plus characteristic 
radiographic abnormalities and at 
least 3 other minor criteria (general 
or gene-specific) 
Molecular screening by 
targeted resequencing of a 
EDS gene panel, including 
B4GALT7, B3GALT6 and 
SLC39A13 but also PLOD1, 
FKBP14, ZNF469, PRDM5,  
CHST14 and DSE, because 
of overlapping phenotypes. 
If necessary CNV analysis 
for deletions and 
duplications.     
GAG deficiency  with 
B4GALT7 and  B3GALT6 
mutations in cultured 
fibroblasts. 
Moderately increased LP/HP 
ratio (to approximately 1 
compared to normal values 
of ~ 0.2) with HLPC for 
SLC39A13 mutations. 
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Hands with finely wrinkled palms 
Atrophy of thenar muscles, tapering fingers
Hypermobility of distal joints 
Characteristic radiographic findings 
Musculocontractural 
EDS 
Congenital multiple contractures 
(adduction-flexion and/or clubfoot) 
Characteristic craniofacial features 
Characteristic cutaneous features 
(hyperextensibility, bruising, 
fragility, atrophic scars, increased 
palmar wrinkling) 
 
Recurrent/chronic dislocations 
Pectus deformities (flat, excavatum) 
(Kypho)scoliosis 
Tapering, slender, cylindrical fingers 
Progressive talipes deformities (valgus, 
planus, cavum) 
Large subcutaneous hematomas 
Chronic constipation 
Colonic diverticula 
Pneumo(hemo)thorax 
Nephro/cystolithiasis 
Hydronephrosis 
Cryptorchidism  
Strabismus 
Refractive errors (myopia, astigmatism) 
Glaucoma/elevated intraocular pressure 
At birth or in early childhood 
Congenital multiple contractures 
AND 
characteristic craniofacial features  
In adolescence and adulthood 
Congenital multiple contractures 
AND 
characteristic cutaneous features 
 
Molecular screening by 
targeted resequencing of a 
EDS gene panel, including 
CHST14 and DSE but also 
PLOD1, FKBP14, ZNF469, 
PRDM5, B4GALT7, 
B3GALT6 and SLC39A13 , 
because of overlapping 
phenotypes. 
If necessary CNV analysis 
for deletions and 
duplications.     
 
Myopathic EDS Congenital muscle hypotonia 
and/or muscle atrophy that 
improves with age 
Proximal joint contractures (knee, 
hip, elbow) 
Hypermobility of distal joints 
Soft, doughy skin 
Atrophic scarring 
Delayed motor developmental 
Myopathy on muscle biopsy 
Congenital muscle hypotonia 
and/or muscle atrophy that 
improves with age plus either one 
other major criterion and/or three 
minor criteria 
 
Molecular screening by 
targeted resequencing of a 
EDS gene panel, including 
COL12A1, and 
COL6A1/A2/A3, because of 
overlapping phenotypes 
(Bethlem and Ullrich) .  
If necessary CNV analysis 
for deletions and 
duplications.    
Periodontal EDS 
 
 
(continued on 
next page) 
Severe, intractable periodontitis of 
early onset (childhood or 
adolescence) 
Lack of attached gingiva 
Pretibial plaques 
Easy bruising 
Joint hypermobility, mostly distal 
Skin hyperextensibility and fragility, wide or 
atrophic scarring 
Increased rate of infection 
Severe, intractable periodontitis of 
early onset (childhood or 
adolescence) OR lack of attached 
gingiva 
plus at least 2 other major criteria 
Identification of known or 
compatible gain-of-function 
mutations by sequence 
analysis of C1R and C1S 
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First degree relative who meets 
clinical criteria 
Hernias 
Marfanoid facial features 
Acrogeria 
Prominent vasculature 
and one minor criterion 
 
 
* The Five-Point Questionnaire (5PQ).  
1. Can you now (or could you ever) place your hands flat on the floor without bending your knees?  
2. Can you now (or could you ever) bend your thumb to touch your forearm? C  
3. As a child, did you amuse your friends by contorting your body into strange shapes or could you do the splits?  
4. As a child or teenager, did your shoulder or kneecap dislocate on more than one occasion?  
5. Do you consider yourself “double-jointed”?  
 
A “yes” answer to two or more questions (= positive 5PQ) suggests joint hypermobility with 80–85% sensitivity and 80–90% specificity. 
 
Adapted from Hakim AJ, Grahame R. Int J Clin Pract 57:163-166, 2003. 
#
 In patients with an acquired connective tissue disorder (e.g. lupus, rheumatoid arthritis, etc.) additional diagnosis of hEDS requires meeting 
both features A and B of criterion 2. Feature C of criterion 2 (chronic pain and/or instability) cannot counted towards a diagnosis of hEDS in this 
situation.
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Glossary 
Autosomal dominant 
Mode of inheritance whereby the disorder often occurs in multiple generations and 
both sexes are equally affected, because the affected gene is located on an autosome (= 
chromosomes 1 – 22; non-sex chromosomes). Generally, in autosomal dominant 
disorders one allele of a gene pair is mutated and the other allele is normal 
(heterozygosity). Since a child inherits one allele of a gene pair, the chance for an 
affected individual of transmitting the mutated allele and having an affected child is 
50% (= ½). 
Autosomal recessive 
Mode of inheritance whereby the disorder occurs most often in a single nuclear family 
and both sexes are equally affected. In autosomal recessive disorders, both alleles of a 
gene pair are mutated (homozygosity/compound heterozygosity). Both parents of an 
affected child are healthy carriers (heterozygosity). Their chance of having another 
affected child is 25% (= ¼), because there is a fifty-fifty chance that one of the 2 
alleles that is transmitted via the parents is the mutated one, and both mutated alleles 
have to be transmitted to cause disease (½ times ½ = ¼). For an affected individual the 
chance of having an affected child is usually low (= 1/100 or less), unless the sexual 
partner is at least carrier of the same abnormal gene. The chance this being the case, is 
higher when the partner is a relative (consanguinity) 
Bi-allelic 
Both alleles (members of a gene pair) of the involved gene are mutated, as occurs in 
autosomal recessive inheritance. 
Compound heterozygous/heterozygosity 
For an autosomal recessive disorder to occur both alleles (members of a gene pair) of 
the involved gene have to be mutated. Compound heterozygosity exists when these 2 
mutations (changes) of the involved gene are not exactly the same. 
Expression 
The degree in which an individual is clinically affected by a genetic disease or 
disorder. Often expression is variable, i.e. ranges from mild or partial features to the 
full scale clinical picture. 
Haemosiderin 
 A protein of red blood cells which presents as brownish iron-containing pigment. 
Haplo-insufficiency 
Generally speaking, genes produce proteins. Haplo-insufficiency relates to the activity 
of a protein and it means that its activity is reduced to - on average - 50%. 
Heterozygous/heterozygosity 
This is the state where only one of the 2 alleles of a gene pair is mutated, which is the 
case in patients suffering from an autosomal dominant disorder and in healthy parents 
(carriers) of a child with an autosomal recessive disorder. 
Homozygous/homozygosity 
This is the state where the 2 alleles of a gene have exactly the same mutation, which 
means disease for the individual in both autosomal dominant and recessive disorders.  
Multifactorial disorder 
Disorder which is caused by the contribution of - mostly - many genes, each having a 
small effect, and exogenous = non-genetic factors.  
Null mutation 
Any mutant allele where the normal gene product is not made or is completely non-
functional. 
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OMIM numbers 
OMIM = Online Mendelian Inheritance in Man = catalogue of heritable traits which 
have got numbers (www.ncbi.nlm.nih.gov/omim). 
Penetrance 
This denotes the percentage of mutation carriers who do have clinical features of the 
given disorder, i.e. who do have the given genetic disorder. 
Proband 
 The first patient in the family in whom a particular disorder has been diagnosed 
X-linked 
Mode of inheritance whereby the disorder often occurs in multiple generations and 
only males are affected. Mothers of affected males are carriers, unless a spontaneous 
mutation has occurred. Though the majority of carriers are healthy, some do have 
features of the involved X-linked disorder. For a carrier mother, the chance of having 
an(other) affected son is 50% (= ½). An affected male will have healthy children 
though all his daughters will be carriers, since the causative mutation is on his X 
chromosome. 
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1. Introduction 
The Ehlers-Danlos syndrome (EDS) comprises a group of inherited disorders, many of which 
involve a genetic defect in collagen and connective-tissue synthesis and structure. 
The condition is extremely heterogeneous, both at the clinical and the molecular level. The 
diagnosis of all EDS types is based primarily on clinical evaluation and family history. 
Laboratory testing is available for a number of types, but is rather complex. This complexity 
results from the underlying genetic heterogeneity. In order to understand the link between 
EDS and genes that cause these disorders, an introduction to the basic principles of genetics 
will be given. An overview of the diagnostic testing possibilities that are currently available 
will be provided. 
 
2. From genes to proteins 
Most living organisms consist of cells that originate from one fertilized egg cell through cell 
division. The nucleus of each cell contains a substance called deoxyribonucleic acid (DNA). 
DNA is wrapped together to form structures called chromosomes. Most cells in the human 
body have 23 pairs of chromosomes, making a total of 46. One of these 23 pairs contains the 
sex chromosomes, XX in females and XY in males. Individual sperm and egg cells, however, 
have just 23 unpaired chromosomes. Each individual receives half of the chromosomes from 
the mother's egg and the other half from the father's sperm cell. A male child receives an X 
chromosome from his mother and a Y chromosome from his father whereas females get an X 
chromosome from each parent. At each cell division, the two chromosomes are duplicated and 
one copy of each chromosome separates into the daughter-cells during a process called 
“mitosis”. In this way, at the end of the cell division, each of the daughter cells has exactly the 
same 23 pair of chromosomes as the mother cell. During egg and sperm formation, DNA 
duplication is followed by two consecutive cell divisions, at the end of which each egg or 
sperm contains only one copy of the 23 chromosomes. This process is called “meiosis”.  
 
DNA consists of a string made of sequences of four building blocks, called bases (adenine, 
thymine, cytosine, and guanine: A, T, C, and G for short) that are strung in patterns on 
extremely thin, coiled strands in the cell nucleus. Each nucleated cell in the human body 
contains about 2 meters  of DNA thread or a total of about 4.8 billion kilometres of DNA, if 
all the DNA strands were stretched out straight. Two complimentary strings of DNA form the 
famous “double helix”.  
 
Genes are sections or segments of DNA that are present on the chromosomes. Genes are 
transmitted from parents to offspring and are considered to be the basic unit of inheritance. 
Through the transmission of genes physical traits, such as eye colour, are inherited in families. 
Because each parent gives a child one chromosome of each pair, in general a child has two 
copies of every gene (except for most of the genes on the X and Y chromosomes in males 
because males have only one of each). Some characteristics come from a single gene, whereas 
others come from gene combinations. Because every person has 20,000 to 25,000 different 
genes, accounting for less than 2% of the total DNA, there is an almost endless number of 
possible combinations. 
 
Genes hold the instructions for making protein products, e.g. pigment that gives eyes their 
colour. The sequence of the bases within a gene forms the code that determines which protein 
is produced. Within a gene, these coding sequences, called exons, are interrupted by non-
coding DNA-sequences, called introns. Also in between genes, non-coding stretches of DNA 
are present. These sometimes have a regulatory function.  
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The information contained in the DNA dictates the composition of the proteins.  This involves 
two processes, called transcription and translation, see figure 3-1. 
 
Figure 3-1 From DNA to protein: schematic overview of transcription and translation 
 
courtesy of proto-col.com  
Briefly, when a gene is active, the DNA-code in the nucleus is first transcribed to a single-
stranded messenger ribonucleic acid (mRNA) that is very similar to DNA. The mRNA then 
migrates form the cell nucleus into the cell cytoplasm to be translated into protein. During this 
process, the non-coding introns are removed by nuclear enzymes (splicing). Via a few more 
steps, this mRNA is subsequently translated into protein. A protein is composed of amino 
acids. The body contains 20 different amino acids and the amino acid sequences that make up 
a protein must somehow be designated by the DNA after transcription into mRNA. Individual 
amino acids are encoded by units of three mRNA bases, termed codons. There are start and 
stop codons to designate the beginning and the end of a gene. Each gene also contains a code 
that determines in which cell-type the gene is active. This code, called the promoter, is 
involved in the regulation and the production of the mRNA and the protein. Finally, before a 
newly synthesized protein can begin its existence as a functional protein, it often undergoes 
further processing, termed posttranslational modification. These modifications can take a 
variety of forms such as, for example, combination with other polypeptides to form a larger 
protein, addition of carbohydrate side chains to the polypeptides etc. An example of a 
clinically important protein that undergoes considerable posttranslational modification is type 
I collagen. 
 
3. Genes and hereditary disorders 
Cells sometimes contain errors in the information in their genes. These errors are called gene 
mutations, and can spontaneously occur during the process of DNA replication or due to 
exposure to certain chemicals or radiation. Fortunately, cells usually recognize these 
mutations and repair them. If not, however, these mutations may cause disorders or illnesses.  
intron 
exon 
DNA code 
transcription 
intron 
exon 
RNA code 
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splicing 
mRNA code 
protein 
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As cells duplicate, they pass the genetic information to new cells. If a pathogenic, clinically 
relevant gene mutation exists in the DNA of an egg or a sperm cell, this will  result in a 
hereditary disease, and children may inherit the mutated gene from their parents. The errors 
(mutations) that cause hereditary diseases are usually very small, often confined to the change 
of only one base in a gene. This then is called a point mutation.  
The human DNA code contains approximately 3 billion bases and 20-25,000 genes. Each 
gene encodes one or more proteins. Although the DNA-code has been almost completely 
unravelled, the functions of most of the genes (i.e. the function of the protein they encode) 
and the genetic cause of many hereditary diseases remain to be elucidated.  
 
4. Heritability 
A hereditary disorder can be dominant or recessive and autosomal or X-linked (see glossary 
chapter 2). For a person to have an autosomal dominant disease or disorder, a mutation in 
only one copy of a gene suffices. However, a person with an autosomal recessive disease or 
disorder has a mutation on both copies of the gene. 
If a person has a dominant mutation in a gene implicated in a disease, he or she will usually 
have the disease. Moreover, each of that person's children will have a 1 in 2 (50%) chance of 
inheriting the gene and getting the disease. Sometimes a dominant disease occurs in a child of 
healthy parents; this is caused by a new mutation, which can then be transmitted to the 
children of that diseased child.  
People who have a mutation in only one copy of a gene implicated in a recessive disease, are 
called carriers, and they usually do not have the disease because they still have a normal gene 
of that pair that can do the job. When two carriers of the same disease have a child together, 
however, the child has a 1 in 4 (25%) chance of getting the mutated gene from both parents, 
which results in the child having the disease. This is the basis of the higher prevalence of 
recessive diseases in children of blood-related or consanguineous (i.e. belonging to the same 
family), clinically healthy parents, who have more gene abnormalities in common, compared 
to not blood-related parents. 
A peculiar situation arises if a disease gene is located on chromosome X (X-linked disorder), 
because this chromosome is present in one copy in males and two copies in females. In this 
case, a single mutation will suffice for a male person to get the disorder. Moreover, the 
mutated gene has always been transmitted to an affected male from his carrier mother, unless 
the affected male has a new mutation. An affected male will transmit the mutated gene to all 
his daughters. Females have two copies of chromosome X, of which only one is active in each 
cell of the organism. Depending on the proportion of cells with an active, mutated gene and 
the dominant or recessive nature of the disorder, females with a mutation in one copy of a X-
linked gene will be clinically unaffected or have (a milder presentation of) the disorder.  
 
Certain disorders are not caused by mutations in a single gene, but can be triggered by 
combinations of several variant genes, which interact with each other and often with the 
environment. These are called “complex or multifactorial disorders”. In case of “complex 
inheritance”, transmission of a “variant” in a gene can increase or decrease the susceptibility 
to develop a disease. 
 
5. Connective tissue, genes and EDS 
EDS is a group of related conditions that share a common decrease in the tensile strength and 
integrity of the skin, joints and other organs with connective tissues. This is mainly caused by 
various abnormalities in the structure of collagen, an important component of the connective 
tissues. 
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Collagens are the most abundant proteins in humans and the animal kingdom. They are 
multimeric and are characterized by the presence of triple-helical domains (so called 
collageneous domains, see figure 3-2).  
 
Figure 3-2 The multimeric and triple-helical domains of collagen. 
 
 
(www.proto-col.com) 
 
To date, 43 collagen genes have been described, the products of which combine to form at 
least 28 different collagen molecules. Besides collagen, connective tissues also contain elastic 
fibres, proteoglycans, and a variety of other different glycoproteins. Elastic fibres are 
composed of two distinguishable components: an amorphous component, “elastin”, which 
contributes to the elasticity of the fibre, and a surrounding sheet of microfibrils. An example 
of a microfibrillar protein is fibrillin, which is abnormal in patients with Marfan syndrome. 
Elastin and other structural proteins are woven onto the microfibrillar array to provide the 
basic meshwork for the connective tissue matrix. Abnormalities of elastin have been 
associated with other connective tissue disorders, such as cutis laxa. Proteoglycans are core 
proteins that are bound to one or more sugar chains (glycans). Essentially, proteoglycans are 
the glue of the connective tissue protein that seal and cement the underlying connective tissue 
matrix. Recently, abnormal proteoglycan metabolism has been shown to underlie a few types 
of EDS. Other glycoproteins of the extracellular matrix include fibronectin, fibulins, laminins 
and tenascins. Tenascin-X has also been implicated in some EDS types (classical-like and 
hypermobile EDS). 
 
EDS is classified into different types, based on the clinical characteristics, the mode of 
inheritance and the underlying molecular and genetic defect . At first, mutations have been 
identified in the genes encoding collagens type I, type III and type V, as well as in genes 
encoding proteins that are involved in posttranslational modifications processes of these 
collagens, such lysyl hydroxylases (PLOD1) and procollagen I-N-proteinase (ADAMTS2). 
The Villefranche classification (1997) of EDS into 6 clinical types was based on this 
knowledge.
1
 Later, also mutations were identified in non-collagenous proteins, showing that 
EDS can also be caused by defects in proteins other than collagen. In the last decade, several 
forms of EDS have been recognised which fall outside the Villefranche classification; this led 
to the 2017 International Classification of EDS (see table 2-1 of chapter 2).
2
 For most of these 
EDS types, one or more underlying genetic defects have been identified. For some of them, 
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the causal molecular defect remains to be discovered. Thus, many different proteins may be 
involved in the pathogenesis of EDS and others still remain to be discovered. Moreover, even 
if the abnormal gene is known, the condition is in almost every family with EDS caused by a 
unique mutation in that gene.  
 
Due to the variability in clinical presentation and the overlap in clinical features among 
different EDS types, the search for the causal mutation in a EDS patient can be a cumbersome 
and time-consuming task. Till a few years ago, a combination of biochemical and molecular 
assays represented the gold-standard- first-step in the diagnostics of EDS. In this “traditional” 
diagnostic approach, biochemical findings are used to confirm or guide molecular analysis of 
the specific collagen gene involved. However, with the introduction of new DNA 
technologies (e.g. Next Generation Sequencing, NGS), rapid search for the disease causing 
mutation by molecular analysis of (all) known EDS genes at once has become possible. This 
technology has been recently introduced in several diagnostic laboratories and will become 
standard routine diagnostic practice in the future. 
 
6. Guidance for diagnostic biochemical and molecular testing  
Clinical diagnosis is the primary means of identifying all EDS types. In many cases, a 
comprehensive clinical evaluation can be sufficient to establish a correct clinical diagnosis. 
However, in a growing subset of EDS types, molecular and, to a lesser extent, biochemical 
and/or ultrastructural analyses can be used in order to confirm the diagnosis.  
 
Traditionally, the first step in the laboratory diagnosis of many EDS types was the 
biochemical analysis of collagen type I, III and V, performed on cultured fibroblasts obtained 
from a skin biopsy. This step could guide molecular diagnostics for several EDS types, 
pinpointing the causative gene, therefore simplifying the search for the underlying genetic 
defect. This approach could help confirming the diagnosis in patients with vascular EDS, in a 
subset of patients with classical EDS, and in patients with arthrochalasia, dermatosparaxis and 
kyphoscoliotic EDS. 
However, biochemical analysis of collagen cannot identify defects in non-collageneous 
related types of EDS. For all these EDS types, molecular analysis of the causative gene is 
necessary to confirm the diagnosis. 
 
With the introduction of new DNA technologies (NGS), the molecular approach is becoming 
the first tool to confirm a clinical diagnosis of EDS. These new technologies allow testing of 
all known genes involved in EDS at once, allowing rapid achievement of a molecular 
diagnosis in important subsets of EDS patients.  
However, not all genes involved in EDS have been discovered as yet. In particular, this is not 
(yet) the case for hypermobile EDS. Haplo-insufficiency of tenascin-X (encoded by TNXB) 
has been associated with hypermobile EDS in a small subset of affected individuals. In most 
individuals with this type of EDS, the underlying genetic defect is unknown and unmapped. 
Also, hypermobile EDS  is not associated with biochemical defects of collagen proteins. 
Therefore, the diagnosis of hypermobile EDS is based entirely on clinical evaluation and 
family history.  
 
The most recent classification of Ehlers-Danlos syndrome types, the inheritance patterns, 
genetic causes and defective proteins, is given in table 2-1 of chapter 2.
2
  
Table 3-1 summarizes the most important differential diagnoses of EDS, their distinguishing 
features, underlying protein and gene defects and their diagnostic work-up. 
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6.1 Ultrastructural and biochemical analyses in EDS  
 
6.1.1 Ultrastructural examination of the skin 
Ultrastructural examination of the skin, performed by electron microscopy, usually reveals 
abnormalities of collagen fibrils in EDS. These include irregular, disrupted collagen fibrils 
(”collagen flowers”) and variability of the diameters of the collagen fibrils. However, these 
abnormalities are found in several EDS variants and are usually insufficient to discriminate 
between EDS types.  
Only in dermatosparaxis EDS, a pathognomonic ultrastructural aspect of the collagen fibril 
architecture is observed. Collagen fibrils in this type lose their normal cross-sectional circular 
aspect and have an irregular, branched, “hieroglyphic” appearance instead.
3
  
 
6.1.2 Skin biopsy for fibroblast culture and biochemical analysis 
Traditionally, the first step in the laboratory diagnosis of EDS, when possible and indicated, 
consisted of a skin biopsy to obtain a fibroblast culture (a culture of the cells that synthesize 
all elements of the connective tissue, including collagen). Biochemical protein-based analysis 
of the collagens type I, III and V, by means of gel electrophoresis, can detect abnormalities of 
these collagen proteins, regardless of the underlying cause. 
In case of vascular EDS, biochemical analysis of type III collagen is highly sensitive and 
probably identifies more than 95% of individuals with structural alterations in the proteins 
synthesized. It allows to detect quantitative abnormalities (reduced amounts of type III 
collagen) or qualitative abnormalities (abnormal type III collagen with altered electrophoretic 
mobility) of type III collagen. 
Biochemical analysis of the fibrillar collagens is also helpful in the diagnosis of the 
arthrochalasia, kyphoscoliotic and dermatosparaxis EDS. For the majority of patients with 
classical EDS, biochemical analysis of type V collagen, which is abnormal in this EDS type, 
is an ineffective method for routine diagnostic evaluation.
4
 The strands of type V collagen are 
synthesized by fibroblasts at a low rate, causing poorly reproducible quantification and 
evaluation of alterations in electrophoretic mobility of this collagen.  
In hypermobile EDS biochemical analysis of the fibrillar collagens shows no abnormalities 
and is therefore not indicated.
5 
 
6.1.3 Other available biochemical assays 
For kyphoscoliotic EDS , a highly specific and highly sensitive urinary assay is available for 
clinical testing.
6
  
A serum-based screening assay has been successfully used to detect tenascin-X-deficiency in 
classical-like EDS.
7 
 
6.2 Molecular genetic testing 
 
6.2.1 Classical EDS and related phenotypes 
In approximately 90% of the patients with classical EDS, mutations in one of the genes 
encoding type V collagen (COL5A1 and COL5A2) are detected.
4
 The most common types of 
defects that are observed in type V collagen lead to the production of about half of the amount 
of type V collagen (quantitative defect) and are caused by a mutation in the COL5A1 gene.
4,8,9
 
Only a minority of identified defects results in the production of a structurally abnormal type 
V collagen (qualitative defect).  
 
More recently, mutations in a non-collagenous protein, tenascin-X, have been shown to cause 
a condition with great similarities to classical EDS and is known as classical-like EDS. A 
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complete lack of tenascin-X in the serum was observed in some patients with a classical EDS-
like phenotype, with hyperextensible skin, hypermobile joints and easy bruising, but without 
atrophic scarring.
7,10
 In contrast to classical EDS, this condition shows recessive inheritance 
and is caused by mutations in both copies of the TNXB gene. These mutations, including a 
deletion which abolishes a large part of the TNXB gene, prevent production of tenascin-X.
10
 
The TNXB gene is located in a very complex genomic region on chromosome 6. This 
complexity has hindered molecular diagnostic of this gene in large groups of patients. 
However, several diagnostic centres are currently offering DNA testing of TNXB.  
 
In a small subsets of patients with clinical symptoms (partially) resembling the classical EDS, 
biochemical defects of collagen type I and/or mutations in the COL1A1 and COL1A2 genes 
have been identified.  
Complete deficiency of the pro-alpha2(I) collagen chains, due to mutations preventing protein 
production in both paternal and maternal COL1A2 genes, has been associated with a rare 
autosomal recessive form of EDS, named cardiac-valvular EDS.
11,12 
Furthermore, mutations in the COL1A1 gene specifically causing the substitution of an 
arginine residue by a cysteine residue in the triple collagen helix, have been described in a 
rare classical EDS variant, with a propensity for arterial rupture.
13,14
  
 
In the remaining patients with classical EDS, no molecular defect is found in any of these 
genes, suggesting that also other genes are involved in this phenotype.  
 
6.2.2 Hypermobile EDS 
To date, the genetic basis of hypermobile EDS remains largely unknown. The diagnosis is 
based entirely on clinical evaluation and family history. 
Carriership of mutations in tenascin-X have been identified in a small subset (~5%) of 
patients with hypermobile EDS.
15
 As previously reported in this chapter, a serum-based 
screening assay to detect tenascin-X-deficiency / haplo-insufficiency is available and several 
centres are offering DNA testing of TNXB.  
 
6.2.3 Vascular EDS 
The diagnosis of vascular EDS is based on clinical findings and confirmed by identification of 
a causative mutation in COL3A1, the only gene in which mutations are known to cause this 
type of EDS. Traditionally, molecular analysis of COL3A1 was performed if an abnormal 
migration pattern of type III collagen was identified by biochemical analysis. With progress 
of DNA technology, molecular analysis of the COL3A1 gene can be considered a rapid and 
highly sensitive first-line diagnostic tool in all cases in whom clinical findings support a 
diagnosis of vascular EDS. This is especially important in clinical life-threatening situations, 
when confirmation of a clinical diagnosis of vascular EDS can have immediate consequences 
for the treatment of the patient. With the introduction in diagnostics of the NGS technology, 
which allows testing of all genes of a panel of genes at once, molecular analysis of the 
COL3A1 gene is also becoming part of the routine diagnostic test in patients presenting with 
vascular symptoms as arterial aneurysms and dissections. As a matter of fact, a few patients 
with COL3A1 mutations have been described, whose clinical manifestations in contrast to  
characteristic vascular EDS phenotype seemed to be limited almost entirely to vascular 
events. In these patients, COL3A1 “null” mutations, having no collagen protein production as 
a result, were found.
16 
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6.2.4 EDS types due to defective processing of collagen type I 
The arthrochalasia EDS is a rare autosomal dominant condition caused by a deletion of a 
well-defined part of one of the genes that code for type I collagen (COL1A1 and COL1A2). 
This deletion inhibits the normal cleavage of the aminoterminal non-helical part of type I 
procollagen. Consequently, type I procollagen, which is a precursor of type I collagen, will 
not be processed correctly. This results in specific abnormalities in the electrophoretic 
mobility of type I procollagen, which can be detected on biochemical analysis.
17,18
 Molecular 
analysis of the COL1A1/A2 genes, targeted to the region containing the cleavage site of the 
aminoterminal non-helical part of type I procollagen, is available.  
Deficient activity of the protein responsible for cleavage of the N-terminal propeptide in type 
I, II and III collagen, due to mutations in the ADAMTS2 gene, causes a rare autosomal 
recessive condition, dermatosparaxis EDS.
19,20
 Molecular analysis of ADAMTS2 is available. 
Moreover, pathognomonic abnormalities of dermal collagen fibril architecture can be detected 
by ultrastructural skin examination, while biochemical collagen protein analysis shows a 
characteristic aberrant migration pattern. 
 
6.2.5 Kyphoscoliotic EDS and related phenotypes 
The kyphoscoliotic EDS is an autosomal recessive disorder caused by deficient activity of the 
lysyl-hydroxylase 1 protein, due to mutations in the PLOD1 gene.
21,22
 This protein is involved 
in the formation of intermolecular cross-links, which provide tensile strength and stability to 
the collagen fibrils. Historically, kyphoscoliotic EDS is the first type of EDS for which the 
molecular defect has been elucidated. For kyphoscoliotic EDS, a highly specific and highly 
sensitive urinary assay is also available for clinical testing i.e. measurement of the urinary 
hydroxy-lysyl and lysyl pyridinoline ratio. Moreover, the activity of the lysyl hydroxylase-1 
activity can be measured in cultured fibroblasts. 
Mutations in the FKBP14 gene, encoding a chaperone protein, thought to be involved in 
protein folding, have been identified in patients with kyphoscoliotic EDS, characterized by 
kyphoscoliosis, myopathy, and hearing impairment.
23,24
 
 
Recently, search of the underlying genetic defect in consanguineous families with a variety of 
rare phenotypes which show overlapping features with the kyphoscoliotic EDS, led to the 
identification of new EDS related genes and biological pathways.  
One of these conditions, spondylodysplastic EDS, was shown to be caused by mutations in 
the SLC39A13 gene. This gene encodes a protein involved in the trafficking of zinc, an 
element which is necessary for normal lysyl hydroxylase-1 activity.  A slightly abnormal 
hydroxy-lysyl and lysyl pyridinoline ratio due to defective lysyl hydroxylase-1 activity can be 
detected in the urine of patients.
25
 Defects of proteoglycan metabolism also underlie 
spondylodysplastic EDS.
26
 This rare recessive condition has recently been associated with 
mutations in the B4GALT7
27,28
 and in the B3GALT6 gene.
29,30
 These genes are involved in the 
correct biosynthesis of the glycosaminoglycan (‘sugar’) side chains of proteoglycans. 
Another of these rare disorders, Brittle Cornea Syndrome, has been associated with mutations 
in two different genes which probably are involved in the same biological pathway: ZNF469, 
which encode a protein of unknown function belonging to the Zinc-finger protein family
31
 and 
PRMD5, which code for a protein involved in the regulation of expression of extracellular 
matrix components.
32
  
In the last years, defects of proteoglycan metabolism have been shown to be responsible for 
some of these rare EDS conditions. One of these is musculocontractural EDS , which can be 
caused by mutations in the CHST14
33,34
 or the DSE gene.
35
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6.2.6 Other EDS types 
Recently, recessive and dominant COL12A1 mutations have been identified in affected 
individuals from two families with a novel overlapping syndrome, which combines 
generalised joint hypermobility with myopathy, myopathic EDS.
36
 COL12A1, coding for 
collagen XII, has been shown to be expressed in collagen I containing tissues and to interact 
with other extracellular matrix components, such as tenascin-X.  
Heterozygous missense or in-frame insertion/deletion gain-of-function variants in C1R and 
C1S cause periodontal EDS, which is characterised by early onset, aggressive periodontitis 
and skin and joint features. C1R and C1S encode subunits C1r and C1s of the first component 
of the classical complement pathway. The exact mechanism of periodontal EDS remains to be 
clarified.
37,38 
 
7. Research topics 
While a growing number of the EDS types has been characterized at the molecular level, the 
genetic basis of some of the most frequent forms, such as the hypermobility type and a subset 
of the classical type have not or not fully been elucidated. Recently, it has been shown that 
other, non-collagenous molecules may be causally involved in the pathogenesis of EDS.  
There are several features which make the search for the genetic causes of hypermobile EDS a 
challenging task. First of all the clinical variability and second, the possible contribution of 
other, genetic and non-genetic, factors in the phenotypic expression of the disorder (e.g. 
hormones may explain the apparently different phenotypic expression between females and 
males); and at last, the disorder is likely to be genetically heterogeneous. 
Elucidation of the genetic bases of these hypermobility syndromes will give better insight into 
the natural history and the biochemical and molecular pathogenesis of these disorders. This 
will improve early recognition and diagnosis of these conditions, lead to a more logical 
classification and possibly will allow development of more effective preventive and 
management strategies.  
 
8. Summary 
EDS is a clinically and genetically heterogeneous group of connective tissue diseases, mainly 
characterised by a decrease in the tensile strength and integrity of the skin, joints and other 
connective tissues.   
Abnormalities in the structure of collagen have long been recognised as being involved in the 
aetiology of this condition. However, in the past years, a growing number of different types 
has been identified, the underlying molecular defect of some of which involves other, non 
collageneous, connective tissue molecules. 
The diagnosis of EDS was traditionally based on a combination of clinical, biochemical and 
ultrastructural examinations which guided molecular analyses of involved genes. With the 
introduction of new DNA technologies (e.g. NGS), rapid search for the disease causing 
mutation by molecular analysis of (all) known EDS genes at once has become possible. This 
technology has been recently introduced in several diagnostic laboratories and will become 
standard routine diagnostic practice in the near future. 
However, in many cases of EDS the underlying molecular defect still is unknown, and the 
clinician as well as the patient must rely on the clinical diagnosis. This holds particularly true 
for hypermobile EDS. 
The ongoing elucidation of the biochemical and molecular basis of EDS together with 
increasing clinical experience, will add value to diagnosis, genetic counselling and 
management of these heritable disorders. Future research will further increase the 
understanding of the molecular mechanisms involved and possibly open perspectives for gene 
therapy.
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Table 3-1 Conditions to be considered in the differential diagnosis of EDS.  
Condition Discriminating signs Protein Gene Laboratory Testing 
Osteogenesis 
imperfecta 
History of multiple fractures 
Short stature 
Blue sclerae 
Type I collagen COL1A1 
COL1A2 
DNA sequencing and quantitative  
analysis of COL1A1/COL1A2 
Marfan syndrome  Marfanoid habitus 
 Ectopia lentis 
Aortic dilatation/aneurysm
Fibrillin 1 FBN1 DNA sequencing and quantitative analysis of 
FBN1 
Loeys-Dietz 
syndrome 
Aortic root and/or arterial 
dilatation/dissection 
Arterial tortuosity 
Hypertelorism 
Bifid uvula 
Cleft palate 
TGFβ receptor 1 
TGFβ receptor 2 
SMAD3 
TGFβ2 
TGFβ3 
TGFβR1 
TGFβR2 
SMAD3 
TGFB2 
TGFB3 
DNA sequencing analysis of 
TGFβR1, TGFβR2, 
SMAD3, TGFB2, TGFB3 
Stickler syndrome Sensorineural hearing loss  
Vitreoretinal abnormalities 
Cleft palate 
Type II collagen 
Type XI collagen 
Type IX collagen 
COL2A1  
COL11A1, 
COL11A2 
COL9A1, 
COL9A2, 
COL9A3
DNA sequencing analysis of COL2A1, 
COL11A1, COL11A2, COL9A1, COL9A2, 
COL9A3 
 
Cutis laxa 
syndromes 
Cutis laxa: redundant skin, hangs in 
loose folds, returns slowly to former 
position 
Normal wound healing 
Absence of skin fragility
Elastin 
Fibulin 4  
Fibulin 5 
A2V- ATPase 
Pyrroline-5-carboxylate reductase 
ELN  
FBLN4  
FBLN5 
ATP6V0A2 
PYCR1
DNA sequencing analysis of  
ELN, FBLN4, FBLN5, ATP6V0A2, 
PYCR1 
Larsen syndrome 
and related 
disorders 
Craniofacial dysmorphism 
Short stature 
Filamin B 
Beta-1,3-glucuronyltransferase 3 
Chondroitin 6-sulfotransferase 
FLNB  
B3GAT3 
CHST3
DNA sequencing analysis of FLNB, B3GAT3, 
CHST3 
Occipital horn 
syndrome 
Presence of “occipital horns” 
(parasagittal bone exostoses arising 
from the occipital bone) 
Bladder diverticulae 
Inguinal herniae 
Vascular tortuosity
Cu++* transporting, α polypeptide 
 
(*Cu++ = copper) 
ATP7A DNA sequencing analysis of ATP7A 
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1. Introduction 
The most common type Ehlers-Danlos syndrome (EDS), after hypermobile EDS (formerly 
EDS hypermobility type or type III) is classical EDS, a combination of what used to be EDS 
type I (gravis) and EDS type II (mitis),  
The estimated overall incidence of EDS is 1:5000 births, of which the classical and 
hypermobility types account for approximately 90%.
1
 A recent questionnaire on EDS sent to 
members of the Dutch EDS Patient Federation showed a similar occurrence of EDS patients 
with classical and hypermobile types. 
Classical EDS is inherited as a autosomal dominant trait. Typically for an autosomal 
dominant trait, it affects males and females equally often and there is interfamilial clinical 
variability. Skin and joint symptoms and signs are often the most common presenting features 
so that early skin fragility is especially typical in toddlers or preschool children.
2
 Causative 
mutations in two collagen type V fibrillar genes COL5A1 and COL5A2 have been identified. 
As a consequence, the faulty type V collagen molecules cause failure in the regulation of 
fibrillogenesis, resulting in misassembly of type I and III collagen fibrils.  
By electron microscopy, this disturbed collagen fibrillogenesis can be observed in a skin 
biopsy as abnormal rosetting (cauliflower fibrils). This finding is, however, not specific for 
one of the EDS types. 
 
The combination of clinical, molecular and ultrastructural diagnostic strategies (as discussed 
in chapters 2 and 3), leads to earlier diagnosis with consequent improvements of clinical 
management and accurate genetic counselling. 
As the skin plays an important role in the diagnosis, this chapter will particularly focus on the 
skin and the symptoms it causes in classical EDS. 
 
2. The skin 
 
2.1 The healthy skin 
The human skin has several distinct layers, see figure 4-1. 
 
Figure 4-1 
 
(www.health-advisors.org)  
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- the epidermis, containing the keratinocytes, pigment cells and cells involved 
in the immunological defence of the body such as the Langerhans cells,  
- the dermis which contains, apart from blood vessels, lymphatic vessels and nerves, the 
connective tissue, and 
- the hypodermis or subcutis, which contains fat-containing adipocytes in addition to blood 
and lymphatic vessels, loosely arranged elastic fibres and fibrous bands of connective tissue. 
The latter anchors the dermis to the hypodermis and the skin to the deep fascia. 
For normal skin mechanics, dermal connective tissue is of major importance. It contains 
elastic fibres, collagen fibres and ground substance, an amorphous substance that fills the 
spaces between the various fibres and bundles. The ground substance contains various 
glycoproteins such as tenascin and various sugar containing proteoglycans, such as hyaluronic 
acid and chondroitin sulphate. Fibrillar collagen fibres are arranged in a wave-like pattern. 
Flattening of these fibres allows normal skin to extend, even though the constituent collagen 
fibres themselves, are relatively inextensible. Extreme extension may damage the skin, which 
is subsequently visible as stretch marks.
3,4
  
Dermal elastic fibres are much sparser and are generally entwined among the collagen 
bundles. Unlike collagen, these fibres are rubber-like and extensible. After stretching they 
return to their original shape. 
Translating this to the mechanical properties of normal skin: the collagen is responsible for 
the strength and stiffness of the skin, consequently limiting skin extension if the collagen is 
normal. Similarly, when extended, return to its normal shape is mediated by elastic fibres. In 
the presence of abnormal collagen, the skin becomes abnormally extensible whilst the normal 
elastic fibres will still have the mechanical properties to make the skin return to its normal 
shape after extension. When elastic fibres are abnormal, as in Cutis Laxa, the skin will not 
return to its normal shape after extension: instead it will be hanging in lax folds. Second, since 
in Cutis Laxa collagens are normal, the skin is not hyperextensible. Furthermore, joint 
hypermobility is the exception rather than the rule. 
 
2.2 The skin in classical EDS 
In short, in classical EDS the skin collagen fibrillogenesis is visibly abnormal. This 
subsequently leads to hyperextensibility of the skin. Both the specific cutaneous and other 
generalised clinical features of classical EDS are caused by the faulty collagen and are 
described below. 
 
2.2.1 Hyperextensibility 
The skin in classical EDS is hyperextensible and seems to be hyperelastic. In the clinical 
setting standard tests to determine this may be used. Beighton suggested an arbitrary score for 
skin extensibility.
5
 He scored cutaneous stretching of the ventral left forearm on a numeric 
rating scale of 0 to 5 in a range of 4 to 8 centimetres. Only in significantly abnormal 
hyperextensibility a score higher than zero will be given. Skin extensibility is easily estimated 
by testing at several sites of the skin such as the elbows, knees, neck or face, or the presternal 
thoracic skin. 
These tests are easy to apply and to interpret in adults, but are less discriminating in children 
(see also chapter 18) since their skin is by nature more extensible than that of adults; 
moreover, the amount of subcutaneous fat is higher in the very young children making tests 
more difficult to perform adequately. To objectively measure the skin extensibility in 
children, the properties of volar forearm skin of 13 children (3-10 years of age) with classical 
EDS were recently studied using a cutometer equipped with a suction head (rheologic 
evaluation), to assess dermal and hypodermal mechanics.
6 
Data of patients with classical EDS 
were compared both to those of patients with hypermobile EDS and to those of age-matched 
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healthy controls. Skin of patients with classical EDS showed both abnormal 
hyperextensibility as well as hyperelasticity when compared to the two other groups. Because 
the dermis is thin in EDS and histology shows rarefaction of connective tissue septae in the 
hypodermis, it was hypothesized by the authors that the “slipping mobility” of the dermis onto 
the hypodermis was the main factor yielding these data, whereas the contribution of the 
dermal component was present, but of less importance. 
 
2.2.2 Reduced skin thickness 
While skin dermal thickness is diminished by 50-66% in all patients with vascular EDS, in 
classical EDS, there is a less impressive reduction in skin thickness. In the latter almost 50% 
of patients is affected, though to a lesser degree. Skin thickness in classical EDS and healthy 
controls was compared on the chest and the lower leg, with a 20MHz ultrasound probe. 
Overall, in 21 patients with classical EDS dermal thickness was significantly lower compared 
to that in controls.
7
 
 
2.2.3 Skin fragility (figure 4-2) 
The skin of classical EDS is abnormally fragile, with gaping wounds following very minor 
traumas, which produce the characteristic fish-mouth or tissue paper scars. Beighton 
suggested the use of an arbitrary analogue score of 1-5 based upon the extent of scarring, 
using five bony sites e.g. left elbow and forearm, right elbow and forearm, left knee, right 
knee and forehead as reference points. Other typical scarring sites are the chin and shins, 
which are not included in the scoring calculations. Because of tissue fragility patients often 
suffer from repetitive hernia, such as inguinal, umbilical, hiatal, or incisional hernia. 
 
Figure 4-2 Skin fragility: cigarette paper aspect 
 

 
 
2.2.4 Easy bruisability 
Classical EDS patients bruise very easily and sometimes extensively, often after  trivial 
injuries. In general, bleeding and clotting tests are normal, and no consistent haematological 
abnormalities are found. Beighton suggested an analogue scoring system, ranging from 0, for 
no bruising, to 5, for gross changes. In the absence of clotting or bleeding abnormalities, 
explanations for the bruising include faulty platelet binding to the abnormal underlying 
collagen fibres, or fragility of connective tissue round small venous and arterial capillaries. 
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2.2.5 Varicosities 
Due to the disturbed type I and III fibril packing, venous walls have a collagen defect.  This, 
together with weakened perivenous connective tissue and faulty venous valve formation, 
predisposes to venous varicosities (an abnormal condition of a vein, characterized by swelling 
and tortuosity).  
 
2.2.6 Molluscoid pseudotumors (figure 4-3) 
Fleshy spongy lumps of 2 to 3 cm in diameter over pressure points, form so-called molluscoid 
pseudotumors. These are usually concentrated at sites such as the Achilles tendons, knees and 
elbows. These sites are easiest identified when the patient is standing. Molluscoid 
pseudotumors probably are benign reactive fibrous hypertrophy, in response to recurrent 
microtrauma and repair. 
 
Figure 4-3 Molluscoid pseudotumors 
 

(www.regionalderm.com, courtesy of RegionalDerm.com) 
 
2.2.7 Spheroids 
Small, mobile, easily palpable, subcutaneous papules are common over the forearms and 
shins. When calcified they may be detected by X-ray examination. The origin of these 
spheroids is not clear: some think they represent subcutaneous fat globules that have lost their 
blood supply, becoming fibrosed and calcified. 
 
2.2.8 Soft skin 
Contact with the skin of patients with classical EDS reveals the interesting clinical sign of soft 
and velvety peach-like skin. Moreover, when shaking hands one directly notices the very 
hypermobile hand joints. The skin softness is presumably related to the misaggregated and 
abnormally packed collagen fibres, characteristic for classical EDS. 
 
2.2.9 Striae distensae 
The occurrence of these linear atrophic depressions of the skin (cutaneous striae) is influenced 
by many factors including hormones (particularly glucocorticoids), mechanical stress, and 
genetic predisposition. Light microscopy shows epidermal atrophy, with some loss of the rete 
ridges and sharply demarcated dense packing of thin, eosinophilic collagen bundles in a 
parallel array, horizontal to the skin surface. Elastic fibres appear to be diminished in a stretch 
mark as well.
4
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Striae are most common in areas of rapid growth, such as breasts and belly in pregnant 
females, lumbar spine in adolescents or upper legs and arms in active sportsmen and 
sportswomen. Caused by easy tearing of collagenous connective tissue, in particular collagen, 
striae are not restricted to classical EDS, but also occur in hypermobile EDS, vascular EDS 
and Marfan syndrome. 
 
2.2.10 Piezogenic papules (figure 4-4) 
Piezogenic papules are small, sometimes painful, reversible herniations of underlying adipose 
tissue globules through the fascia into the dermis, such as on medial and lateral aspects of the 
feet on standing. 
 
Figure 4-4 Piezogenic papules on lateral side of the foot 
 
 
(www.pediatricsconsultant)  
 
3. Joint hypermobility 
Joint hypermobility is common in classical EDS, just as it is in most other types, and will be 
dealt with specifically in chapter 5. Just as mentioned earlier for scarring and bruising 
assessments, a similar analogue scoring system exists for joint hypermobility. 
 
4. Other features 
Classical EDS is generally not characterized by vascular complications, though arterial 
rupture does occur.
7
 However, recently, a subtype of classical EDS has been identified which 
is clinically also characterized by a propensity to arterial rupture and molecularly - as it seems 
- by a specific mutation in COL1A1 (c.934C>T; p.R134C).
8,9,10
 For other features, like gastro-
intestinal, neurological, urological and gynaecological/obstetric: see the respective chapters 
10, 13, 16 and 17. 
 
5. Objective criteria for diagnosing classical EDS 
When the adapted scoring system of Beighton is used, the sum of the skin hyperextensibility 
score, the scarring and bruising score adds up with the hypermobility score (see table 2-3 of 
chapter 2). If this total score is > 7, further diagnostic procedures should start to confirm or 
reject the diagnosis of classical EDS.
1
 However, most clinicians will require the presence of 
the three major Villefranche criteria, i.e. skin hyperextensibility, dystrophic scarring and joint 
hypermobility, in order to establish the diagnosis classical EDS. In 2017 a new international 
classification of EDS has been published with new diagnostic criteria for the different EDS 
types, including classical EDS and with management related aspects of the different types.
11,12 
Minimal diagnostic criteria for classical EDS are the presence of skin hyperextensibility and 
atrophic scars, plus either generalized joint hypermobility and/or 3 minor criteria (see also 
chapter 2, table 2-5) 
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6. The laboratory diagnosis of classical EDS 
 
6.1 Histopathology of the skin. 
Skin biopsies of classical EDS may show minor increases of collagen/elastin ratios. 
Sometimes dermal collagen is more intensely stained and shows an irregular pattern.
11
 
However, diagnostically, it is of no use. 
 
6.2 Electron microscopy of the skin 
Ultrastructural examination of dermal collagen in classical EDS typically shows variable 
diameters of collagen bundles and irregular contours in cross-section, some showing flower-
like appearances.
13
 These changes are best visualised at a print magnification of 50-70,000. 
They are caused by longitudinal mispacking and unravelling of type I and III collagen fibres, 
which is the result of the faulty type V collagen. Haplo-insufficiency or other mutations of 
collagen type V have this effect. Cauliflower fibrils are a consistent feature of classical EDS, 
but are not specific for it, as they may be seen in other inherited defects of connective tissue 
as well, such as pseudoxanthoma elasticum (PXE), osteogenesis imperfecta, and scleredema 
adultorum of Buschke.
13
 Therefore, it is of very limited diagnostic use. 
 
6.3 Collagen protein and DNA analysis 
Collagen type V, which was first purified from placenta,
14
 is a typical fibrillar collagen, in 
which a central perfect uninterrupted triple helix, of general formula (Gly-X-Y)333, has both 
specific N- and C-terminal extensions.
15
 These fibrillar triple helices co-assemble in a so-
called quarter staggered format. Compound fibrils of for example types I, III and V collagen 
are formed in skin, whilst in the vitreous there are heterogeneous associations of collagens 
types II, Valpha2 and XIalpha1. Unlike collagens types I, II and III, which have small N- 
terminal extensions, those of type V collagen, coded by the COL5A1 and COL5A2 genes, are 
much larger. Collagen type V proteins form four different types of alpha chains, alpha1(V), 
alpha2(V), alpha3(V) and alpha4(V), of which the most common is, especially in the skin, a 
heterotrimer consisting of two alpha1(V) chains and one alpha2(V) chain. Whilst types I, III 
and V fibrils co-assemble, the N- terminus of type V collagen has a special role in regulating 
fibril growth, length and lateral associations. This has been convincingly demonstrated by 
Birk and colleagues, both in vivo and in vitro, in tissues such as skin, ligaments and cornea, in 
mice made haplo-insufficient for the equivalent mouse Col5a1 gene.
16
 Such animals had signs 
very similar to classical EDS in humans, with decreased tensile strength of normal or 
wounded skin and vasculature. The decreased dosage of collagen type V allowed the 
formation of both relatively normal and highly abnormal type I collagen fibrils. The latter was 
caused by faulty nucleation, lateral aggregation and longitudinal growth, resulting in the 
formation of abnormal rosettes, triggered by the unrestrained growth of type I collagen fibrils. 
This is caused by the absence of the restraining type V protein.
17
 Eyelids and corneal tissues
18
, 
in which type V collagen forms 10-20% of corneal collagens, were studied in the Col5a1 
mouse and compared to similar studies of defined human COL5A1 or COL5A2 mutants. In 
brief, affected patients had thin, steep and transparent corneas, with lax eyelids, blue sclerae, 
scleral fragility, microcornea, keratoconus, keratoglobus, ectopia lentis and retinal 
detachment. The mouse model showed significantly enlarged and distorted corneal collagen 
fibrils, however, less severely disrupted than dermal fibrils. 
The recognition that collagen type V mutations caused classical EDS lagged more than 20 
years behind similar discoveries of the role of collagen III in vascular EDS. Retrospectively, 
this was due to the rarity of collagen V protein abnormalities. Nevertheless in 1994
19
 a 
shortened alpha1(V) chain in a classical EDS (mitis) variant was discovered, which showed 
impressively disorganised collagen fibrils in dermis and various ligamentous tissues, as well 
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as corneal flattening.
18
 Later it became apparent that this was caused by a 54bp deletion 
leading to heterozygous skipping of exon 65 of the COL5A1 gene.
20
 Other mutations quickly 
followed, including a translocation, which interrupted the COL5A1 gene.
21
 Gene linkage 
confirmed that the COL5A1 gene is involved autosomal dominant classical EDS.
22,23
 At least 
one of the mutations of COL5A2, causing both , the gravis and mitis variants of classical 
EDS,
24,25
 showed deficiency of collagen alpha2 chains, in vitro. Later, haplo-insufficiency of 
COL5A1 gene dosage, caused by a variety of mechanisms,
26, 27
 proved to be the most common 
cause of EDS classical type. Furthermore, this caused a misdirection of collagen 
fibrillogenesis. Very occasionally, and rather puzzlingly
28
, homozygosity for a helical glycine 
mutation can also cause a mild form of classical EDS. A 2005 study of 48 patients with 
classical EDS, showed abnormal collagen protein profiles in only 2/48 (4.4%), whilst ten 
times as many (43%) were haplo-insufficient. In these 48 patients, 22 mutations of either 
COL5A1 or COL5A2 were detected, including 17 stop codons and 5 structural mutations of 
the types mentioned above. As three of the patients with a positive null allele test carried no 
detectable COL5A1 mutation, only 52% of classical EDS patients have detectable COL5A1 or 
COL5A2 defects.
29
 Ritelli et al. also found in 50% of their 40 cases a mutation in COL5A1 
(18) or COL5A2 (2).
30 
However, Symoens et al. detected in over 90% of patients, who fulfil 
all three major Villefranche criteria for classical EDS (n = 102), a defect in (products of) 
either COL5A1 (80) or COL5A2 (13).
31
 It remains to be seen whether other elements in 
fibrillogenesis, such as COL5A3, decorin, tenascin X, thrombospondin or unidentified 
extracellular matrix constituents contribute to the molecular pathology of classical EDS.  
The recently identified subtype of classical EDS which is clinically characterized by a 
propensity to arterial rupture, is caused - as mentioned earlier - by a specific mutation in 
COL1A1 (c.934C>T; p.R134C).
8,9,10 
 
7. Differential diagnosis 
Here we address only those inherited defects of connective tissue, in which cutaneous 
symptoms and signs predominate (see
32
). 
 
7.1 Tenascin-X (TNX) deficient EDS  
TNX deficient EDS is an autosomal recessive variant of classical EDS, named classical-like 
EDS (see chapter 2).
11
 Clinically it shows elastic, velvety skin, hypermobile joints and easy 
bruising, without abnormal wound healing or atrophic scars. In 3 of the 8 patients described, 
multiple subluxations were part of the clinical picture and in 2 cases joint pain was 
mentioned. Moreover, the patients were also reported to have a range of additional clinical 
problems not frequently associated with EDS, including spina bifida occulta, mitral-valve 
prolapse, stroke, gastrointestinal bleeding and premature arteriosclerosis. It is not clear 
whether these findings are related to the TNX deficiency. Skin biopsy shows both abnormal 
elastic fibres and reduced collagen deposition. TNX may contribute to matrix stability by 
interacting with other matrix components, such as proteoglycans. This might also regulate 
collagen fibrillogenesis.
33
 TNX is undetectable in serum in affected homozygotes, whilst it is 
50% of normal control levels in heterozygotes carriers of whom some had signs and 
symptoms of hypermobile EDS.  
 
7.2 Other similar EDS types 
Classical EDS must be distinguished from other EDS types, especially hypermobile EDS, 
with which there may be clinical overlap. Particularly in mild cases of classical EDS, 
hypermobile EDS can be difficult to distinguish.  
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7.3 The Occipital Horn syndrome 
The Occipital Horn syndrome is a very rare disorder of copper metabolism which, in the old 
Berlin classification of 1988, was included as a curious form of EDS, but it is no longer part 
of the EDS classification. It is an X-linked recessive syndrome. Clinical features include soft, 
mildly extensible, loose and redundant skin with easy bruisability, but without fragility. Other 
clinical signs include a persistent anterior fontanel, frequent loose stools, obstructive uropathy 
and mild mental retardation. Increased joint hypermobility may occur, except for the knee and 
elbow joints which show only limited extension. Radiologically, occipital horns, wedge 
shaped calcifications at the attachment sites of the trapezius and sternocleidomastoid muscles, 
are characteristic. It is caused by a mutation in the Cu(2+)-transporting ATPase, alpha 
polypeptide. The concentrations of copper and ceruloplasmin in serum are low and probably 
impair collagen cross-linking. 
 
7.4 Cutis Laxa 
Cutis Laxa (CL) refers to the redundant inelastic quality of the skin, which, in contrast to 
EDS- types, is not (hyper)elastic. Original descriptions of EDS often did not readily 
distinguish between the easily stretched skin of EDS and the ill-fitting, overstretched 
integument of true CL. Autosomal dominant and autosomal recessive as well as X-linked 
subtypes of primary CL, frequently seen with accompanying lung and aortic pathology, are 
caused by abnormalities of elastin or elastic microfibrils. Secondary CL complicates 
conditions such as PXE and EDS.  
 
7.5 Child abuse 
Child abuse is certainly included in the differential diagnosis of classical EDS. Not 
surprisingly, the predisposition to bruising and cutaneous damage sometimes raises this 
possibility. Similarly, EDS is included in the differential diagnosis of child abuse. Of course, 
it must be realised that EDS and child abuse are not necessarily mutually exclusive diagnoses.  
In distinguishing the one from the other, familiarity with the various clinical criteria included 
in the most recent classification is essential, as is a thorough family history, clinical 
examination and, where indicated, laboratory tests, such as electron microscopy, protein 
electrophoresis, metabolic analysis and DNA analysis. Similarly, there are very well 
established clinical criteria which deal with bruise distribution and morphology, and other 
accompanying clinical signs, likely to indicate child abuse.
34
  
For example, in child abuse, bruising mostly occurs over relatively protected sites of the skin 
(trunk, buttocks, genital area), while in traumas and in classical EDS and other types, the 
knees, the anterior tibial area and bony prominences are mostly affected.
35
  
 
8. Protection and preventative measures 
Here we focus mainly upon measures which protect the skin or promote cutaneous wound 
healing. For measures concerning other problems associated with classical EDS, one is 
referred to other chapters, like 10, 13, 16 and 17. Unfortunately, in the absence of specific 
therapy for classical EDS or any other type, only simple preventive measures to protect the 
skin are applicable. All are anecdotal, common sense measures, rather than evidence based 
upon appropriate clinical trials. 
 
8.1 Protection 
Particularly in younger children, protective bandages or pads applied at sites of repetitive 
trauma such as the forehead, elbows, knees and shins, can minimise wounds and lacerations. 
Older children might prefer protection by more fashionable sports devices, such as those used 
for knees, elbows and shins in skiing, skating or football rather than protection by medical 
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bandages. Head protection for certain contact sports or cycling is also desirable, whilst for 
games such as tennis and squash eye protection with fragmentation resistant goggles is 
desirable. 
At home the corners of tables and other furniture can be protected and the tables or other 
barriers should not be put in the centre of the room, in order to prevent trauma. 
Contact sports are to be discouraged. 
In case more specific advice is needed, one may consider rheologic evaluations of the skin 
(see 2.2.1), since these tests may detect patients with very vulnerable skin more reliably; it 
also may be used to predict the difficulty in suturing.
3
  
 
8.2 Bleeding prevention 
In case of bruising, a pressure bandage can be used, or elevation of the affected limb will help 
to prevent further cutaneous bleeding. In case of tooth extractions, surgery and a history of 
heavy bleeds, further bleeding and clotting tests are indicated and, if abnormal, measures can 
be taken, see chapter 11. 
 
8.3 Sun protection 
Skin thinning and increased fragility, together with reduced subcutaneous fat formation, is 
part of normal ageing. Although this occurs also in sun protected areas, it is especially evident 
in sun-exposed areas. Sunlight damages the epidermis, leading to a higher risk of skin 
tumours, but also damages the dermis. In the latter, it causes loss of elasticity in elastic fibres 
(elastosis). Also sunlight causes collagen-fibres to decrease and degenerate. This effect is 
magnified in classical and other EDS types, in which the underlying collagen is already 
abnormal. Sun protection is therefore particularly important in EDS patients.  
 
8.4 Smoking 
Smoking is also associated with elastosis (see 7.3) among both sexes,
36
 so it is wise to refrain 
from smoking in case of EDS. 
 
8.5 Medication 
Suggestions made in the literature that the use of 1-2 grams of ascorbic acid (vitamin C) a day 
may promote collagen synthesis, thereby assisting collagen repair and wound healing or even 
reduce vascular fragility, should be regarded as unproven. 
Generally avoiding aspirin (acetylsalicylic acid) or non-steroidals such as ibuprofen, all of 
which enhance bleeding and bruising due to their negative effect on platelet function, is 
sensible. Similarly, skin atrophy as adverse effect of chronic inhaled or systemic 
glucocorticoid treatment is more outspoken in EDS than in otherwise normal individuals. 
 
9. Surgical advice 
All surgical procedures have additional risks in classical EDS, since the skin is fragile: it heals 
slowly and sutures are more damaging and less stable than in normal skin. Specific advice on 
how to treat wounds is given in the addendum on surgery. Bearing these facts in mind, major 
elective surgery can be surprisingly uncomplicated. This contrasts with vascular EDS, in 
which the repair of hollow organs and vascular anastomoses can be very problematic. 
Procedures such as dermabrasion or skin filling are probably contraindicated and laser 
treatment carries the risk of hypertrophic scarring. See also the addendum. 
 
 
 
 
Chapter 456
 
 
10. Areas of uncertainty 
 
10.1 Absence of inferior labial or lingual frenulum 
As the labial and lingual frenula consist mainly of ligament-like connective tissue structures, 
the morphology of these structures has been examined in EDS.
37
 Opinions vary as to whether 
the fraenum of the lower lip and the sublingual frenulum are missing in classical EDS. 
37,38,39
 
Further studies are required to resolve these disparities.  
Previously, a positive Gorlin sign was regarded as common in EDS. The sign is positive when 
the tip of the nose can be touched by the tip of the tongue.
40
 Presently, its exact frequency in 
classical EDS is unclear and further studies are needed. 
 
10.2 Knowledge of the aetiology 
As described earlier in section 6, mutations of COL5A1 or COL5A2 explain 50 to over 90% of 
classical EDS. It remains to be seen which other matrix genes and proteins are involved in the 
remainder of the patients.  
 
10.3 Treatment possibilities 
So far, no double blinded, placebo controlled trials have been done to test the efficacy of 
substances such as ascorbic acid, glucosamine, Coenzyme Q10, pycnogenol and may be 
others.
41
 Because the expected effect will most probably be not too big, multicentre trials of 
adequate numbers of EDS patients would be necessary to prove therapeutic efficacy.  
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1. Introduction 
Joint hypermobility is defined as an increased range of movement in one or more joints. 
When many joints are hypermobile in an individual, we speak of generalised joint 
hypermobility, a relatively common condition. There are several classification criteria and 
scores sets for this physical trait - scores of Beighton and Bulbena are presented in chapter 
2;
1,2
 classification criteria are discussed in other paragraphs.
3
 While the Beighton score is 
limited to the assessment of the range of motion of a pre-determined set of joints/groups of 
joints, the Bulbena score also scores ecchymosis. For this reason, the Beighton score is now 
considered the most appropriate tool for assessing generalised joint hypermobility in adults 
and children, though with different cut-offs.
4
 The adjective “generalised” implies that joint 
hypermobility is present at multiple sites, but distribution and extent of joint hypermobility 
are quite variable and influenced by constitutional and acquired factors. A scoring system 
ideally accounting for all variables has not yet been developed and scoring with available 
tools is influenced by the practitioner’s experience. 
Individuals with (generalised) joint hypermobility may be asymptomatic. Often, however, 
joint hypermobility is accompanied by musculoskeletal symptoms such as pain in joints, 
ligaments, entheses (attachment sites of tendons or ligaments to the bone) and muscles - this 
may be referred to as symptomatic joint hypermobility. In addition, (generalised) joint 
hypermobility can be associated with a wider spectrum of symptoms and signs reflecting 
involvement of other tissues, organs, and organ systems, attributable to the pleiotropic nature 
of underlying defects. In such cases the term “joint hypermobility syndromes” seems 
appropriate. The term “syndrome” refers to group of signs and symptoms recurring in 
association and defining a cluster of clinical relevance, known or thought to be causally 
(etiologically) related. Joint hypermobility syndromes are conditions with a strong genetic 
basis, in which (generalised) joint hypermobility is the shared congenital trait. 
Although many individuals with (generalised) joint hypermobility do not stand out clinically, 
and do not meet criteria of a specific syndrome, others meet criteria of a specific defined 
syndrome, potentially associated with chronic disabilities or life-threatening complications. 
This makes it important not to overlook these diagnoses. 
The aim of this chapter is to provide the rheumatologist and other health professionals an 
overview of the broad spectrum of symptomatic joint hypermobility and joint hypermobility 
syndromes they may be confronted with, as guidance in daily practice. Clinical aspects, with 
emphasis on musculoskeletal problems, are described and clues for diagnosis and 
management are provided. 
 
2. Epidemiological aspects 
Generalised joint hypermobility may actually be a variant of normal joint mobility, along the 
upper tail of the Gaussian curve describing the range of motion of normal joints in the 
population, just as individuals can be short or tall. In general, the range of motion of most 
joints and thus the chance of observing generalised joint hypermobility decreases with 
increasing age. Generalised joint hypermobility is more common in females than males and 
occurs more often in some racial groups, e.g. Asians when compared to Caucasians.
5
 Many 
healthy young individuals, especially females performing ballet or gymnastics, would 
probably meet the criteria of generalised joint hypermobility according to the Beighton set, if 
they were screened. In some sports, generalised joint hypermobility may be an advantage, but 
it may also be a liability due to the increased risk of injuries.
6,7
 Reassuringly, a study among 
professional dancers concluded that generalised joint hypermobility was not associated with a 
higher risk of injuries when assessed prospectively.
8
 However, this observation does not rule 
out an increased risk of injury associated with generalised joint hypermobility in the (less 
trained) general population. In fact, those more prone to injuries may have fallen short of a 
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desired professional sports career. 
People presenting for medical care with symptomatic joint hypermobility are most probably a 
subgroup of those with generalised joint hypermobility in the population. Furthermore, not all 
cases of this subgroup will meet criteria of available scoring systems for generalised joint 
hypermobility. An even smaller number will meet criteria for a specific joint hypermobility 
syndrome, such as Ehlers-Danlos syndrome (EDS), a group of syndromes with as key features 
multi-site joint hypermobility, abnormal skin texture and a variable range of dysfunctions or 
fragility of vessels and internal organs. A description of all EDS types is beyond the scope of 
this chapter. 
Exact prevalence estimates for EDS are difficult to make for two main reasons. First, there is 
the problem of recognition: not all individuals with joint hypermobility have relevant 
symptoms and reach medical attention. If generalised joint hypermobility is borderline and 
skin manifestations are mild, they might stay unrecognized. As a consequence, estimates on 
the prevalence of EDS types depend on whether they are based on clinical reports of the 
syndromes or on screening studies in populations and, in this case, on methodological 
properties of screening methods. In the latter case, the prevalence estimates will be probably 
more accurate and higher. A study in a general dermatology population revealed that common 
variants (phenotypes, see chapter 2) of EDS might be present in up to 9% of this population.
9
 
Second, there is the problem of older and current classifications: significant overlap exists 
between the signs, symptoms and classification criteria of hypermobile EDS and those of the 
benign joint hypermobility syndrome (BJHS),
10
 both of which may show familial aggregation. 
In the past, the presence of generalised joint hypermobility and its secondary musculoskeletal 
manifestations was thought sufficient for defining a “genetic syndrome”; e.g. BJHS may be 
diagnosed, if a Beighton score ≥4 and joint pain at multiple sites (i.e. the two major Brighton 
criteria) are present. But, familial clustering of generalised joint hypermobility (either 
symptomatic or not) is not always the marker of a hereditary syndrome affecting multiple soft 
connective tissues. This was in 2016 the rationale to mend the double, overlapping 
terminologies and keep a single syndromic entity (i.e. hypermobile EDS), which would define 
only patients with a likely multisystem disorder. Alternative names (not including the term 
“syndrome”) should be preferably used for patients showing symptomatic generalised joint 
hypermobility, but not meeting the criteria for hypermobile EDS or any other partially 
overlapping hereditary soft connective tissue disorder. Recently, the term “hypermobility 
spectrum disorders” has been proposed as an exclusion diagnosis for those individuals who 
show some range of joint hypermobility and related musculoskeletal complaints, but who do 
not meet the criteria for presently defined joint hypermobility syndromes, including 
hypermobile EDS.
11
 
The prevalence of what was classed as generalised joint hypermobility was estimated to range 
from 10–30% in adults, varying from 10-15% in male youngsters between 11–17 years and up 
to 20–40% in girls of this age group,
12
 which seem high percentages. The prevalence of EDS 
is probably higher than the current estimate of 1: 5,000,
13
 although the most recent and stricter 
criteria for hypermobile EDS will impact such an assumption. 
 
3. General symptoms, signs and complications of generalised joint hypermobility and 
joint hypermobility syndromes 
Patients with symptomatic generalised joint hypermobility may share many clinical 
characteristics, typically including chronic musculoskeletal pain, fatigue, signs of autonomic 
dysfunction, functional gastro-intestinal manifestations and joint (sub)luxation. Pain and 
fatigue are the dominant symptoms. In the following section, we discuss the most prevalent 
symptoms and signs the clinician and health professional are confronted with, and their 
associations. Among these general symptoms, the non-musculoskeletal functional ones (e.g. 
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fatigue, cardiovascular dysautonomia, gastrointestinal motility issues) are now termed as 
“joint hypermobility-related co-morbidities”.
11
 Joint hypermobility-related co-morbidities 
may be common in individuals with non-syndromic, symptomatic joint hypermobility (i.e. 
hypermobility spectrum disorders) as well as in the various joint hypermobility syndromes. 
Hence, joint hypermobility-related co-morbidities are not specific enough for etiological or 
nosologic discrimination, although their assessment is crucial for prognostication and 
management. 
 
3.1 Pain 
There is an increased prevalence of arthralgia (joint pain), chronic generalised myalgia and 
fibromyalgia (chronic generalised pain in muscles and joints) in children and adults with 
generalised joint hypermobility.
5,10,14-20
 In adults, joint hypermobility is also associated with 
back pain.
18,21
 Perhaps surprisingly, the basis of the association of joint hypermobility and 
pain is not established. The most consensual view is that pain is due to repetitive strain, sprain 
and microtraumas of muscles and ligaments by the abnormal range-of-motion permitted by 
hypermobile joints, aggravated by diminished joint proprioception, position sense,
22-24
 and 
decreased passive muscle tension.
25
 Pain is also related with anxiety and depression, both of 
which seem to be more prevalent in EDS, especially hypermobile EDS, as well as in the 
former BJHS.
26-28
 It is commonly believed that chronic pain elicits depressive feelings and 
that depression has an amplifying effect on chronic pain and fatigue, leading to a vicious 
circle. These latter symptoms could lead to reduced physical activity and thus physical 
deconditioning (reduced physical condition), increasing the propensity to injury, chronic pain 
and fatigue and initiating a downward negative spiral.  
Furthermore, there seems to be a primary involvement of muscle in hypermobile EDS: muscle 
weakness has been found in the absence of reduced muscles mass, which would have been 
present if muscle weakness was the results of reduced physical activity only.
29
 A hypothetic 
model of pain, including fatigue and physical deconditioning is depicted in figure 5-1. 
 
3.1.1 Insufficient effect of local analgesics 
An insufficient effect of local analgesics either by intradermal injection or as topical cream 
application has been reported in patients with hypermobile EDS. A similar ineffectiveness has 
been observed in patients with generalised joint hypermobility.
30
 This was thought to be due 
to the lax connective tissues in the skin allowing too much dispersal of the analgesic.
31,32
 
However, the dispersal of a radioisotope labelled solution following deep dermal injection did 
not differ between EDS patients and healthy controls in a small study.
33
 So, the reason for the 
insufficient effect of local analgesics is not yet known.  
 
3.2 Fatigue 
Generalised joint hypermobility syndromes, particularly hypermobile EDS, are associated 
with increased fatigue.
34-36
 A hypothesis is that fatigue is a symptom of autonomic 
dysfunction or dysautonomia, described below.
35,36
 Others suggest that the ligamentous laxity 
demands increased vigilance, muscle tension and coordination to maintain adequate joint 
position and body balance,
24,37,38
 thus leading to fatigue. In addition, these patients often show 
muscle weakness,
29
 reduced exercise tolerance, physical deconditioning and pulmonary 
symptoms (see below),
39
 commonly attributed to reduced exercise because of chronic pain 
(figure 5-1). Finally, fatigue could be associated with depression and other psychological 
problems associated with generalised joint hypermobility.
36,40
 Most probably, fatigue is 
caused by a constellation of these factors, of which the individual impact will vary between 
patients.  
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Figure 5-1 Vicious circle in generalised hypermobility of chronic pain and fatigue 
 
 
Via several mechanisms, pain and chronic fatigue may ensue, leading to less physical 
exercise. This leads to physical deconditioning, associated with chronic pain and fatigue, and 
a vicious circle. The way to break this vicious circle and often downward spiral is to prevent 
or treat (further) physical deconditioning by daily physical training (exercises). Not all 
features have to be clearly present in all patients. 
 
Fatigue and generalised pain are paramount among the symptoms that establish a clinical 
similarity and diagnostic confusion between joint hypermobility syndromes and 
fibromyalgia
14-17,41
. Some authors even argue whether fibromyalgia is merely a description of 
the symptoms of EDS or a separate disease entity in these patients.
14-17
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3.3 Autonomic dysfunction 
Autonomic dysfunction comprises disturbances in a variety of functions dependent on the 
autonomic nervous system, leading for instance to orthostatic hypotension or tachycardia, 
leading to (pre)syncope and palpitations. Such symptoms have been reported in higher than 
expected frequency in patients with BJHS and EDS.
35,36
 Lower urinary tract dysfunction 
associated with generalised joint hypermobility might also be related to autonomic 
dysfunction, alongside laxity of the connective tissue of the pelvic floor and the sphincter.
42,43
 
Gastro-intestinal disturbances, such as gastro-oesophageal reflux, constipation and irritable 
bowel syndrome or malabsorption, are more common in BJHS and EDS, and might share a 
similar pathophysiology.
44
 The prevalence of both urinary and faecal incontinence has been 
described as significantly higher in women with joint hypermobility syndromes than in 
women without these conditions.
42,43,45-48
 
 
3.4 Joint (sub)luxation 
Joint luxation or subluxation are not specific features of generalised joint hypermobility and 
generalised joint hypermobility syndromes. Probably (sub)luxation reflects the severity of the 
joint laxity and impaired local muscle strength and coordination. If (sub)luxation occurs 
frequently in a specific joint, this often becomes less painful and sometimes (sub)luxation can 
be demonstrated by the patient on request.  
 
3.5 Decreased bone mass and increased risk of fractures 
In EDS and Marfan syndrome, a higher prevalence of low bone mineral density, osteopenia or 
osteoporosis are reported in most studies,
49-53
 but not all.
54
 In a study with 23 patients with 
hypermobile EDS and 23 matched controls, EDS subjects had a significantly lower bone 
mineral density at the femoral neck, but this difference disappeared after adjustment for body 
height, weight and physical activity levels.
55
 Thus, reduced exercise or immobility induced by 
generalised joint hypermobility may be important in determining osteopenia, probably in 
association with the inherited structural deficit. Furthermore, an increased incidence of falls 
(and thus increased risk of fractures) has been reported in hypermobile EDS,
38
 due to 
impaired balance and muscle weakness. This might be at least partially preventable by 
appropriate exercise programs. Early-onset osteoporosis and increased risk of fractures are 
features of rare EDS types with marked bone involvement, such as the EDS/osteogenesis 
imperfecta overlap.  
 
3.6 Osteoarthritis 
A relationship between joint hypermobility syndromes and osteoarthritis would be expected 
especially as long-term complication in patients with frequent (sub)luxations. However, the 
literature data are equivocal: while some papers describe a relation between joint 
hypermobility and osteoarthritis
56,57
, others even indicate an inverse relation.
54,58,59
 
 
3.7 Life-threatening manifestations and complications 
Some specific joint hypermobility syndromes, e.g. vascular EDS, Marfan syndrome and 
Loeys-Dietz syndromes may have life-threatening manifestations, such as aneurysms and 
arterial ruptures. Next to vascular complications, life-threatening ruptures of the bowel and of 
the pregnant uterus are also manifestations of vascular EDS.
60,61
 Fortunately, these 
manifestations or complications do not happen in the more frequently occurring joint 
hypermobility syndromes. 
 
4. Classification into a specific joint hypermobility syndrome 
For some of the joint hypermobility syndromes, the diagnosis can be made early based on 
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evident signs and symptoms, although because of profound muscle hypotonia, patients 
initially are suspected of having a muscle disorder. However, more frequently, the clinician 
will be faced with previously undiagnosed generalised joint hypermobility in a patient 
presenting with symptoms; in such cases, it most often concerns hypermobile EDS.
62
 More 
rarely, such patients may present with another syndrome, such as classical EDS, Marfan 
syndrome or vascular EDS (yet without clear vascular complications). 
So, the first and most important step in eliciting such diagnosis is awareness of the broad 
spectrum of joint hypermobility syndromes. 
Would classification of such cases into a specific syndrome be clinically important? And, if 
so, how could we best do that? 
 
4.1 Why classify generalised joint hypermobility? 
It is important to identify and classify generalised joint hypermobility, not only to optimise 
management, but also because some syndromes are associated with life-threatening risks 
outside the musculoskeletal system, as described above. Although these diseases cannot be 
cured and complications cannot be totally prevented, awareness and appropriate measures will 
diminish the risks of such events. For patients with these severe disorders, family planning 
and management are also indicated.  
 
4.2 How to go about classification? 
Clinical diagnosis was in the past, for most of the syndromes, based on clinical recognition of 
reported symptoms and signs at physical exam, but nowadays the diagnosis of most 
syndromes is supported by molecular testing, which is especially important for syndromes 
with life-threatening risks, like vascular EDS, Marfan syndrome and Loeys-Dietz syndromes. 
Hence, a formal diagnosis of a recognized syndrome with joint hypermobility should be 
always supported by a positive molecular testing and/or strict adherence to available 
diagnostic criteria. The hypermobile EDS, presumably the most common clinical variant of 
EDS, still remains without any confirmatory molecular testing. In order to support clinicians 
in the assessment of this condition, the most recent classification of EDS includes a detailed 
description of the procedural diagnostics and stricter diagnostic criteria for the hypermobile 
EDS (see chapter 2),
3 
compared to the former classification of EDS hypermobility type. 
For nomenclature, it is recommended that specific joint hypermobility syndromes are only 
diagnosed or referred to if published classification criteria are satisfied. Patients who do not 
satisfy such classification criteria should be described simply as having generalised joint 
hypermobility, no specific syndrome or hypermobility spectrum disorders, according to the 
most recent EDS classification. Clinicians should refrain from using supposed synonyms for 
specific syndromes, composed of various combinations of terms ‘benign’, ‘familial’, 
‘generalised’, ‘articular’, ‘joint’, ‘hypermobility’ and ‘syndrome’, leading to abbreviations 
like AHS, BFHS, BHS, BJHS, BJFHS, FAH, FGAH, FHS, JHS and HS. Such terms do not 
correspond to distinctive features and their use adds to confusion. Given the overlap of former 
EDS hypermobility type and BJHS, many clinicians considered these two disorders one and 
the same, sometimes referred to with the acronym (B)JHS/ EDSht. This approach has been 
demonstrated realistic in familial cases with a convincing Mendelian pattern of inheritance, 
although doubts still remain for sporadic/simplex cases. 
 
5. Specific hypermobility syndromes presenting to the clinician 
It can be challenging to classify a patient with generalised joint hypermobility. Note that 
specific joint hypermobility syndromes differ most in the non-musculoskeletal symptoms and 
signs. In fact, if such non-musculoskeletal symptoms and signs are absent or scarce, clinical 
classification is difficult given that the skeletal manifestations are very similar. In the face of 
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such uncertainty, it is important to remind what the key objective is: to make sure that 
syndromes with a high risk of life threatening, especially vascular, complications are not 
overlooked.  
Pattern recognition and evaluation of discriminating features (table 5-1) help making the right 
diagnosis. Important clues come from the patient’s history. For example, uncomplicated 
bowel and vascular surgery and uncomplicated vaginal delivery are arguments against 
vascular EDS, even if they do not exclude this diagnosis completely.
63,64
 Specific 
discriminating signs or symptoms include the specific physique (phenotype) and lens 
dislocations in Marfan syndrome and the appearance of the skin,
65,66
 for instance in EDS. A 
family history of people dying relatively young of cardio-vascular complications, especially 
vascular ruptures, are clues for vascular EDS, the related Loeys-Dietz syndromes and Marfan 
syndrome. 
 
5.1 Joint hypermobility syndromes with potentially life-threatening complications 
Recognizing these conditions early in their course is important, as they lead to chronic 
disabilities with loss of many working days, force patients to multiple consultations and a 
myriad of ineffective therapies, and decrease quality of life. This is especially true for joint 
hypermobility syndromes with potentially life-threatening complications. These include 
vascular EDS, Loeys-Dietz syndrome,
67,68
 and Marfan syndrome. 
 
Vascular EDS is associated with a severe prognosis: patients often die prematurely from 
rupture of arteries and/or hollow organs, such as intestines and uterus during pregnancy.
69
 The 
typical phenotype consists of thin and translucent skin, showing underling veins, giving 
especially the hands an aged appearance (‘acrogeria’, see figure 5-2) and nonspecific 
dysmorphic features of the face. However, typical features may be absent. 
 
Figure 5-2 Acrogeria in a 32-year old woman with vascular EDS: the hand looks much older 
than the patient really is 
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The family history may reveal cases of ruptures of arteries and/or hollow organs, but the 
presenting patient could also be the only one in the family with vascular EDS, due to a novel 
point-mutation in the COL3A1 gene. So, making a clinical diagnosis is not always easy; 
luckily there are genetic tests for this EDS type. 
Measures to prevent complications are possible, including life-style measures: avoiding sports 
with risk of trauma and with elevations of blood pressure, stop smoking, meticulous 
monitoring and control of blood pressure to low-normal values. In a study of 5-years duration, 
therapy with the beta-blocker celiprolol prevented major complications in patients with 
vascular EDS, compared to EDS patients randomly assigned no drug therapy.
70,71
 
 
The phenotype of Loeys-Dietz syndromes partially overlaps that of vascular EDS (vascular 
ruptures and extensive easy bruising) and of Marfan syndrome (aortic aneurysm/dissection, 
dolichostenomelia and arachnodactyly). The syndrome is caused by TGFBR1, TGFBR2, 
TGFB2, TGFB3 and SMAD3 mutations. TGFBR1 or TGFBR2 mutations are in the genes 
encoding for transforming growth factor β receptor type 1 or type 2, respectively. 
Transforming growth factor β is a cytokine that exerts diverse roles in cell proliferation and 
differentiation, apoptosis (programmed cell death), and extracellular matrix formation.
72
 
Patients with TGFBR1 or TGFBR2 tend to have aortic dissections at smaller aortic-root 
diameters compared to patients with Marfan syndrome, but compared to patients with 
vascular EDS , outcomes after aortic surgery are better.
68,73
 Patients with a mutation in the 
SMAD3 gene, next to vascular complications, have osteoarthritis at a relatively young age.
74
 
Patients with mutations in TGFB2 and TGFB3 are at the moment phenotypically not 
distinguishable from those with mutations in TGFBR1 and TGFBR2.  
 
Marfan syndrome is an autosomal dominant hereditary connective tissue disorder with a 
prevalence of about 1:5000; about 25% of the cases is caused by a new mutation.
72,75
 The 
1996 Ghent criteria for diagnosis of Marfan syndrome
76
 have been updated in 2010,
77
 and 
include involvement of the skeletal system (generalised hypermobility and marfanoid habitus), 
of the ocular system (lens dislocation), the cardiovascular system (increase aortic diameter or 
dissection), results of genetic testing and the skin.
78
 However, among individual patients, 
considerable heterogeneity of phenotype, signs and symptoms is present.
72
  
Genetic testing of Marfan is directed at finding a causative mutation in the FBN1 gene, 
encoding the structural protein fibrillin-1. Less than 10% of patients fulfilling the revised 
Ghent criteria for Marfan syndrome have no mutation in this gene. The angiotensin II receptor 
blocker losartan seems to inhibit progressive aortic root dilation in patients with Marfan 
syndrome.
75,79
  
 
5.2 Stickler syndrome  
Stickler syndrome (hereditary progressive arthro-ophthalmopathy) is another likely under-
recognized hereditary connective tissue disorder which may show generalised joint 
hypermobility. It shares a leptosomic/dolichostenomelic habitus with Marfan syndrome and 
joint pain/arthralgia with EDS. However, skin laxity and severe vascular complications are 
not features of this syndrome (table 5-2).
80,81
 It is usually distinguished by the typical facial 
features, cleft palate, severe and early-onset myopia, and deafness. Although typical cases 
may be recognized at a young age, the diagnosis often is delayed due to the variability of the 
phenotype.
82
 Different variants of Stickler syndrome exist, distinguishable by the 
presence/absence of key clinical features and/or inheritance pattern.
83
 Genetic testing of the 
COL2A1, COL11A1, COL11A2, COL9A1, COL9A2, COL9A3 and LOXL3 genes can confirm 
the clinical diagnosis.  
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6. Principles of management of musculoskeletal problems in patients with symptomatic 
joint hypermobility and joint hypermobility syndromes 
Although there are no randomized controlled studies regarding the effects of existing 
treatments for musculoskeletal problems in patients with symptomatic hypermobility, this 
does not mean that certain therapeutic strategies could not be helpful.
84
 They are mentioned 
only briefly below. 
 
6.1 Education is the first step after the diagnosis. It should tackle the feelings of frustration 
with misunderstanding of the complaints by the medical profession and social entourage, 
often during many years;
85
 and the frustration about the absence of clear physical signs and 
laboratory abnormalities. It also comprises life-style advices (e.g. on rest, sleep hygiene, 
activities, prevention of trauma and of overweight), directions on self-help, redirecting false 
cognitions and other cognitive-behavioural strategies, coping, improving patient self-esteem 
and self-efficacy, genetic counselling. 
 
6.2 Physical therapy and daily exercises at home should be performed: toning exercises for 
stabilization of joints, exercises improving proprioception, exercises diminishing physical 
deconditioning (figure 5-1) and improving posture. Heavy resistance training seems feasible 
and effective in classical EDS patients, improving tendon and skeletal muscle properties.
86
 In 
patients with osteoarthritis of the hip or knee (without a joint hypermobility syndrome) 
exercise therapy has demonstrated efficacy in reducing pain and disability;
87
 in hypermobile 
children also a beneficial effect of physiotherapy on pain was found.
88
 It seems prudent to 
advice exercises to improve muscle strength and proprioception of joints, although in patients 
with joint hypermobility syndromes there is lack of data.
89
 The prospective study showing no 
relationship between joint hypermobility and injury in dancers,
8
 who often have a trained 
body, could also be an argument for exercises. There seems to be no contra-indication against 
prudent stretching exercises, but prolonged joint hyperextension, e.g. standing with 
hyperextended knees, should be avoided. 
Modalities like heat or cold application, electrical stimulation to alleviate pain, acupuncture, 
acupressure, biofeedback, yoga and conscious relaxation are not evidence-based, but might 
have a beneficial effect on pain in some patients. 
It seems prudent to advise weight-bearing exercises for the long bones and spine and an 
adequate intake of calcium and vitamin D in patients with symptomatic joint hypermobility, 
to prevent fractures. 
 
6.3 Adaptations and assistive devices (braces, grasps, waterbed, mattress, wheelchair, 
electric scooter), adapted shoes, adaptations to living and working environment could all have 
a place in the management strategy. Care should be put in avoiding that adaptations and 
assistive devices lead to less physical exercises or activities, as this could potentially be 
harmful by increasing physical deconditioning and ensuing complaints. However, adaptations 
and assistive devices may lead to increased activities and there can be medical and social 
reasons to prescribe them. 
 
6.4 Drugs, such as medications for pain, disturbed sleep, depression and fatigue could have a 
place in the management of selected patients with symptomatic hypermobility. However, in 
chronic diseases, these drugs usually only have a mild, often temporarily symptomatic effect. 
Apart from treating hypertension, which is always necessary, in Marfan syndrome losartan 
has a place and celiprolol in vascular EDS,
71
 to diminish the risk of vascular complications. 
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6.5 Surgical procedures on joints should be avoided, if possible. For example, in patients 
with joint hypermobility and repetitive luxation of the shoulder, surgery often is ineffective, 
according to clinical experience. 
 
7. Areas of uncertainty 
The exact incidence of most of the joint hypermobility syndromes is not known. Possibly 
specific (types of) joint hypermobility syndromes are genetically based on different genetic 
defects; most new types of EDS have been recognized on the basis of genetic defects over the 
past years. Although specific drugs have been shown beneficial in Marfan syndrome and 
vascular EDS, it has not been investigated whether (other) antihypertensive medications 
would have a similar effect. Although scarce literature data indicate a beneficial effect of 
physiotherapy and exercises, the real long-term effect is not known, nor the effects, pros and 
cons of specific physiotherapeutic modalities. 
 
8. Summary 
Symptomatic joint hypermobility is a frequent occurring condition among patients referred to 
the rheumatologist or seen by other health care professionals. In a subset of patients, a further 
classifying diagnosis of a specific syndrome can (and should) be made, based on pattern 
recognition and knowledge of the spectrum of hypermobility syndromes. Diagnostic clues are 
the patient’s and family history and signs at physical examination, including skin 
abnormalities. It is especially important to recognize hypermobility syndromes with 
potentially life threatening complications. Genetic testing is available for many syndromes 
and is now indicated to confirm/exclude the diagnosis in most circumstances. Referral to a 
specialized centre for diagnosis and long-term management is recommended.  
The therapy is for the major part of conditions featuring joint hypermobility only 
symptomatic; key features of management are education and physical exercises; joint surgery 
is to be avoided. 
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Table 5-1 Classification of generalised joint hypermobility syndromes* 
 
Classification Possibly distinguishing feature(s) 
Generalised joint hypermobility, no 
specific syndrome 
None, associated/secondary musculoskeletal 
manifestations only 
Ehlers-Danlos syndromes * Abnormal skin texture, fragility and/or 
dysfunctions of internal organs and vessels, 
additional features by EDS type 
Osteogenesis imperfecta Liability to fractures, intensely blue sclera, bone 
deformities, dentinogenesis imperfecta, deafness 
Loeys-Dietz syndromes Vascular tortuosity and dissections, progressive 
aortic dilatation, facial dysmorphism, 
dolichostenomelia, arachnodactyly 
Stickler syndrome Early-onset myopia, vitreous degeneration, 
deafness, facial dysmorphism, cleft palate, 
spondyloepiphyseal dysplasia 
Marfan syndrome Progressive aortic dilatation, lens dislocation, 
dolichostenomelia, arachnodactyly 
 
 
* not comprehensive; see related chapters 
 
Chapter 572
 
 
Table 5-2 Involved organ systems with their manifestations in Stickler syndrome* 
81
 
 
• Orofacial abnormalities: 
o cleft palate (open cleft, submucous cleft, or bifid uvula), highly arched palate 
o characteristic face (malar / midfacial hypoplasia, broad and/ or flat nasal 
bridge, micro / retrognathia) 
 
• Ocular abnormalities: vitreous and retinal degeneration (lattice degeneration, retinal 
hole, detachment or tear), high myopia 
 
• Auditory abnormalities: 
o high frequency (4–8 kHz) sensorineural hearing loss: at age<20: ≥ 20 dB, at 
age 20–40: ≥ 30 dB and at age >40: ≥ 40 dB  
o hypermobile tympanic membranes 
 
• Skeletal abnormalities and symptoms: 
o generalised joint hypermobility 
o chronic musculoskeletal pain 
o femoral head disorders (slipped epiphysis or Legg–Perthes-like disease) 
o radiographically demonstrated osteoarthritis before age 40 
o scoliosis, spondylolisthesis, or Scheuermann-like kyphotic deformity 
o mild spondyloepiphyseal dysplasia 
o pectus excavatum or carinatum 
 
 
* This list is by no means exhaustive; there is variable intra- and interfamilial heterogeneity in the 
involvement of these organ systems 
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1. Introduction and historical perspective 
Although first described as a form of Cutis Laxa in 1892 by Tschernogobov, Ehlers-Danlos 
syndrome (EDS) vascular type was later recognized as autosomal dominantly inherited by 
Weiner in 1924 and finally categorized as a specific disorder of connective tissue by 
McKusick in 1956. A single patient with a vascular EDS phenotype was also clearly 
described by Sack (1936); the disorder was more formally defined by Barabas, as a separate 
type in 1967.
1
 He recognized that the combination of extensive easy bruising and bleeding 
was associated with potentially lethal arterial fragility. Barabas and then Beighton (1968), 
almost simultaneously, proposed three or four distinctive types,
2
 followed by McKusick’s 
1972 proposal of 5 types including the rare X-linked form first recognized by Beighton.
3 
Later 
this was followed by the Berlin (1988), the Villefranche nosologies (1997), and then the 2017 
International classification.
4,5,6
 Similarly, the nosology of vascular EDS has varied, including 
terms such as EDS IV, EDS vascular type, acrogeria and ecchymotic EDS. As regards the role 
of defective connective tissue, by 1955, Jansen suggested that a genetic defect of the collagen 
“wickerwork” of the connective tissue would explain the mutant phenotypes.
7
 In 1975, Pope 
et al. described type III collagen deficiency in the aorta and skin of three patients, including a 
teenage boy with “acrogeric EDS type IV”, who had died of a dissecting subclavian aneurysm 
and ruptured aorta.
8
 The family and biochemical data strongly suggested that the defect was a 
homozygous deficiency of procollagen type III.
9
 Later, Byers et al. (1981) confirmed that, 
although procollagen type III secretion was indeed diminished, there also was intracellular 
accumulation, due to altered post-translational modification.
10
 Furthermore, in common with 
COL1A1 and COL1A2 defects, this phenomenon became explicable by the dominant-negative 
effect of single mutations upon triple-helical assembly.
11
 The first COL3A1 mutations were 
published in 1989 by Superti-Furga et al.
12 
A very recent review on vascular EDS was 
published by Byers et al.
13
  
 
2. Epidemiology 
The prevalence of vascular EDS has been estimated at 1/50.000 to 1/150.000.
14
 Actually, the 
true rate is unknown and estimates based on ascertained cases might be serious 
underestimates of the prevalence in the population. Vascular EDS has been estimated to 
account for 5-10% of the six Villefranche classified EDS types.
15
  
 
3. Clinical presentation 
Vascular EDS (old designation EDS vascular type or type IV) is a member of the so-called 
inherited defects of connective tissue diseases family, which include disorders such as Marfan 
Syndrome, osteogenesis imperfecta, cutis laxa, pseudoxanthoma elasticum and EDS. Unlike 
other forms of EDS, the skin hyperextensibility and joint hypermobility in vascular EDS are 
variable, often being mild or even absent. In 1997, a medical advisory group sponsored by the 
Ehlers-Danlos Foundation (USA) and the Ehlers-Danlos support group (UK) defined at 
Villefranche a modified set of diagnostic criteria which refined the previous Berlin 
classification, and more clearly distinguished the various EDS types.
4
 In this Villefranche 
nosology, the clinical categorization of vascular EDS is based on four major criteria: (1) a 
characteristic facial aspect (Madonna facies, see below) (2) thin and translucent skin with 
visible subcutaneous veins, (3) easy bruising with haematomas and ecchymoses and finally 
(4) arterial, intestinal and uterine ruptures. The combination of any of the two major 
diagnostic criteria is highly specific for vascular EDS. Further biochemical and genetic testing 
is recommended to confirm the diagnosis. The presence of one or more minor criteria 
supports the clinical diagnosis of vascular EDS vascular type but is not sufficient to establish 
the diagnosis. Minor criteria include a positive family history of sudden death from vascular 
or intestinal rupture in a close relative, acrogeria (aged aspect of the hands and/or feet), 
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hypermobility of small joints, tendon and muscle rupture, club foot (talipes equinovarus), 
early onset varicose veins and spontaneous pneumothorax or haemothorax. In the 2017 
International classification the minimal criteria for diagnosis are a family history of vascular 
EDS, arterial rupture or dissection <40 years, unexplained sigmoid colon rupture or 
spontaneous pneumothorax in the presence of other features consistent with vascular EDS 
should each lead to verifying diagnostic tests as does a combination of other minor criteria 
(for details see chapter 2, table 2-5).
6 
 
3.1 Facial appearance 
Characteristic acrogeric facial appearance of vascular EDS patients is present only in about 
30% of patients.
16
 Acrogeria defines features such as an emaciated facies with prominent 
cheek bones and sunken, hollow cheeks. The eyes may be sunken, (perhaps due to a lack of 
orbital fat), or more commonly, bulging often with darkly coloured orbits, and capillary 
telangiectasia of the eyelids.
17
 The nose is pinched, delicate and thin, as are the lips, 
particularly the upper lip. Sometimes tightness of the skin over the face may lead to a more 
youthful appearance, similar to a face-lift and this is known as Madonna facies. The ears are 
firm and tight, frequently with small ear lobes. There is sometimes accompanying diffuse 
alopecia and such patients have been categorized as having metageria.
18 
 
3.2 Cutaneous changes 
Unlike in other types of EDS, affected individuals often have inelastic, thin, translucent 
skin.
19
 The skin is smooth and soft (and sometimes referred to as “velvety”). The capillaries 
and subcutaneous veins under the skin are easily visible, especially over the chest, shoulders, 
thighs and calves, or less often, the abdomen. The dorsal skin of the hands and feet is often 
very thin with atrophic fine wrinkling: acrogeria.
15
 Bazex and Dupre noted that forward 
flexion of the trunk easily reveals subcutaneous veins on the lower back, although it might 
also be seen in other EDS types.
20
 Fragility of the skin, especially of knees and shins, is less 
severe than in classical EDS. Poor quality wound healing and pretibial deposition of orange 
blue haemosiderin occurs in vascular EDS, as well as in classical and periodontal EDS. Scar 
formation can be abnormal, leading to atrophic, widened scars, referred to as cigarette paper 
scarring. Keloid formation and elastosis perforans serpiginosa are suggestive of vascular EDS, 
but not specific for it. Typically, elastosis perforans serpiginosa presents with well marginated 
circular lesions with central atrophy, typically distributed over the neck and upper and lower 
extremities. Biopsy with staining of elastic fibres distinguishes this from granuloma annulare, 
perforating collagenosis and fungal infections. 
 
3.3 Easy bruising 
Excessive bruising is a common sign and is often the first presenting complaint, but is not 
specific for vascular EDS, as it is also common in classical and arthrochalasia EDS.
21
 Gum 
fragility following normal dental hygiene is common, but also complicates the hypermobile 
and periodontal (formerly type VIII) EDS , whilst profuse bleeding after tooth extraction can 
also occur. Bleeding and clotting studies are usually normal, as in other EDS types, whilst the 
Rumpel-Leede or Hess test may be positive, suggesting capillary fragility (see Chapter 11).
22 
 
3.4 Vascular fragility 
Vascular fragility in vascular EDS is manifested both in the arterial and the venous vascular 
bed.  
Arterial complications include arterial dissection and rupture, aneurysm formation, carotid-
cavernous and other arterio-venous fistulae. Arterial dissection or rupture is the most common 
cause of death in vascular EDS, but the vascular pathology varies widely among individuals. 
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In many patients ruptures occur at locations that appear normal by angiography.
23
 In a 
literature review, Berqvist et al. reported arterial rupture without underlying aneurysm in 33% 
of patients with a serious haemorrhagic complication.
23
 Aneurysmal dilatation may occur at 
any site, with ensuing risk for dissection and arterio-venous fistulae, especially of the carotid 
cavernous sinuses. The visceral branches of the aorta, especially the renal, mesenteric, iliac 
and femoral arteries are particularly affected.
24
 In series by Pepin et al. about half of the 
arterial complications in vascular EDS involved the thoracic and abdominal arteries and the 
rest was equally divided between the head, neck and limbs.
25
 The distribution in the Mayo 
clinic series showed a higher proportion of complications in the thoraco-abdominal region.
26
 
There may also be widespread multifocal segmental arterial abnormalities.
16
 Histological 
changes include thinning of the medial layer of the arteries, collagen depletion and elastic 
fragmentation and hypertrophy.  
Intracranial haemorrhages occur in 4% of cases and although uncommon, vascular EDS is a 
cause of stroke in young adults.
27
 In a series on neurological complications inpatients with 
vascular EDS, the mean age of onset of intracranial aneurysmal rupture, spontaneous carotid-
cavernous sinus fistula and cervical artery aneurysm was 28 years.
28
 Carotid-cavernous 
aneurysms commonly present with acute unilateral exophthalmos and cranial nerve palsies, 
manifested by tinnitus, thrill, headaches or pulsating exophthalmos with Horner 
syndrome.
28,29
  
Although acute myocardial infarction is a rare complication, a number of case reports has 
been published.
30,31,32
 Specific pathology includes coronary artery dissection, saccular, 
fusiform or other coronary aneurysms, or pericardial tamponade from ventricular rupture.
33
 In 
one case this was accompanied by coincidental dextrocardia.
34
 In our own series of vascular 
EDS, some of which is unpublished, there were three cases of vascular EDS with myocardial 
infarction, two of which were caused by coronary artery dissection. One of these had 
previously presented with a carotid-cavernous sinus aneurysm
35
, another is described in 
Soonaawale et al.
36
, whilst a third, a 28 year old female declined further investigation, 
because of insurance pressures.  
Early onset varicose veins have been documented in up to 1 out of five patients in the Mayo 
clinic cohort
26
 and venous aneurysms have also been reported.  
 
3.5 Intestinal rupture 
Since intestinal walls are rich in collagen type III, intestinal fragility is also an important risk 
in vascular EDS patients. Most perforations occur in the sigmoid colon but the small intestine 
can also occasionally be affected.
15
 Spontaneous ruptures of the spleen and the liver have also 
been described.
37
 Exceptionally, oesophageal rupture during vomiting (Boerhaave syndrome) 
has been observed.
38
 There is a high risk (50%) of multiple colonic perforations and leakage 
from the anastomosis in case of simple segmental resection with immediate re-establishment 
of continuity.
39 
 
3.6 Uterine ruptures 
Uterine rupture in the last trimester of pregnancy, during labour or soon after delivery is a 
well-known complication of vascular EDS. Maternal mortality has historically been estimated 
as high as 12%.
25
 Pregnancy is also associated an increased risk of vascular ruptures either at 
delivery or post-delivery, although many women with vascular EDS have uncomplicated 
pregnancies.
40
 Recent observations in a large study by Murray et al. reported slightly lower 
percentages of pregnancy-related deaths in 5.3% of pregnancies and found no difference in 
survival between parous and nulliparous women, suggesting that age is the main risk factor 
and not pregnancy itself.
41
 The most common pregnancy-related complications in this study 
were third-/fourth-degree lacerations (20%), arterial dissection/rupture (9.2%), uterine rupture 
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(2.6%), and surgical complications (2.6%). Preterm delivery (occurring in up to 19% of 
cases), occurs more frequently when the foetus is affected, owing to increased fragility of the 
membranes.
42 
 
3.7 Other findings and complications 
Although earlier reports have suggested an association with mitral valve prolapse and aortic 
root dilatation, more recent studies could not confirm these finding.
40,43,44
 Mitral valve 
prolapse reports are limited to case reports. There are other published examples of mitral 
valve pathology in vascular EDS such as that confirmed at post-mortem examination, 
including that following papillary muscle rupture by Seve et al. and the case report of 
Watanabe et al.
45,46
 Mitral valve prolapse should therefore be regarded as an nonspecific but 
possible complication of vascular EDS. Whether the nature of aortic root dilatation is 
progressive is also a matter of debate. 
Pneumothorax and haemorrhagic cavitary lesions of the pulmonary parenchyma have 
occurred in vascular EDS.
47
 Recurrent haemoptysis was also reported.
46 
Low birth weight, club foot and congenital hip dislocation can be early presentations of 
vascular EDS. In childhood, nonspecific complications such inguinal hernia or joint 
hyperlaxity with dislocations may be present, just as they do in other EDS types and other 
inherited defects of connective tissue. 
 
4. Natural history 
Out of a large survey of patients with vascular EDS, 220 patients with biochemically proven 
vascular EDS and 199 of their affected relatives have been described.
25
 Among the 220 index 
patients, 154 had at least one complication. Overall complications were rare in childhood but 
25% of patients had a first complication by the age of 20 years and more than 80% had 
suffered from at least one complication by the age of 40 years. The average age at the time of 
a first complication was 23.5 years. The median survival was 48 year meaning that 50% of 
patients had died before that age. There were no differences between men and women. 
Survival ranged from 6 to 73 year, showing extensive individual variability. Arterial and 
organ rupture are associated with a higher mortality rate than intestinal rupture (estimated 
only 2%), which was more often amenable to surgical treatment. Also, the nature of the first 
complication does not seem to predict the nature of the next complication. 
This large series essentially reported on the natural evolution. A more recent smaller scale 
study on 31 patients treated for vascular events showed slightly better survival rates with 68% 
of patients surviving at the age of 50 years.
26
  
As both of these reported surveys were retrospective, caution in the interpretation is 
warranted. Prospective large scale studies are essential for the correct interpretation of 
survival rates. 
 
5. Biochemical and molecular diagnosis 
 
5.1 Biochemical diagnosis 
The gold-standard for confirmation of a clinical diagnosis of vascular EDS, still is the 
biochemical testing of cultured dermal fibroblasts. Collagen proteins synthesized by these 
cells are labelled with radioactive-labelled proline and separated by SDS-PAGE (sodium 
dodecyl-sulphate polyacrylamide gel electrophoresis) (see chapter 3). This technique 
quantitatively measures both the proportion of secreted type III collagen, secreted into the 
medium, or retained intracellularly, together with its electrophoretic migration. Vascular EDS 
fibroblasts have abnormal type III procollagen production, intracellular retention, reduced 
secretion and/or altered mobility. Biochemical testing identifies an estimated 95% of vascular 
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EDS mutants. Only patients with more rare and subtle quantitative decreases of collagen type 
III may be missed by this technique.
25,48 
 
5.2 Molecular genetics 
Having preselected those affected by vascular EDS by protein screening, direct sequencing 
either of cDNA or gDNA COL3A1 sequences should follow. The latter approach, although 
generally efficient, can miss whole exon, multiple exon or whole gene deletions. To detect 
these, a COL3A1 null allele test and/or MLPA testing can be performed. MLPA testing will 
allow to detect intragenic duplications and deletions. More recently, next generation 
sequencing is evolving as the new sequencing methodology. In this approach COL3A1 might 
be part of a larger set of genes involved in aortic/arterial aneurysm and dissection or vascular 
fragility (see chapter 3). 
 
6. Genetics 
 
6.1 COL3A1 gene 
Type III collagen is coded by a unique fibrillar collagen gene, COL3A1, located on 
chromosome 2q24.3-q31 (www.le.ac.uk/ge/collagen/nomenclature.html). In keeping with 
other fibrillar collagens, there are N and C terminal propeptides, coded respectively by 5 
exons for the N propeptide and 4 exons for the C propeptide and in between an 
uninterrupted perfect triple helix coding for Gly XY triplets, in which X or Y are frequently 
lysine (4%) or proline (10%). COL3A1 has close analogies with the various other fibrillar 
collagens, especially the COL1A1 and COL1A2 genes of type I collagen. Like COL1A1 it has 
52 exons, but unlike COL1A1 and COL1A2, exons 4 and 5 combine in a single exon (4/5).  
 
6.2 Types of mutations 
Mutations of the triple helix are generally caused by missense point mutations converting 
glycine to some other larger amino acid. Such errors distort the dimensions of the triple helix, 
such that helical winding and therefore incorporation of mutant alpha chains into mature triple 
helices, is impaired. This leads to diminished collagen secretion and assembly, such that 
tissues which contain the mutant molecules become seriously weakened. Similar effects arise 
from exon skips in which shortened triple helices are similarly disruptive. In the case of stop 
codon mutations or large deletions, dosage effects are exerted, by virtual haplo-insufficiency. 
Unlike the COL1A1 and COL1A2 genes in which exon 6 mutations which disrupt the N 
terminal protease cleavage site, so disrupting collagen fibrillogenesis, no such mutations have 
been detected in EDS vascular type. By analogy however, this may be explicable by 
phenotypical variability, such that a syndrome other than EDS vascular type occurs. 
Alternatively this may be genetically lethal. Similar to COL1A1 and COL1A2 genes in which 
homozygous mutations causing autosomal recessive osteogenesis imperfecta or 
valvular/arterial fragility
49
, a recent report also suggests the existence of rare cases of 
compound heterozygous COL3A1 mutations with more severe clinical presentations.
50
 It is 
not unconceivable that COL3A1 homozygotes are mostly genetic lethals, as they often are in 
mice explaining the paucity of this observation.
51 
An extensive list of COL3A1 mutations and polymorphisms can be found at 
www.le.ac.uk/ge/collagen/col3a1.html. 
 
6.3 Genotype/phenotype correlation 
Two recent studies have suggested that individuals with glycine substituting missense 
mutations and splice site or in frame insertions-deletions have a more severe and earlier onset 
than COL3A1 null mutations, non-glycine mutations or mutations in the N- or C-terminal part 
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of COL3A1.
52,53
 The latter groups also have less digestive complications.
53
 Within the glycine 
substituting group, substitutions for serine and arginine seem to have a better outcome than 
those for valine and aspartic acid.
52
 Others have suggested that the acrogeroid appearance is 
more common in patients with mutations that affect the carboxy-terminal of the type III 
collagen triple helix.
54 
In one family with clinical findings compatible with hypermobile EDS, a COL3A1 mutation 
was identified but it is likely that this family was a mild presentation of vascular EDS.
55
 In 
many other families with hypermobile EDS, no type III collagen abnormalities were detected 
on collagen biochemistry. COL3A1 mutations are occasionally encountered in patients 
presenting with thoracic aortic dissections.
56
 
Despite the fact that vascular EDS is known for a long time and the identification of the 
underlying genetic defect dates from the early 1990’s, there has been limited progress in 
understanding the disease mechanism beyond that of connective tissue weakness due to 
structural defects or reduced amounts of type III procollagen. Based on the recent established 
role of the altered TGFβ-signalling in Marfan syndrome and related thoracic aortic aneurysm 
disorders, the role of this mechanism was studied by Morissette et al. They observed that 
mutations in COL3A1 do not seem to alter the TGFβ-signalling pathway in dermal fibroblasts 
of vascular EDS patients.
57
 Data regarding TGFβ-signalling in arterial tissue are unfortunately 
not yet available. 
 
6.4 Mosaicism 
Somatic and germline mosaicism, although rare, may occur in vascular EDS.
58
 
 
7. Differential diagnosis 
 
7.1 Classical EDS (MIM 130000, ORPHA 287 – COL5A1, COL5A2, COL1A1) 
This type of EDS can be differentiated from vascular EDS by the presence of skin 
hyperelasticity, more pronounced abnormal scarring and significant large-joint hypermobility 
(with dislocations) without accompanying arterial, bowel and organ rupture. In addition, both 
types are usually distinguishable by light microscopy and electron microscopy (EM). In 
vascular EDS light microscopy shows striking depletion of collagen dermal thickness with 
elastin hypertrophy. At the EM level the cauliflower rosettes of classical EDS are easily 
distinguished from the irregularity of collagen fibril diameters which characterize vascular 
EDS.
59
  
 
7.2 Kyphoscoliotic EDS (MIM 225400, ORPHA 1900 – PLOD1, FKBP14) 
This autosomal recessive form of EDS can be distinguished from vascular EDS by the 
presence of congenital kyphoscoliosis, severe neonatal hypotonia and ocular problems (scleral 
fragility, globe rupture, microcornea). These patients can present with vascular ruptures, but 
show no distinguishable histological features. 
 
7.3 Periodontal EDS (MIM 130080, ORPHA 75392 – C1R, C1S) 
Patients with this type of EDS share the easy bruising with EDS vascular type patients, but 
differ in some respects. Very obvious cases can be distinguished by the presence of early 
onset severe periodontal disease leading to early teeth loss and the typical appearance of 
chronically inflamed pretibial plaques. In families with more subtle periodontal fragility, 
formal testing is necessary to distinguish them. It should also be noted that mild premature 
periodontal recession and pretibial haemosiderosis can also complicate some families with 
classical EDS. 
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7.4 Loeys-Dietz syndrome (MIM 609192, 610380, 610168, 608967 - ORPHA 60030 – 
TGFBR1/2, SMAD3, TGFB2/3) 
In its most typical presentation Loeys-Dietz syndrome (LDS) presents with the triad of 
hypertelorism, cleft palate/bifid uvula and arterial aneurysm with tortuosity. Other systemic 
findings include craniosynostosis, joint hypermobility, bicuspid aortic valve, blue sclerae. At 
the other end of the clinical spectrum patients with vascular EDS like presentation (but 
normal collagen type III biochemistry) have been recognized and identified with mutations in 
the TGFBR1/2 genes (transforming growth factor beta receptor 1 or 2 genes). These patients 
also present with widespread vascular involvement (aneurysms throughout the arterial tree) 
and thin, velvety skin. In contrast to vascular EDS, vascular complications are mostly 
preceded by aneurysm formation and hence regular imaging of the vascular tree is a crucial 
screening tool. Although the arterial dissections in LDS tend to occur at an earlier age 
compared to those in vascular EDS they are amenable for surgery and therefore mandate early 
and extensive arterial imaging.
60
 The presence of bifid uvula or hypertelorism may allow to 
suspect TGFBR1/2 mutations in patients with a vascular-like EDS presentation. More 
recently, three other genes (SMAD3, TGFB2, TGFB3) have been identified in patients with 
phenotypes that show many similarities to LDS.
61,62,63 
 
7.5 Marfan syndrome (MIM 154700, ORPHA 558 – FBN1) 
Cardinal clinical manifestations in Marfan syndrome are ectopia lentis and aortic root 
dilatation. Other important features include long bone overgrowth (dolichostenomelia, pectus 
deformities and arachnodactyly). The diagnosis of Marfan syndrome is based on the 
identification of typical clinical manifestations as defined in the revised Ghent nosology.
64
 
Arterial dissection in Marfan syndrome is confined to the aorta and is nearly always preceded 
by aortic dilatation. Most dissections (>85%) are type A dissections. The risk of aortic rupture 
or dissection is not only influenced by the degree of aortic dilation.
65
 Silverman et al. 
demonstrated that a family history of severe cardiovascular complications in MFS is 
associated with increased aortic diameter and decreased survival.
66 
Unlike in patients with vascular EDS, surgical outcome in Marfan syndrome patients is 
excellent in an elective setting and prophylactic aortic root replacement is generally 
recommended at diameters exceeding 50 mm.
67,68
 Marfan syndrome also has hypermobility 
and pneumothorax in common with vascular EDS. 
 
7.6 Arterial tortuosity syndrome (MIM 208050, ORPHA 3342 – SLC2A10) 
This autosomal recessive disorder is characterized by generalized tortuosity of arteries, but 
can also present with other connective tissue findings such as cutis laxa, joint hypermobility 
or skin hyperextensibility. Arterial stenoses may occur in the systemic as well as in the 
pulmonic vascular bed and mild aortic root dilatation has occasionally been reported. So far, 
no vascular ruptures have been reported in patients with this syndrome.
69,70 
 
7.7 Pseudoxanthoma elasticum (MIM 264800, ORPHA 758 – ABCC6) 
Isolated gastrointestinal bleeding, with haematemis and melaena are relatively rare but typical 
features of pseudoxanthoma elasticum (PXE). In PXE, haematemesis and melaena are due to 
a variety of causes, including microaneurysms, arterio-venous malformations, ulceration and 
increased susceptibility to bleeding induced by the use of non-steroidal anti-inflammatory 
drugs. Other key features of PXE include angioid streaks and related retinal abnormalities, 
elastic cutaneous flexural infiltrates of the neck, axillae and flexural skin with either peau 
d’orange or macular, ivory-yellow cutaneous deposits. In common with vascular EDS, PXE is 
also associated with elastosis perforans serpiginosa and premature coronary artery disease. 
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Skin biopsy with collagen and elastic fibre staining will unambiguously discriminate vascular 
EDS from PXE, as will collagen protein analysis, if necessary.
71 
 
7.8 Other inherited disorders with vascular fragility 
Other conditions that can present with aortic and arterial aneurysms are autosomal dominant 
polycystic kidney disease (ADPKD), familial thoracic aortic aneurysm disease (FTAAD, 
ORPHA 91387), a heterogeneous group of diseases with predominant aortic 
aneurysm/dissection as the presenting symptom and fibromuscular dysplasia (FMD). ADPKD 
can be easily diagnosed by ultrasound of the kidneys which reveals the presence of multiple 
cysts. FTAAD usually presents with no or minor systemic involvement. Several genes 
causing FTAAD have been identified: ACTA2, MYH11, MYLK, MAT2A, MFAP5.
72
 In 
addition, mutations in nearly all genes that may underlie LDS (TGFBR1/2, SMAD3, 
TGFB2/3) and the gene causing Marfan syndrome (FBN1) have been identified in patients 
presenting FTAAD.
73,74,75 
Importantly, aortic aneurysms in FTAAD can also occur distally from the sinuses of Valsalva 
warranting imaging of the entire aorta. Clinical presentation is extremely variable with 
regards to the age of onset and degree of progression of the dilation.  
FMD is a non-atherosclerotic, non-inflammatory vascular disease that can affect almost every 
artery, but most frequently affects the renal and internal carotid arteries. Most commonly 
medial hyperplasia leads to a classic “strings of beads” stenotic arterial appearance. Macro-
aneurysms and dissections are complications. 
 
8. Management and treatment 
 
8.1 Preventive measures 
Given the known tissue and especially vascular fragility it is sensible to limit exposure to 
vigorous contact sports and isometric exercise, such as weight lifting, the carrying of 
unusually heavy loads, or sudden changes of acceleration because of risk of bruising and 
increases in blood pressure, respectively. Thus whilst jogging is acceptable, sprinting is 
contraindicated and similar considerations apply to tennis as contrasted with squash rackets. 
Similarly, because of the adverse effects of vascular overload, regular monitoring of blood 
pressure and meticulous control to normal values is sensible in both young and older adults. 
Because of significant risks of arterial pathology and fragility, any sudden onset of unusual 
pain needs prompt and meticulous investigation, by both clinical examination and appropriate 
non-invasive imaging. 
Anti-platelets and anticoagulants should be used only after careful consideration of the risks 
and benefits. This also applies to the use of NSAID’s. A Medical Alert Bracelet or the 
carrying of a note with essential medical information which briefly notifies attending 
physicians of potential vascular EDS complications. When at home affected patients should 
identify a specific medical attendant, such as a general practitioner, paediatrician, adult 
physician or clinical geneticist, who can co-ordinate information for emergency treatment, if 
required. Some general guidelines for anaesthesia and surgery have been suggested.
76
 These 
include cross-matching of adequate amounts of blood for transfusion, avoid intramuscular 
premedication, establish adequate peripheral venous access and the avoidance of arterial lines 
and central venous lines whenever possible. 
 
8.2 Vascular management 
In general, the management of a vascular dissection or rupture should be conservative, 
whenever possible. If surgery is unavoidable, minimal and very gentle vessel manipulation is 
essential and anastomoses should be strengthened with Teflon pledgets (non-absorbable 
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fabrics that act as bolsters when placed on a suture) and carried out without tension.
26
 Surgery 
is more likely to be successful if the surgeon is well-informed about the condition. The types 
of technical difficulties in vascular emergencies have been well illustrated by Ascione et al., 
who clearly describe the problems associated with venous ligature and arterial repairs.
77
 
Endovascular repair has also been successful in this context.
76
 Ideally and wherever 
practicable the management and imaging of such complex and potentially lethal problems 
should be centralized in designated specialist vascular centres. The outcome of surgical 
management in such highly specialized centres is better than the average natural evolution, 
but remains associated with high morbidity as demonstrated by complication in 46% in a 
series of 31 patients from the Mayo clinic and in 33% in 9 patients from the Johns Hopkins 
hospital.
26,79
 In a recent systematic review by Bergqvist, including 231 patients, arterial 
aneurysms (often multiple) were reported in 40% of cases, arterial ruptures without preceding 
aneurysms in 1/3 of the patients and carotid-cavernous fistulae in 18%.
23
 Mortality of open 
surgery and endovascular procedures was 30% and 24% respectively and the overall mortality 
was 39%. As with all retrospective analyses, and especially in the case of rare disorders, 
selection bias cannot be excluded. 
Intracranial and carotid-cavernous aneurysms are very acute medical emergencies, which may 
often be managed successfully by interventional neuroradiology, with coil embolization. 
Generally, apart from these particular intracranial aneurysms, conservative vascular imaging 
by MRI is preferable to the more invasive angiography because of the intrinsic arterial 
fragility of vascular EDS.  
Once the acute event has stabilized, more extended non-invasive vascular imaging (echo 
doppler, angio-MRI, CT-angioscan) may be indicated for detection of arterial aneurysms or 
dissections in the remainder of the arterial tree. Invasive vascular procedures, requiring 
catheterization should be avoided because of the risk of vascular ruptures. Arterial thrombosis 
after dissection may require conservative and carefully controlled anti-coagulation.
15
 
Recombinant Factor VIIa fraction proved useful in controlling persistent intra-abdominal 
haematoma formation in one case.
80
  
The pros and cons of serial vascular imaging are so far unclear, but are probably at least 
potentially beneficial. One should balance the risk of causing anxiety against the potential 
benefits of detecting previously unknown aneurysms or progressive dilatations that are 
potentially treatable and potentially life-saving.
23,26
 So far, the reduction of mortality or 
morbidity by serial imaging capable of predicting potential early signs of arterial wall 
weakness has not been systematically explored in vascular EDS .  
Boutouyrie et al. demonstrated that abnormally low intima-media thickness, potentially 
increases the risk of dissection and rupture, by generating higher mechanical mural stress.
81
 
This led to the hypothesis that treatment by celiprolol, a cardioselective β1 blocker with β2 
agonist vasodilatory properties could decrease the continuous and pulsatile mechanical stress 
on collagen fibres within the arterial wall. A multicentre randomized open label controlled 
trial with celiprolol in 53 patients was ended prematurely due to treatment benefit with a 36% 
reduction in vascular events in the treated group as compared to the untreated group.
82
 It 
needs to be acknowledged though that the occurrence rate of vascular events remained high at 
20% in the treated patient group.  
 
8.3 Intestinal management 
Colonic perforations are a very serious complication, with a high mortality are common in 
vascular EDS families. Because of the high risk of leakage and new perforations at the site of 
anastomosis, a de-functioning colostomy, with or without partial colectomy, is a very safe 
emergency procedure. The re-establishment of secondary continuity also has significant risks 
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of re-perforation and leakage, but is sometimes successful.
39,83
 Alternatively, total colectomy 
with closure of the rectal stump or ileo-rectal anastomosis have both been suggested.
84 
 
8.4 Pregnancy and embryo selection 
Because of the multiple risks (uterine and arterial), it is prudent to follow pregnant vascular 
EDS women in a high-risk obstetrical program (see Chapter 17). Although no randomized 
trial data are available, prudent clinical management includes early pre-delivery hospital 
admission, followed by elective caesarean section in a tertiary centre, with access to vascular 
surgical assistance and a department experienced in vascular coiling. Routine caesarean 
section is generally surgically uncomplicated. It is also prudent to have adequate supplies of 
fresh frozen plasma available and occasionally the administration of desmopressin is a useful 
option.
85 
 
Given the 50% chance of transmitting vascular EDS to future children, some families opt 
either for adoption or to remain childless. However, modern techniques of embryo selection 
should certainly be considered by the spouses of affected vascular EDS men. Such 
manoeuvres are potentially much more hazardous for affected females, as laparoscopic ovum 
collection itself may be risky, the well-known pregnancy complications, notwithstanding. 
Similar considerations also apply to the technically simpler techniques of foetal blood 
sampling, testing for vascular EDS, followed by selective termination of the pregnancy, if the 
test is positive for vascular EDS (see chapter 17). 
 
9. Areas of uncertainty regarding medication 
 
9.1 Beta-blockers or angiotensin receptor blockers 
A trial comparing the effect of beta-blockers or angiotensin receptor blockers is currently 
testing the benefit of the use of these agents to prevent complications of the disease (primary 
prevention). 
 
9.2 Desmopressin 
A recent retrospective study of 26 EDS children suggested that desmopressin which is known 
to stimulate the release of endothelial von Willebrand factor and of aminocaproic acid to 
counteract fibrinolysis can normalize bleeding times, when abnormal.
86
 This had been 
suggested earlier but needs specific confirmation in vascular EDS.
87 
 
9.3 Vitamin C 
Although vitamin C has been suggested as a possible therapeutic agent, helping to decrease 
bruising, no firm proof for its effect has been provided. 
 
10. Summary 
In addition to marked tissue fragility, patients with vascular EDS most often present with a 
thin, translucent skin, easy bruising and a family history of premature death whereas the 
characteristic facial appearance with low amounts of subcutaneous fat is less prevalent. 
Neonates may present with clubfoot and/or congenital dislocation of the hips. In childhood, 
inguinal hernia, pneumothorax, and recurrent joint dislocation or subluxation can occur. 
Typically, vascular involvement affects the middle-sized, predominantly thoracic or 
abdominal arteries, but aortic complications have been reported. In a substantial subset of 
patients, arterial ruptures or dissections are not preceded by progressive dilatation. This, 
together with the need to stay as conservative as possible in case of vascular signs and 
symptoms (see above), questions the use of standard screening for vascular abnormalities. 
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The vascular complications of vascular EDS are difficult to manage and cause premature 
death, with a median age of death being 48 years in a retrospective series and slightly better in 
a cohort of treated patients. The role for beta-blockade or prophylactic repair of un-ruptured 
aneurysms is unclear. Moreover, surgery is frequently complicated by severe bleeding and 
problems related tissue fragility. Although arterial ruptures are considered the landmark of 
this type of EDS, about one quarter of all major complications include spleen, uterus but most 
often bowel rupture. Colostomy is the preferred treatment in case of bowel rupture. The 
diagnosis of vascular EDS is based on clinical findings and confirmed by abnormal type III 
collagen biosynthesis as evidenced by qualitative and quantitative electrophoretic evaluation 
of the type III collagen production by skin fibroblasts. Subsequently, a mutation in COL3A1 
may be identified that is autosomal dominantly inherited. In individuals with a clinical 
suspicion of vascular EDS and normal collagen biochemistry, the diagnosis of LDS should be 
considered and molecular analysis of the TGFβ-pathway related genes should be performed. 
  
Chapter 690
 
 
References 
 1 Barabas AP. Heterogeneity of the Ehlers-Danlos syndrome: description of three clinical 
types and a hypothesis to explain the basic defect(s). Br Med J 1967;2:612-3. 
 2 Beighton P. Lethal complications of the Ehlers-Danlos syndrome. Br Med J 1968;3:656-
9. 
 3 Beighton P. X-linked recessive inheritance in the Ehlers-Danlos syndrome. Br Med J 
1968;3:409-11. 
 4 Beighton P, de Paepe A, Danks D, et al. International Nosology of Heritable Disorders of 
Connective Tissue, Berlin, 1986. Am J Med Genet 1988;29:581-94. 
 5 Beighton P, De Paepe A, Steinmann B, et al. Ehlers-Danlos syndromes: revised nosology, 
Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos 
Support Group (UK). Am J Med Genet 1998;77:31-7. 
 6 Malfait F, Francomano C, Byers P, et al. The 2017 International classification of the 
Ehlers-Danlos syndromes. Am J Med Genet Part C Semin Med Genet 2017;175C:8-26. 
 7  Jansen LH. The structure of the connective tissue, an explanation of the symptoms of the 
Ehlers-Danlos syndrome. Dermatologica 1955;110:108-20. 
 8 Pope FM, Martin GR, Lichtenstein JR, et al. Patients with Ehlers-Danlos syndrome type 
IV lack type III collagen. Proc Natl Acad Sci U S A 1975;72:1314-6. 
 9 Pope FM, Martin GR, McKusick VA. Inheritance of Ehlers-Danlos type IV syndrome. J 
Med Genet 1977;14:200-4. 
10 Byers PH, Holbrook KA, Barsh GS, et al. Altered secretion of type III procollagen in a 
form of type IV Ehlers-Danlos syndrome. Biochemical studies in cultured fibroblasts. 
Lab Invest 1981;44:336-41. 
11 Tromp G, Kuivaniemi H, Shikata H, et al. A single base mutation that substitutes serine 
for glycine 790 of the alpha 1 (III) chain of type III procollagen exposes an arginine and 
causes Ehlers-Danlos syndrome IV. J Biol Chem 1989;264:1349-52. 
12 Superti-Furga A, Steinmann B, Ramirez F, et al. Molecular defects of type III 
procollagen in Ehlers-Danlos syndrome type IV. Hum Genet 1989;82:104-8. 
13 Byers PH, Belmont J, Black J, et al. Diagnosis, natural history, and management in 
vascular Ehlers-Danlos syndrome. Am J Med Genet Part C Semin Med Genet 
2017;175C:40-7. 
14 Perdu J, Boutouyrie P, Lahlou-Laforet K, et al. [Vascular Ehlers-Danlos syndrome]. 
Presse Med 2006;35:1864-75. 
15 Germain DP. Ehlers-Danlos syndrome type IV. Orphanet J Rare Dis 2007;2:32. 
16 Zilocchi M, Macedo TA, Oderich GS, et al. Vascular Ehlers-Danlos syndrome: imaging 
findings. AJR Am J Roentgenol 2007;189:712-9. 
17 Germain DP, Herrera-Guzman Y. Vascular Ehlers-Danlos syndrome. Ann Genet 
2004;47:1-9. 
18 Gilkes JJ, Sharvill DE, Wells RS. The premature ageing syndromes. Report of eight cases 
and description of a new entity named metageria. Br J Dermatol 1974;91:243-62. 
19 Heidbreder AE, Ringelstein EB, Dittrich R, et al. Assessment of skin extensibility and 
joint hypermobility in patients with spontaneous cervical artery dissection and Ehlers-
Danlos syndrome. J Clin Neurosci 2008;15:650-3. 
20 Bazex A, Dupre A. [Case of acrogeria of Gottron; place of acrogeria among various types 
of congenital skin atrophy]. Ann Dermatol Syphiligr (Paris) 1955;82:604-25. 
21 De Paepe A, Malfait F. Bleeding and bruising in patients with Ehlers-Danlos syndrome 
and other collagen vascular disorders. Brit J Haematol 2004;127:491-500. 
22 Anstey A, Mayne K, Winter M, et al. Platelet and coagulation studies in Ehlers-Danlos 
syndrome. Br J Dermatol 1991;125:155-63. 
Vascular Ehlers-Danlos syndrome 91
 
 
23 Bergqvist D, Bjorck M, Wanhainen A. Treatment of vascular Ehlers-Danlos syndrome: a 
systematic review. Ann Surg 2013;258:257-61. 
24 Cikrit DF, Miles JH, Silver D. Spontaneous arterial perforation: the Ehlers-Danlos 
specter. J Vasc Surg 1987;5:248-55. 
25 Pepin M, Schwarze U, Superti-Furga A, et al. Clinical and genetic features of Ehlers-
Danlos syndrome type IV, the vascular type. N Engl J Med 2000;342:673-80. 
26 Oderich GS, Panneton JM, Bower TC, et al. The spectrum, management and clinical 
outcome of Ehlers-Danlos syndrome type IV: a 30-year experience. J Vasc Surg 
2005;42:98-106. 
27 Schievink WI, Limburg M, Oorthuys JW, et al. Cerebrovascular disease in Ehlers-Danlos 
syndrome type IV. Stroke 1990;21:626-32. 
28 North KN, Whiteman DA, Pepin MG, et al. Cerebrovascular complications in Ehlers-
Danlos syndrome type IV. Ann Neurol 1995;38:960-4. 
29 Schievink WI, Piepgras DG, Earnest Ft, et al. Spontaneous carotid-cavernous fistulae in 
Ehlers-Danlos syndrome Type IV. Case report. J Neurosurg 1991;74:991-8. 
30 Ades LC, Waltham RD, Chiodo AA, et al. Myocardial infarction resulting from coronary 
artery dissection in an adolescent with Ehlers-Danlos syndrome type IV due to a type III 
collagen mutation. Brit Heart J 1995;74:112-6. 
31 Kitazono T, Imaizumi T, Imayama S, et al. Two cases of myocardial infarction in type 4 
Ehlers-Danlos syndrome. Chest 1989;95:1274-7. 
32 Catanese V, Venot P, Lemesle F, et al. [Myocardial infarction by spontaneous dissection 
of coronary arteries in a subject with type IV Ehlers-Danlos syndrome]. Presse Med 
1995;24:1345-7. 
33 Athanassiou AM, Turrentine MA. Myocardial infarction and coronary artery dissection 
during pregnancy associated with type IV Ehlers-Danlos syndrome. Am J Perinatol 
1996;13:181-3. 
34 Jazayeri S, Gomez MC, Tatou E, et al. Fatal cardiovascular complications in a patient 
with Ehlers-Danlos syndrome type IV and dextrocardia. Cardiovasc Surg 2002;10:640-3. 
35 Fox R, Pope FM, Narcisi P, et al. Spontaneous carotid cavernous fistula in Ehlers Danlos 
syndrome. J Neurol Neurosurg Psychiatry 1988;51:984-6. 
36 Soonawalla Z, Pope FM, Puntis M. Type IV Ehlers-Danlos syndrome: a surgical 
emergency. Postgrad Med J 2002;78:501-2, 6. 
37 Harris SC, Slater DN, Austin CA. Fatal splenic rupture in Ehlers-Danlos syndrome. 
Postgrad Med J 1985;61:259-60. 
38 Reis ED, Martinet OD, Mosimann F. Spontaneous rupture of the oesophagus in an 
adolescent with type IV Ehlers-Danlos syndrome. Ehlers-Danlos and spontaneous 
oesophageal rupture. Eur J Surg 1998;164:313-6. 
39 Freeman RK, Swegle J, Sise MJ. The surgical complications of Ehlers-Danlos syndrome. 
Am Surg 1996;26:869-73. 
40 Pope FM, Nicholls AC. Pregnancy and Ehlers-Danlos syndrome type IV. Lancet 
1983;1:249-50. 
41 Murray ML, Pepin M, Peterson S, et al. Pregnancy-related deaths and complications in 
women with vascular Ehlers-Danlos syndrome. Genet Med 2014;16:874-80. 
42 Lind J, Wallenburg HC. Pregnancy and the Ehlers-Danlos syndrome: a retrospective 
study in a Dutch population. Acta Obstet Gynecol Scand 2002;81:293-300. 
43 Wenstrup RJ, Meyer RA, Lyle JS, et al. Prevalence of aortic root dilation in the Ehlers-
Danlos syndrome. Genet Med 2002;4:112-7. 
44 Dolan AL, Mishra MB, Chambers JB, et al. Clinical and echocardiographic survey of the 
Ehlers-Danlos syndrome. Br J Rheumatol 1997;36:459-62. 
Chapter 692
 
 
45 Seve P, Dubreuil O, Farhat F, et al. Acute mitral regurgitation caused by papillary muscle 
rupture in the immediate postpartum period revealing Ehlers-Danlos syndrome type IV. J 
Thorac Cardiovasc Surg 2005;129:680-1. 
46 Watanabe S, Ishimitsu T, Inoue K, et al. [Type IV Ehlers-Danlos syndrome associated 
with mitral valve prolapse: a case report]. J Cardiol Suppl 1988;18:97-105, discussion 6. 
47 Herman TE, McAlister WH. Cavitary pulmonary lesions in type IV Ehlers-Danlos 
syndrome. Pediatr Radiol 1994;24:263-5. 
48 Schwarze U, Schievink WI, Petty E, et al. Haploinsufficiency for one COL3A1 allele of 
type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos 
syndrome, Ehlers-Danlos syndrome type IV. Am J Hum Genet 2001;69:989-1001. 
49 Schwarze U, Hata R, McKusick VA, et al. Rare autosomal recessive cardiac valvular 
form of Ehlers-Danlos syndrome results from mutations in the COL1A2 gene that 
activate the nonsense-mediated RNA decay pathway. Am J Hum Genet 2004;74:917-30. 
50  Joergensen A, Fagerheim T, Rand-Hendriksen S, et al. Vascular Ehlers-Danlos syndrome 
in siblings with biallelic COL3A1 sequence variants and marked clinical variability in the 
extended family. Eur J Hum Genet 2015;23:796-802. 
51 Liu X, Wu H, Byrne M, et al. Type III collagen is crucial for collagen I fibrillogenesis 
and for normal cardiovascular development. Proc Natl Acad Sci U S A 1997;94:1852-6. 
52 Pepin MG, Schwarze U, Rice KM, et al. Survival is affected by mutation type and 
molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV). Genet Med 
2014;16:881-8. 
53 Frank M, Albuisson J, Ranque B, et al. The type of variants at the COL3A1 gene 
associates with the phenotype and severity of vascular Ehlers-Danlos syndrome. Eur J 
Hum Genet 2015 [Epub ahead of print]. 
54 Johnson PH, Richards AJ, Lloyd JC, et al. Efficient strategy for the detection of 
mutations in acrogeric Ehlers-Danlos syndrome type IV. Hum Mutat 1995;6:336-42. 
55 Narcisi P, Richards AJ, Ferguson SD, et al. A family with Ehlers-Danlos syndrome type 
III/articular hypermobility syndrome has a glycine 637 to serine substitution in type III 
collagen. Hum Mol Genet 1994;3:1617-20. 
56 Tromp G, Wu Y, Prockop DJ, et al. Sequencing of cDNA from 50 unrelated patients 
reveals that mutations in the triple-helical domain of type III procollagen are an 
infrequent cause of aortic aneurysms. J Clin Invest 1993;91:2539-45. 
57 Morissette R, Schoenhoff F, Xu Z, et al. Transforming growth factor-beta and 
inflammation in vascular (type IV) Ehlers-Danlos syndrome. Circ Cardiovasc Genet 
2014;7:80-8. 
58 Milewicz DM, Witz AM, Smith AC, et al. Parental somatic and germ-line mosaicism for 
a multiexon deletion with unusual endpoints in a type III collagen (COL3A1) allele 
produces Ehlers-Danlos syndrome type IV in the heterozygous offspring. Am J Hum 
Genet 1993;53:62-70. 
59 Pope FM, Narcisi P, Nicholls AC, et al. COL3A1 mutations cause variable clinical 
phenotypes including acrogeria and vascular rupture. Br J Dermatol 1996;135:163-81. 
60 Loeys BL, Schwarze U, Holm T, et al. Aneurysm syndromes caused by mutations in the 
TGF-beta receptor. N Eng J Med 2006;355:788-98. 
61 van de Laar IM, Oldenburg RA, Pals G, et al. Mutations in SMAD3 cause a syndromic 
form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet 
2011;43:121-6. 
62 Lindsay ME, Schepers D, Bolar NA, et al. Loss-of-function mutations in TGFB2 cause a 
syndromic presentation of thoracic aortic aneurysm. Nat Genet 2012;44:922-7. 
63 Bertoli-Avella AM, Gillis E, Morisaki H, et al. Mutations in a TGF-beta ligand, TGFB3, 
cause syndromic aortic aneurysms and dissections. J Am Coll Cardiol 2015;65:1324-36. 
Vascular Ehlers-Danlos syndrome 93
 
 
64 Loeys BL, Dietz HC, Braverman AC, et al. The revised Ghent nosology for the Marfan 
syndrome. J Med Genet 2010;47:476-85. 
65 Groenink M, de Roos A, Mulder BJ, et al. Changes in aortic distensibility and pulse wave 
velocity assessed with magnetic resonance imaging following beta-blocker therapy in the 
Marfan syndrome. Am J Cardiol 1998;82:203-8. 
66 Silverman DI, Burton KJ, Gray J, et al. Life expectancy in the Marfan syndrome. Am J 
Cardiol 1995;75:157-60. 
67 Gott VL, Greene PS, Alejo DE, et al. Replacement of the aortic root in patients with 
Marfan's syndrome. N Eng J Med 1999;340:1307-13. 
68 Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and 
treatment of aortic diseases: Document covering acute and chronic aortic diseases of the 
thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and 
Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 
2014;35:2873-926. 
69 Coucke PJ, Willaert A, Wessels MW, et al. Mutations in the facilitative glucose 
transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet 
2006;38:452-7. 
70 Callewaert BL, Willaert A, Kerstjens-Frederikse WS, et al. Arterial tortuosity syndrome: 
clinical and molecular findings in 12 newly identified families. Hum Mutat 2008;29:150-
8. 
71 Uitto J, Bercovitch L, Terry SF, et al. Pseudoxanthoma elasticum: progress in diagnostics 
and research towards treatment : Summary of the 2010 PXE International Research 
Meeting. Am J Med Genet A 2011;155A:1517-26. 
72 Luyckx I, Loeys BL, Curriculum topic: Disease of the a, et al. The genetic architecture of 
non-syndromic thoracic aortic aneurysm. Heart 2015;101:1678-84. 
73 Milewicz DM, Michael K, Fisher N, et al. Fibrillin-1 (FBN1) mutations in patients with 
thoracic aortic aneurysms. Circulation 1996;94:2708-11. 
74 Attias D, Stheneur C, Roy C, et al. Comparison of clinical presentations and outcomes 
between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related 
disorders. Circulation 2009;120:2541-9. 
75 Regalado ES, Guo DC, Villamizar C, et al. Exome sequencing identifies SMAD3 
mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial 
and other arterial aneurysms. Circ Res 2011;109:680-6. 
76 Dolan P, Sisko F, Riley E. Anesthetic considerations for Ehlers-Danlos syndrome. 
Anesthesiology 1980;52:266-9. 
77 Ascione R, Gomes WJ, Bates M, et al. Emergency repair of type A aortic dissection in 
type IV Ehlers-Danlos syndrome. Cardiovasc Surg 2000;8:75-8. 
78 Bade MA, Queral LA, Mukherjee D, et al. Endovascular abdominal aortic aneurysm 
repair in a patient with Ehlers-Danlos syndrome. J Vasc Surg 2007;46:360-2. 
79 Brooke BS, Arnaoutakis G, McDonnell NB, et al. Contemporary management of vascular 
complications associated with Ehlers-Danlos syndrome. J Vasc Surg 2010;51:131-8; 
discussion 138-9. 
80 Faber P, Craig WL, Duncan JL, et al. The successful use of recombinant factor VIIa in a 
patient with vascular-type Ehlers-Danlos syndrome. Acta Anaesthesiol Scand 
2007;51:1277-9. 
81 Boutouyrie P, Germain DP, Fiessinger JN, et al. Increased carotid wall stress in vascular 
Ehlers-Danlos syndrome. Circulation 2004;109:1530-5. 
82 Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular 
events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-
endpoints trial. Lancet 2010;376:1476-84. 
Chapter 694
 
 
83 Berney T, La Scala G, Vettorel D, et al. Surgical pitfalls in a patient with type IV Ehlers-
Danlos syndrome and spontaneous colonic rupture. Report of a case. Dis Colon Rectum 
1994;37:1038-42. 
84 Germain DP. Clinical and genetic features of vascular Ehlers-Danlos syndrome. Ann 
Vasc Surg 2002;16:391-7. 
85 Erez Y, Ezra Y, Rojansky N. Ehlers-Danlos type IV in pregnancy. A case report and a 
literature review. Fetal Diagn Ther 2008;23:7-9. 
86 Mast KJ, Nunes ME, Ruymann FB, et al. Desmopressin responsiveness in children with 
Ehlers-Danlos syndrome associated bleeding symptoms. Brit J Haematol 2009;144:230-
3. 
87 Stine KC, Becton DL. DDAVP therapy controls bleeding in Ehlers-Danlos syndrome. J 
Pediatr Hematol Oncol 1997;19:156-8. 
Vascular Ehlers-Danlos syndrome 95
This page intentionally left blank
 
 
Chapter 7. Kyphoscoliotic, arthrochalasia and dermatosparaxis Ehlers-Danlos 
syndrome 
C Giunta, HN Yeowell and B Steinmann 
 
 
Cecilia Giunta, PhD 
University Children's Hospital and Children’s Research Centre 
Division of Metabolism, Connective Tissue Unit 
Steinwiesstrasse 75 
CH-8032 Zürich, Switzerland 
Phone ++41-(0)44-266 7758 
e-mail: cecilia.giunta@kispi.uzh.ch 
 
Heather N. Yeowell, PhD 
Professor emerita of Medicine 
Department of Dermatology 
PO Box 3135 
Duke University Medical Center 
Durham, NC 27710 
Phone (919) 684 6242 
e-mail: heather.yeowell@duke.edu 
 
Beat Steinmann, MD 
Professor emeritus  
Division of Metabolism and Children’s Research Centre 
University Children's Hospital 
Steinwiesstrasse 75 
CH-8032 Zurich, Switzerland 
Phone  ++41-(0)44-266 7111 
e-mail : beat.steinmann@kispi.uzh.ch 
97
 
 
1. Introduction 
This chapter describes three types of Ehlers-Danlos syndrome (EDS): kyphoscoliotic EDS 
(formerly EDS type VI), arthrochalasia EDS (formerly EDS types VIIA and B), and 
dermatosparaxis EDS (formerly EDS type VIIC). Each of these types manifests 
characteristics of EDS with affected skin and joints. Kyphoscoliosis is a combination of 
kyphosis and scoliosis in which the spine respectively makes an exaggerated curve backward 
and sideward; arthrochalasia means abnormal relaxation or floppiness of joints; and 
dermatosparaxis stands for sagging of skin and very fragile skin. Clinically, the appearance or 
phenotype of the kyphoscoliotic type is severe muscle hypotonia (floppiness) at birth, fragile, 
easily bruisable skin and generalized joint laxity, accompanied by kyphoscoliosis. Patients 
with arthrochalasia EDS have severe generalized joint hypermobility with relatively 
unaffected skin, whereas patients with dermatosparaxis EDS do not have lax joints but are 
characterized by extremely fragile skin which tears easily. 
 
The aim of this chapter is to describe these three types of EDS in terms of their clinical and 
biochemical characteristics, their prevalence and demographics, and their genetic defects and 
pathomechanisms. The diagnostic tests for these types will be described, together with a 
differential diagnosis. Finally, the management and treatment of each type will be addressed. 
 
2. Kyphoscoliotic EDS  
The kyphoscoliotic EDS (OMIM 225400 and 614557) is caused 1. by the deficiency of the 
collagen-modifying enzyme procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1 or 
LH1 [lysyl hydroxylase 1], OMIM 153454), due to homozygosity or compound 
heterozygosity for mutant PLOD1 allele(s) and 2. by the deficiency of FKBP22 (OMIM 
614505), due to homozygosity or compound heterozygosity for mutant FKBP14 allele(s). It is 
clinically characterized as follows
1,2
: 
Major diagnostic criteria 
o Congenital muscle hypotonia 
o Congenital or early onset kyphoscoliosis  
o Generalized joint hypermobility with multiple dislocations/subluxations 
 
Minor diagnostic criteria 
o Skin hyperextensibility 
o Easy bruisable skin 
o Rupture/aneurysm of a medium-sized artery 
o Osteopenia/osteoporosis 
o Blue sclerae 
o Hernia (umbilical or inguinal) 
o Pectus deformity 
o Marfanoid habitus 
o Talipes equinovarus 
o Refractive errors (myopia, hypermetropia) 
 
PLOD1 specific minor criteria 
o Skin fragility (e.g. atrophic scarring, friable skin) 
o Scleral/ocular fragility/rupture 
o Microcornea  
o Facial dysmorphology (e.g. low-set ears, epicanthal folds, down-slanting fissures, 
synophrys, high palate) 
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FKBP14 specific minor criteria 
o Congenital sensorineural, conductive or mixed hearing impairment  
o Follicular hyperkeratosis 
o Muscle atrophy 
o Bladder diverticula 
 
Minimal criteria for diagnosis are congenital muscle hypotonia and congenital or early onset 
kyphoscoliosis plus either generalized joint hypermobility and/or 3 minor criteria (general or 
gene-specific). When these minimal criteria are met, verifying laboratory testing is warranted. 
In the majority of cases, the condition is caused by the LH1 enzyme deficiency. This enzyme 
deficiency - and not FKBP14 deficiency - leads to an abnormal pattern of urinary pyridinoline 
cross-links and thus to an increased ratio of lysyl-pyridinoline (LP) to hydroxylysyl-
pyridinolines (HP).
2,3
 
 
2.1 Background 
EDS comprises a group of inherited disorders of connective tissue that is clinically, 
biochemically and genetically heterogeneous.
1,3
 The kyphoscoliotic EDS caused by LH1 
enzyme deficiency was the first type of EDS to be characterized at the biochemical level. In a 
1972 study, a family was described with two sisters with the now-known clinical 
characteristics of kyphoscoliotic EDS.
4
 Their parents and an older sister were unaffected. 
Amino-acid analysis of skin collagen showed a marked decrease of 5-hydroxylysine to 
approximately 5% of control and an assay of lysyl hydroxylase activity showed it to be 
decreased to 10% of control. As these amino-acid and enzyme levels were normal in the 
clinically unaffected family members, an autosomal recessively inherited disorder was 
suspected. Several years later following cloning of the gene coding for lysyl hydroxylase,
5-7
 
now described as PLOD1, it was shown that this type of EDS was caused by mutations in one 
of the three LH genes, PLOD1, coding for LH1, that normally hydroxylates specific Lys 
residues in the –Y- position of the –Gly-X-Y- tripeptide repeat in the collagen triple helix.
3,8
 
Lysyl hydroxylase plays an important role as a post-translational modifying enzyme in 
collagen biosynthesis exemplified by the fact that the hydroxylated side chains can both serve 
as attachment sites for galactose or glucosylgalactose and can also participate in cross-link 
formation with hydroxylysine and lysine side chains in collagen telopeptide (non-helical) 
sequences. 
Over the past twenty years, it has become clear that many individuals with a clinical diagnosis 
of kyphoscoliotic EDS but a normal ratio of urinary total LP to HP do exist. In 2012, linkage 
analysis in one family identified bi-allelic nonsense variants in FKBP14 in 2 affected 
individuals, and in an additional 4 individuals confirmed FKBP14 mutations as the cause of 
an autosomal-recessive variant of Ehlers-Danlos syndrome (EDS) characterized by severe 
muscle hypotonia at birth, progressive scoliosis, myopathy, hearing impairment, and normal 
pyridinoline excretion in urine.
9 
Due to the major clinical overlap of this phenotype with 
kEDS-PLOD1, both conditions are now grouped within the kyphoscoliotic EDS in the 2017 
EDS classification.
1 
 
2.2 Clinical findings 
A range of clinical severity is observed in individuals with the kyphoscoliotic EDS.
3,9,10,11 
 No 
relationship has been reported between the location/type of mutation in either the PLOD1 or 
the FKBP14 genes and the severity of the clinical phenotype. Figures 7-1 and 7-2 below show 
all the mutations identified in the PLOD1 and FKBP14 genes, respectively and their locations 
in the gene. 
 
Kyphoscoliotic, arthrochalasia and dermatosparaxis Ehlers-Danlos syndrome 99
 
 
Figure 7-1 Structure of the PLOD1 gene coding for LH1 and mutations leading to 
kyphoscoliotic EDS  
 
 
The shaded boxes represent the 19 exons in the PLOD1 gene joined by the single lines 
representing the introns (not drawn to scale). Below the line, the effects of point mutations, 
insertions, and deletions on the amino acid sequence are shown; ‡ represents mutations that 
produce downstream premature termination codons. Above the line, the effects of other 
mutations in the DNA are shown; † represents mutations that produce downstream premature 
termination codons and * represents splice site mutations that result in exon skipping. The 
common duplication of exons 10-16 is represented by (↔). The large deletion which produces 
abnormal transcripts is represented by (←−→). (Adapted with permission from
32
) 
 
Figure 7-2 Structure of the FKBP14 gene coding for FKBP22 and mutations leading to 
kyphoscoliotic EDS 
 
 
 
The boxes 1-4 represent the 4 exons and the rather large 5' and 3' UTR regions encoded by 
exon 1 and exon 4, respectively. The introns are represented by shaded boxes and are not 
drawn to scale. The six mutations published to date are shown with both cDNA and protein 
nomenclature.
9,20, 21
 
 
2.2.1 Clinical findings in kEDS-PLOD1 
A total of 94 reported and unreported patients with kEDS-PLOD1 are known to the authors, 
in which the clinical findings have been biochemically confirmed. The newborns with 
available neonatal history are generally described as floppy, with a weak cry, difficulty in  
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sucking, and delayed motor development. Sometimes poor foetal movements were reported 
by the mothers. In infants, the observed muscle hypotonia accompanied by muscle weakness 
contributes to the phenotype of the floppy infant syndrome. As this has the characteristics of a 
neuromuscular disorder, extensive neuromuscular work-ups are often initially carried out to 
give normal results. It is only at this late stage that a diagnosis of kyphoscoliotic EDS is 
considered.
12,13
 Intellect is unaffected. All individuals with kyphoscoliotic EDS have 
hyperelastic and easily stretched skin, with an estimated 60% of individuals subject to 
abnormal scarring, characterized by thinness and widening. Bruising occurs easily in all 
patients and, in about 50% of cases, bruising is severe. 
 
Kyphoscoliosis is generally present at birth and is progressive and severe in most cases 
examined, Figure 7-3. As the vertebral bodies are structurally normal, the scoliosis is 
attributed to muscular hypotonia together with laxity of ligaments and is often resistant to 
external bracing. As reported in 3 cases, adults with severe kyphoscoliosis are at risk for 
complications from restrictive lung disease, recurrent pneumonia, cardiac insufficiency and 
early death. A Marfanoid habitus is often striking. Osteoporosis occurs in all individuals but 
without tendency to fracture. Recurrent joint dislocations are a common serious problem. 
Ocular fragility, which was observed in the original reports of individuals with LH1 
deficiency is found in a minority of individuals.
4
 It can lead to retinal detachment and 
bleeding and rupture of the globe, rather than of the cornea as in the brittle cornea syndrome 
after minor trauma.
14
 High myopia (near sightedness) is common. Most patients have 
microcornea. The sclerae often have a bluish hue. 
 
Vascular rupture is the major life-threatening complication in this disorder. One patient died 
at 51 years with symptoms typical of dissecting aneurysm of the aorta and her brother had a 
cerebral accident in the distribution of the right middle cerebral artery at age 19,
15
 and a third 
patient died of arterial rupture at age 14.
16
 Mitral valve prolapse is common. Maternal and 
perinatal mortality in pregnancy has been reported in a case of kyphoscoliosis. Autopsy of the 
mother showed a spontaneous rupture of the right iliac artery;
17
 on the other side, two affected 
cousins with the homozygous PLOD1 mutation (c.2198C>T; p.Arg703X) had a total of seven 
pregnancies resulting in three miscarriages and four healthy children, three of whom were 
born vaginally at term and the fourth was born at 24 weeks; there were no maternal 
complications . 
Steinmann, Rosser and Giunta, unpublished 
 
Life span is markedly shortened because of arterial rupture and cardiopulmonary insufficiency 
due to severe kyphoscoliosis. 
Interfamilial variability of kEDS-PLOD1 is quite considerable, and intrafamilial variability 
has been observed in al least 8 pairs of siblings (one pair of siblings ‘a’ and ‘e’ are shown in 
Figure 7-3). 
8,10,own observation
 This suggests the influence of other factors such as environmental 
and genetic factors other than, or in addition to, mutations in the PLOD1 gene in determining 
the clinical phenotype. 
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Figure 7-3 Kyphoscoliotic EDS caused by PLOD1 mutations  
Patients a and e are the third and fifth children of healthy parents from Qatar who are first 
cousins. This family was the first in which the disorder was characterized at the molecular 
level.
8
 
(a) The 5½ years old girl presents with severe kyphoscoliosis, dislocation of the right 
shoulder, flat feet in valgus position, microcornea. 
(b) X rays of the spine 4 years after Harrington rodding and 3 years after removal of the rod 
because of its displacement due to premature loading (11 years). 
(c) X ray of the shoulder showing dislocation of the right humerus (11 years). 
(d) X ray of the foot showing marked osteoporosis and flat feet (11 years). Because of joint 
instability, arthrodesis of the lower ankle joint was required 2 years later. 
(e) The younger affected sibling who has a much milder phenotype, at age 5 years, is shown 
for comparison, and thereby demonstrating marked intrafamilial variability. (a and e, and b, 
c, and d are reprinted with permission from
82 
and
3
, respectively). 
 
a
e
c
d
b 
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2.2.2 Clinical findings in kEDS-FKBP14 
Individuals with kEDS-FKBP14 present with a clinical phenotype almost indistinguishable 
from kEDS-PLOD1 but with a normal ratio of total urinary LP and HP (Figure 7-4 shows 6 
patients with kEDS-FKBP14). There are currently 30 patients diagnosed with this disorder on 
a molecular level which are known to the authors (26 of them have been published).
18,19,20,21
  
 
All affected individuals are reported to have muscle hypotonia at birth and delayed gross 
motor development, progressive scoliosis either congenital or of later onset, joint 
hypermobility, hyperelastic skin, myopathy and hearing impairment.
21
 Because of severe 
early onset muscle hypotonia and delayed motor development, affected children usually 
undergo extensive neuromuscular workup in the neonatal period. However, symptoms of 
congenital hypotonia and weakness may improve with age during childhood. Unassisted 
walking has been shown to be delayed ranging from 2 to 7 years.
21
 Reduced motor function 
and fatigue in adulthood was only reported in 2 adult patients 
9,19
 and might represent an age-
dependent feature in the natural course of the disorder. 
In 7 patients prominent congenital contractures of fingers, wrist, elbows or knees have been 
described
 
and amelioration was documented in half of the affected.
21 
A cleft of the soft palate was observed in two patients
9
, a bifid uvula in one patient
20
. and a 
cleft palate, defined as bifid uvula with submucous cleft palate or wide cleft palate was found 
in five patients.
21
 
 
Vascular complications, for instance a dissection of the celiac artery at age 41 years
19
, a 
hypogastric artery pseudoaneurysm rupture at age 6 years
20 
, an internal carotid artery 
dissection at age 50 years
21
 and tortuosity of the arterial tree have been described. Moreover, 
in a baby at one month of age echocardiogram showed a pseudo bicuspid valve, small 
muscular ventricular septum defect (VSD), and dilatation of the ascending aorta, but normal 
cardiac function. A later echocardiogram at 10 months in addition showed a small atrial 
septum defect (ASD) and aortic dilatation with a Z score of +3.75 just beyond the tubular 
junction.
21
 
 
Occasional features underlying systemic connective tissue involvement have been described 
such as subdural hygroma (potentially due to subdural bleeding or spontaneous intracranial 
hypotension), bluish sclerae, bladder diverticula, inguinal or umbilical herniae, and premature 
rupture of membranes.
21
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Figure 7-4 Kyphoscoliotic EDS caused by FKBP14 mutations: clinical findings 
  
 
 
The clinical phenotype of six patients with kEDS-FKBP14. (a) 8 year-old patient with the 
p.Met48Lys mutation after surgical correction of the progressive severe scoliosis; joint 
hypermobility, congenital talipes and pes planus; (b) 4 year-old boy with severe 
kyphoscoliosis (onset at 6 months of age) and postural talipes; (c) Micrognathia at age 1 
year, skin hyperextensibility valgus position of the foot and hallux varus; (d) Pes planovalgus 
and rocker bottom feet; small joint hypermobility; (e) 8 year-old girl presenting with pectus 
excavatum; (f) Girl aged 9 years with contracture of the elbows, kyphoscoliosis, pes 
planovalgus and follicular hyperkeratosis. 
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2.3 Prevalence and demographics 
The kyphoscoliotic EDS is rare; the exact prevalence is unknown. A disease incidence of 
approximately 1:100,000 live births is a reasonable estimate. Prevalence does not vary by 
gender, race or ethnicity. The carrier frequency is estimated to be 1:150. 
 
2.4 Genetic defect 
 
2.4.1 The normal PLOD1 gene product  
Lysyl hydroxylase 1 (LH1; EC 1.14.11.4; procollagen-lysine, 2-oxoglutarate 5-dioxygenase; 
PLOD1; OMIM 153454) exists as a dimer of identical subunits of molecular weight 
approximately 80-85 kDa, depending on the state of glycosylation.
22
 Each unit is comprised 
of 709 amino acids with a signal sequence of 18 residues. The C-terminal region is very well 
conserved among species; residues 570-709 of the processed polypeptide are 94% identical 
between chicken and human LH1 and the region between residues 621 and 697 is even more 
highly conserved (99%) and is thought to contain the active site of the enzyme. In the human 
polypeptide, two histidine residues (H638 and H690) and one aspartate (D640) that bind to 
Fe
2+
, together with an arginine (R700) that binds to α-ketoglutarate, have been shown to be 
critical residues in the active site of the LH isoforms.
23,24
 Human LH1 has four potential 
attachment sites for asparagine-linked oligosaccharide units.
23
 Unlike prolyl 4-hydroxylase (P 
4-H), LH1 does not have endoplasmic reticulum (ER)-specific retention motifs in the primary 
structure, but a single 40 amino acid C-terminal peptide segment has been identified in LH1 
that mediates both membrane association and localization of LH in the ER.
25 
 
2.4.2 Enzyme and cofactors  
The ascorbate-dependent enzyme LH requires Fe
2+
, α-ketoglutarate, and O2 as cofactors and 
catalyses the formation of hydroxylysines in collagen chains and other proteins with collagen-
like amino-acid sequences.
26,27
 The hydroxylysine groups of collagen have at least two 
important functions: their hydroxy groups are essential for the stability of the intermolecular 
collagen cross-links that provide tensile strength to most soft tissues and bone, and they serve 
as attachment sites for galactose or glucosylgalactose. This enzymatic glycosylation event is 
catalysed by another member of the LH family, the multifunctional enzyme LH3.
28 
 
2.4.3 Collagen cross-linking  
The strength and type of collagen cross-links formed depend on telopeptide (non-helical) 
lysines and whether or not they are hydroxylated. The cross-links that are formed between 
lysyl and hydroxylysyl residues can be formed via two major related routes: the allysine route 
in which the cross-link is formed from telopeptide lysine, and the hydroxyallysine route in 
which the cross-link is formed from telopeptide hydroxylysine. The bifunctional cross-links 
formed via the hydroxyallysine route (in which the hydroxylysine-derived aldehyde reacts 
with a specific peptidyl lysyl or hydroxylysyl residue in the triple helical domain of a 
neighbouring collagen molecule) mature into either the trifunctional crosslinks, hydroxylysyl-
pyridinoline (HP; formed from three hydroxylysyl residues) or lysyl-pyridinoline (LP; formed 
from two hydroxylysyl and one lysyl residue). The relative expression of these two types of 
cross-links therefore demonstrates the degree of lysyl hydroxylation which has occurred and 
provides the basis for a diagnostic test for lysyl hydroxylase deficiency in which a highly 
increased LP : HP ratio is indicative of kyphoscoliotic EDS.
29 
 
2.4.4 PLOD1 gene  
The 40kb PLOD1 gene coding for human LH1 is located in the p36.2→p36.3 region of 
chromosome 1 and includes 19 exons and an unusually large first intron of 12.5kb.
6
 The gene 
Kyphoscoliotic, arthrochalasia and dermatosparaxis Ehlers-Danlos syndrome 105
 
 
has a 5’ flanking region with characteristics shared by housekeeping genes.
30
 The constitutive 
expression of the gene in different tissues suggests that LH1 has an essential function.
7
 The 
presence of five and eight Alu-sequences located in introns 9 and 16, respectively, result in 
extensive homology thereby offering potential sites for recombination.
31 
 
2.4.5 Mutations in the gene coding for lysyl hydroxylase 
The mutations in the PLOD1 gene responsible for decreased enzyme activity that result in the 
clinical phenotype of kyphoscoliotic EDS are described in Figure 7-1. More than 30 different 
mutations in PLOD1 have been associated with kyphoscoliotic EDS.
10,11,32-35 
These mutations 
are located throughout the gene. The most common mutation, an 8.9-kb duplication of seven 
exons (exons 10 to 16), is caused by a homologous recombination event between identical 44-
bp Alu sequences in introns 9 and 16.
36
 The allele frequency of the duplication is 20% in 
probands with kyphoscoliotic EDS, from 94 families.
37
 Two other common mutations in 
PLOD1 occur in exon 9 (R319X) and exon 14 (Y511X) at allelic frequencies of 10% and 5%, 
respectively. Other mutations are as described in Figure 7-1. 
 
2.4.6 FKBP14 gene and FKBP22 protein function  
The 16kb FKBP14 gene coding for human FKBP22 maps to the minus strand of chromosome 
7p14.3 and consists of 4 small exons and 3 rather large introns. It is conserved among 
chimpanzee, Rhesus monkey, dog, cow, mouse, rat, chicken, zebrafish, fruit fly, mosquito, 
and frog. FKBP22 belongs to the FK506-binding protein (FKBP) class of immunophilins, 
which have been implicated in catalysing cis-trans-isomerization of peptidyl-prolyl peptide 
bonds and are supposed to accelerate protein folding. It has been shown that FKBP22 
catalyses the folding of type III collagen and interacts with type III collagen, type VI collagen, 
and type X collagen, but not with type I collagen, type II collagen, or type V collagen.
38
 
Remarkably, mutations in type III and type VI collagens are the genetic hallmark of the 
vascular type of EDS (vEDS) and of COL6-related dystrophies, respectively. Therefore, the 
clinical features of vascular abnormalities and myopathy documented in the affected 
individuals clearly correlates with the interaction of FKBP14 with type III and VI collagens.
21
 
 
2.4.7 Mutations in the gene coding for FKBP22  
The mutations in the FKBP14 that result in the clinical phenotype of kyphoscoliotic EDS are 
described in Figure 7-2. Nucleotide numbering starts with +1, which corresponds to the first 
ATG translation initiation codon at position 294 of the reference sequence NM_017946.3, 
whereas amino acid residues are numbered from the first methionine residue of the reference 
sequence NP_060416.1 
Since its first description in 2012
9
 only six different mutations have been associated with the 
disorder.
21 
These disease causing variants are located throughout the gene. The mutation 
c.362dupC p.(Glu122Argfs*7) which is found with a frequency of approximately 70% and it 
is thus considered to be a common disease variant, has been linked to the same haplotype in 
all individuals tested.
9,19
 
 
2.5 Inheritance 
The kyphoscoliotic EDS is inherited as an autosomal recessive trait. This is supported by the 
occurrence of affected siblings from unaffected parents and by the birth of affected children 
from consanguineous parents. 
 
2.6 Diagnostic tests 
The clinical diagnosis of kyphoscoliotic EDS is generally suspected very late and often only 
after a negative workup of neuromuscular disorders. For kEDS-PLOD1, the clinical diagnosis 
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is confirmed biochemically by measuring the ratio of collagen-derived pyridinoline cross-
links in the urine. Whereas, for kEDS-FKBP14 molecular genetic analysis by either Sanger 
sequencing of FKBP14 or NGS sequencing of a gene panel including FKBP14 is mandatory 
for confirming the clinical diagnosis.  
 
1) Deficiency of the enzyme LH1 results in a significant decrease in hydroxylysine-based 
pyridinoline cross-links in collagens. Detection of an increased ratio of lysyl-pyridinoline 
(LP) to hydroxylysyl-pyridinoline (HP) cross-links in urine, quantitated by high-performance 
liquid chromatography (HPLC) is a non-invasive, highly sensitive and specific test for kEDS-
PLOD1. The normal ratio of cross-links LP : HP is approximately 1 : 4 (~0.2), whereas in 
kyphoscoliotic EDS due to PLOD1 mutations the ratio is approximately 6 : 1 (10-40 times 
increase, range 2-9).
3
 Such testing is clinically available.
39
 Obligate heterozygous parents 
have normal values. 
2) Mutation analysis of the PLOD1 gene may be carried out to identify the mutation(s) 
responsible for the enzyme deficiency.
2,10,32
 As the most common mutation in the PLOD1 
gene is the large seven exon duplication caused by an Alu-Alu recombination in introns 9 and 
16 in the PLOD1 gene occurring at a frequency of approximately 30%,
2
 the gene should be 
initially screened for this mutation. The duplication can be readily detected/confirmed in 
genomic DNA by MLPA of PLOD1 or PCR using duplication-specific primers.
11,34 
Detection 
of other mutations may involve sequence analysis of all exons and flanking intronic 
sequences.
13
 Otherwise, mutation analysis can be carried out by targeted resequencing of a 
gene panel that includes PLOD1, a method that also allows the detection of the common 
duplication. 
3) The determination of LH activity in patients’ fibroblasts as well as the measurement of 
hydroxylysine content of dermis is now used for research purposes, only.
40,41
 
It should be noted here that carriers of a PLOD1 mutation can only be identified by mutation 
analysis and not by biochemical testing or enzyme assay.  
 
2.7 Prenatal testing 
Prenatal diagnosis for pregnancies at risk is possible by analysis of DNA extracted from foetal 
cells obtained by amniocentesis usually performed at approximately 15-18 weeks' gestation or 
chorionic villus sampling (CVS) at approximately 10 to 12 weeks' gestation. Both disease-
causing alleles must be identified before prenatal testing can be performed.
32,42
  
 
2.8 Differential diagnosis  
The kyphoscoliotic EDS has some overlapping clinical features with other types of EDS, 
particularly classical and vascular EDS. Abnormal wound healing and joint laxity are present 
in many EDS types. Although all types of EDS are characterized by a relatively high risk of 
scoliosis compared to the general population, scoliosis in kyphoscoliotic EDS is usually more 
severe and of earlier onset than that seen in other EDS types. Most congenital myopathies 
present with poor muscle tone and increased range of motion of small and large joints. Joint 
laxity can be difficult to distinguish from muscle hypotonia, particularly in infants and 
children. In kyphoscoliotic EDS, in which both hypotonia and joint laxity are present, the 
increased range of motion is often striking. Primary myopathies caused by mutations in 
collagen, such as the type VI (COL6) collagenopathy Ullrich congenital muscular dystrophy 
(UCMD; MIM 254090) may show substantial connective tissue involvement including 
kyphoscoliosis, joint hypermobility, joint contractures and abnormal scar formation, however 
velvety and hyperextensible skin is absent and motor function does not improve with age. 
Unlike spinal muscular atrophy, kyphoscoliotic EDS is characterized by normal tendon 
reflexes. Many syndromic and metabolic disorders include early-onset hypotonia. In these 
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disorders, however, the other manifestations of kyphoscoliotic EDS are generally absent, and 
additional features usually present. Kyphoscoliotic EDS needs also to be differentiated from 
myopathic EDS, a new entry in the 2017 International classification and due to heterozygous 
or biallelic COL12A1 mutations, since it also features congenital muscle hypotonia (see also 
chapter 2, table 2-5).
1,2 
 
The Nevo syndrome, first reported in 1974, has been identified as an allelic condition to the 
kyphoscoliotic EDS and is clinically indistinguishable from it.
43 
 
 
Recently, rare autosomal recessive entities with distinct molecular and biochemical 
abnormalities such as Brittle cornea syndrome, musculocontractural EDS, and the 
spondylodysplastic EDS have been described which should be considered in the differential 
diagnosis of the kyphoscoliotic EDS.
2
 These disorders
 
have been classified among the types 
of EDS because of shared common characteristics, such as joint hypermobility, skin 
hyperextensibility, and tissue fragility. These disease entities except for spondylodysplastic 
EDS, due to SLC39A13 mutations, are biochemically distinct from kyphoscoliotic EDS since 
the urinary pyridinoline ratios measured in the patients are within the normal range.  
 
Brittle cornea syndrome (BCS; MIM 229200) is an autosomal recessive generalized 
connective tissue disorder caused by mutations in ZNF469 and PRDM5.
44,45
 It is characterized 
by extreme thinning and fragility of the cornea that may rupture in the absence of significant 
trauma leading to blindness. Keratoconus or keratoglobus, high myopia, blue sclerae, 
hyperelasticity of the skin without excessive fragility, and hypermobility of the small joints 
are additional features of BCS.  
 
The musculocontractural EDS is due to mutations in CHST14 (OMIM 601776) and DSE 
(OMIM 615539), respectively.
46
 Neonates with mc-EDS present with distal arthrogryposis 
and muscular hypotonia. Musculocontractural EDS patients develop a Marfanoid habitus with 
narrow shoulders and spinal and pectus deformities, brachycephaly, a characteristic facial 
appearance, hyperextensible and bruisable skin, a tendency to atrophic scars, tapering fingers, 
instability of large joints, hyperalgesia to pressure, and recurrent subcutaneous haemorrhages 
are consistent clinical findings. Musculocontractural EDS patients show muscular hypoplasia 
and weakness. 
 
The spondylodysplastic EDS (OMIM 612350)
47,48
 is a very rare, recessive connective tissue 
disorder caused by mutations in SLC39A13 (OMIM 608735) encoding the zinc transporter 
ZIP13. Clinically it resembles kyphoscoliotic EDS, with some distinct phenotypic 
manifestations including platyspondyly, osteopenia, short stature, widened metaphyses, 
tapered fingers, thenar muscle atrophy and a tendency to develop contractures of the small 
joints. An elevated ratio of urinary pyridinolines LP : HP (but to a lesser degree than in 
kyphoscoliotic EDS), and underhydroxylated collagens in culture despite normal in vitro 
activities of lysyl-and prolyl 4-hydroxylases, respectively, are characteristic biochemical 
findings.
47
 Spondylodysplastic EDS can also be caused by mutations in 2 other genes, 
B4GALT7 and B3GALT6 (see also chapter 2, table 2-5), in which the LP : HP ratios are 
normal.
1,2 
 
Establishing a specific diagnosis of patients with features resembling the kyphoscoliotic EDS 
currently relies on the analysis of urinary pyridinoline cross-links, and upon exclusion of this 
form, on the accessibility of modern genomic technologies based on gene targeted exome-
sequencing. 
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2.9 Management  
 
2.9.1 Evaluations following initial diagnosis  
To establish the extent of disease in an individual diagnosed with kyphoscoliotic EDS, the 
following evaluations are recommended: 
*Musculoskeletal: To evaluate kyphoscoliosis, photographic and radiologic documentation of 
the spine are recommended in view of the often progressive character of the kyphoscoliosis. 
Physical therapy evaluation is needed to develop a plan for ongoing therapy.  
*Cardiovascular: Measurement of aortic root size and assessment of heart valves by 
echocardiogram should be carried out at the time of diagnosis or by age five years. Awareness 
for possible serious vascular complications in different age groups in patients with kEDS-
FKBP14 should be raised, and vascular screening should start at pediatric age. 
*Ophthalmologic: Formal ophthalmologic evaluation is needed at diagnosis for myopia, 
astigmatism, and potential for retinal detachment. 
 
2.9.2 Treatment of manifestations 
*Musculoskeletal: Referral to an orthopaedic surgeon for management of kyphoscoliosis is 
appropriate. Orthopaedic surgery is not absolutely contraindicated in individuals with 
kyphoscoliotic EDS and can be performed if necessary. Physical therapy is recommended for 
older children, adolescents, and adults to strengthen large muscle groups, particularly at the 
shoulder girdle, and to prevent recurrent shoulder dislocation. Swimming is recommended. 
*Cardiovascular: Vigilant observation and control of blood pressure can reduce the risk of 
arterial rupture. Vascular surgery is fraught with danger. Although virtually no surgical 
literature exists on kyphoscoliotic EDS, a review on surgical complications of vascular EDS 
is relevant.
33
 Individuals with aortic dilation may require treatment with beta blockers or 
losartan to prevent further expansion. 
*Ophthalmologic: Myopia and/or astigmatism may be corrected by glasses or contact lenses. 
Laser treatment of the retina is indicated in case of imminent detachment. 
 
2.9.3 Surveillance 
The following routine examinations are recommended: 1. Ophthalmologic examination for 
management of myopia and early detection of glaucoma or retinal detachment. 2. Routine 
examination for inguinal hernia and surgical referral as necessary. 3. Vigilant observation of 
blood pressure. 4. Regular follow-up by an orthopaedic surgeon for management of 
kyphoscoliosis. 5. Echocardiogram at five-year intervals (or less, depending on the severity of 
findings), even if the initial echocardiogram is normal by ultrasound measurements. 
 
2.9.4 Other  
Ascorbate has been suggested as a treatment, but its effectiveness has not been biochemically 
proven.
2
 
 
3. Arthrochalasia EDS  
 
3.1 Diagnostic criteria 
The arthrochalasia EDS is a rare inherited autosomal dominant trait caused by mutations 
leading to the entire or partial loss of exon 6 of COL1A1 (formerly EDS type VIIA) and 
COL1A2 (formerly EDS type VIIB) during pre-mRNA maturation, and thus affecting the 
processing of the amino terminal end of proα1(I) or proα2(I) chains of collagen I, 
respectively. It is characterized as follows:
1
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Major diagnostic criteria 
o Congenital bilateral hip dislocation 
o Severe generalized joint hypermobility with multiple dislocations/ subluxations 
o Skin hyperextensibility 
 
Minor diagnostic criteria 
o Muscle hypotonia 
o Kyphoscoliosis 
o Mild osteopenia (X-ray) 
o Tissue fragility, including atrophic scars 
o Easy bruisable skin 
 
Minimal criteria for diagnosis are congenital bilateral hip dislocation plus either skin 
hyperextensibility or severe generalized joint hypermobility with multiple dislocations/ 
subluxations and at least 2 other minor criteria. When these minimal criteria are met, 
verifying laboratory testing is warranted.
1,2
  
 
3.2 Background 
Hass and Hass suggested that there is a distinct entity of loose-jointedness, which they called 
arthrochalasis multiplex congenita (congenital flaccidity of the joints), which represents, to 
some extent, the antithesis of “arthrogryposis multiplex congenita” (a rare congenital disorder 
characterized by multiple joint contractures) and which may occur with or without skin 
changes.
49
 This disorder was classified as EDS type VII.
50
 In 1973, three patients with EDS 
type VII were reported who accumulated procollagen in their skin and tendons, and it was 
thought, therefore, that their disorder resembled dermatosparaxis in cattle.
51
 Since it was felt 
that the accumulation of procollagen was most likely to be due to a defect in the conversion of 
procollagen to collagen, the activity of the converting proteinase was determined in the 
culture medium of fibroblasts from these patients and found apparently to be reduced to 
between 10 and 40% of normal.
51,52
 However, when Steinmann and colleagues reinvestigated 
the youngest of the three reported patients
52
 they found the activity of the procollagen 
N-proteinase to be normal in cell extracts, and the presence of mutant pNα2(I)-like chains in 
collagen extracted from skin or produced by fibroblasts.
53
 The authors concluded that there 
was a structural abnormality in the portion of the proα2(I) chain that is normally cleaved by 
N-proteinase (and other proteinases). The authors speculated further, that for sterical reasons 
molecules containing pNα2(I) chains would interfere with fibrillogenesis and cross-linking, 
thus leading to abnormal collagen fibrils and increased solubility of collagen. After the 
description of a similar patient, in whom the condition was due to a mutant pNα1(I) rather 
than pNα2(I) chain, the classification of EDS VII was subdivided into types VIIA and VIIB, 
respectively, depending on whether the α1(I) or α2(I) chain was affected.
2,3,54
  
 
3.3 Clinical findings 
The hallmark of arthrochalasia EDS is the involvement of ligaments and joint capsules. The 
disorder is characterized by severe multiple joint hypermobility and recurrent subluxations 
and luxations of both small and large joints, and ligamentous tears. To date, there are at least 
51 patients from 38 families published or known to the authors. All patients are ascertainable 
in the newborn period, although the correct diagnosis is still frequently only made years later. 
Congenital bilateral hip dislocation is the rule (Figure 7-5a and 7-6), and muscular hypotonia 
is prominent; both factors predispose to the high incidence of breech presentation and delayed 
gross motor development. Short stature, if present, is due to severe thoracolumbar scoliosis  
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and hip dislocation. In striking contrast to dermatosparaxis EDS, the skin is only moderately 
affected; it is usually thin, velvety, and moderately extensible, doughy and redundant over the 
limbs. An unusual criss-cross patterning of the skin on the hands and feet has been observed 
(Figure 7-5e and 7-5f)
55
, and occasionally the skin is affected by poor healing of wounds with 
atrophic and haemosiderotic scars, especially in the adult. The face appears to be normal, 
however facial dysmorphic features with frontal bossing, hypertelorism, depressed nasal 
bridge, macrostomia and bluish sclerae have been described (Figure 7-5a and 7-5b).
55
 Judging 
by six affected members from a three-generation family, intrafamilial variability is slight. 
The occurrence of recurrent fractures, Wormian bones (also known as sutural bones or Inca 
bones: abnormal extra bone plates in the skull), and abnormally wide fontanels indicate that 
the arthrochalasia EDS phenotype includes bone changes and fragility similar to those 
reported in mild osteogenesis imperfecta (OI).
56
 Wormian bones have been observed in 
several patients. X-rays of one of our patients
56
 disclosed bone abnormalities such as 
exostoses, e.g. discrete occipital horns (parasagittal bone exostoses arising from the occipital 
bone), a thickened calvarium (skullcap), and Wormian bones. 
 
Figure 7-5 Arthrochalasia EDS. Clinical photos before and after open reduction of the hip 
dislocation
 55
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a, c, e, f: The patient at 12 months of age presents with bilateral hip dislocation with 
lateralisation and elevation of both femurs, and anterolateral subluxation of the knees. The 
skin is doughy and redundant mostly over the abdomen, the limbs, the fingers and the toes. A 
marked criss-cross patterning of the skin on the hands and feet, and contractures of the first, 
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second and fourth digits of both hands are present (e, f). Note the excess skin folds and the 
large umbilical hernia (c, circle).  
b, d: The patient at 23 months of age, photographed 6 months after successful open reduction 
of bilateral hip dislocation. Postural thoracolumbar kyphosis due to hypotonia and ligament 
laxity is shown (d). From 
55
 with permission. 
 
Figure 7-6 Arthrochalasia EDS, due to COL1A1 mutation. Radiographs before and after open 
reduction of the hip dislocation 
55
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Radiograph of the pelvis from the patient at 12 months of age shows bilateral luxation of the 
hips, and anterolateral subluxation of the knees due to severe ligamentous instability.  
b) Radiograph of the pelvis from the patient at 23 months of age, 6 months after open reduction, 
shows successful correction of bilateral dislocation of the hips.  
c) A radiograph of the right foot shows the disorganization of the metatarsal bones. Please note 
the striking osteopenia which is more marked than in arthrochalasia EDS due to COL1A2 
mutation. From 
55
 with permission. 
 
3.4 Defect and pathogenesis 
The molecular defect in all cases elucidated to date is remarkably homogeneous: entire or 
partial loss of exon 6 during pre-mRNA processing causes lack of the N-telopeptide linking 
the N-propeptide to the major triple helical domain of the α1(I) and the α2(I) chain, 
respectively. Deletion of the N-telopeptides in the pro-α1(I) (24 amino acid residues) and the 
pro-α2(I) chain (18 amino acid residues
57
) results in loss of the small globular region of the 
Chapter 7112
 
 
N-propeptide (present only in the pro-α1(I) chain), the N-proteinase cleavage site (Pro-Gln 
and Ala-Gln), the cross-linking lysine residue of the N-telopeptide, the cleavage site for 
proteinases (for example, pepsin and a-chymotrypsin) and the first triplet of the main helical 
Gly-X-Y domain. The loss of the N-proteinase cleavage site causes the retention of the N-
propeptide in the mature α1(I) and α2(I) molecules, which are referred to as pNα1(I)- and 
pNα2(I)-like chains, respectively. 
In two patients with arthrochalasia EDS, a G to C change at the splice acceptor site of intron 5 
in COL1A2 activates a cryptic splice site in exon 6, removing 5 amino acid residues including 
the N-proteinase cleavage site, but preserving the cross-linking lysine residue.
58, Giunta & 
Steinmann, unpublished
 Both mother and son, and father and daughter, respectively, were affected 
with typical arthrochalasia EDS. 
Analysis by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) of pepsin-digested 
collagens produced by fibroblasts of affected patients reveals, in addition to normal α1(I) and 
the α2(I) chains, the presence of mutant pNα1(I)- or pNα2(I)-like chains, respectively. The 
pNα2(I)-like chains migrate between the α1(I) and the α2(I) chains of collagen I, whereas the 
pNα1(I)-like chains migrate as a faint band just above the normal α1(I) chains (Figure 7-7).  
Studies by Wirtz et al.
59
 showed that in arthrochalasia EDS (type VIIB), the α1(I) 
N-propeptide, although cleaved from the α1(I) chain by the N-proteinase or (less likely) by 
non-specific proteases, is retained by non-covalent association with the mutant pNα2(I) chain 
in native mutant collagen molecules, both in vivo and in vitro; the α1(I) N-propeptide was 
readily demonstrable by Western blotting of skin extracts, and rotary shadowing of 
pepsin-treated collagen produced in culture disclosed kinked molecules which were longer 
than their normal counterparts.
59
 These data suggest that the retention of a partially cleaved, 
but essentially intact N-propeptide in mutant collagen may play a critical role in the 
pathogenesis of this disease. 
 
Figure 7-7 SDS–PAGE gel electrophoresis of collagens produced by skin fibroblasts from 
patients with EDS VIIA (arthrochalasia EDS, due to COL1A1 mutation) and EDS VIIB 
(arthrochalasia EDS, due to COL1A2 mutation) and controls (C) 
 
 
Legend: Collagens extracted from the medium fraction (A) and the cell layer (B) are shown. 
The strong pNα1(I) band in the EDS VIIA patient is barely detectable in the control (C). 
Similarly, the pNα2(I) band is present in the EDS VIIB patient only. From 
55
 with permission. 
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3.5 Morphology 
The skin collagen fibrils have a smaller and more variable diameter than normal. They are 
irregular in outline, and also appear to be more loosely and randomly organized into fibrils 
resembling a loosely wound rope (Figure 7-8).
55,60
 These changes are more pronounced in the 
patients affected with arthrochalasia EDS, due to mutation in COL1A1 (Figure 7-8a and 7-8c) 
compared to those observed in arthrochalasia EDS, due to COL1A2 mutation (Figure 7-8b and 
7-8d), but less severe than those present in dermatosparaxis EDS (Figure 7-9). 
 
3.6 Inheritance 
Arthrochalasia EDS is inherited as an autosomal dominant trait, and some of the sporadic 
cases have been shown to be heterozygous for a new mutation. Gonadic mosaicism may 
occur. From published results, it appears that the relative incidence of arthrochalasia EDS, 
due to COL1A2 mutation is higher compared to that of arthrochalasia EDS due to COL1A1 
mutation, although the risk of a spontaneous mutation affecting exon 6 is expected to be 
similar for both COL1A1 and COL1A2 genes.
2
 This may have to do with the difficulty in 
detecting the latter type by routine standard biochemical techniques, as shown recently.
55 
 
3.7 Genotype-phenotype correlation and locus heterogeneity 
Interfamilial and intrafamilial phenotypic variability seems to be slight. In arthrochalasia 
EDS, due to COL1A2 mutation, the heterotrimeric collagen I molecules consist of one 
population of normal collagen I and one population of abnormal collagen I containing the 
mutant α2(I) chain. In contrast, in arthrochalasia EDS, due to COL1A1 mutation, three 
quarters of collagen I molecules would be expected to be abnormal because they contain one 
or two mutant α1(I) chains and, thus, the phenotype would be expected to be more severe 
than that due to COL1A2 mutation. 
The clinical documentations demonstrate the severity of COL1A1 mutation type and clearly 
suggests that the COL1A1 mutation type is more severe than the COL1A2 mutation type, as 
expected by the different stoichiometry of the α(I)-chains.
55
 This statement is supported by 
the more extensive ultrastructural changes of the collagen fibrils
55
, as well as by the 
comparison of the five personally examined patients with the COL1A2 mutation type. 
However, among the reported cases of the COL1A1 mutation type, three involve substitutions 
for the last nucleotide of exon 6. This results in two alternative splice variants, one in which 
the exon 6 sequence from mRNA is completely deleted, and another in which normal splicing 
is permitted, and the protein product contains an isoleucine rather than a methionine at 
position 3 of the first Gly-X-Y triplet of the triple helix. The normally spliced product 
containing an amino acid substitution diminishes the dysfunctional effect of the three quarters 
of abnormal molecules; this results in a less severe clinical phenotype which is 
indistinguishable from that of the COL1A2 mutation type. In contrast, complete skipping of 
exon 6 from mutant proα1(I) chains leads to three quarters of the collagen I molecules being 
abnormal and dysfunctional, thus explaining the more severe phenotype, which almost 
resembles dermatosparaxis EDS, in which none of the collagen I molecules are processed.
56 
Locus heterogeneity (trait caused by mutations in genes at different chromosomal loci) is 
exemplified by several patients who are clinically similar to arthrochalasia EDS. However, 
they have smooth, hyperelastic skin but without skin fragility. Their fibroblasts produce 
normal collagens
53
, the procollagen N-proteinase is active and the electron microscopic 
appearance of dermal collagen fibrils is normal. It remains uncertain whether patients such as 
these are examples of EDS types of unknown cause, or whether they represent the extreme 
end of severity of hypermobile EDS.  
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Figure 7-8 Ultrastructural appearance of collagen fibril cross sections in the dermis of two 
patients with arthrochalasia EDS: one due to COL1A1 mutation (VIIA; a and c) and one due to 
COL1A2 mutation (VIIB; b and d) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend: The skin collagen fibrils of the EDS VIIA patients (a
55
; c
83
) are more loosely and 
randomly organized, and have highly irregular contours (note the “angel-like” shape of the 
fibril in the left inset) and have more variable diameters than normal (right inset). Two 
patients with EDS VIIB (b
56
; d (figure 32
3
) have loosely organized fibrils with irregular 
contours and more variable diameters than controls; however the contours of the fibrils are 
far less abnormal than those of arthrochalasia EDS, due to COL1A1 mutation (VIIA) . Please 
note that the EM photographs are at different scales (the black bars correspond to 500 nm, 
while the white bars correspond to 600nm). From 
55
 with permission. 
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Figure 7-9 Structure of collagen fibrils: of normal human controls, of mouse models of 
dermatosparaxis EDS, of patients with dermatosparaxis EDS 
 
 
 
 
Collagen fibrils from skin of human (A, D, E, F) and mouse (B, C) studied by transmission 
electron microscopy. In normal skin (A, B), collagen fibrils appear cylindrical in cross 
section and elongated with a typical banded pattern in longitudinal section. In the animal 
model for the disease (C, ADAMTS2 null mouse), and in dermatosparaxis EDS patients (D: 
P7; E, and F: P8), fibrils are hieroglyphic in cross section and disorganized in longitudinal 
section. The level of observed hieroglyphic pattern is influenced by the angle of the section 
and can vary slightly between different regions within a single skin biopsy (C-F). Scale: 
lengths of black bars in right lower corners = 0.3μm. 
 
3.8 Diagnosis and differential diagnosis – EDS-OI overlapping syndrome 
The diagnosis is first made on clinical grounds, supported by the abnormal collagen fibril 
morphology, as well as by protein data pertaining to collagen extracted from skin or produced 
by fibroblasts, and proven by the demonstration of complete or partial loss of exon 6 in cDNA 
and of the mutation in genomic DNA. The existence of individuals with a clinical picture of 
arthrochalasia EDS but normal collagen I structure, normal procollagen N-proteinase activity 
and normal electron microscopic findings in skin indicates further heterogeneity. 
 
Congenital hip dislocation is also found in Larsen syndrome (OMIM 150250, 245600), and as 
an isolated disorder (OMIM 142700), and in an as yet less well defined disorder, i.e., 
dislocation of the hip, congenital, with hyperextensibility of fingers and facial dysmorphism 
(OMIM 601450). 
 
Assuming paternity, the risk to healthy parents of having another affected child is small, and 
due to the possibility of parental germline mosaicism. The mother of the four patients 
reported
61
 was the least severely affected individual within the family and may either 
represent a symptomatic mosaicism of the mutation in COL1A2, or may simply be the 
expression of intrafamilial variability (G. Wallis, personal communication 1991). The risk of 
Chapter 7116
 
 
an affected person transmitting the disorder is 50%, and prenatal diagnosis is possible by 
either DNA or protein studies on a chorionic villus biopsy if the defect in the index case has 
been characterized.
62
  
Glycine substitutions in the first 90 residues of the α1(I) helical region disrupt a stable 
N-anchor domain and prevent or delay N-propeptide removal. The pNα1(I) chain is 
incorporated into the matrix, decreases fibril size and causes a phenotype with characteristics 
of both OI and EDS.
63,64
 Disruption of N-propeptide processing by defects in the helical part 
of the α2(I) chain also leads to this phenotype.
65-70
 In particular, one patient
70
 presented with 
generalized osteoporosis, platyspondyly, Wormian bones, blue sclerae, but no fractures, and 
carried a 19 bp deletion that caused skipping of exon 11 of COL1A2,
67
 thus deleting one of the 
lysyl residues involved in intermolecular cross-link formation. The presence of the shortened 
proα2(I) chain in procollagen synthesized by the proband's fibroblasts both lowered the thermal 
stability of the molecules and prevented or delayed their processing by procollagen 
N-proteinase.
65
 Thus, the deletion disturbed both the helical domain and the cleavage site of the 
molecule, thereby resulting in the mixed EDS-OI phenotype, which is not included in the 2017 
International EDS classification. 
 
3.9 Management 
The orthopaedic outcome is often unsatisfactory as premature degenerative arthritis of the 
hips and other joints occurs.  
 
The principal orthopaedic problem in arthrochalasia EDS patients is bilateral congenital 
dislocation of the hips. To gain an insight into the management of this problem, Giunta et al. 
reviewed the treatments and their outcomes in 16 patients from 12 families.
56
 Stable 
reductions were infrequently achieved following closed reduction with orthoses or hip spicas. 
Anterolateral open reductions with capsular plication, even in infancy, were also inadequate 
as most of the patients continued to have subluxated or dislocated hips. The poor outcome of 
the latter procedure is likely to be due to early stretching of the capsulorrhaphy sutures. In 
contrast, in few patients the addition of an iliac osteotomy of the Pemberton or Salter type 
with or without femoral osteotomy achieved some good results. 
 
From published results and the findings of Giunta et al., it appears that open reduction with 
capsulorrhaphy and iliac osteotomy, with the addition of femoral osteotomy in some cases, is 
required to achieve and maintain stable reduction.
9,47
 These requirements are similar to those 
shown to be necessary to achieve and maintain stable reduction in other laxity conditions such 
as Down and Larsen syndromes. As with the latter conditions, careful planning of osteotomy 
is required to ensure that adequate acetabular coverage of the femoral head is achieved in the 
functional positions of the limb.
56 
 
Generalized joint hypermobility is worst in infancy when marked muscular hypotonia 
accompanies the severe ligamentous laxity. Motor development is consequently slow, and 
aids such as knee-ankle-foot and ankle-foot orthoses are often required to stabilize the lower 
limb joints for standing and walking. As muscle tone improves, the knee-ankle-foot orthoses 
may be reduced to ankle-foot orthoses. Surgical procedures to stabilize the knees and the 
patello-femoral joints have been used occasionally. Orthotic stabilization is likely to be more 
reliable. Ankle or subtalar fusions have been undertaken in a few cases but the arthrodesed 
joints need to be in an optimal position for this to be successful.
56 
Recurrent and/or persistent dislocations, as well as hypermobility of upper limb joints, are 
also frequently disabling. Operative procedures appear rarely to have been undertaken in the 
upper limbs and one would predict that capsulorrhaphy and osteotomy would not stabilize 
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these joints.
56
 Arthrodesis may be useful in stabilizing some small joints, such as the 
metacarpophalangeal joints of the thumbs, although fusion rates cannot be predicted. 
 
Postural thoracolumbar kyphosis due to hypotonia and ligamentous laxity is a feature of 
infants (Figure 7-5d). The spinal posture improves as the children gain in muscle power. 
However, structural scoliosis has been reported in eight cases. Spinal fusion was undertaken 
in two patients, although few details are available concerning curve patterns and surgery. 
Spondylolisthesis of L5-S1 was noted in one patient only. 
 
The findings in 20 molecularly proven cases of arthrochalasia EDS reviewed show how 
difficult the management is and how important early diagnosis may be.
47
 The homogeneous 
nature of the molecular defects allows laboratories with the appropriate expertise rapidly to 
establish the diagnosis, after which the clinical problems, in particular those relating to the 
dislocated hips, can be predicted. Adequate physical and occupational therapy and orthotic 
management can be given to assist with standing, walking and activities of daily living. 
Appropriate surgical treatment of the dislocated hips should also diminish the frequency of 
hip re-dislocation, recurrent dislocation, avascular necrosis and premature osteoarthritis. 
However, more experience correlating detailed orthopaedic management and long-term 
outcome is needed before sound recommendations can be made.
56 
 
4. Dermatosparaxis EDS  
The dermatosparaxis EDS (OMIM 225410) is caused by deficiency of procollagen N-terminal 
proteinase as a result of homozygosity or compound heterozygosity of mutant alleles coding 
for the enzyme procollagen N-proteinase. This disorder is inherited as an autosomal recessive 
trait and is clinically characterized as follows:
1
 
 
Major diagnostic criteria 
o Extreme skin fragility with congenital or postnatal skin tears 
o Characteristic craniofacial features  
o Redundant, almost lax skin, 
o Increased palmar wrinkling 
o Severe bruisability 
o Umbilical hernia 
o Postnatal growth retardation 
o Short limbs, hands and feet 
o Perinatal complications due to connective tissue fragility 
 
Minor diagnostic criteria 
o Soft and doughy skin texture 
o Skin hyperextensibility 
o Atrophic scars 
o Generalized joint hypermobility 
o Complications of visceral fragility (bladder/diaphragmatic rupture, rectal prolapse) 
o Delayed motor development 
o Osteopenia 
o Hirsutism  
o Tooth abnormalities 
o Refractive errors (myopia, astigmatism) 
o Strabismus 
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Minimal criteria for diagnosis are extreme skin fragility with congenital or postnatal skin tears 
and characteristic craniofacial features plus either 1 other major and/or 3 minor criteria. When 
these minimal criteria are met, verifying laboratory testing is warranted.
1,2
 
 
4.1 Background 
Dermatosparaxis (torn skin) in cattle was the first defect in collagen metabolism to be 
elucidated, whereas it has only relatively recently been defined in man.
71,72
 The hallmark of 
dermatosparaxis EDS is the excessive fragility of the skin with mild to absent involvement of 
tendons and ligaments; this distinguishes this disorder from arthrochalasia EDS in man, which 
is characterized by extreme joint laxity. 
 
4.2 Clinical findings 
Currently, only 15 patients from 14 unrelated families have been identified to date. Nine of 
the patients were born prematurely after rupture of the membranes, two of them by Caesarean 
section one because of breech presentation and the other at 33 weeks gestation because of 
foetal heart decelerations.
73
. Two additional patients were delivered at term by Caesarean 
section, one because of large size, another due to breech presentation. One patient died shortly 
after birth (39 weeks of gestation) due to severe hemorrhage and shock.
74
 The premature boy 
born with a gestational age of 33 weeks presented at birth with excessive skin folds, multiple 
skull fractures and extensive subgaleal hemorrhage.
73
 He died at 145 days from septic shock 
due to a secondary infection. Most patients display a severe phenotype that is clinically 
recognizable at birth and is characterized by premature rupture of the membranes, extreme 
fragility and laxity of the skin, soft and doughy skin texture, excessive and severe bruising 
with the formation of large subcutaneous hematomas, delayed closure of the fontanels, 
umbilical hernia, postnatal growth retardation and characteristic dysmorphic features. These 
include prominent and protuberant eyes with puffy, edematous eyelids and excessive 
periorbital skin, large fontanels and/or wide cranial sutures, a hypoplastic chin, and blue or 
gray sclerae. Nonrhizomelic shortening of the limbs and short, plump hands and feet with 
stubby fingers and toes have been reported in eleven patients. Joint hypermobility is common 
but often mild at birth and becomes more pronounced with age. A history of fractures has 
been reported in four patients, including (congenital) skull fractures in three, whereas 
osteopenia has been reported in only two patients. Delayed ossification of the cranial vault in 
three individuals, Wormian bones and delayed bone age in two patients, and persistence of 
woven bone in the ribs of one patient
74
 have been described. Increased palmar wrinkling and 
atrophic scarring has been reported in half of the patients. In three patients described 
recently,
75
 at birth and in infancy the typical facial features were absent and skin fragility was 
quite mild. However, their clinical presentation become more pronounced and similar to the 
reported phenotype during childhood.
75
 
 
4.3 Genetic defect 
The defect is due to an autosomal recessively inherited deficiency of procollagen N-
proteinase due to loss-of-function bi-allelic mutations in the ADAMTS2 gene.  Only eight 
different ADAMTS2 mutations have been reported to date.
75
 The enzyme is mainly 
responsible for cleavage of the N-terminal propeptide of procollagen type I. This has been 
demonstrated by the direct measurement of enzyme activity. Indirect evidence is given by the 
extraction of pN-collagen from fibroblast cultures of skin from patients with dermatosparaxis 
EDS which could be cleaved by the addition of N-proteinase activity or normal cell 
extracts.
72,76
 In addition, cultured fibroblasts from dermatosparaxis EDS patients failed to 
cleave the amino-terminal propeptides from the proα1(I) and proα2(I) chains of type I 
collagen.
78
 These findings confirmed that the enzyme, not the substrate, was defective. 
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Procollagen N-proteinase (ADAMTS-2, a disintegrin and metalloproteinase with 
thrombospondin type I motifs, OMIM 604539) is a large, neutral zinc metalloproteinase 
which is expressed in all tissues rich in type I collagen. This enzyme, isolated by affinity 
chromatography on immobilized collagen XIV cleaves the amino-propeptides in the 
processing of pN-collagens I and II to collagens I and II, respectively.
77
 The N-proteinase 
includes 1,205 amino acid residues with two sequences in the N-terminal domain that are 
substrates for furin-like enzymes. This suggests that the proenzyme is processed to its mature 
form as is generally observed for metalloproteinases.
77
 This has been confirmed in more 
recent work showing that the activation of the ADAMTS-2 zymogen involves several 
cleavages and generates at least seven distinct processed forms with different levels of 
activity.
78
 In addition, the C-terminal domain was shown to negatively regulate enzyme 
activity, whereas two thrombospondin repeats were enhancer regulators. Results from this 
study suggested that ADAMTS-2 may act as a multifunctional enzyme, acting via different 
cleavage specificities. 
 
4.4 Diagnosis and differential diagnosis 
The diagnosis is suspected on a clinical basis. As a consequence of the uncleaved pN-
propeptides, their incorporation disturbs the normal collagen fibril formation and leads to a 
decrease in the normal tensile strength of tissues. Striking abnormalities of the collagen fibril 
architecture are observed in skin, with fibrils that have lost their normal cross-sectional 
circular appearance and have an irregular, branched, hieroglyphic appearance instead (Figure 
7-9c-f). Longitudinally, the fibrils resemble ribbons twisting in both directions (Figure 7-9d 
and 7-9e).
76,79
 Although distinctive, these abnormal collagen fibrils may be almost 
indistinguishable from those in certain patients with the arthrochalasia EDS.
75,80
 Furthermore, 
the collagen fibril abnormalities can be mild and their degree of severity may differ upon 
region within the same skin biopsy. Biochemical confirmation is based on the electrophoretic 
analysis showing the accumulation of pNα1(I) and pNα2(I) chains of type I collagen extracted 
from dermis in the presence of protease inhibitors.
71
 Determination of N-proteinase activity is 
performed on a research basis only. Direct mutational analysis of the ADAMTS2 can be 
performed
79,81 
otherwise, targeted resequencing of a gene panel that includes ADAMTS2 is 
indicated. 
 
5. Areas of uncertainty 
- Comprehensive prevalence and natural history studies are needed for each type. 
- Comprehensive genotype-phenotype studies for each type are needed.  
- Due to their rarity, management of the types discussed in this chapter should be centralized 
in centres of excellence. 
- For the same reasons international registers are needed for all types. 
- What is the frequency of kyphoscoliotic EDS among cases of neonatal hypotonia and/or 
those suspected of having a myopathy? 
- How should patients, who want to become pregnant, be counselled and how to manage 
pregnancies?  
- Is there a place for Celiprolol in the management of kyphoscoliotic EDS? 
- Next generation sequencing techniques using targeted EDS panels needs to be used in order 
to allow early diagnosis and management of these rare types. 
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1. Introduction 
Although most physicians and paramedics at some time have heard of Ehlers-Danlos 
syndrome (EDS) and can generally visualise patients with loose skin and joints that are prone 
to subluxations and dislocation, it is not always clear how such patients present and what is 
required to treat his or her complaints.
1,2,3
 A much more critical view than that of the past has 
been adopted regarding the correct diagnosis of EDS and a formal diagnosis of EDS is 
therefore made less frequently. On further investigation several patients diagnosed with EDS 
in the past were found not to have this condition, but benign joint hypermobility syndrome 
(BJHS). Obviously this does not lessen the problem of painful joints prone to dislocation or of 
other related complaints such as fatigue.  
Recently, the two conditions BJHS and EDS hypermobility type have been recognized as one 
and the same clinical spectrum ranging from apparently symptomatic generalized joint 
hypermobility to the most disabled individuals fitting the new diagnostic criteria. These new 
criteria are more strict than the Villefranche criteria and the Brighton criteria for BJHS in 
order to define a homogeneous phenotype for management and scientific purposes. Within the 
new EDS nosology, its name is hypermobile EDS (see chapters 2 and 5). 
 
This chapter begins by describing a case with hypermobility and providing a summary of the 
history and classification of EDS. Some of the basic aspects of anatomy that are relevant to a 
better understanding of EDS are discussed. The complaints and symptoms that can 
accompany hypermobility will subsequently be reviewed, and, finally, consideration will be 
given to the various conservative and surgical treatment options available. Although these 
paragraphs discuss the joints of patients with classical and hypermobile EDS, generally the 
text applies as well to those patients who do not have EDS, but another hypermobility 
disorder. 
 
Patients with a hypermobility syndrome can easily be missed in orthopaedic practice. This 
will be illustrated by describing a patient with EDS. 
 
2. Case study 
In 1985, a woman of approximately 25 years of age presented at an orthopaedic clinic. She 
had dislocated her right shoulder whilst sporting; it was an injury she had sustained several 
times before, each time with increasing ease. The shoulder dislocated when she raised her 
right arm above 60 degrees. A surgical intervention (capsular shift) was proposed with which 
the surgeon had obtained good results in the past. No complications occurred during the 
operation and the patient left the hospital in good health with her arm in a sling and the advice 
to see a physiotherapist for guided active exercises. While the shoulder had dislocated 
anteriorly (towards the front) before the operation, after some time, the humeral head was 
seen to descend caudally (downward). The shoulder became increasingly painful as the 
humeral head progressively dislocated caudally and, finally, again anteriorly. The patient 
could not move her arm now due to the pain. Even bending her elbow caused pain in her 
shoulder.  
 
At that time, EDS was becoming better known. An EDS patient organisation had been 
established and although the Internet did not yet exist, this patient and her doctor had done 
their ‘homework’ and studied the available literature. Together, they came to the conclusion 
that EDS must be the condition involved, due to the hypermobility, also of  other joints and 
the soft velvet-like skin. After some time, when the shoulder condition had become 
unbearable, the patient underwent a shoulder arthrodesis, an operation in which the joint 
between the arm and the shoulder blade is immobilised permanently (as example arthrodisis 
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in another patient is depicted in figure 8-1). After consolidation of the arthrodesis, the patient 
was completely pain-free and although her shoulder joint was immobile, due to powered 
motion she enjoyed increased movement of the arm as a whole, which she had not 
experienced for many years. This movement occurs between the shoulder blade and the 
thoracic cage. Powered motion is purposeful movement using muscle contraction (muscle 
power), in contrast to undirected movement, which occurs not by means of muscle power but 
by gravitational force.  
 
Figure 8-1 Possible arm movement following shoulder arthrodesis 
 
 
 
Left image: patient with right shoulder arthrodesis (the joint between the arm and shoulder 
blade has been permanently immobilised) with the arm at maximum abduction. The 
remaining stable and pain-free movement occurs between the shoulder blade and the thoracic 
cage: abduction of the arm causes the shoulder blade to tilt. 
Right image: accompanying x-ray image: arm at maximum abduction. 
 
Some years later, the patient presented again to her orthopaedic surgeon, explaining that her 
other shoulder now also dislocated regularly. The doctor subsequently explained that although 
it is possible to immobilise both shoulders and live well with two arthrodesed joints, the 
advantages of this would not outweigh the disadvantages. She was given a supportive 
orthosis, which allowed her to move the shoulder without dislocating it. 
The lesson to be learned from this case is that an hidden, underlying condition may exist even 
if the cause of the dislocation (in this case a sports injury) appears to be obvious. This case 
also teaches us that whilst arthrodesis can indeed result in a limited range of movement in a 
part of the body, overall function can sometimes increase. Finally, it shows that similar 
problems do not always require the same solution. 
 
3. History 
In 1682, Van Meek’ren first described a patient with EDS, a Spaniard who could pull the skin 
of the right part of his chest up to his left ear and the skin from under his chin over his head. 
In 1891,Tschernogobow published the first clinical (i.e. the first medico-technical) description 
of fragility and hyperelasticity of the skin (see chapter 4), the inability of the skin to maintain 
sutures and the presence of molluscoid pseudotumours (wart-like bumps) around the knees 
and elbows. Furthermore, he described the hypermobility of joints and their enhanced 
susceptibility to dislocation. It was only in 1901 that Ehlers described the first clinical case of 
patients with loose joints and subcutaneous bleedings, while Danlos described patients with 
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subcutaneous pseudotumours in 1908. In later medical literature, the syndrome acquired the 
name it is known by today: Ehlers-Danlos syndrome. 
EDS is a group of hereditary conditions affecting the connective tissue,. They share 
characteristics such as hyperelastic, thin and fragile skin, loose joints, and easy bruising.
3,4 
A 
significant number of EDS patients cannot be classified in one single type. There is a wide 
variability of expression and a significant clinical heterogenicity.
3,5
  
Due to the nature of the underlying pathology, in particular the inherited congenital defects of 
the collagen, EDS belong to the class of diseases for which there is, as yet, no cure. It is only 
possible to relieve the symptoms, but not to eradicate the underlying cause. 
 
4. Classification  
Until some years ago, EDS had been classified into nine types.
6
 Increasing knowledge and 
availability of diagnostics tests led in 1997 to a classification system, which recognised only 
six types.
7
 Recently, a new classification, recognizing 13 EDS types was published.
8
 The 
classification shows that the key feature, hypermobility, is accompanied by others, which are 
characteristic for each type. Bearing this in mind is of importance in determining the type and 
prognosis of the disease, particularly with regard to the therapeutic options available and the 
quality of life experienced by the patient.  
In order to diagnose hypermobility, a score can be used that was published by Beighton and 
Horan in 1969 and by Beighton et al. in 1973.
2,9
 They gave the first systematic description of 
the anomalies of the musculoskeletal system in EDS and formulated the score, which 
comprises five tests (see chapters 2 and 5). The Beighton score only proves the existence of 
generalised hypermobility. However, the diagnosis of EDS remains exclusive to those patients 
with hypermobility that is accompanied by abnormalities of the skin. Diagnosis is mainly 
clinical, but laboratory tests on tissue samples increasingly play an important role, though not 
so in hypermobile EDS (see chapters 2 and 3). 
 
5. Anatomy 
In order to assess the effect that collagen defects have on the structure and function of the 
musculoskeletal system, it is important to understand some of the basic aspects of the 
components that form a joint. The short description covers those aspects that are relevant to 
understanding how EDS can affect joints and it is not intended as a comprehensive guide.  
Bone in EDS is normal in shape and function
10 
and is usually normal in strength. Osteoporosis 
(decalcification of bone) can occur, but this is rare, and fractures heal normally and can be 
treated according to protocol. Also the hyaline cartilage is normal in EDS. The bony and 
cartilaginous aspects of joints in EDS are therefore morphologically normal.  
Some joints, such as the hip, have deep sockets; the hip socket, for example, surrounds over 
half of the femoral head. Simply as a result of its shape, an adult hip joint is extremely stable 
and is therefore unlikely to dislocate. However, the shoulder joint, with its often very shallow 
socket, makes the shoulder a naturally unstable joint. As a consequence, dislocations of the 
shoulder occur frequently, even in patients who do not have EDS.  
Ball and socket joints are held together within a joint capsule, which is composed largely of 
densely packed collagen fibres forming a joint plate, and are sometimes further supported by 
bands (ligaments). The capsule is firmly attached to both ends of the connecting bones along 
the border of the cartilage, forming a fully encapsulated joint cavity. The inner surface of the 
capsule (the fibrous capsule) is lined with a mucous membrane (the synovial capsule), which 
produces synovial fluid. If the synovial capsule becomes irritated due, for example, to 
dislocation of the joint, other injuries or as a result of inflammation, extra synovial fluid is 
produced which leads to oedema (accumulation of fluid) . This occurs in what is known as 
‘footballer’s knee’. Oedema is an unequivocal sign of damage to or inflammation of the joint. 
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The strength of the capsule is of great importance in maintaining joint stability, particularly in 
those joints that have shallow sockets, such as the shoulder, wrist, ankle, jaw and finger joints. 
These joints therefore lose their stability in EDS patients, because the capsule is weak and 
often ‘stretched’ as a result of multiple dislocations. Dislocations contribute towards 
increasing instability in joints. Each new dislocation becomes less painful, and more easy to 
reduce. When this affects the shoulder, it is referred to as ‘habitual shoulder dislocation’. 
Once the capsule has become stretched due to repeated dislocations, normal joint function 
becomes more and more difficult, due to the joint’s tendency to dislocate and the difficulty 
experienced in exerting pressure. Each dislocation causes damage, not only to the capsule, but 
also to the cartilage. Following damage, cartilage generally lacks the ability to recover. 
Damage caused by a dislocation is therefore additional to any damage sustained previously. 
The cartilage becomes severely worn and the joint gradually becomes arthritic, known as 
degenerative ‘wear and tear’. The more often a joint dislocates, the sooner arthritis will occur 
and the more serious it will be, particularly when it affects weight-bearing joints such as the 
knees. Arthritis therefore, occurs more frequently in patients with EDS than in patients who 
do not have these conditions.
5
 
 
6. Signs and symptoms 
EDS patients usually consult an orthopaedic surgeon due to pain or instability in one or 
several joints. Joint and back pain is very frequent and appears to increase with advancing 
age. On the other hand, instability and hypermobility appear to decrease with age as do 
dislocations, unless these are already habitual. Over half of EDS patients over the age of forty 
suffer from varying degrees of degenerative arthritis,
3,5 
with joints that are severely 
hypermobile being particularly susceptible. There is a direct relationship therefore between 
the incidence of degenerative arthritis and the degree of hypermobility. Persistent joint 
oedema occurs in 20 percent of EDS patients. Dislocations of the shoulder, ankle, jaw and 
patella (knee cap) occur most frequently. Instability of the ankles (sprains) and of the knees in 
children is often accompanied by delayed motor development
3,5 
as a result of poor limb 
control. Pectus excavatum (sunken or funnel chest) also occurs frequently
 3,5
, as do flat feet 
(pes planus). Scoliosis (lateral curvature of the spine) occurs in 50 percent of cases, 
particularly in adults (see figure 8-2). 
A distinction can be made between scoliosis that can be corrected, for example, by a brace, 
resulting in a normal-shaped spine, and those in which this correction is not possible. In 
young children, scoliosis can sometimes be corrected easily but, if a brace is not applied over 
a long period, it will progress rapidly nevertheless. Later in life, this abnormal curvature of 
the spine tends to become increasingly rigid and thus more difficult to correct. Therefore, 
particularly in young patients, frequent follow-up visits are required in order to determine 
whether the scoliosis is progressing, and if the scoliosis has exceeded the critical angle of 30 
degrees. Then the body becomes unstable and the vertebral column should be surgically 
stabilised (see figure 8-2). The risk of the original angle of the curve progressing quickly is 
less frequent in older patients, in whom the potential increase in secondary spinal curves 
presents a greater problem. Although in most patients treatment of scoliosis is not necessary, 
frequent follow-up examinations are  advisable.
11,12
  
Extreme mobility of the vertebral column can sometimes result in dislocation of vertebrae, 
which occurs in the small intervertebral joints behind the vertebral bodies. Excessive pressure 
to the spine as a result of a fall, for example, can cause a spinal cord lesion or even complete 
paraplegia. 
  
Orthopaedic issues in Ehlers-Danlos syndrome 131
 
 
Figure 8-2 Scoliosis in EDS and X-ray showing surgical treatment 
 
 
 
 
Left image: a 35-year-old woman with a right-sided convex scoliosis as a result of EDS. 
Notice the trunk asymmetry demonstrated by the left and right-sided asymmetrical spaces 
between the arms and trunk. 
Middle image: an X-ray of the vertebral column in an adult EDS patient with severe scoliosis, 
which was progressive despite conservative treatment, causing vertebral column instability 
and pain, and therefore necessitating surgical treatment. 
Right image: an X-ray of the patient shown in the middle image, in whom the vertebral 
column had undergone major correction and fixation (= spondylodesis = arthrodesis of the 
spine) using bars and screws. 
 
The ribs are attached to the spine and the sternum (breastbone) by small joints. The capsule of 
these joints can become increasingly slack, which can result in subluxations and dislocations. 
No effective therapy is available for these often very painful subluxations and dislocations, as 
mobility of these joints is required to facilitate breathing. Over time, the abnormal mobility 
can cause the breastbone to drop forwards and downwards, decreasing the distance between 
the first rib and the clavicle, thereby putting pressure on important structures such as the 
blood vessels and nerves that pass from the thorax to the arm. This can result in symptoms 
typical of ‘thoracic outlet syndrome’, which include pain radiating from the neck and the 
shoulder to the arm and hand.  
Hypermobility of the hand and wrist are very frequent. Dislocation of the hip is rare in adults 
without dysplasia of the hip thanks to the unusual shape of the joint, as said before. Only as a 
result of force being exerted, such as in an accident, luxation takes place. In young children 
dislocation of the hip occurs but it  is usually caused by factors such as the abnormal and 
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EDS-unrelated development of the hip (hip dysplasia). In combination with EDS-related 
collagen defects, the joint’s tendency to dislocate increases. Bone fractures are not more 
frequent in EDS patients than in healthy persons and, if a fracture does occur, healing is 
usually normal.  
Chronic pain is a frequent symptom of EDS and is usually localised in the shoulders, hands 
and knees.
13,14
 Nocturnal cramps are also very frequent. These may be the result of poor blood 
circulation at night or excessive exertion during the day. In the nocturnal recuperation phase, 
when the muscles are not helping pump blood to the legs, circulation is inadequate and 
accumulated lactic acid can cause spastic contractions of the muscle fibres. Muscular 
weakness also is a common symptom as the muscles become deconditioned.
5
 It is not clear 
whether this is a direct result of EDS or a result of decreased muscle use, due either to pain or 
weakening of the tendons and ligaments, whereby muscle tone diminishes (see chapter 13). 
Fragility makes the skin highly prone to injury and bruising and adversely affects healing of 
wounds following trauma or surgery.  
Fatigue has a crippling effect on many EDS patients
15
, although the exact way in which this is 
related to EDS is still unclear. One possible explanation is, that chronic pain in the muscles 
and joints causes fatigue, as does the use and coordination of weakened muscles. Orthostatic 
problems such as venous insufficiency, particularly in the legs, may cause excessive fatigue. 
 
7. Management 
Not all patients with hypermobility have a hypermobility syndrome; hypermobility can also 
be localised, and likewise not all patients with generalised hypermobility have EDS. There are 
many different treatment options, depending particularly on the severity of the complaints and 
the stage of the disease. Many patients with hypermobile EDS have relatively few symptoms 
and do not require any treatment at all. These patients can often benefit from a well 
maintained exercise regimen at home, particularly in the early stages of the disease, provided 
the regimen has been explained adequately and patients have the option for counselling when 
necessary. 
Orthopaedic treatment options are either non-surgical (conservative) or surgical, although 
conservative treatment remains the primary option of choice where possible.
3
 If this proves 
inadequate, surgery may then be considered. The results of surgery are never entirely 
predictable; recurrence and complications can occur and the results of surgical intervention 
are usually irreversible.
12
 The conservative and surgical treatment options available are 
discussed below.
 
 
7.1 Conservative treatment 
It is always essential to fully inform patients, particularly those with non-curable, chronic 
conditions such as EDS. It is essential that patients learn to recognise and accept their own 
limitations and adopt a suitable lifestyle that includes a good balance between physical load 
and their capacity for load-bearing with regard to daily activities, occupation and sport. For 
the same reason overweight has to be avoided. It cannot be stressed enough that the limited 
reserve capacity of the musculoskeletal system is what determines the limitations experienced 
by EDS patients. It is important for patients with EDS to realise that their body has a limited 
capacity to withstand physical load. Physical loads which are too heavy, too protracted and 
too frequent can lead to the early onset of chronic fatigue and pain due to unstable joints and 
arthritis. 
 
7.1.1 Physiotherapy – exercise therapy (see also chapter 22) 
It is important to realise that active exercise therapy
16
 should be carried out in carefully 
controlled way. Following physiotherapy, patients should not experience more pain than 
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beforehand. If this occurs, the therapy was too strenuous, exercises too heavy and weight 
training too intense. Physiotherapy should be used in moderation and the intensity increased 
only very gradually. If the pain or cramp increases nevertheless, the therapy should be 
adapted in intensity, force and duration. Particular care must be taken with weight training. 
The force exerted by muscles is transferred to the tendons, ligaments and joint capsules, 
which are highly prone to ‘stretching’. It is not possible to strengthen these structures through 
exercise or weight training. Weight training can cause joints to become unstable and painful if 
they were not so already.  
It is possible, however, to train muscle coordination and in some cases proprioception (the 
sense of how one's own limbs are oriented in space).
16 
 Proprioception coordinates muscle 
activity, or the subtle interplay between agonists and antagonists, allowing for smooth joint 
movements (see chapter 13). A well-trained muscular system can help to stabilise the function 
of unstable joints. It is more important for patients to be able to make smooth, well-
coordinated movements than to be able to exert great force. Moreover, it is rarely necessary 
for the patient to exert great force in their daily activities, and many assistive devices are 
available to help patients to, quite literally, save their strength. However, this does not mean 
patients no longer have to exercise actively. On the contrary, home exercises must be carried 
out twice a day for at least thirty minutes to prevent further muscle deconditioning and loss of 
the muscles’ capacity for coordination. 
EDS patients who regularly experience pain, must be taught how to cope with the pain. They 
should be discouraged to become passive, becoming bedridden or chair/wheelchair bound 
without moving. The motto ‘to move is to live’ also applies for EDS patients. Almost all 
rehabilitation centres have a programme dedicated to dealing with pain. If necessary, 
particularly in cases of acute pain, temporary analgesia may be given to relieve the symptoms, 
although it is important that these are prescribed with caution, partly due to the risk of side-
effects. EDS patients must continue to walk as much as possible as this (more than any other 
activity) helps to maintain good physical condition. Unlike in the past, it is nowadays 
accepted that fatigue, which is a common complaint in EDS patients, must not be treated with 
long-term rest. Acute fatigue may be treated with short periods of rest. Chronic fatigue must 
be treated using periods of rest alternated with controlled periods of movement and walking 
or exercise. 
 
7.1.2 Mensendieck therapy and Cesar therapy  
It can often help patients to determine a daily routine of movement tailored to their own 
capacity, and help them find a balance between physical load and the patient’s physical 
capacity. 
 
7.1.3 Occupational therapy (see also chapter 24)  
It can be helpful in treating patients to cope with the limitations experienced in day-to-day 
activities and to help protect joints using, for example, assistive devices and instruments. 
Crutches may be required for patients with leg problems although care must be taken in 
ensuring that this does not cause new problems in the shoulders and wrists, which are highly 
prone to instability. A wheelchair may be useful in some cases, although it is important that, 
where possible, wheelchair use is alternated with walking, even when only for short distances. 
Patients with EDS may benefit in the early stages of the disease from intermittent wheelchair 
use for long distances and long-term physical load in order to use their physical capacity 
reserves as efficiently as possible. In later stages wheelchair use can be necessary more 
frequently. Unstable joints can be stabilised externally, using braces, which allow movement 
of the joints. Braces can also be made in such a way that they only allow limited joint 
movement, or only a slight range of movements. These braces are sometimes available over-
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the-counter but can also be made to measure by an orthopaedic instrument technician. Spinal 
braces have only a very limited application for back complaints such as scoliosis. Scoliosis is 
progressive in some patients, often despite the use of a brace. Evidence has shown that many 
patients, adults in particular, discard the brace after a short time as they find it highly 
inconvenient. It is essential that the progression of the scoliosis is checked regularly (see 
above). 
 
7.1.4 Orthopaedic shoes  
Arch supports and orthopaedic shoes can be tailor-made (see chapter 24), often preventing or 
postponing the need for surgery. Surprisingly, patients often prefer to walk in shapeless sports 
shoes that no longer offer any support. This is acceptable in the short term, provided they do 
not result in further problems, but this type of footwear does not help to maintain correct 
shape and therefore function of the foot in the long term. Often, it is only later in life that 
patients realise how much pain can be caused by malformed feet, for which it is also more 
difficult to find proper shoes. Nowadays, orthopaedic footwear by using modern materials are 
much lighter and more elegant than they used to be. 
 
7.2 Surgical treatment methods 
Orthopaedic surgery, and joint replacement surgery in particular, can be successful and 
contribute to the patient's quality of life. Unfortunately, this does not always apply for patients 
with EDS. The specific collagen abnormalities in EDS patients can result in complications of 
the healing process in the various layers of the surgical wound. Joint surgery always involves 
wounds to the skin, the underlying fibrous tissue and tendons, muscles, ligaments and the 
joint capsule. Efficient healing of these layers requires normal collagen and scar tissue 
formation. Scar tissue is known to be naturally inferior to normal tissue in its ability to 
withstand wear and tear, as the collagen in scar tissue is different and often of poorer quality 
than in normal tissue. The collagen in EDS patients is abnormal in composition and patients 
therefore have an increased risk of experiencing problems with wound healing. Problems 
range from, sometimes very severe bleeding
17
, particularly during and following surgery, the 
‘bursting’ open of surgical scars that would normally have healed (wound dehiscence), wide 
and distorted scar formation, and defects in subcutaneous fibrous and adipose tissue, causing 
wound herniation. The scar itself can be as thin as cigarette paper (see figure in chapter 4) and 
therefore remain vulnerable to damage. Tendons, ligaments and capsules that have been cut 
during the operation and which already had the tendency to overstretch, might weaken and 
stretch due to their poor healing quality and the inferior scar tissue, even after healing well 
initially. The intended effect of tightening the capsule and ligaments is therefore often lost 
entirely within several months. Attempts to stabilise loose and unstable joints in EDS patients 
by ‘soft tissue operations’ are therefore generally ineffective. The joints usually become 
unstable again, and sometimes even more unstable, soon after the operation. Operations to 
strengthen capsules and ligaments using artificial or donor ligaments are usually also 
unsuccessful. Artificial ligaments have a limited lifespan, particularly in physically active 
patients, and often rupture within two years on average due to material fatigue.  
Those who advocate the use of artificial ligaments maintain that these have usually become 
infiltrated with the patient’s own collagen already. Even if this is the case, the infiltrated 
fibres are composed mainly of inferior scar collagen which also contains EDS abnormalities 
and are therefore inherently weaker than normal tissue. This also applies for donor ligaments. 
Replacing unstable, painful joints with artificial joints in EDS patients is usually unsuccessful 
and therefore not recommended. Artificial joints are made up of two parts, a ball and a socket, 
both of which have to be attached to bone. They are usually held in place by the patient’s own 
joint capsule. The capsule is opened surgically in order for the two joint sections to be 
Orthopaedic issues in Ehlers-Danlos syndrome 135
 
 
attached to the bone and must be repaired and closed up once the two components have been 
inserted. This again results in the formation of scar tissue containing EDS collagen in the 
inferior quality capsule. Moreover, there is a high risk that the artificial joint will not function 
adequately due to instability. The only type of operation with reasonable potential for success 
is arthrodesis, in which the unstable joint is fixed permanently by removing the cartilage and 
fusing the two bones with metal plates and screws (see figure 8-1 and 8-2). A plaster cast can 
subsequently provide temporary support for several weeks or months. When the two bones 
have fused firmly, the metal can then be removed surgically (methods vary for the different 
types of arthrodesis). Scoliosis can be treated relatively successfully in this way, although 
sometimes the metal components can become loose. Arthrodesis of the hand, wrist, ankle and 
foot can also be successful, providing good stability and pain relief.  
Nevertheless, the indications for arthrodesis must be considered very carefully. It is important 
to realise that eliminating the movement in one joint results in extra load to both adjacent 
joints in the movement chain, increasing the risk of instability and pain. For this reason, it is 
also advisable to further discuss the balance between physical load and physical capacity 
following surgical stabilisation of a joint. 
 
8. Conclusion 
The main orthopaedic treatment options comprise conservative measures with moderate and 
well-balanced exercise therapy, the use of braces, and adaptive measures in a patient’s daily 
routine and environment with the aim of achieving a balance between physical load and 
physical capacity. Surgical intervention, such as arthrodesis, can also be successful provided 
the indications are correct. On the other hand, reconstructive surgery, such as soft tissue 
procedures (tightening or shortening the ligaments and capsules, and inserting artificial and 
donor ligaments, and joint replacement surgery are not usually recommended. These 
interventions are likely to fail within a short time. The indication for conservative treatment 
becomes more urgent as the degree of instability and hypermobility becomes more severe. 
The use of a wheelchair, particularly for long distances, to preserve the patient’s remaining 
mobility may be unavoidable in such cases. 
 
Addendum by the editors 
In the March 2017 issue of the American Journal of Medical Genetics Part C Seminars in 
Medical Genetics, all papers were devoted to EDS, covering a new EDS nosology,
8
 new 
diagnostic criteria of the different types and also management related topics (see also chapter 
2). One of these papers entitled “Orthopaedic management of the Ehlers-Danlos sydromes”, is 
recommended for further reading.
18 
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1. Introduction 
For a plastic surgeon, the skin is the central issue of the Ehlers-Danlos syndrome (EDS); skin 
abnormalities often occur in EDS patients.
1
 The skin often is thin (likened to cigarette paper), 
hyperextensible, vulnerable and prone to easy injury. The skin consists of two layers, the 
epidermis (upper layer) and dermis. In EDS the dermal collagen is abnormal, in particular 
collagen type 1, 3, and 5. A slight trauma, e.g. on the shin, elbow, or knee may result in a 
wound. Once sutured, the stitches tear easily and the scar may widen. With the application of 
plastic surgical techniques the risk of such problems can be reduced.
2,3,4
 Of course, not all 
wounds of EDS patients have to be treated by a plastic surgeon; practitioners should be 
familiar with EDS and have mastered basis plastic surgical techniques. One of these 
techniques is the use of so called Lange’s skin lines or lines of relaxed skin tension. When an 
incision is made in one of these skin lines, it is possible to close it with minimal tension which 
will result in better healing. For surgery, another problem is the diminished effect of local 
anaesthetics,
5,6
 which cannot be explained by rapid dispersal of the solution because of the lax 
skin.
7
 
Typical complaints of EDS patients visiting a plastic surgeon are poor and disfiguring scars 
after an operation or injury, and permanent skin pigmentation after haemorrhages. Additional 
problems are ligament injuries of the wrist and finger joints, as well as general cosmetic 
interventions like breast enlargement or reduction and facial improvements. Ruptures of scar 
tissue are also treated by general surgeons.  
General guidelines and recommendations for operations on EDS patients will be discussed as 
well as surgery for specific EDS abnormalities, and general cosmetic procedures. 
 
2. General measures and precautions concerning surgery of EDS patients 
 
2.1 Surgery in general  
Medically necessary surgery can and should take place as normal, but regarding 
"rejuvenations" and other cosmetic operations, the risks of poor and disfiguring scar 
formation and the likelihood of other complications should be weighed against the possible 
benefits. EDS patients are also at greater risk of haemorrhaging and bleeding. 
 
2.2 Acute lacerations (injuries) 
The patient with classical EDS, with "cigarette paper skin" is at risk of wide disfiguring scar 
tissue, often with brown pigment spots in or around the injured area. Lacerations of the skin 
should be closed in 2 layers, with minimal tension on the stitches. Usage of adhesive 
bandages should be dissuaded, as blisters will appear quickly while the skin is pulled to bring 
the edges of the wound together. After stitching the wound, local immobilisation by means of 
a plaster cast is recommended, as well as leaving the stitches in for a few extra days compared 
to the normal situation. This is necessary since the wound is less resistant to stretch compared 
to stitched wounds in normal individuals, and therefore there is a risk of wound dehiscence 
after removing the stitches too soon. Normally, stitches in the face are removed after 5-7 days 
and elsewhere in the body after 10-14 days, depending on the location. The use of skin glue in 
EDS patients has thus far not been shown to be of benefit. 
 
2.3 Scars 
Correcting a wide scar may be necessary if the wound has healed “per secundam” or by 
secondary intention, i.e. the wound has not been stitched, but has healed over time after the 
formation of granulation tissue. Also a wide scar as a result of stitching the skin under tension 
or without local immobilization can be corrected. Scar tissue running over the joints often 
becomes wide due to movement of the joint and is therefore unlikely to be improved 
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permanently by revision. Brown pigment spots in the skin are the result of iron disposition, 
due to bruising. It may not be possible to remove them.  
 
3. Correction of abnormalities related to EDS 
 
3.1 Molluscoid pseudotumours 
These are benign swellings (tumours) that originate in pressure locations such as elbows or 
knees. They can be 2 to 3 cm in diameter and are probably the result of repeated 
haemorrhages with scarring, or herniations of subcutaneous fat tissue through the weak 
dermal fibrous tissue. Removal is possible, but should only be done in case of complaints, e.g. 
if it results in discomfort or injury of the skin when wearing shoes. Such a pseudotumour can 
be removed by dissecting the swelling with a surgical incision parallel to the direction of the 
collagen fibres.  
 
3.2 Epicanthic eye folds 
These are symmetric extra skin folds in the inner corners of the eye giving the impression of 
the nose being widened. In case of the classical type this is often diagnosed during childhood 
and frequently spontaneously disappears with age. 
 
4. Joints and tendons 
Painful wrist or finger joints of EDS patients are not necessarily the result of a trauma 
(injury). The ability to overstretch the joints when using the joints, which are ‘designed’ for a 
normal range-of-motion, may lead to abnormal strain, resulting in inflammation, swelling, 
cartilage damage and eventually osteoarthritis with joint degeneration.
8
 
Joints may become even more unstable, eventually resulting in (sub)luxations. Instability of 
the wrist is not very common, however instability is common in finger joints, making e.g. 
typing and opening bottles difficult. In general, splint therapy would be indicated, but it 
should be mentioned that this is not always satisfactory and sometimes arthrodesis (fixation of 
the joint) is necessary. A disadvantage of arthrodesis is that as a result the adjoining joints 
have to compensate for the loss of function, and therefore more strain is put on the adjoining 
joints. Plastic surgery of tendons for stabilization of joints is not meaningful in EDS patients 
as the effect is short-lived, as we learned in the past, especially if it was unclear that we were 
dealing with EDS. 
EDS patients may also develop luxation of tendons, due to stretching of the sheaths or 
grooves the tendons run through. Correction is not easy; furthermore in time the reconstructed 
tendon will stretch again and will thus become unstable again. Another complication of EDS 
is tendon rupture.
9
 
 
5. Aesthetic surgery 
 
5.1 Correction of droopy eyelids 
Correction of bags of the upper and/or lower eyelids takes place on a daily basis in hospitals 
and private clinics. In classical or vascular EDS, this problem might occur more frequently 
compared to other types of EDS. The “excess” and/or droopy skin is removed, often including 
removal of the small surplus fat lumps in the eyelids. In theory, this is a safe operation; 
however, it does have its challenges. If too much skin is removed the eye will remain open. A 
bleeding could occur in the eye socket which should be treated urgently due to risk of 
blindness. Evidently this should be taken into account when planning to undergo such an 
operation; probably EDS patients are at higher risk for complications of this type of surgery.  
 
The role of plastic surgery in Ehlers-Danlos syndrome 141
 
 
5.2 Facelift 
Due to the deficiency of collagen support in the skin, premature skin ageing often is a feature 
of EDS. A facelift might be desirable, but can have significant complications.
10
 The skin 
cannot be excessively tightened due to danger of tearing; scars in front of the ear may become 
wide and noticeable while the greater chance of bleeding may result in haematomas. Smoking 
increases the risk of premature skin ageing via a negative effect on collagen and probably also 
the risk of complications of this kind of surgery in EDS patients. For wrinkles, laser therapy 
could be an option.
11
 
 
5.3 Breast enlargement 
Although no literature concerning breast enlargements in EDS patients is available, a few 
comments can be made. Breast enlargement, also called mamma augmentation, is performed 
by placing a (silicone) prosthesis below the mammary gland or - deeper - below the pectoral 
muscle. To be able to do this an incision should be made in the fold below the breast or in the 
armpit. Subsequently, an opening is made to fit the prosthesis. The risk of haemorrhage is 
greater, which, if not drained, could result in infection and extra scarring. This increases the 
risk of a “capsular contracture”, where scar tissue around the implant contracts to form a firm 
ball. This may be symptomatic as well as disfiguring. In addition as a result of tension on the 
wound, disturbance to the healing process can occur with the possibility of wound dehiscence. 
If this occurs, the prosthesis has to be removed. Finally, a warning should be given for the risk 
that the skin will generate “striae”, because of the weight of the prostheses and the tension on 
the lax skin.  
 
5.4 Breast reduction 
Breast or mamma reductions are often done because of functional considerations. Patients are 
weighed down by the heavy breasts, with neck and shoulder pain and sometimes complaints 
of chafing the skin under the breasts. A breast reduction could then be the solution. During the 
operation a reasonably large wound is made that has to be stitched, so haemorrhaging could 
be a complication. When stitching the breast, no tension should occur, to prevent tearing of 
the wound or development of wide scars. After a successful operation a well supporting bra 
should be worn day and night for at least 6 weeks in order for the breasts to heal steadily.  
 
6. Summary 
Although the risk of complications of surgery is increased, with careful surgical techniques 
and after weighing risks and benefits of surgery (especially whether the improvement will be 
lasting),
12
 much is possible.
13
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1. Introduction 
Gastrointestinal (GI) involvement in Ehlers-Danlos syndrome (EDS) is well known from 
decades, since the seminal work by Beighton and co-workers
1
 consisting of a survey of GI 
manifestations in 125 patients with various clinical forms of EDS. Vascular EDS is the best 
known EDS type associating with GI manifestations. Since its actual clinical and molecular 
definition,
2
 patients with vascular EDS usually present abdominal complaints acutely in form 
of vascular or internal organ ruptures. These complications are often severe and may need 
surgery. Abdominal and GI manifestations are also registered in other EDS types, mostly 
classical and hypermobile EDS (hEDS). Although hEDS and the (benign) joint hypermobility 
syndrome have been considered one and the same entity by many researchers and 
clinicians
3,4
, the 2017 International Classification of EDS and related disorders put more order 
around the concept of “joint hypermobility”. In particular, it is now accepted that “joint 
hypermobility” is not a disorder per se, but it is just a clinical sign. Joint hypermobility is a 
common feature of many genetic disorders and, among them, EDS is a prototype. 
Nevertheless, many patients suffering from musculoskeletal complaints secondary to joint 
hypermobility are not affected by a recognizable syndrome. Hence, a spectrum of phenotypes 
is now defined ranging from isolated, non-syndromic joint hypermobility to hEDS. The gap is 
filled by the hypermobility spectrum disorders (HSDs), which are transitory, exclusion 
diagnoses for all individuals manifesting features related to joint hypermobility but who do 
not carry mutations in known genes and do not respect the new hEDS criteria.
5,6
 For 
conservative reasons, in this chapter the term hEDS/HSDs is used for all papers published 
before the 2017 classification and dealing with patients with hEDS and/or benign joint 
hypermobility syndrome according to the old diagnostic criteria.  
In this chapter, the connections between an inherited defect of collagen biogenesis and gut 
involvement are presented by an extensive literature review concerning GI manifestations 
associated to the following phenotypes: vascular EDS, hEDS/HSDs, classical EDS, 
unspecified/non-syndromic generalized joint hypermobility, and EDS of unclassified variants. 
Along with a detailed report on available data concerning type and rate of a variety of GI 
features in the studied phenotypic categories, considerations on presumed pathogenesis as 
well as reasonable assessment and treatment approaches are also reported.  
 
2. Gastrointestinal manifestations in vascular EDS 
Numerous case reports have been published about the, often disastrous, gastrointestinal 
manifestations of vascular EDS. The twenty-seven case reports or small case series reported 
below show considerable overlap, but one feature is striking: in eighteen papers the described 
GI problem caused the first presenting symptoms leading to the diagnosis of vascular EDS. In 
nine reports GI manifestations in known vascular EDS patients are described. Eleven papers 
describe a spontaneous rupture or perforation of the sigmoid colon,
7-17
 while a iatrogenic 
perforation of the sigmoid colon during colonoscopy is described in one case report.
18
 Dunn 
and colleagues described a sigmoid hematoma that was surgically resected under the 
impression that it was a neoplasm; histopathologic evaluation, however, pointed in the 
direction of vascular EDS.
19
 Rupture of solid organs has been described as well, both splenic 
rupture
20,21
 and liver plus vena cava rupture.
22
 Van Bon et al. described peliosis (e.g. presence 
of benign, irregular cystic blood-filled cavities within the parenchyma of solid organs) of the 
spleen preceding the rupture.
20
 Isolated vascular ruptures leading to massive haemorrhage can 
occur anywhere in the body in vascular EDS, and the abdomen is not spared. Rupture of 
splenic artery aneurysm,
23
 ileocolic artery
24
 and other mesenterial vessels
7,11,25
 have all been 
described as the presenting symptom of vascular EDS. 
In known vascular EDS patients rare abdominal vascular abnormalities have been described: 
hepatoportal fistula,
26,27
 hepatic artery aneurysm,
8,28
 rupture of a splenic artery aneurysm,
29
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aneurysm of the celiac trunk
30
 and spontaneous retroperitoneal haemorrhage.
31
 Diverticula of 
various organs have been described as well: biliary diverticula, sigmoid diverticula and 
bladder diverticula all in the same patient,
26
 presumably these can also lead to perforation, as 
has been described in the small bowel.
32
 
 
3. Gastrointestinal manifestations in hEDS/HSDs 
Studies exploring GI manifestations in hEDS/HSDs include (i) case-series showing rough 
rates of selected GI features in hEDS/HSDs,
33-37
 (ii) case-control studies comparing rates of 
selected GI features between hEDS/HSDs and general population,
38-41
 (iii) studies 
investigating the variability of GI features and their relationships with other 
manifestations/characteristics of hEDS/HSDs,
42-44
 and (iv) case reports on surgical abdominal 
and GI findings in hEDS/HSDs.
45-56
  
Hakim and Grahame
33
 first noted GI complaints in 37% of hEDS/HSDs women. In this study, 
the value was cumulative for nausea, stomach ache, diarrhoea and constipation, and separated 
rates were not available. By describing obstetric and gynaecological findings in 82 women 
with hEDS/HSDs, Castori et al. found GI complaints in 72% and rectal prolapse in 11% of 
cases.
36
 Three further works reported prevalences for selected GI features,
34,35,37
 including 
dysphagia (14%), dyspepsia/chronic gastritis (8-67%), gastro-oesophageal reflux (20-74%), 
bloating (57%), nausea (57%), vomiting (57%), recurrent abdominal pain (26-86%), 
constipation/diarrhoea (33-76%), abdominal hernia (5-20%). The rate of many of them seems 
to significantly increase with age,
33
 often with an identifiable natural history.
57
 Zarate et al. 
offered more details on a series of GI physiology investigations in HEDS/HSDS patients, 
including oesophageal manometry, 24 h pH-metry, gastric emptying study, small bowel 
manometry and colorectal physiology study, with positive findings in 33% (4/12), 42% 
(5/12), 80% (12/15), 44% (4/9) and 100% (6/6) of cases, respectively.
37
 
Findings of the three case-control and one cross-sectional studies are summarized in table 10-
1.
38-41
 In the paper by Manning et al. women with lower urinary tract dysfunction were 
investigated for clustering of specific features and a clear relationship between hEDS/HSDs 
and defecatory problems emerged in this patient subgroup.
38
 Danese et al. reported a small 
study suggesting a relationship between celiac disease and hEDS/HSDs comparing data 
between 31 patients of both sexes and with various ages,
39
 to previously published data on 
rate of celiac disease in the general population.
58,59
 Mastoroudes et al. demonstrated a 
significant excess of various defecatory problems in 60 women compared to highly matched 
controls.
40
 The largest study is that by Fikree et al. on 187 adults compared to 372 controls, all 
attending a gastroenterology clinics.
41
 In this work, patients were more commonly females 
and younger than controls and tended to display more commonly several upper GI 
complaints. An association of extra-GI autonomic complaints, fibromyalgia and chronic pain 
with hEDS/HSDs was also confirmed.  
De Wandele et al. by carrying out a questionnaire study on 78 HEDS/HSDS adults, found 
three phenotypic clusters by an agglomerative hierarchical cluster analysis. GI complaints 
occurred more commonly in cluster 2, which showed the highest rate of fatigue, sleeping 
disorders, orthostatic intolerance, thermoregulatory problems, inflammatory signs and 
cardiovascular symptoms, as well as the largest functional impairment and the most severe 
pain.
42
 In a further work, the group compared the rate and impact on quality of life of selected 
“autonomic” complaints in hEDS/HSDs with classical and vascular EDS, fibromyalgia and 
healthy controls. Among the EDS groups, hEDS/HSDs showed the highest rate of autonomic 
features, and the burden was comparable with fibromyalgia.
43
 Pacey et al. presented the 
results of a questionnaire study in 89 children with HEDS/HSDS.
44
 Analysis of phenotypic 
data identified five subtypes by a loading matrix generated displaying the extent of the 
correlation between each of the included measures and the identified factors. One of these 
Gastrointestinal complications of Ehlers-Danlos syndromes and hypermobility spectrum disorders 147
 
 
subtypes (called “systemic BJHS”) was characterized by the unique symptoms of skin 
involvement and urinary stress incontinence, as well as a high rate of recurrent joint instability 
and GI involvement. GI involvement was defined by the presence of recurrent constipation, 
diarrhoea or abdominal pain, or the diagnosis of slow transit constipation or irritable bowel 
syndrome.  
All case reports describing abdominal and GI surgical manifestations in hEDS/HSDs are 
reported in table 10-2.
45-56
 In hEDS/HSDs, surgery appeared repeatedly successful for treating 
diaphragmatic defects leading to a variety of clinical presentations,
46,47,49
 while on the 
contrary, surgery was often ineffective for the correction of visceroptosis and pelvic organ 
prolapse.
51,53
 Laparoscopic subtotal colectomy for bowel ptosis had positive results in one 
instance,
52
 as well as the repair of a recto-vaginal fascia with porcine small intestinal 
submucosa mesh in a woman with pelvic organ discomfort for multiple prolapses.
55
 The 
injection of 5 ml of 5% phenol in almond oil resulted in effectively treating recurrent rectal 
prolapse in a 2-year-old infant.
45
 
 
4. Gastrointestinal manifestations in classical EDS 
Our knowledge concerning GI manifestations in classical EDS is actually limited to single 
clinical reports, mainly focused on surgical aspects. All available case reports are summarized 
in table 10-3.
60-70
 Considering the presumed rate of classical EDS in the general population as 
one of the most common EDS types,
69
 GI involvement seems relatively rare in this condition. 
Among the eleven reported patients with (presumed) classical EDS and GI manifestations, 
bowel dilatation with or without malrotation occurred four times,
61,65,68,70
 gut diverticula and 
related complications (i.e. diverticulitis, gut perforation) trice,
60,61,68
 spontaneous gut 
perforation (apparently, not secondary to diverticula) twice,
64,65
 eventration of the diaphragm 
twice,
63,64
 multiple mucosal erosions (possibly leading to anaemia) twice,
65,68
 haemorrhoids 
once,
61
 rectal redundancy and inguinal hernia once,
66
 and lethal haemorrhage due to 
intrabdominal vascular fragility once.
67
 Surgery was indicated for reasons unrelated to the 
underlying connective tissue disorder in two cases, appendectomy due to acute appendicitis
62
 
and liver transplantation for end-stage liver insufficiency.
69
 Hence, compared to hEDS/HSDs, 
GI involvement in classical EDS appears less common and most patients were referred for 
(acquired) structural anomalies rather than functional symptoms. Whether GI involvement in 
classical EDS also comprises a spectrum of functional GI symptoms similar to (or perhaps 
overlapping) hEDS/HSDs is still a matter of debate and needs dedicated studies. The 9-year-
old boy with classical EDS due to mutation in COL5A1, reported by de Leeuw et al., who 
died because of a rupture of an intra-abdominal vessel, shows that an acute presentation 
resembling vascular EDS is possible in classical EDS.
67
 
 
5. Gastrointestinal manifestations in unspecified generalized joint hypermobility 
Fifteen case-control studies compared the rate of specific GI features in subjects with 
unspecific/non-syndromic generalized joint hypermobility. Twelve studies (80.0%) yielded 
positive results and are summarized in table 10-4.
37,72-82
 The remaining gave negative 
results.
83-85
 However, while in one of these studies a relationship between unspecified 
hypermobility and pelvic organ prolapse was not identified, the authors found an association 
between pelvic organ prolapse and other “soft” markers, such as easy bruising and varicose 
veins, of an underlying connective tissue disorder. Of the twelve studies with positive results, 
four studied adult females only,
73,76,78,81
 five adult males and females,
37,74,75,77,79 
two children 
and adolescents from both sexes,
80,82
 and one children, adolescents and adults from both 
sexes.
72
 These studies were strikingly heterogeneous for the assessing method for unspecified 
hypermobility, which was the Beighton score with a positive cut-off of >4 in four,
37,76,77,78
 
Beighton score with a positive cut-off of ≥4 in two,
75,82
 Beighton score with an undefined 
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positive cut-off in one,
79
 the self-reported 5-point questionnaire in one,
80
 and a self-developed 
screening method in four.
72,73,74,81
  
Association between unspecified hypermobility and chronic constipation, alternatively termed 
chronic intestinal pseudoobstruction
74
 or slow transit constipation,
80
 appeared the most 
consistent, being observed four times in both sexes from all ages.
74,77,78,80
 Also the association 
between unspecified hypermobility and rectal/pelvic prolapse and anal/faecal incontinence 
appeared strong in women.
72,73,76,77,81
 A study pointed out a relationship between constipation 
and a past history of pelvic prolapse in females.
80
 Three further papers highlighted the 
association between unspecified hypermobility and gastro-oesophageal reflux and bloating,
37
 
hiatus hernia,
75
 and Crohn disease.
79
 The net prevalence of an absent precipitating factor for 
constipation and upper GI complaints was demonstrated twice in individuals with unspecified 
hypermobility compared to non-hypermobile subjects.
37,80
 This evidence further supports the 
“functional” nature of these complaints in association with unspecified joint hypermobility. A 
further, not tabulated paper analysed the prevalence of specific anamnestic features in 568 
women at 12 months postpartum after a high risk delivery (i.e. instrumental delivery and/or 
high birth weight infant), and found a relationship between faecal incontinence and 
unspecified hypermobility in the patient group.
86
 
 
6. Gastrointestinal manifestations in unclassified EDS 
A handful of papers reports large data on various GI aspects in EDS without a clear separation 
of results by clinical type. In 1969, Beighton et al.
1
 reported a retrospective study on GI 
complications in 125 EDS patients. Stratification was not available and vascular 
complications are likely related to the vascular EDS (see below). However, in this work, the 
authors pointed out a non-stochastic association between EDS and a series of GI and 
chronic/recurrent abdominal features, including diverticula at different points of the gut, rectal 
prolapse, and various abdominal and diaphragmatic hernias. A more recent study found 
swallowing difficulties in 39% of 411 EDS patients affected by the types I and II (classical 
EDS), III (hEDS/HSDs), IV (vascular EDS) and VI (kyphoscoliotic EDS).
87
 Carley and 
Schaffer, by reporting data on urinary incontinence and pelvic organ prolapse in 12 Marfan 
and 8 EDS women, described rectal prolapse in 2 (25%) EDS patients.
88
 More recently, 
Zeitoun et al. reported the results of a questionnaire study on 134 patients with various EDS 
types and found a high rate of symptoms of dyspepsia and gastro-oesophageal reflux, irritable 
bowel syndrome and functional constipation.
89
 The Gastrointestinal Quality of Life index was 
significantly lower in the EDS cohort compared to controls. Based on their experience, the 
authors considered endoscopy of the upper gut relatively safe, while they were more sensitive 
in performing colonoscopy due to organ fragility in vascular EDS and the risk of mucosal 
bleeding in most EDS types. Abonia et al. described a 8-fold risk of eosinophilic esophagitis 
in patients with hereditary connective tissue disorders, like EDS, Marfan and Loeys-Dietz 
syndromes, compared to the general population.
90
 A peculiar face in patients with the 
combination of connective tissue disorder and eosinophilic esophagitis was also proposed. 
Although literature is scanty on this argument, GI manifestations could be encountered also in 
other EDS types included in the 2017 International classification.
5
 Among them, 
dermatosparaxis EDS deserves mention as umbilical hernia is included as a major criterion for 
the clinical diagnosis of this EDS type.  
 
7. Summarising considerations 
Actual knowledge concerning GI manifestations in EDS chiefly concerns the commonest 
clinical types, namely hEDS/HSDs, classical and vascular EDS. In particular, most studies are 
focused on hypermobile and vascular EDS, while GI involvement in classical EDS is, at the 
moment, reported in a dozen of single case reports. The spectrum of GI manifestations linked 
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to EDS is wide and ranges from (i) acquired and congenital structural anomalies of the 
abdominal wall, diaphragm, pelvis and gut, to (ii) chronic functional symptoms and related 
disability, to (iii) acute presentations due to vascular or hollow organ spontaneous (or 
iatrogenic) ruptures. While manifestations of (i) and (ii) are typical of hEDS/HSDs, (iii) is 
specific of vascular EDS. Concerning classical EDS, accumulated data are too scarce to depict 
a recurrent GI phenotype. However, classical EDS patients seem to present manifestations 
mostly belonging to acquired and congenital structural anomalies of the abdominal wall, 
diaphragm, pelvis and gut, although also spontaneous vascular ruptures may rarely occur. In 
addition, mucosal fragility manifesting as multiple mucosal erosions possibly leading to 
occult haemorrhages and chronic anaemia is a further possibly underestimated GI 
manifestation of classical EDS.  
 
8. Pathogenic considerations 
Pathogenesis of GI manifestations in EDS is still partly unknown and the existence of specific 
factors often remains speculative. On a wider perspective, connective tissue is strongly 
represented in various components of the GI tract, such as peritoneal ligaments, gut wall and 
splanchnic vessels. Peritoneal ligamentous laxity leading to hypermobility of the intra-
abdominal viscera is considered a predisposing factor to abdominal twists and torsions,
91
 and 
could also facilitate visceral prolapse or hernias under the additive effect of gravity and 
factors increasing intra-abdominal pressure, such as pregnancy and chronic constipation. 
Accordingly, Curci et al. found subtle alterations of the elastic fibres in the supporting 
ligaments of the gastro-oesophageal junction in patients with gastro-oesophageal reflux and 
hiatus hernia.
92
 
An abnormal connective tissue content within the gut wall may affect its functions by 
increasing the compliance of hollow viscera with excessive distension, as well as by directly 
interfering with gut mechano-receptors embedded in the connective tissue-rich muscularis 
externa.
93
 Summative effects of this process may include influences on pain thresholds and 
gut motility, both known contributors to various functional GI complaints, such as gastro-
oesophageal reflux, abdominal pain, bloating, diarrhoea and constipation.
94
 Furthermore, a 
defect of the extracellular matrix in the lamina propria and secondary alterations of luminal 
microbiota may affect permeability of gut mucosa, a mechanism which may explain, in part, 
the associations with celiac disease,
39
 Crohn disease
80
 and eosinophilic esophagitis.
90
 
Capillary fragility is a well-known cutaneous and oral manifestation of hEDS/HSDs.
95
 
Although accurate data are lacking, an extension of this feature to the entire GI mucosa is 
reasonable and may explain a presumed propensity to minor haemorrhages. A reduced 
capillary and small vessels resilience may also contribute to peripheral blood steal, which may 
exacerbate various autonomic manifestations, such as nausea and bloating. This may account 
for the repeated evidence of apparently spontaneous mucosal erosions possibly leading to 
chronic occult haemorrhages in classical EDS.
66,68
 Increased vascular resilience to external 
forces may also exacerbate the transitory effects of mesenteric tractions and compressions on 
peripheral blood supply, which, in turn, is related to peritoneal ligamentous hypermobility. 
Acute presentation due to (spontaneous) ruptures of intra-abdominal vessels and/or organs is 
typical of EDS patients with mutations in COL3A1 (i.e. vascular EDS). This is thought to be 
related to the peculiar excessive fragility of the connective tissue surrounding medium and 
small size vessels, hollow viscera and spleen in this EDS type. Theoretically, similar GI 
complications could be observed in other EDS types with vascular fragility, including 
classical EDS with vascular ruptures due to mutations in COL1A1 and COL1A2, and 
kyphoscoliotic EDS due to mutations in PLOD1. However, maybe also patients with classical 
EDS due to mutations in COL5A1 need to be followed cautiously.
68
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Interestingly, particular attention has been posed on dysautonomia as a major contributor to 
onset and/or progression of a wide spectrum of functional GI complaints in 
hEDS/HSDs.
37,42,43,96,97
 The strength of this hypothesis, though promising, is actually 
hampered by the descriptive nature of published studies and the difficulties encountered in 
investigating its underlying pathophysiology objectively. In hEDS/HSDs, dysautonomia as a 
contributor to other GI manifestations, such as internal organ prolapse and mucosal bleeding, 
is, however, unlikely. The tight relationship between GI involvement and additional 
dysautonomic complaints
42
 strongly suggests an influence of autonomic disturbance in the 
onset and/or manifestations of various functional GI complaints.  
 
9. Impact of gastrointestinal complaints in EDS 
In order to assess the impact the GI complaints on the daily lives of EDS patients, two of the 
authors
98
 carried out a questionnaire investigation. Three questionnaires were sent to all 
members of the Dutch EDS patient support organisation. The first questionnaire inquired 
about socio-demographics, medication and need of a wheelchair. The second questionnaire 
inquired about GI symptoms and included questions about five domains: gastro-oesophageal 
reflux symptoms, functional dyspepsia (FD) and irritable bowel syndrome (IBS) according to 
Rome III criteria, and diarrhoea and constipation. The RAND-36 health-related quality of life 
(HRQoL) questionnaire, which assesses HRQoL across nine scales (physical functioning 
(PF), social functioning (SF) physical role limits (PR) emotional role limits, mental health, 
vitality (VI), pain, general health experience (GH) and health change (HC)), concluded the 
inquiry. Multiple linear regression, correcting for age, sex, BMI, need of wheelchair and 
medication with an effect on the GI-tract (opiates, antidepressants, medication for neuropathic 
pain, benzodiazepines, non-steroidal anti-inflammatory drugs) was used to analyse impact of 
GI symptoms on HRQoL. Of 650 questionnaires, 287 were sent back completed (response 
rate 44.2%). Fourteen subjects were excluded because EDS diagnosis had not been 
established by a medical specialist. Overall, 235 subjects (86.1%) had one or more 
gastrointestinal symptoms in one or more of the five domains. 157 (57.5%) had one or more 
reflux symptoms, 56 (20.5%) FD, 117 (42.9%) IBS, 159 (58.2%) diarrhoea and 144 (52.7%) 
constipation. The presence of one or more symptoms in any of the five domains had a 
negative impact on four HRQoL scales: PF (p=.049), PR (p=.005), VI (p=.005) and pain 
(p<.0005). When the five GI-symptom domains were analysed separately, reflux symptoms 
had a negative impact on the score on the pain scale only (p=.038). FD had no impact on any 
scale. IBS symptoms had a negative impact on the pain (p=.02) and GH (p=.004) scales. 
Diarrhoea had a negative impact on the GH scale (p=.001). Constipation had a negative 
impact on PF (p=.013), SF (p=.004), PR (p=.036), VI (p=.029), pain (p=.033) and HC 
(p=.011) scales. We concluded that GI symptoms are common in EDS and have an 
independent negative impact on HRQoL. Constipation appears to be the symptom domain 
with the largest impact on HRQoL. 
 
10. Assessment and treatment strategies 
In general, the assessment of GI complaints/complications in the various types of EDS is 
performed according to standard procedures, i.e. there is not an universally accepted flow-
chart for patients affected by EDS. Therefore, the overall approach to the EDS patient and the 
non-EDS patient attending gastroenterology clinic is fairly similar concerning the repertoire 
use of available investigations. However, tissue fragility and the risk of iatrogenic vascular 
and visceral rupture should be always taken into consideration, though with different degrees 
in the various EDS types. This risk seems higher in vascular EDS, in which any endoscopic, 
laparoscopic and endovascular investigation should be carried out with great caution and used 
only in presence of a high clinical suspicion and/or in an emergency setting. Prudence is 
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envisaged also for rarer EDS variants with marked soft tissue fragility, such as kyphoscoliotic 
and dermatosparaxis EDS. Conversely, in classical and hEDS/HSDs, such a risk is moderate 
to mild. Therefore, many invasive procedures are considered relatively safe in these patients, 
with the exception of colonoscopy, which should be considered potentially dangerous in all 
EDS patients.
89
 Surgery in EDS is indicated in disease-related complications such as 
abdominal vascular complications, abdominal organ ruptures, hernias and pelvic prolapses, as 
well as for treating unrelated diseases. Recommendations for anaesthesia and perioperative 
procedures are available in the Appendix and in the recent literature.
99,100,101
 All EDS patients 
and, in particular, those affected by the vascular EDS should be informed that the risk of 
surgery is substantially greater than in patients without EDS. This informed consent, however, 
can be hard or even impossible to obtain when a hitherto unknown vascular EDS patient 
presents with a life-threatening complication. In patients with a previously defined EDS type, 
the informed consent procedure can be tailored to the estimated risk of that type. Single case 
reports successfully demonstrate that when the physical condition of the patient allows for 
conservative treatment of surgical problems, this may be the preferred choice.
16,32
 In light of 
these considerations, principles of best practice suggest to postpone decision-making on 
clinical issues after stringent definition of the EDS type. This is usually carried out in 
specialized clinics with the support of customized molecular testing.  
Assessment and treatment of functional complaints, as mostly reported in hEDS/HSDs, are a 
hard task due to the absence of sensitive investigations and the general unawareness on the 
wider consequences that a defective connective tissue can have on the GI system. Actually, 
non-pharmacologic and pharmacologic treatment of GI functional complaints in EDS follow 
standard procedures.  
 
11. Areas of uncertainty 
GI involvement is a clinically relevant feature of many EDS types, but actual knowledge is 
fragmented and remains largely unsupported by evidence. Hypermobile and vascular EDS are 
the most studied EDS variants concerning this issue. Available data typically relate to referred 
patient-referred symptoms without consistent investigative findings in the former, while the 
range of GI events is mainly depicted by case reports or small case series in the latter. 
Treatment and prevention of GI complications in vascular EDS are not still object of formal 
research due to the rarity of this EDS types and the high lethality rate of such complications in 
this condition. Further research is also expected aimed at clarifying the functional basis of the 
various chronic disabling GI symptoms in hEDS/HSDs in order to find more specific lifestyle, 
dietary and pharmacologic treatments. Multicentric studies could be designed in order to 
investigate whether GI involvement is clinically relevant also in rarer EDS types.  
 
12. Summary 
GI involvement is a well-known complication of EDS. Historically, GI manifestations are 
best known when associated with vascular EDS, in which abdominal complaints usually 
present acutely by sudden vascular or internal organ rupture. In this EDS type, investigations 
and surgical procedures should be carried out with caution due to the extreme tissue fragility 
and, hence, the increased risk of serious iatrogenic complications. Other EDS types, chiefly 
classical and hEDS/HSDs, most typically present GI involvement in form of non-life-
threatening manifestations, such as abdominal and diaphragmatic hernias and functional GI 
disorders. In this chapter, the entire spectrum of GI manifestations in EDS is reviewed with 
separate sections dedicated to vascular, classical and hEDS/HSDs, unspecified generalized 
joint hypermobility, as well as patient cohorts with unclassified EDS types. Pathogenesis of 
GI manifestations in EDS is likely heterogeneous and can include peritoneal ligamentous 
laxity, hypotonia/hyperextensibility of the abdominal wall, pelvis and diaphragm, and 
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capillary, larger vessels and mucosal fragility. GI immune system dysregulation and 
cardiovascular dysautonomia may be further major contributors. A summary of available 
assessment and treatment approaches is presented.  
 
Addendum by the editors 
In the March 2017 issue of the American Journal of Medical Genetics Part C Seminars in 
Medical Genetics all papers were devoted to EDS, covering a new EDS nosology,
5
 new 
diagnostic criteria of the different types and also management related topics (see also chapter 
2). One of these papers is entitled “Gastrointestinal involvement in the Ehlers-Danlos 
syndromes”, which is recommended for further reading.
102 
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Table 10-1 Case-control/cross-sectional studies comparing selected gastrointestinal features 
between hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders   and 
controls 
Reference
1
 Characteristics of 
patients 
Characteristics of 
controls 
Investigated 
GI feature(s) 
Rate in 
patients 
Rate in 
controls 
 p value 
Manning et
 
al., 2003 (ref. 
38) 
404 women with 
LUTD and obstructed 
defecation 
397 women with 
LUTD and without 
obstructed defecation
hEDS/HSDs 
“features” 
70.6% 50.0% <0.0001 
499 women with 
LUTD and 
hEDS/HSDs 
339 women with 
LUTD and without 
hEDS/HSDs 
Childhood 
constipation 
7.7% 3.2% 0.01 
Frequent loose 
stools 
29.5% 22.6% 0.03 
Frequent hard 
stools 
36.7% 25.0% 0.0005 
Frequent hard 
and loose  
stools 
8.8% 4.9% 0.04 
Danese et al., 
2011 (ref. 39) 
25 females and 6 
males (years) with 
hEDS/HSDs 
attending clinical 
genetics clinic 
Italian general 
population; 
previously published 
data
2
 
Celiac disease 
(Marsh 
classification) 
16.1% 1.0%  0.002 
Mastoroudes 
et al., 2013 
(ref. 40) 
60 females (18-60 
years) with 
hEDS/HSDs 
attending 
hypermobility clinic 
60 females (18-60 
years) without 
hEDS/HSDs 
recruited from 
hospital staff  
Vaginal bulge 
interfering 
defecation  
23.0% 5.0% 0.007 
Straining for 
defecation 
61.7% NA <0.001 
Incomplete 
emptying after 
defecation 
63% NA 0.001 
Need of 
digitation for 
defecation  
33.3% NA <0.001 
Fikree et al., 
2014 (ref. 41) 
123 females and 57 
males with 
hEDS/HSDs 
attending 
gastroenterology 
clinic 
203 females and 169 
males without 
hEDS/HSDs 
attending 
gastroenterology 
clinic  
Age (mean) 40.6 
years 
44.2 
years 
0.003 
Gender 
(female) 
68.3% 54.6% 0.002 
Heartburn 33.0% 23.5% 0.01 
Water brash 30.9% 18.5% 0.001 
Postprandial 
fullness 
41.4% 27.1% 0.006 
GI: gastrointestinal; hEDS/HSDs: hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders. 
LUTD: lower urinary tract dysfunction; NA: not available. 
1
: only features with statistically significant 
differences between patient and control groups are reported in the table (i.e. p value <0.05). 
2
: from Menardo et 
al.
59
 and Dubé et al.
58
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Table 10-2 Case reports on GI-surgical findings in hypermobile Ehlers-Danlos 
syndrome/hypermobility spectrum disorders    
Reference Age, sex GI-related 
symptom(s) at 
presentation 
Anatomical 
finding/feature(s) 
Treatment 
Douglas and 
Douglas, 1973 
(ref. 45) 
2 years, NA Recurrent rectal 
prolapse 
Rectal prolapse Effective treatment with 
the injection of 5 ml of 5% 
phenol in almond oil 
Shaikh and 
Turner, 1988 
(ref. 46) 
17 years, F Epigastric pain, 
emesis and an 
history of 
generalized 
abdominal pain 
Strangulation and infarction 
of the stomach through the 
diaphragm 
Effective gastrectomy with 
pyloroplasty  
Leung, 1989 
(ref. 47) 
22 years, M Epigastric pain, 
emesis 
Strangulation of the stomach Effective repair of the 
diaphragmatic defect 
Defuentes et al., 
2004 (ref. 48) 
25 years, F Abdominal pain 
with fever 
Multiple diverticula of 
descendent and transverse 
colon  
None 
Levine and 
Adler, 2005 (ref. 
49) 
22 years, F Emesis after 
pharmacologic 
therapy for a 
dislocation  
Rupture of diaphragm, para-
oesophageal hernia 
Effective repair of the 
diaphragmatic defect and 
Nissen fundoplication 
Chen and Jao, 
2007 (ref. 50) 
20 years, M Defecation 
problems 
Rectal prolapse Effective conservative 
treatment 
de Weerd et al., 
2012 (ref. 51) 
47 years, F Incomplete 
evacuation, 
constipation, pelvic 
pain and discomfort 
Hiatal hernia, anal mucosal 
prolapse, recto-anal 
intussusception, small 
rectocele and large 
enterocele 
Abdominal plastic surgery, 
previous unsuccessful 
operation for anal prolapse 
and recto-anal intus-
susception, Nissen 
fundoplication, 
hysterectomy  
Reinstein et al., 
2012 (ref. 52) 
28 years, M Disabling 
abdominal 
distension and 
bloating 
Prolapse of the small bowel 
and transverse colon, 
increased bowel mobility 
under direct manipulation 
Effective laparoscopic 
subtotal colectomy 
Dordoni et al.,
 
2013 (ref. 53) 
38 years, F Dyspepsia and 
constipation 
Prolapse of stomach, liver, 
small and large bowel, left 
kidney, ovaries 
Recurrence after repeated 
gastropexy and 
nephropexy 
70 years, M Irritable bowel 
syndrome 
Mild prolapse of the small 
bowel, inguinal hernia 
None 
Fogel, 2013  
(ref. 54) 
35 years, F NA Multiple sepsis with 
microperforations of the 
colon, small bowel 
obstruction 
Cholecystectomy, 
appendectomy, total 
abdominal colectomy and 
ileostomy, lysis of 
adhesions  
Sardeli et al., 
2013 (ref. 55) 
57 years, F Inability to 
evacuate, 
constipation and 
mass sensation in 
the vagina  
Rectocele Successful correction of 
the defect in the recto-
vaginal fascia with porcine 
small intestinal submucosa 
mesh 
Plackett et al., 
2014 (ref. 56) 
34 years, F Rectal bleeding Haemorrhoids Conservative treatment 
(outcome not available) 
F: female; GI: gastrointestinal; M: male; NA: not available.  
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Table 10-3 Case reports on GI-surgical findings in classical Ehlers-Danlos syndrome 
Reference Age, sex GI-related 
symptom(s) at 
presentation 
Anatomical 
finding/feature(s) 
Treatment 
Green et al., 
1966 (ref. 60) 
64 years, M Fever and abdominal 
cramps 
Sigmoid diverticulitis Persistent drainage and 
subsequent surgery; 
recurrent  post-operative 
haemorrhage and post-
operative death 
Harris, 1974 
(ref. 61) 
53 years, M Chronic anaemia Small bowel dilatation, 
single diverticulum of 
the ascending colon, 
haemorrhoids 
Conservative treatment 
Hulme and 
Wilmshurst, 
1976 (ref. 62) 
15 years, M Abdominal pain and 
vomiting 
Acute appendicitis Successful standard 
surgical repair; purulent 
swelling under the 
incision with normal 
subsequent wound repair
Phadke, 1978 
(ref. 63) 
71 years, F Recurrent emesis Eventration of left 
diaphragm and torsion of 
stomach 
Effective repair of the 
diaphragmatic defect 
Iwama et al., 
1989 (ref. 64) 
41 years, F Sudden dyspnoea Eventration of the 
diaphragm 
Successful placation of 
the diaphragm with 
residual hiatus hernia
 Subsequent years, 
F (same patient) 
Multiple events of 
acute abdominal pain
Diverticulitis of colon 
with recurrent 
perforations; 
spontaneous perforation 
of the jejunum
Successful treatment by 
various surgical 
techniques and 
uneventful wound 
healing 
Leake et al., 
2010 (ref. 65) 
53 years, F Abdominal pain and 
vomiting 
Malrotation of the large 
bowel, multiple loops 
and dilated jejunum and 
ileum, occult and 
multiple small bowel 
perforations
Successful resection of 
the gut affected segment 
Ratan et al., 
2011 (ref. 66) 
1 month, M Inguinal mass Right inguinal hernia Successful surgical 
treatment; post-operative 
scrotal wound dehiscence
  Post-operative 
abdominal distension
Rectal redundancy with 
anterior displacement of 
the anus
Successful rectal 
resection 
de Leeuw et al., 
2012 (ref. 67) 
9 years, M Severe abdominal 
cramps and pain 
Retroperitoneal 
hematoma and aneurysm 
of the superior 
mesenteric artery 
An attempt of 
endovascular treatment 
caused rupture of the 
aneurysm, disintegration 
of the common femoral 
artery and necrosis of 
small bowel and cecum; 
the patient died shortly 
after 
Kishikawa et 
al., 2012 (ref. 
68) 
40 years, M Dizziness and melena Multiple diverticula of 
oesophagus, distal 
jejunum and sigmoid 
colon; multiple erosions 
of the distal jejunum and 
ileum
Not performed 
(continued on next page)  
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Bohorquez et 
al., 2013 (ref. 
69) 
39 years, F End-stage liver 
disease 
Non-alcoholic 
steatohepatitis 
Successful liver 
transplantation; peri-
operative retroperitoneal 
haematoma and post-
operative small bowel 
perforation 
Pelizzo et al., 
2013 (ref. 70) 
14 years, F Chronic intestinal 
pseudo-obstruction 
symptoms
Dilatation of the 
ascending colon and 
terminal ileum
Recurrence after 
repeated ileostomy 
F: female; GI: gastrointestinal; M: male.  
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Table 10-4 Association studies exploring the relationship between selected gastrointestinal 
features and generalized joint hypermobility  
(continued on next page)  
Reference
1
 Characteristics of 
patients 
Characteristics of 
controls 
Investigated 
feature(s) 
Rate in 
patients 
Rate in 
controls 
p value 
Marshman et 
al.,1987 (ref. 72)
 
4 females and 21 
males (6-93 years) 
who undergone 
surgery for 
complete rectal 
prolapse 
4 females and 21 
males (mean 67 
years) admitted for 
surgery but 
without rectal 
prolapse 
Fifth finger 
extension 
81 ± 2.2 
degrees 
68 ± 1.7 
degrees 
0.001 
Norton et al., 
1995 (ref. 73) 
39 females (49-57 
years) with JH  
69 females (51-59 
years) without JH  
Rectocele (any 
grade)
84% 48% 0.0002 
Rectocele 
(grade 2&3)
34% 13% 0.009 
Pulliam and 
Schuster, 1995 
(ref. 74) 
39 females and 4 
males (18-62 
years) with chronic 
intestinal pseudo-
obstruction 
1566 unselected 
individuals with 
GI symptoms 
JH 46.5% 13.9% < 0.001 
Al-Rawi et al., 
2004 (ref. 75) 
28 men and 22 
women with hiatus 
hernia at 
endoscopy 
30 men and 20 
women with 
normal endoscopy 
JH 22% 6% 0.001 
Jha et al., 2007 
(ref. 76) 
30 females (20-58 
years) with JH 
attending 
rheumatologic 
clinic; Caucasians, 
Asian, 
Afrocaribbean 
30 females (22-56 
years) without JH 
attending a 
rheumatologic 
clinic; Caucasians, 
Asian, 
Afrocaribbean
Anal 
incontinence 
23% 0% 0.01 
Reilly et al., 2008 
(ref. 77) 
13 females and 26 
males (7-17 years) 
with slow transit 
constipation 
18 females and 23 
males (7-17 years) 
without 
constipation 
requiring medical 
treatment
GJH (males) 38% 4% 0.004 
Arunkalaivanan 
et al., 2009 (ref. 
78) 
148 fault females 
with JH members 
of the 
Hypermobility 
Syndrome 
Association; 
Caucasians (98%) 
General adult 
population; 
previously 
published data
2
 
Faecal 
incontinence 
14.9% 2.2% <0.05 
Vounotrypidis et 
al., 2009 (ref. 79) 
32 females and 37 
males (18-50 
years) with 
inflammatory 
bowel disease; 
Greek Caucasians 
29 females and 38 
males (18-50 
years); Greek 
Caucasians 
JH
2
 70.3% 
(Crohn 
disease) 
 
25.4% <0.0001
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GI: gastrointestinal; GJH: generalized joint hypermobility. JH: joint hypermobility. 
1
: only features with 
statistically significant differences between patient and control groups are reported in the table (i.e. p value 
<0.05). 
2
: from Nelson et al.
103
 
Mohammed et 
al., 2010 (ref. 80) 
63 females and 2 
males (15-80 
years) with JH and 
intractable 
constipation  
116 females and 
19 males (20-83 
years) with 
intractable 
constipation and 
without JH 
Gender 
(female/male)
96.9%/3.1
%
85.9%/14.1
% 
0.02 
Previous 
surgery for 
pelvic organ 
prolapse
30.7% 17.0% 0.04 
Incomplete 
rectal 
evacuation
80% 59% 0.004 
Functional 
rectocele 
58% 39% 0.01 
Extrinsic 
compression 
of the anterior 
rectal wall
11 1 0.006 
Zarate et al., 
2010 (ref. 37) 
54 females and 9 
males (16-71 
years) with JH and 
unexplained GI 
symptoms  
43 females and 23 
males (18-78 
years) 
without JH and 
unexplained GI 
symptoms  
Known 
aetiology
19% 59% <0.0001
Age  37 years 
(mean)
44 years 
(mean) 
0.01 
Gender 
(female)
86% 65% 0.008 
Gastro-oeso-
phageal reflux 
56% 30% 0.005 
Bloating 62% 46% 0.05
Lammers et al., 
2012 (ref. 81) 
110 females (51-
89 years) with JH 
attending 
gynaecological 
clinic 
110 females (51-
95 years) without 
JH attending 
gynaecological 
clinic
Pelvic organ 
prolapse 
19% 2% <0.01 
Kajbafzadeh et 
al., 2014 (ref. 82) 
113 children (5-14 
years) with 
voiding 
dysfunction; 
Iranians
113 healthy 
schoolchildren (5-
14 years); Iranians 
JH (total) 45% 17% 0.001 
JH (females) 44% 23% 0.017 
JH (males) 34% 5% 0.04
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1. Introduction 
Ehlers-Danlos syndrome (EDS) is probably one of oldest known causes of bruises and 
bleeding and takes a prominent place among the syndromes and affections associated with a 
bleeding tendency. An abnormal tendency to bleed – be it spontaneously, or provoked by 
minimal trauma – in which the degree of bleeding, bruising or haematoma formation is out of 
proportion to the mildness of the trauma – is called bleeding tendency. Easy bruising 
constitutes one of the official criteria by which most of the EDS types are defined; however, 
not so in the commonest one, hypermobile EDS. Easy bruising and bleeding in EDS is not so 
much due to disorders in clotting and platelet function, but a prominent feature of this 
heritable collagen disorder.
1,2
 Easy bruising and vascular vulnerability, sometimes leading to 
life threatening bleeding, are a hallmark of vascular EDS. Vascular fragility affects medium-
sized and large arteries and veins in this type of EDS. In other types of EDS, bleeding 
tendencies have been described in isolated cases, and fragility of capillaries and perivascular 
connective tissues may cause those. There are descriptions of clotting or platelet disorders 
associated with bleeding and bruising in EDS. Although these various and scanty observations 
do not suggest a definite link between EDS and platelet or clotting abnormalities, we will 
describe if, and how, specific derangements in haemostasis could affect patients with EDS, 
covering also diagnostic and therapeutic aspects. 
 
2. EDS and haemostasis 
Haemostasis (the clotting of blood) involves the interaction of three components: the vessel 
wall, the clotting cascade and platelets.  
 
2.1 The vessel wall 
Easy bruising, bleeding gums, prolonged bleeding after dental procedures, operations and 
menstrual periods are manifestations of a bleeding tendency that may contribute to a diagnosis 
of EDS. The key problem in EDS is the formation of structurally abnormal collagen.
2
 The 
collagen defect not only causes abnormal stretching of skin and tendons and disturbed wound 
healing. In vascular EDS, it also affects the normal architecture of the vessel wall. All arterial 
blood vessels are made up of three layers: the inner intima, the interface between blood and 
the vessel wall; the media, containing single or more layers of smooth muscle cells and 
collagen fibres; and the adventitia, mainly collagen fibres locking in place the vessel in the 
surrounding tissue. Collagen defects may affect the strength of the media and adventitia and 
facilitate the occurrence of tears in the walls of smaller vessels such as capillaries. This may 
become visible as petechiae or bruises of skin and mucous membranes: ‘easy bruising’. 
Larger vessels may also be affected, and this could lead to life threatening bleeding. Vascular 
EDS is characterized by extreme vulnerability not only of blood vessels but also of internal 
organs.
3,4
 The bleeding tendency in vascular EDS thus is a direct consequence of the collagen 
defect in the vessel wall and not caused by abnormalities in the haemostatic process.
5
 In other 
types of EDS, structurally abnormal collagen in perivascular connective tissues result in less 
firm pressure on damaged vessels in case of traumas and thus prolonged and more extensive 
bleeds. Easy bruising, bleeding after dental extractions or surgical procedures or heavy 
menstrual blood loss are not specific traits of vascular EDS, but rupture of internal organs 
(bowel, uterus), leading to life threatening internal bleeding are. A problem is that vascular 
EDS may reveal minimal clinical signs until a life threatening internal bleeding occurs. 
 
2.2 The clotting cascade 
The haemostatic process is an interaction of blood platelets, clotting proteins, natural clotting 
inhibiting proteins, and fibrinolytic (clot lysing) proteins. A cut through the skin will activate 
this process. Damage to capillaries and larger vessels will expose collagen and other factors in 
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the vessel wall to blood. This will activate the clotting mechanism in which both platelets and 
clotting factors will be involved in a natural response of the organism to the inflicted trauma, 
aimed at ‘damage control’. As a result, damaged vessels will constrict, thereby minimizing 
blood loss, and platelets will adhere to the damaged vessel wall and aggregate together 
forming a primary haemostatic response. The activation of the clotting cascade will result in 
the formation of a fibrin network that stabilizes the platelet aggregate. This is described as 
secondary haemostatic response. Simultaneously, natural clotting inhibition will restrict the 
haemostatic response to the site of vessel wall damage. The wound healing process involves 
the fibrinolytic system that contributes to eventual clot solution and restoration of the normal 
vessel wall and tissue (skin) structure.  
Bleeding disorders are usually described as a ‘platelet type’ or a ‘haemophilia type’ bleeding 
tendency. The platelet type is characterized by point-like skin bleedings (petechiae and 
ecchymoses), bleeding at puncture sites, skin cuts and after dental extractions. This type 
occurs with either a defect in the normal function of platelets (thrombocytopathy), critically 
reduced platelet counts (thrombocytopenia), or in von Willebrands disease (defects or 
deficiencies in von Willebrand factor (vWf), a protein that binds platelets). Haemophilia-type 
bleeding is caused by a defect or deficiency of a clotting protein, causing joint and muscle 
haematomas. These are usually inherited diseases. Haemophilia A is characterized by 
deficiency of clotting Factor VIII, and haemophilia B by a deficiency of Factor IX. 
Different defects in the haemostatic process have been described in patients with several EDS 
types. These descriptions are mostly isolated case histories. This gives, apart from the well-
established association of vascular EDS with easy bruising and vascular tears, a rather 
inconsistent picture of any further association of EDS with bleeding. In some cases 
consanguinity is involved, and this may bring to expression both clotting defects and EDS in 
parallel. Such cases may suggest an association between separate hereditary diseases, while a 
causal relationship remains difficult to establish and may have to be refuted eventually. For 
instance, the old assumption of a causal relation between EDS and mental retardation, 
probably is based on the same association due to consanguinity and mental retardation as a 
characteristic of EDS has been refuted. Case studies of EDS patients with clotting defects are 
reviewed here. 
A large study involving 51 patients with EDS describes potential haemostatic defects.
6
 In only 
eight of these 51 patient histories there was no bleeding tendency. In nine patients a 
significant clotting defect was established: four had a platelet defect, three had a deficiency in 
clotting Factor XI, and two had a Factor XIII deficiency. Minimal defects were detected in 16 
patients, and the significance of these findings remained unclear. Of 24 patients with a normal 
laboratory profile, 20 had a bleeding tendency. It was impossible to establish a pattern that 
could identify certain types of EDS with the observed bleeding tendencies. The authors 
concluded that the strictly normal laboratory findings in 83 percent of patients with a 
clinically manifest bleeding tendency constituted a strong argument pointing towards a defect 
in collagen structure of skin and connective tissue around vessel walls as the bleeding cause, 
rather than an intrinsic haemostatic defect. 
Unexplained haematomas and bruises in children may lead to consulting a paediatrician. A 
study of unexplained haematomas described 44 children, who were further examined with 
regard to clotting defects.
7
 No haemostatic abnormalities were detected in the laboratory, 
while in all 44 children signs suggestive of collagen structural defects were detected, such as 
increases in thumb extensibility. Therefore, also in these children, bruising tendency appeared 
to be caused by a collagen defect rather than by intrinsic haemostatic abnormalities. Overall, 
the studies suggest that bleeding in EDS may result primarily from defects in perivascular 
collagen structure rather than from systematic associations of clotting defects. 
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2.3 Blood platelets 
A disturbance in platelet function could theoretically result from either a defect in factors that 
activate platelets, or intrinsic platelet function defects. Both mechanisms could therefore play 
a role in observed bleeding tendencies in EDS patients, but evidence so far does not support 
this hypothesis. Collagen is an important agonist of platelet activation. Collagen exposure to 
blood, as occurs with cutting of a blood vessel, leads to platelet activation and subsequent 
haemostatic response. Theoretically, structurally abnormal collagen (such as in EDS) could 
cause a diminished activation of platelets in the primary haemostatic response. Structural 
defects in collagen therefore could incur a bleeding tendency by increased vulnerability of the 
vessel wall, the perivascular connective tissue and by a weakened platelet response. Studies in 
patients do not support this hypothesis so far. Platelet function tests in several families with a 
platelet type bleeding tendency were carried out.
8
 A family with classical EDS, a family with 
hypermobile EDS, and a patient with an isolated, not classified type of EDS all had a slightly 
prolonged bleeding time. None of them ever had experienced bleeding complications after 
surgical procedures. In vitro platelet activation and aggregation by collagen from these 
patients was completely normal. Another family with a platelet function defect and vascular 
EDS was examined and showed independent inheritance of the platelet defect and of EDS: so 
the platelet defect was not a disease manifestation of EDS.
9
  
Storage pool deficiency is a mild bleeding tendency caused by a diminution of substances that 
are stored within platelet granules. Normally, upon platelet activation these substances are 
secreted and cause platelet aggregation, therefore a deficiency leads to a defect in platelet 
aggregation. This leads to easy bruising, bleeding after dental extractions and surgical 
procedures, and increased menstrual blood loss. It is the most frequently described platelet 
function defect among patients with EDS. It has been observed in patients with vascular 
EDS
10
 and in classical EDS.
11
 It is not unique to EDS and is observed in several other rare 
diseases and also in otherwise healthy persons.  
Another platelet aggregation defect was described in a family with a potentially separate form 
of mild EDS with recessive inheritance pattern. The platelet defect disappeared in the 
presence of fibronectin.
12
 Interestingly, fibronectin is a protein that contributes to vessel wall 
structure. In this family, both the mild bleeding tendency and generalized hypermobility were 
ascribed to a defect in fibronectin. 
Taken together, these observations do not indicate a causal association of platelet function 
defects and EDS. Only in the family with a defect in fibronectin both EDS and the bleeding 
tendency can be ascribed to one common defect. However, this fibronectin deficient EDS is 
not any longer recognized in the 2017 International EDS classification.
13
  
 
3. Diagnostic work-up of bleeding tendency 
An observed bleeding tendency usually leads to a search to establish the cause. The medical 
history and clinical evaluation of the patient are the first and most important clues towards a 
diagnosis of a bleeding disorder: platelet type or haemophilia type. It includes the Rumpel-
Leede test, which determines capillary fragility and might be positive in EDS patients. 
Laboratory testing may corroborate the clinical diagnosis.
14
 After screening with general 
clotting tests and platelet function analysis to establish an overall picture of the haemostatic 
system, more specific assays may form the next step. 
Traditionally, platelet function testing consisted of a bleeding time and platelet aggregation 
studies. A bleeding time is performed by application of a standardized skin wound and 
measuring the time until blood clotting occurs. If the bleeding time exceeds the normal range 
(usually 4-8 min, depending on the equipment used) further platelet analysis involves in vitro 
platelet aggregation studies. Platelet concentrates ex vivo can be exposed to several agonists, 
such as collagen and adenosine diphosphate, in a light transmitting cuvette. The pattern of 
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light transmission is indicative of the function of platelets (ability to aggregate and remain 
aggregated). In routine clinical practice, platelet function is often assessed by an overall 
function test called platelet function analysis. It is at best an alternative to the standardized 
skin bleeding time. The presence and function of coagulation proteins can be tested by several 
clotting assays mainly based on principles of dilution and reconstitution. It is also possible to 
measure concentrations of individual clotting factors by special assays. 
In EDS, testing of the haemostatic system may be appropriate if surgical procedures are 
indicated. However, as mentioned before, a causative association between platelet and 
specific clotting abnormalities and EDS has not been established. Careful history taking in the 
individual, a complete family history including information on past generations, and complete 
physical examination provide the most important information. Subsequently, an approach of 
the problem in an individual patient, tailored to the specific clinical situation appears useful. 
For instance, in an otherwise healthy individual who has to undergo a major operation, careful 
history taking and physical examination will practically eliminate the possibility of a bleeding 
tendency that may complicate a surgical procedure, and this may well apply to the individual 
with EDS without any signs and symptoms indicative of a bleeding tendency. In other 
individuals, such as patients with vascular EDS, a thorough examination of platelet function 
and clotting may be more appropriate, as these persons are already subject to bleeding from 
ruptured vessels or organs and an intrinsic clotting defect may complicate clinical outcome. In 
summary, routine laboratory clotting testing in individuals with EDS is not advocated. The 
importance of individual and family history taking together with complete physical 
examination cannot be stressed enough. It is important to consider the diagnosis of vascular 
EDS in patients with otherwise unexplained bleeding in internal organs. Though easy bruising 
is not a major or minor criterion for the diagnosis of hypermobile EDS, it has been reported 
that 39/91 (43%) of children with joint hypermobility syndrome had a history of easy 
bruising.
15
 
Jackson et al. tried to answer the question whether collagen disorders are more prevalent 
among patients seen at a bleeding clinic. In a relatively small case-control study it was found 
that 13/55 (24%) of selected bleeding patients had a suspected collagen disorder compared to 
1/50 (2%) among controls, while 10/13 of suspected collagen disorder patients had a personal 
or family history of EDS, benign joint hypermobility syndrome or osteogenesis imperfecta.
16 
 
4. Therapeutic approach to bleeding tendency and vascular complications in EDS 
 
4.1 General measures 
In EDS as in other conditions it remains important to control the risk of vascular damage by 
elimination or improving the well-known risk factors of atherosclerotic cardiovascular 
disease. These risk factors include smoking, hypertension, dyslipidaemia, overweight and 
obesity, and diabetes mellitus. Smoking also has a deleterious effect on collagen, clinically 
visible as premature aging of the skin with wrinkles. A healthy life style applies to all in every 
aspect and this includes a balanced diet with ample fruit and vegetables, a reduced intake of 
saturated fats, daily physical exercise, and avoidance of overweight and stopping of smoking. 
Only moderation of alcohol consumption is appropriate (1-2 units per day), as daily intake of 
3 units or more of alcoholic beverages increases the blood pressure. Strictly speaking, no 
information is available on development of atherosclerotic vascular disease in patients with 
EDS, as this condition remains too rare to establish any associations. As such, 
recommendations of a healthy life style have a general character applicable to the general 
population, including individuals with EDS. 
Bleeding tendencies in EDS, including storage pool deficiency, are mild, with the exception 
of bleeding complications in vascular EDS. The only reasonable recommendation that can be 
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made is to avoid circumstances that may provoke bleeding, such as contact and group sports. 
These sports are also contraindicated because of the risk of skin wounds and subsequent scar 
formation, and (sub)luxations. 
 
4.2 Potential hazards from drugs or clinical procedures 
Drugs that interfere with the haemostatic process should be avoided by patients with any type 
of EDS. Drugs that interfere with platelet function include aspirin (acetylsalicylic acid, ASA), 
dipyridamole, clopidogrel, and non-steroidal anti-inflammatory drugs (NSAIDs) such as 
ibuprofen and diclofenac. These drugs affect platelet function thereby prolonging the bleeding 
time. Aspirin, clopidogrel and dipyridamole are being prescribed on a large scale as 
therapeutic agents in patients with coronary artery disease, cerebrovascular disease, and 
peripheral arterial disease. In these cases, pros and cons of these medications will have to be 
weighed by the treating clinician. Ibuprofen and diclofenac are popular as pain killers and 
anti-inflammatory agents. Paracetamol (acetaminophen) and COX-1 sparing NSAIDS do not 
influence haemostasis and can be considered safe, albeit that COX-1 sparing NSAIDS 
increase the risk of cardio-vascular disease. Use of anticoagulant drugs by definition will 
increase the bleeding tendency. This group includes the traditional oral vitamin K antagonists 
(coumarins) such as acenocoumarol, fenprocoumon and warfarin; heparin and low molecular 
weight heparins (LMWH), pentasaccharides, and the newer oral thrombin inhibitors and 
pentasaccharides. Use of these drugs should be avoided if possible, especially in individuals 
with vascular EDS. Vascular procedures such as arterial punctures, catheterization, 
intravenous or intra-arterial lines should also be avoided in these persons. 
 
4.3 DDAVP 
The vasopressin analogue DDAVP (desmopressin acetate, 1-Desamino-8-D-Arginine 
Vasopressin) may help to reduce a bleeding tendency temporarily in subjects undergoing a 
dental or surgical procedure. DDAVP increases the concentrations of Factor VIII-vWf 
temporarily, whether administered intravenously, subcutaneously, or by nasal spray. This 
effect is ascribed to induced release of these factors from storage sites in vascular endothelial 
cells.
17
 Intravenous administration of vasopressin to subjects with mild haemophilia or von 
Willebrand disease has enabled dental procedures, tonsillectomies and even larger surgical 
procedures to be carried out without abnormal bleeding. It has been successfully applied in 
other patients with a variety of qualitative platelet abnormalities such as uraemia or liver 
cirrhosis. It is important to test the effect of vasopressin before a procedure is carried out, to 
be certain of its effect. Vasopressin can be of use for patients with EDS who do not have a 
haemostatic defect but who have a prolonged bleeding time due to an abnormality in the 
vessel wall. Two children, one with periodontal EDS (formerly type VIII) and one with 
kyphoscoliotic EDS, both with a prolonged bleeding time, had a normal bleeding time after 
administration of vasopressin. Both children successfully underwent surgical procedures 
without bleeding complications. One patient continued using intranasal vasopressin to avoid 
nasal and gum bleedings. The authors suggest considering vasopressin administration in other 
individuals with EDS with a bleeding tendency.
18
 Mast et al confirmed the usefulness of 
DDAVP in children with EDS.
19
 Vasopressin is an antidiuretic hormone causing water 
retention in the body, leading to high blood pressure and decreased serum sodium levels. The 
use of its analogue DDAVP has these same properties and because of potential dangers 
associated, should only be used in specialized settings and care centres.  
 
4.4 Vitamin C 
Vitamin C is involved in collagen synthesis. Two sites of action on collagen metabolism have 
been proposed. First, it is a cofactor for collagen hydroxylating enzymes and regulates the 
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posttranslational hydroxylation of collagen lysyl and prolyl residues. Furthermore, it also 
stimulates collagen synthesis at a transcriptional, or mRNA processing level. Vitamin C may 
reduce easy bruising but has no effect on the primary findings of skin hyperextensibility, 
atrophic scarring, and joint hypermobility. In general, a dose of two grams per day is 
recommended for adults, with proportionally reduced doses for children; however, there is no 
limitation.
20 
 
4.5 Celiprolol 
Ong et al. have reported on a positive effect of celiprolol on prevention of cardiovascular 
events in vascular EDS.
21
 Further studies are needed in order to judge more specifically the 
quantitative and qualitative aspects. 
 
4.6 Recombinant factor VIIa 
Perioperative use of recombinant factor VIIa may be useful in management of intractable 
bleeding after surgical repair of ruptured medium-sized vessels. A case report describes the 
successful use of recombinant factor VIIa in a patient with vascular EDS, in whom continued 
bleeding was successfully halted after intravenously administered recombinant factor VIIa. Of 
note, the platelet count, prothrombin time and activated partial thromboplastin time were all 
normal.
22
 
 
5. Conclusion  
A bleeding tendency in EDS may result from structural collagen abnormalities in the skin and 
supporting tissues around vessels and in vascular EDS, in the vessel wall proper. Observed 
bleeding tendencies in infants and children may lead to a diagnosis of EDS or a defect in the 
haemostatic system. In subjects with EDS abnormalities in the haemostatic system are 
detected more often than in the general population (an increased relative risk), but in most 
cases of EDS (80 percent in one study) the haemostatic system proved to be normal 
(indicating a low absolute risk). A mild bleeding tendency in EDS may have clinical 
significance. Preoperative attention for the haemostatic system is therefore recommended in 
all subjects with EDS. Individuals with a platelet type bleeding tendency whether or not due 
to a qualitative platelet function defect, may receive a test dose of DDAVP to assess whether 
they may benefit from this compound, especially in preventing perioperative bleeding. There 
is only anecdotal evidence for the use of recombinant factor VIIa in prolonged bleeding 
despite surgical haemostasis in vascular EDS. 
Bleeding tendency in Ehlers-Danlos syndrome 173
 
 
References  
 1. De Paepe A, Malfait F. Bleeding and bruising in patients with Ehlers-Danlos syndrome 
and other collagen vascular disorders. Br J Haematol 2004;127:491-500.  
 2. Malfait F, De Paepe A. Bleeding in the heritable connective tissue disorders: 
mechanisms, diagnosis and treatment. Blood Rev 2009;23:191-7. 
 3. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of 
Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 2000;342:673-80. 
 4. Pyeritz RE. Ehlers-Danlos syndrome. N Engl J Med 2000;342:730-1. 
 5. De Paepe A. The Ehlers Danlos Syndrome: a heritable collagen disorder as a cause of 
bleeding. Thromb Haemostas 1996;75:379-86. 
 6. Anstey A, Mayne K, Winter M, de Pette JV, Popes FM. Platelet and collagen studies in 
Ehlers-Danlos syndrome. Br J Dermatol 1991;125:155-63. 
 7. Kaplinsky C, Kenet G, Seligsohn U, Rechavi G. Association between hyperflexibility of 
the thumb and an unexplained bleeding tendency: is it a rule of thumb? Br J Haematol 
1998;101:260-3 
 8. Uden A. Collagen and bleeding diathesis in Ehlers-Danlos syndrome. Scand J Haematol 
1982;28:425-30. 
 9. Grenko RT, Burns SL, Golden EA, Byers PH, Bovill EG. Type IV Ehlers-Danlos 
syndrome with aspirin sensitivity. A family study. Arch Pathol Lab Med 1993; 117: 989-
92.  
10. Espanol I, Hernandez A, Pujol RM, Urrutia T, Pujol-Moix N. Ehlers-Danlos syndrome 
with platelet delta-storage pool disease. Ann Hematol 1998;77:47-50. 
11. Chouza C, Caamano JL, De Medina O, et al. Familial spastic ataxia associated with 
Ehlers-Danlos syndrome with platelet dysfunction. Can J Neurol Sci 1984;11:541-9. 
12. Arneson MA, Hammerschmidt DE, Furcht LT, King RA. A new form of Ehlers-Danlos 
syndrome. Fibronectin corrects defective platelet function. JAMA 1980;244:144-7. 
13. Malfait F, Francomano C, Byers P, et al. The 2017 International classification of the 
Ehlers-Danlos syndromes. Am J Med Genet Part C Semin Med Genet 2017;175C:8-26.  
14. Greaves M, Watson G. Approach to the diagnosis and management of mild bleeding 
disorders. J Thromb Haemost 2007;5:167-74. 
15. Adib N, Davies K, Grahame R, Woo P, Murray KJ. Joint hypermobility syndrome in 
childhood. A not so benign multisystem disorder? Rheumatology 2005;44:744-50. 
16. Jackson SC, Odiaman L, Card RT, van der Bom JG, Poon MC. Suspected collagen 
disorders in the bleeding disorder clinic: a case-control study. Haemophilia 2013;19:246-
50. 
17. Balduini CL, Noris P, Belletti S, Spedini P, Gamba G. In vitro and in vivo effects of 
desmopressin on platelet function. Haematologica 1999;84:891-6.  
18. Stine KC, Becton DL. DDAVP controls bleeding in Ehlers-Danlos syndrome. J Pediatr 
Hematol Oncol 1997;19:156-8. 
19. Mast KJ, Nunes ME, Ruymann FB, Kerlin B. Desmopressin responsiveness in children 
with Ehlers-Danlos syndrome associated bleeding symptoms. Br J Haematol 2009;144: 
230–3. 
20. Malfait F, Wenstrup R, De Paepe A. Ehlers-Danlos Syndrome, Classic Type. In: Pagon 
RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, 
eds. GeneReviews. Seattle, USA: University of Washington, Seattle; 2011:1993-2014.  
21. Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular 
events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-
endpoints trial. Lancet 2010;376:1476-84. 
Chapter 11174
 
 
22. Faber P, Craig WL, Duncan JL, Holliday K. The successful use of recombinant factor 
VIIa in a patient with vascular-type Ehlers-Danlos syndrome. Acta Anaesthesiol Scand 
2007;51:1277-9.  
 
Bleeding tendency in Ehlers-Danlos syndrome 175
This page intentionally left blank
 
 
Chapter 12. Cardiac abnormalities and complications in Ehlers-Danlos 
syndrome 
WL Mosterd 
 
 
Willem L. Mosterd, MD, PhD, cardiologist, sports physician 
Prof emeritus of Cardiology 
Department of Cardiology 
Meander Medical Center 
Amersfoort, The Netherlands 
E-mail willemmosterd@planet.nl 
  
177
 
 
1. Introduction 
The Ehlers-Danlos syndrome (EDS) is a relatively rare example of a group of comparable 
genetic disorders of connective tissue (collagen) with consequent hypermobile joints, 
distensile and fragile skin and ruptures in arteries, intestine and uterus. Although there are no 
hard data, the prevalence of EDS is estimated at 1:5000 without sex or ethnic bias.
1
 In the 
Netherlands this would translate into approximately 3000 persons with EDS. The most 
common types of EDS are classical (formerly denoted as types I and II), hypermobile 
(formerly EDS type III) and vascular (formerly EDS type IV) EDS.
2,3 
 
In a number of case reports and in older textbooks an association is suggested between EDS 
in general and various cardiac disorders.
4-16
 The described abnormalities include congenital 
anomalies of the heart, valvular abnormalities, heart rhythm and conduction disorders, rupture 
of the ascending aorta, widening of the coronary arteries and myocardial infarction at a young 
age. This chapter will specifically address the question of cardiac abnormalities in classical 
and hypermobile EDS and their prevalence in a comparable normal population.  
 
The discussion will be mainly limited to the classical and hypermobile EDS as the 
abnormalities and complications of the vascular type are discussed elsewhere in this book (see 
chapter 6). However, some attention will be given to the secondary prevention of 
complications in EDS, especially vascular EDS. 
Next to vascular EDS, also in kyphoscoliotic EDS major vascular complications occur;
17,18
 in 
arthrochalasia EDS these have been described as well.
19
 
In 2004, Schwarze et al. and later Malfait et al. described a new and rare EDS type: cardiac-
valvular EDS. Apart from typical EDS features, it is associated with severe aortic and/or 
mitral valve insufficiency, necessitating valve replacement at relatively young age. The 
inheritance is autosomal recessive. It is due to homozygous or compound heterozygous 
COL1A2 null mutations.
20,21
  
 
2. Cardiac abnormalities in EDS 
 
2.1 Classical and hypermobile EDS 
In classical EDS, occasionally cardiac disorders have been described, including mitral valve 
prolapse (figure 12-1) and mild cardiac arrhythmias.
22
 In generalized hypermobility, cardiac 
arrhythmias seem to be based on derangement of the autonomic regulation of heart rhythm.
23
 
To what extent there is a direct rather than a coincidental relationship between heart disease 
and EDS in these types is unclear. This issue has stimulated research interest that has been 
hampered by the very low incidence of EDS.  
In a group of 71 patients with EDS, the diameter of the aortic root was measured by 
echocardiography. In 28% of these patients, the diameter was found to be larger than average 
by a factor twice the standard deviation from the mean of normal. This means that the 
enlarged cross section cannot be attributed to chance, but constitutes a real anomaly. Fourteen 
of these patients (14/42 = 33%) had classical EDS and six patients (6/29 = 17%) hypermobile 
EDS. If the aortic root increases in diameter during the following years, the aortic valves, 
located in the root, might not properly close, resulting in aortic valve insufficiency (figure 12-
2). A surprising finding was that dilatation of the aortic root was found more often than mitral 
valve prolapse, an abnormality previously considered to be closely associated with EDS.
24 
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Figure 12-1 Mitral valve prolapse 
 
 
 
Echocardiographic image of posterior mitral valve leaflet (PMVL) prolapse in the left atrium 
(LA). 
Apical 3-chamber view with left ventricle (LV) in the upper and middle left parts of the 
picture, the LA in the lower part. The right part of the view shows the right ventricle with at  
the bottom the outflow tract of the LV, aortic valve and the origin of the aorta. The small 
vertical line in the ECG lead indicates that it is a late systolic contraction of the heart. It is 
clearly visible that during this contraction the PMVL protrudes in the LA. 
 
A similar study was performed in a cohort of 38 EDS patients in 2006.
25
 That study also 
demonstrated mild abnormalities in these patients but unfortunately insufficient follow-up 
data are available to provide any conclusive opinion about the possible progression of these 
abnormalities. However, given the normal life expectancy of individuals with classical and 
hypermobile EDS in contrast to those with the vascular type, it may be assumed that this 
progression is unlikely to be serious. But in a few recent case reports, occasionally more 
severe complications including aortic root aneurysm and myocardial infarction have been 
reported.
26
 These findings might, however, reflect EDS types with a slightly different genetic 
basis compared to classical EDS. For the time being the evidence would suggest that classical 
and hypermobile EDS are unlikely to result in serious cardiac or vascular clinical sequels. In 
2011, Atzinger et al. did a similar study in 252 patients and similarly concluded that, although 
aortic root size is increased and mitral valve prolapse is more frequent in patients with 
classical and hypermobile EDS, they tend to be of little clinical consequence.
27 
Recently, a subtype of classical EDS has been identified which is clinically characterized by a 
propensity to arterial rupture and molecularly by a specific mutation in COL1A1 (classical 
EDS is caused by mutations in COL5A1 and COL5A2).
28  
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Figure 12-2 Dilated aortic root 
 
A B                                          
C D 
 
CT angiography of the thoracic aorta. (A) Axial 2 mm multiplanar reconstruction of the 
enlarged aortic root at the level of the left coronary artery (arrow). (B) coronal 3 mm 
maximum intensity projection (MIP) image showing a dilated aortic root and proximal part of 
the ascending aorta. 20mm sagittal oblique MIP without (C) and with (D) aortic diameter 
measurements. 
 
2.2 Vascular EDS 
This EDS type is probably present in less than 1:100.000. Reduced life expectancy and 
frequency of complications clearly demonstrate the seriousness of the disease. Complications 
in childhood are rare; 25% of the patients having their first complication in their twenties and 
more than 80% experiencing one complication by the age of 40. More than 80% of these 
patients have one or two serious complications during their lifetime.
29
 Translated to a 
population of 16 million in the Netherlands this would account for 200 serious lifetime 
incidents, 25% of which involve the bowel or uterus. There are approximately 150 
complications involving the aorta or the medium-sized arteries, but occasionally also cardiac 
complications might occur.
30
 By an estimated average life expectancy of 50 years, this means 
that only three serious vascular complications will happen per year in the Netherlands. 
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Despite this low yearly prevalence there is still the need for adequate diagnosis and urgent 
referral to experienced vascular surgeons. 
It is suggested that complications in patients with vascular EDS are related to the COL3A1 
mutation type involved. In patients with mutations leading to haplo-insufficiency (with 
production of 50% of the normal amount of type III collagen), in contrast with mutations with 
production of 10% or less of the normal amount, life span is extended, the age of first 
complication is delayed by almost 15 years and major complications are limited to vascular 
events.
31,32
 A recent large study confirmed this association between COL3A1 mutation and 
phenotype and severity.
33
  
Recently, Monroe et al. reported a family with an lethal EDS vascular phenotype and a 
COL5A1 mutation, including a review of 4 other published cases.
34
  
The literature also reflects that in vascular EDS, the occurrence at a young age of coronary 
artery aneurysms or myocardial infarction is very infrequent
7,8,10
 and that (in a study of 220 
patients) there is absence of any clear proof of frequent, clinically-relevant cardiac disease 
other than coronary artery aneurysms or myocardial infarction.
25
 
 
3. Secondary prevention of EDS 
 
3.1 Classical and hypermobile EDS 
Authors who have reported cardiac disorders associated with these EDS types suggest 
screening these patients for evidence of aortic root abnormalities and if detected, to introduce 
close monitoring. However, the practicality of such a routine intervention is questionable 
given the limited evidence. A more acceptable recommendation might be to screen these 
groups before any surgery for cardiac valve abnormalities using echocardiography, to 
minimalize the risk of complications such as bacterial endocarditis, frequently associated with 
cardiac valve abnormalities.  
 
3.2 Vascular EDS 
Patients and doctors must remain vigilant for any signs or symptoms that may suggest 
complications associated with this EDS type. Early intervention is essential but this may be 
avoided by the implementation of preventive strategies including the optimal regulation of 
blood pressure, the avoidance of certain medication such as anticoagulants and regular, 
physical activity avoiding peak muscle loading and intense competitive sports.  
 
Cardiologists and other physicians, consulted by patients with vascular EDS should be 
cautious when dealing with these individuals. Box 12-1 highlights some of the risks they 
might encounter in the course of additional investigations. Invasive techniques such as venous 
or arterial puncture, all forms of endoscopy and heart catheterization are inducing a high risk 
of complications. If possible, noninvasive alternatives such as echocardiography, computer 
tomography (CT), magnetic resonance imaging (MRI) and magnetic resonance angiography 
(MRA) should be used in preference to standard invasive procedures.  
 
At the end of the day, the need for any invasive examination needs to be thoroughly 
questioned, particularly if the risk of the procedure outweighs the potential for any diagnostic 
benefit. And in the light of current developments in non-invasive imaging techniques utilizing 
smaller equipment to rapidly produce high quality images, one questions the place of invasive 
techniques that carry a risk to patients, particularly the group we are currently discussing. 
Today, echocardiographic techniques can be enhanced and CT and MRI scanned images of 
the heart and major vessels are of the highest quality.  
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Box 12-1 Advices for guiding and examination patients with vascular EDS 
 
1. Competitive sports are contraindicated. The load in aerobic exercises must be 
submaximal. Peak loads and press-ups should be avoided. 
2. Regular control of blood pressure is necessary and optimal treatment of high blood 
pressure is indicated. To lower the pressure in the arteries one should try to reach values 
beyond those of healthy persons of the same age. 
3. Medication which influences coagulation and can promote bleeding, anticoagulants, 
acetylsalicylic acid and conventional NSAIDs, are contraindicated.  
4. Punctures of arteries and catheterizations for diagnostic reasons should not be 
undertaken and a noninvasive alternative should be sought.  
5. Any form of endoscopic examination should be avoided and replaced by appropriate 
non-invasive techniques. This includes esophageal echocardiography and examination 
of the gastro-intestinal tract. 
 
Surveillance of the arterial tree is justified if interventions have been proven to be effective in 
decreasing risks of arterial dissection or rupture and prolong life. As endovascular approaches 
to management of aneurysms and dissection become more available, intervention is 
considered earlier and surveillance is seen to have greater benefit. There are, however, no 
published data that assess the efficacy of screening strategies to identify the regions in the 
arterial vasculature at highest risk.
35
  
 
In a clinical trial among 53 patients with vascular EDS investigating the effect of celiprolol on 
the occurrence over 5 years of arterial events (rupture or dissection, fatal or not), these 
complications occurred in five patients (20%) in the group treated with celiprolol and in 14 
patients (50%) not treated with celiprolol, a promising result that warrants further 
investigation.
36
 
 
4. Centre of expertise for patients with vascular EDS 
More than 10% of patients with vascular EDS die as the consequence of their first 
complication, without prior knowledge of the actual diagnosis. Although the vascular type is 
very rare, the dramatic course of the disease regularly draws much attention, and rightly so. 
Regularly case reports are published by physicians who describe their once-in-a-lifetime 
experience with such a patient. The rarity of vascular EDS makes every vascular surgeon, 
neurosurgeon or neurologist an “expert”, if exceptional circumstances or coincidence 
confronts him or her with two or three patients in a few years. Cardiologists less frequently 
encounter these patients in the role of first responsible physician and in the Dutch National 
Registry of Congenital Cardiac Malformations (CONCOR) there is no facility to register 
vascular EDS, although Marfan syndrome is included. However, cardiologists are often 
involved in additional examinations, once the diagnosis has been made. 
 
There is a great need for further research that will, with a greater number of patients, provide 
valuable insight into the prevalence of (cardio-)vascular abnormalities and complications of 
this type of EDS.  
 
The realization of a Centre of Expertise, perhaps involving international collaboration of 
universities with multi-disciplinary input, would contribute to our understanding of this 
condition and optimize patient management. The development of psychological support and 
guidance for EDS patients should also be part of such an initiative. However, in the present 
economic climate, the fear remains that insufficient funding will prevent such a development; 
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this leaves clinicians to rely on case reports and anecdotal comment rather than benefit our 
patients through sound, evidence-based knowledge.  
 
5. Conclusion 
In classical, hypermobile and vascular EDS no indications could be found for the presence of 
anatomical cardiac disorders other than coronary artery aneurysms in vascular EDS, which 
could lead to clinical manifest cardiac problems, when compared with a healthy population. 
However, more research is needed to distinguish the varieties of EDS, to concentrate 
knowledge of such a rare disease with small numbers of patients and to share this information 
in a multidisciplinary clinical setting. The optimal environment for this initiative would be a 
collaborative Centre of Expertise. Patients would then gain the maximum benefit of the 
collective wisdom of clinicians and scientists working in the area.  
 
6. Areas of uncertainty 
Due to the lack of systemic investigations among sufficient numbers of patients, it is not 
certain to which extent the present information on certain functional and anatomic cardiac 
abnormalities in EDS is really giving the complete picture. It could well be that systemic 
investigations would indicate higher prevalences of cardiac morbidity in patients with 
different types of EDS. 
 
The author wants to thank Dr. David Gerrard of Otago University, Dunedin, New Zealand for his comments and 
suggestions for English text.  
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1. Introduction 
Ehlers-Danlos syndromes (EDS) are heritable connective tissue disorders primarily affecting 
skin, joints, vessels and internal organs. Nevertheless, their consequences seem to span much 
beyond these tissues and also extend to the central and peripheral nervous system and 
muscles. In fact, recurrent muscle cramps have been reported in EDS since the late sixties.
1
 
After this early paper, which actually focused on orthopaedic aspects of EDS, many other 
reports have highlighted a possibly prominent involvement of the nervous system and muscles 
in this condition. However, an increasing attention on neurological aspects of EDS has been 
posed only in 2009 by Voermans et al., who reported their findings in 40 EDS patients and 
demonstrated a subtle, but significant neuromuscular involvement in this disorder.
2
 A recent 
review, primarily intended for a readership of child neurologists, emphasized a heterogeneous 
and potentially disabling neurological involvement in EDS with a wide range of apparently 
low-frequency, but possibly type-specific anomalies of the nervous system.
3
 Additionally, at 
least for the hypermobile EDS (hEDS) , musculoskeletal pain, fatigue and headache represent 
the master contributors to patients’ referral to the practitioner and quality of life 
deterioration.
4
  
In this chapter, neurological complications of EDS are illustrated in separated sections, 
including pain, fatigue, cardiovascular dysautonomia (as discussed in Chapter 5), headache 
and head pain, cerebrovascular disease, brain and spine structural abnormalities, epilepsy, 
muscular features, neuropathy, and developmental features. Before the publication of the 
2017 international classification of EDS, the prevalent hypothesis has been put forward to 
consider hEDS and benign joint hypermobility syndrome (BJHS) one and the same condition 
at the clinical level (see also the discussion in chapter 5).
5,6
 The contemporary nosology of 
EDS and joint hypermobility disorders has removed the term “benign joint hypermobility 
syndrome” (and synonyms). Now, the existence of a continuous spectrum ranging from 
isolated, non-syndromic joint generalized joint hypermobility to hEDS is recognized. Within 
the spectrum, the term hEDS is now restricted to the most systemic/Mendelian phenotypes, 
while the term hypermobility spectrum disorders (HSDs) is introduced to fill the gap between 
the two ends. For conservative reasons, in this chapter the term hEDS/HSDs is used for all 
papers published before the 2017 classification and dealing with patients with hEDS and/or 
benign joint hypermobility syndrome according to the old diagnostic criteria. The following 
contents are partly extracted from a recent review on neurological manifestations in EDS 
written by the authors of this chapter.
7
  
 
2. Pain 
Pain is now accepted as a common and potentially disabling feature of various forms of EDS, 
especially hEDS/HSDs.
4
 This is testified by the inclusion of chronic musculoskeletal pain as 
minor feature in the 2017 International EDS classification criteria for hEDS (see chapter 2, 
table 2-5 and chapter 5).
6
 Conversely, in the early EDS literature, pain was recognized as a 
marginal finding, usually occurring acutely due to (sub)luxations, spontaneous rupture of 
vessels
8
 and internal organs,
9
 or recurring in relation to piezogenic pedal papules
10
 or 
gynaecologic/obstetric complications.
11
 In 1994, Lumley et al. first pointed out a possible role 
of chronic pain in the quality of life of EDS patients by studying psychosocial functioning in 
48 subjects with various forms of EDS.
12
 Furthermore, the repeated evidence of resistance to 
local anaesthetics in hEDS/HSDs
13
 suggests a more complex effect on pain perception and 
modulation processes in EDS. Scientific awareness of the clinical significance of chronic pain 
in EDS increased in 2010, when Voermans et al. published the results of their questionnaire 
study on 273 patients with various forms of EDS (mainly, classical, hypermobile and vascular 
types) and found pain as common, severe, and associated with functional impairment. 
Interestingly, pain seemed more severe in hEDS/HSDs than classical and vascular EDS, and 
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pain severity was correlated with hypermobility, dislocations and previous surgery.
14
 This 
preliminary observation prompted the same research group to state that pain and fatigue are 
possible important determinants of disability of hEDS/HSDs.
15
 On a clinical perspective, 
chronic-recurrent joint pain is the most common presentation of pain in hEDS/HSDs, which is 
reflected in the diagnostic criteria.
6
 Additional manifestations of musculoskeletal pain in 
hEDS/HSDs, and perhaps other EDS types, include muscle cramps,
1
 fibromyalgia
16,17
 and 
compression/peripheral neuropathies.
18,19
 Pain is not limited to the musculoskeletal system 
and often presents with visceral involvement, in the form of various gastrointestinal chronic 
and recurrent symptoms,
20
 as well as dyspareunia, vulvodynia and dysmenorrhea.
21,22
 
Headache is also common in EDS
23
 and is discussed in a separate section. The study of the 
natural history of hEDS/HSDs tells us that pain changes in time and among individuals in 
EDS, and its functional consequences are influenced by the adaptation strategies that affected 
individuals develop, as a whole, to face repetitive pain perception.
4
 Accordingly and 
following previous postulations,
4
 a recent work by Rombaut et al. demonstrated the presence 
of hyperalgesia in hEDS/HSDs.
24
 This finding may represent a preliminary proof for central 
sensitization processes in those EDS patients, who develop the most severe disabilities 
associated to pain. A more extensive description of pain manifestations and management in 
EDS is reported in chapter 21 (“Causes and treatment of chronic pain in EDS”). 
 
3. Fatigue 
Though largely ignored in the past, severe fatigue is now considered a common 
accompanying feature of EDS, particularly hEDS/HSDs, as it has for the first time been 
reported in up to 84% of the patients.
25
 Similar results are obtained by other research 
groups.
26,27
 More specifically, the frequency (and, perhaps, severity) of fatigue is influenced 
by age with a rate of 28% in the first decade of life to 90% in adults over 40 years of age.
27
 In 
hEDS/HSDs, the impact of fatigue on daily life is often equal to or more dramatic than the 
impact of pain;
25
 a fact that underscores the importance of fatigue for both assessment and 
treatment planning in these patients. A complex presentation of fatigue resembling chronic 
fatigue syndrome according to Fukuda et al.
28
 is reported in most adults with hEDS/HSDs.
29
 
Some possible contributors to fatigue-related disability in EDS have been identified and 
include sleep disturbances, concentration problems, impaired social functioning and self-
efficacy concerning fatigue, and pain severity.
25
 A few experimental studies demonstrated that 
fatigue associates with muscle weakness,
30,31
 worsens with exercise
32
 and affects gait 
pattern.
33
 Recently, dysautonomia was recognized as one of the most relevant pathogenic 
factors influencing fatigue onset and evolution. This argument is discussed in extension in a 
following section.  
 
4. Headache and head pain 
In 1996, Spranger et al. first reported headache, drop attacks and white matter abnormalities 
in a 37-year-old woman with EDS with periodontitis.
34
 One year later, a larger study on 50 
individuals with different forms of EDS (including 13 patients with classical EDS, 28 with 
hEDS/HSDs, 7 with vascular EDS, and 2 with unclassified type) showed that neck pain and 
headache are present in 30-40% of cases.
23
 A subsequent case series reported 9 EDS patients 
presenting with various forms of headache, including (i) migraine with aura, (ii) migraine 
without aura, (iii) tension-type headache, (iv) a combination of tension-type headache and 
migraine, and (v) post-traumatic headache.
35
 Additional papers on small case series confirmed 
the high prevalence of headache in hEDS/HSDs.
36,37
 More specifically, Bendik et al. showed 
that migraine (with or without aura) was approximately three times more common among a 
group of 28 women with hEDS/HSDs compared to 232 controls, with a cumulative frequency 
of 75%.
38
 In a 36-year-old woman with orthostatic headache and idiopathic intracranial 
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hypertension, the diagnosis of BJHS - now considered hEDS/HSDs - was reached two years 
after the onset of head pain.
39
 This patient displayed increased insulin growth factor 1 (IGF-1) 
plasma levels and the authors speculated on a possible pathogenic link. The elevation of IGF-
1, in association with elevations of growth hormone and insulin, has been described 
previously in 31 BJHS patients.
40
 The relationship between elevated IGF-1 plasma levels and 
headache in BJHS is not clear, but the presence of IGF-1 receptors in the choroid plexus
41
 
may suggest an overstimulation of cerebrospinal fluid production by the excess of circulating 
IGF-1 molecules.  
Head pain is not limited to headache in EDS. In a cohort of 31 EDS patients (including 16 
with hEDS/HSDs, nine with classical and six with vascular EDS), De Coster et al. 
demonstrated temporomandibular joint dysfunction in 100% of the cases, unilateral 
myofascial pain (i.e. temple headache) in 83%, and unilateral or bilateral temporomandibular 
joint pain in 28% and 51% of the patients, respectively.
42 
Another cause of headache in EDS is occipital neuralgia is a distinct type of headache 
characterized by piercing, throbbing, or electric-shock-like chronic pain in the upper neck, 
back of the head, and behind the ears, usually on one side of the head. Typically, the pain of 
occipital neuralgia begins in the neck and then spreads upwards. Some individuals will also 
experience pain in the scalp, forehead, and behind the eyes. Their scalp may also be tender to 
the touch, and their eyes especially sensitive to light. The location of pain is related to the 
areas supplied by the greater and lesser occipital nerves, which run from the area where the 
spinal column meets the neck, up to the scalp at the back of the head. The pain is caused by 
irritation or injury to the nerves, which can be the result of trauma to the back of the head, 
pinching of the nerves by overly tight neck muscles, compression of the nerve as it leaves the 
spine due to osteoarthritis, or tumours or other types of lesions in the neck. A positive 
response (relief from pain) after an anaesthetic nerve block will confirm the diagnosis. 
Treatment is generally symptomatic and includes massage and rest. In some cases, 
antidepressants may be used when the pain is particularly severe. Other treatments may 
include local nerve blocks and injections of steroids directly into the affected area. Occipital 
neuralgia is not a life-threatening condition. Many individuals will improve with therapy 
involving heat, rest, anti-inflammatory medications, and muscle relaxants. Recovery is 
usually complete after the bout of pain has ended and the nerve damage repaired or lessened. 
While many EDS patients may develop chronic or recurrent headache, individuals with EDS 
types with vascular fragility are at increased risk of sudden headache secondary to acute 
cerebrovascular disease. In particular, acute headache may occur together with 
ophthalmoplegia or tinnitus due to spontaneous direct cavernous-carotid fistula in vascular 
EDS.
43,44
 Additional observations point out possible associations between localized or 
generalized joint hypermobility and specific subsets of primary and secondary types of 
headache, including new daily persistent headache
45
 and headache attributed to spontaneous 
(idiopathic) cerebrospinal fluid leakage.
46,47
 Cervical spine hypermobility/dysfunction is also 
anecdotally considered a predisposing factor for cervicogenic headache
48,49
 and neck-tongue 
syndrome.
50-52
 In line with this, Di Palma and Cronin reported a 27-year-old woman with 
classical EDS with a long-lasting pulsating headache associated with C2 dislocation.
53
 
 
5. Cardiovascular dysautonomia 
The first evidence for a tight link between EDS and autonomic dysfunction was obtained in 
1999, when Rowe and co-authors studied 11 young patients (6 with classical and 6 with 
hEDS/HSDs) all showing either postural tachycardia (a.k.a. postural orthostatic tachycardia 
syndrome - POTS) or neurally mediated hypotension.
54
 Four years later, Gazit et al. found 
orthostatic hypotension, POTS, and uncategorized orthostatic intolerance in 21 out of 27 
(78%) hEDS/HSDs patients.
55
 More specifically, this study revealed a greater drop in systolic 
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blood pressure during hyperventilation and a greater increase in systolic blood pressure after a 
cold pressure test in patients compared to controls. The authors suggested the existence of 
increased alpha-adrenergic and beta-adrenergic hyper-responsiveness in hEDS/HSDs.
55
 These 
preliminary findings pointed out the need of paying more attention to non-musculoskeletal 
symptoms of hEDS/HSDs (and other EDS types) which, in turn, may be linked to 
dysautonomia as the underlying pathogenic mechanism.
56
 Accordingly, non-musculoskeletal 
symptoms are now accepted as an important manifestation of EDS and their clustering 
determines a worse physical and psychosocial health within the wider clinical spectrum of 
hEDS/HSDs.
57
 Accordingly, the autonomic burden in EDS, and more particularly in 
hEDS/HSDs than in classical and vascular EDS, seems comparable to that in fibromyalgia.
58
 
The same research group further investigated the dysautonomic profile of hEDS/HSDs with 
autonomic functional testing and found a higher low frequency/high frequency ratio (i.e. an 
increase of the physiological heart rate variability), a greater blood pressure fall during 
Valsalva manoeuvre and a smaller initial systolic blood pressure increase during tilt in a 
cohort of 39 affected women compared to controls.
59
 They also found POTS as the most 
prevalent autonomic profile in hEDS/HSDs and identified sympathetic neurogenic 
dysfunction as the most likely explanation for dysautonomia in this condition.  
The list of direct and remote clinical implications of dysautonomia, mostly in form of POTS, 
in EDS is wide (box 13-1). In presence of constellation of symptoms suggestive of 
dysautonomia, a head-up tilt-test is indicated (Table 13-1). If confirmed, the treatment of 
dysautonomia is challenging especially in EDS due to a possibly increased rate of adverse 
effects for many standard treatments. Management recommendations for POTS in general are 
summarized in Mathias et al.,
60
 while some suggestions tailored to hEDS/HSDs are proposed 
by Castori et al.
61
 The mechanisms underlying cardiovascular dysautonomia in EDS are not 
well understood. A sympathetic neurogenic dysfunction is actually considered the major 
primary effector, but connective tissue laxity and vasoactive medication may also play a 
role.
59
 
 
Box 13-1. Spectrum of EDS features which may be related to an underlying dysautonomia.  
• Cardiovascular manifestations: postural or paroxysmal tachycardias, palpitations, 
(atypical) chest pain, shortness of breath, flushing, livedo reticularis.  
• Neurologic manifestations: syncope, dizziness, fainting, light-headedness.  
• Sudomotor/exocrine manifestations: acral hyperhidrosis, night sweating, dry eyes, dry 
mouth, dry vaginal mucosa.  
• Gastrointestinal and urinary manifestations: oesophageal dysmotility, nausea, stomach 
ache, abdominal pains, diarrhoea, constipation, underactive/overactive bladder.  
• Indirect manifestations: fatigue, poor sleep quality, fever, lymph node pain, anxiety, 
depression, panic attacks, headache, concentration/memory troubles, visual disturbances. 
 
6. Cerebrovascular disease 
Most reports on stroke and cerebrovascular disease in EDS concern vascular EDS and include 
intracranial aneurysms, subarachnoid haemorrhage, spontaneous arterial dissection and 
cavernous sinus fistula. Vascular EDS is characterized by thin but often not hyperextensible 
skin, acrogeria, extensive easy bruising, hypermobility of the small joints, and spontaneous 
vascular and hollow viscera ruptures. The diagnosis can be confirmed by molecular testing of 
the COL3A1 gene. In patients with classical EDS, aneurysms occur occasionally whereas 
other vascular abnormalities are rare.
62
 Accordingly, the presence of stroke in patients with 
cutaneous features of classical EDS should also prompt molecular investigation of COL1A1, 
COL5A1 and COL5A2. As kyphoscoliotic EDS features vascular fragility,
6
 PLOD1 molecular 
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testing is a further investigation to be considered in presence of other findings suggestive of 
this rarer EDS variant.  
In 1990, Schievink et al. reported two patients with vascular EDS, one with a spontaneous 
internal carotid artery dissection and one with an aneurysmal subarachnoid haemorrhage and 
multiple aortic dissections.
63
 Both patients were deficient in collagen type III, analysed in 
cultured skin fibroblasts. Subsequently, the same author reported a 20-year-old woman with 
vascular EDS who presented with a spontaneous carotid-cavernous fistulae and a cervical 
artery dissection.
64
 The clinical features of 19 vascular EDS patients with ages ranging from 
17 to 48 years were also reviewed.
65
 The spectrum of cephalic vascular complications 
included intracranial aneurysms with secondary haemorrhage, spontaneous carotid-cavernous 
sinus fistula, and cervical artery dissection. Since collagen type III deficiency plays a role in 
the pathogenesis of intracranial saccular aneurysms, it is likely to be involved in the 
pathogenesis of carotid cavernous fistulas and dissections of cervical arteries.
63
 In 1995, 
North et al. studied cerebrovascular complications in a cohort of 202 patients with vascular 
EDS.
66
 Nineteen patients had cerebrovascular complications, including intracranial aneurysms 
with secondary haemorrhage, spontaneous carotid-cavernous sinus fistula and cervical artery 
dissection. Aneurysms typically develop in the cavernous sinus or directly adjacent to it, and 
bilateral and recurrent carotid aneurysms have also been reported.
67-71
 Aneurysmal rupture 
can occur spontaneously or during vigorous activity.
63,66
 A carotid-cavernous fistula can 
develop after minor head trauma but in most cases it develops spontaneously after a rupture of 
the internal carotid artery aneurysm within the cavernous sinus.
64
 These carotid-cavernous 
fistulae often present with exophthalmos, chemosis, pain, ophthalmoplegia and bruits, which 
result from their high blood flow which allows pressurized arterial blood to connect directly 
to the venous cavernous sinus, resulting in venous hypertension and reversal of venous 
drainage.
72
 
Although it is a relatively uncommon clinical type of EDS (compared to classical and 
hEDS/HSDs), vascular EDS is a potential cause of stroke in young people.
73-75
 In typical 
cases, the disorder is readily identifiable by clinical evaluation focused in assessing joint 
mobility and checking for typical cutaneous and historical features and, then, it can be 
confirmed by targeted molecular testing. However, the phenotypic variability of vascular EDS 
could lead to underdiagnosis, especially in an emergency setting.
74
 Hence, a full clinical 
history and examination and a complete familial history should be emphasized, as often only 
the combination of all these data will raise suspicion of vascular EDS. This is crucial since the 
diagnosis has important implications for acute and long-term management and, potentially, 
for other family members.
74
 
In vascular EDS, the traditional approach has been to treat such complications conservatively 
unless they are life threatening. Recent reports challenge this treatment paradigm.
76
 In a 
randomized study, treatment with the beta-blocker celiprolol was shown to be associated with 
a three-fold decrease in arterial rupture in vascular EDS.
77
 Novel approaches using 
endovascular therapy with coil embolization have shown good results in the treatment of 
ruptured pseudo-aneurysms and carotid-cavernous fistulas.
72,76
 Nevertheless, complications 
are frequently reported. Anticoagulation therapy may result in increased bruising or bleeding 
and should be used with caution.
62,78
 Because conventional angiography may exacerbate 
severe complications, non-invasive magnetic resonance angiography is the investigation of 
choice. 
 
7. Brain and spine structural anomalies  
Brain MRI is usually unremarkable for major structural anomalies in EDS. Therefore, with 
the exception of acute presentations where cerebrovascular disease is suspected, such an 
investigation usually is not indicated in the baseline assessment of EDS patients. 
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Nevertheless, the presence of clear-cut X-linked dominant transmission and/or the coexistence 
of seizures should elicit the exclusion of the rare form of EDS with periventricular 
heterotopias often due to mutations in FLNA (not any longer included in the 2017 
International EDS classification).
6,79,80
 Single reports also associate EDS (undefined type) 
with polymycrogyria,
81
 agenesis of the corpus callosum,
82
 dilatation of the 4
th
 ventricle, 
supracerebellar cistern and lateral ventricle, or disproportional enlargement of anterior horn of 
lateral ventricle,
83
 but the consistency of such associations awaits confirmation.  
Conversely, clinical practice suggests a high rate of degenerative findings, in form of 
generalized, early-onset spondylosis and disc hernias, at spine MRI. However, this evidence 
remains anecdotal
84
 and needs systematic confirmation. Spine MRI may also show meningeal 
cysts, as reported in a 7-year-old girl with kyphoscoliotic EDS,
85
 in an adult with classical 
EDS
86
 and with a low frequency in hEDS/HSDs.
61
 In EDS, meningeal (or Tarlov) cysts are 
apparently rare and very few or single. In contrast, Marfan syndrome often associates with a 
more homogeneous dilatation of the meninges particularly at the lumbosacral vertebrae, 
which is termed “dural ectasias”. The 40-year-old woman with multiple and bilateral Tarlov 
cysts along the entire spine and originally diagnosed as suffering from (unclassified) EDS by 
Isono et al.,
87
 can be best labelled with the diagnosis of lateral meningocele syndrome,
88
 an 
apparently distinct form of hereditary connective tissue disorder with severe thecal 
involvement.
89
 The clinical significance of meningeal cysts is still unknown in EDS, although 
a link with orthostatic headache due to spontaneous cerebrospinal fluid leaks may be 
inferred,
90,91
 similarly as in Marfan syndrome. Meningeal involvement is a diagnostic feature 
of Marfan, in which it is usually referred to as “dural ectasia”, indicating a multidirectional 
enlargement of spinal canal particularly at the lumbosacral level with possible herniations of 
the meninges at the intervertebral holes (for more details on the different meningeal 
involvements in EDS types, Loeys-Dietz syndromes and Marfan syndrome see ref. no. 88).  
The concurrence of Chiari malformation (type I) is a further apparently underreported feature 
of EDS, as to date observed in single patients only (box 13-2 and figure 13-1).
35,37
  
 
Figure 13-1 Chiari Malformation type I in hypermobile Ehlers-Danlos syndrome 
 
 
MRI of a Chiari malformation type I in a 33-year-old woman with hEDS/HSDs. The diagnosis 
was made after exacerbation of her long-lasting occipital headache. The asterisk indicates the 
downward displacement of the cerebellar tonsils through the occipital hole.  
 
 
Neurological complications of Ehlers-Danlos syndromes and hypermobility spectrum disorders 193
 
 
Box 13-2. Illustrative case report.  
A 33-year-old woman presented with chronic headache, which had progressed from 
previously recurrent occipital headache in association with abrupt onset of dysesthesias 
extended below the umbilicus, tremors of the upper limbs and weakness of the lower limbs. 
Such a worsening of the pre-existing headache followed a new employment as an archivist, 
which caused repetitive flexion movements at the cervical spine. Her past medical history 
included clumsiness, two dislocations of the left shoulder, chronic-recurrent 
musculoskeletal pain at hips, temporomandibular joints, shoulders and calves, orthostatic 
intolerance, chronic constipation, easy bruising and gingival fragility. A brain MRI 
revealed type I Chiari malformation (figure 13-1).  
At examination, she displayed positive Romberg test, brisk deep tendon reflexes at all 
limbs, generalized mild hypotonia, paraesthesia at the oral cavity and external ear canals 
with exacerbation of the neck pain during active and passive flexion and rotation of the 
neck (neck-tongue syndrome), generalized joint hypermobility with a Beighton score of 
6/9, bilateral hallux valgus, soft and velvety skin, and short lingual frenulum with tongue 
dyspraxia. The diagnosis of hypermobile Ehlers-Danlos syndrome was proposed once any 
other partially overlapping hereditary connective tissue disorders is excluded.  
 
However, in a surgically-oriented paper on hundreds of patients originally ascertained for 
symptomatic Chiari malformation, a subgroup of them showed a high rate of recurrence after 
surgery and multiple features of an underlying hereditary connective tissue disorder. This 
cohort presented minor, but measurable neuroradiological features of occipitoatlantoaxial 
instability: posterior gliding of the occipital condyles, and reduction of the clivus-axis angle, 
clivus-atlas angle, and atlas-axis angle in the upright position.
92
 In these patients a congenital 
laxity of the ligaments surrounding the occipitoatlantoaxial joints is presumably the cause of 
herniation of the cerebellar tonsils within a wider spectrum of features suggestive of a 
hereditary connective tissue disorder. 
In line with this, an early report described 2 vascular EDS patients with radiologically evident 
atlantoaxial subluxation.
93
 Hence, investigating for cerebellar tonsils herniation and an occult 
occipitoatlantoaxial instability is relevant during the assessment of patients with occipital or 
postural/orthostatic headache, and/or additional unexplained neurological symptoms, such as 
paresthesias and weakness. Assessing non-traumatic occipitoatlantoaxial instability is a hard 
task with standard imaging and need meticulous measuring of the changes in spatial 
relationships between the basiocciput and the first two cervical vertebrae (i.e. C0-C2) at 
different positions (e.g. anterior flexion of the neck, posterior extension, lateral flexion). 
Major limitations of this approach include the lack of easily available parameters and 
nomograms for such measurements, and the limited applications of second-line investigations 
(such as MRI and CT) in assessing vertebral mobility. In addition, cervical spine instability is 
not limited to the upper vertebrae in EDS and can also extend to other parts of the spine. Both 
upper and lower cervical spine instability may also predispose to traumas and the congenital 
laxity of the surrounding tissues should be considered in the subsequent management 
procedures (Figure 13-2).
94
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Figure 13-2 Musculocontractural Ehlers-Danlos syndrome due to a homozygous CHST14 
mutation 
 
 
Pre- and postsurgery X-ray of a luxation of C5-C6 (spondylolisthesis) in a patient previously 
been described by Voermans et al,
94
 with a fractured fragment of corpus C6. This occurred at 
a fall while walking on a frozen street. Most likely, the distal and proximal muscle weakness 
had made her more vulnerable to falling. The fracture was stabilized (C4-6 spondylodesis) by 
posterior instrumentation, but a post-operative kyphosis of the adjacent proximal level 
occurred. During a six-month follow up the junctional kyphosis of the cervical spine was 
stabile despite the swan neck deformity. An MRI scan did not show severe compression of any 
of the neurological structures.  
 
8. Epilepsy 
The mechanisms explaining the possible association between EDS and seizures are likely 
heterogeneous. In 1981, Cupo et al. reported a 30-year-old woman with EDS who died due to 
an intractable ventricular fibrillation due to myocardial infarction. She also presented seizures, 
aneurysms of the sinus of Valsalva and severe panacinar emphysema. Necropsy finding 
included cerebral heterotopias.
95
 Since this early description, additional reports suggested the 
existence of a distinct form of EDS with cutaneous features resembling the classical type, 
coupled with periventricular subependymal heterotopias.
79
 In most cases, this presentation is 
transmitted in a X-linked dominant pattern and is associated with mutations in the FLNA 
gene.
80,96
 Furthermore, Jacome reported 7 EDS patients, two of them affected by occipital-
horn disease, which was considered a type of EDS but which is actually removed from the 
EDS classification, with epilepsy and various concomitant neurological complications.
97
 Of 
the 5 remaining individuals with a more stringent diagnosis of (unclassified) EDS, possible 
nervous system determinants for seizures include basilar artery hypoplasia, hemispheric 
atrophy, venous parietal angioma, previous intracranial bleed and previous stroke. Additional 
reports of EDS with seizures included a 29-year-old man with unclassified EDS and bilateral 
frontocentral and frontoposterior polymicrogyria with hypoplasia of the cerebellar vermis, a 
20-year-old woman with hEDS/HSDs and bilateral perisylvian polymicrogyria,
81
 and a 16-
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year-old man with classical EDS and agenesis of the corpus callosum.
82
 These reports might 
suggest a small increased rate of epilepsy in EDS, but this could also be positive publication 
bias. Although in many cases structural brain anomalies (particularly, periventricular 
heterotopias) may be identified, mechanisms linking seizures to a hereditary defect of the 
connective tissue remain poorly studied. 
 
9. Muscular features 
EDS is associated with a variety of neuromuscular features (see figure 13-3 and chapter 5), 
and vice versa, a variety of congenital myopathies are associated with joint hypermobility 
and, to a lesser extent skin changes.
98
 Awareness of this clinical overlap between inherited 
connective tissue disorders and certain congenital myopathies might be helpful in recognition 
of these rare disorders.
99 
The initial reports of Beighton already included a high prevalence of 
myalgias and nocturnal muscle cramps involving the calves, especially in hEDS/HSDs.
1,100
 
This author also detected hypotonia, progressive muscle weakness, poorly developed 
musculature, and scapular winging, all without signs of concomitant myopathy, see figure 13-
3. It was suggested that the muscle hypotonia might have a basis in the abnormality of the 
collagen in muscle sheaths rather than in the muscle fibres itself, but this was deemed 
unlikely. In contrast, these symptoms were considered to be secondary to avoidance of 
exercise because of the hypermobility, joint pain and instability of joints.  
This might have contributed to the relative neglect of muscle features in EDS, and for years 
only few case reports pointed to these EDS manifestations. Banerjee et al. reported a nine year 
old boy presenting with delayed walking and abnormal gait.
101
 The presence of marked 
muscle hypoplasia with hypotonia led to the initial diagnosis of primary muscle disease; later, 
he was found to have hyperextensible and fragile skin and hypermobile joints and EDS was 
diagnosed. A second case was reported by Bertin et al. showing combination of EDS and 
muscular dystrophy in a 16-year old male patient.
102
 Furthermore, Palmeri et al. reported the 
association of chronic muscle pain and cramps and vascular EDS.
103
 The first study on the 
physiological basis of muscle weakness in EDS was performed by Bilkey et al. suggesting 
that muscle weakness was due to the adaptation of learned motor patterns in response to the 
alterations in the connective tissue surrounding the muscle cells.
104 
In 2009, Voermans et al. performed a prospective study in 40 genetically or biochemically 
confirmed patients with various forms of EDS (vascular, classical, hypermobile and classical-
like TNXB-deficient EDS), showing that mild-to-moderate neuromuscular involvement is 
common in these types.
2
 Patients reported muscle weakness, myalgia, easy fatigability, and 
limited walking distance. Physical examination revealed mild to moderate muscle weakness, 
reduction of vibration sense, and mild impairment of mobility and daily activities. Ancillary 
investigations showed only mild, aspecific myopathic signs, see figure 13-4. The findings of 
this study have increased awareness of neuromuscular symptoms in EDS patients. Muscle 
biopsies to exclude presence of a co-existent myopathy might not be necessary if typical 
clinical and neurophysiological findings are encountered and the EDS diagnosis is confirmed 
by an expert in the field. 
Another finding in this study was the remarkable relation between residual TNX levels and 
degree of neuromuscular involvement, compatible with a "dose"-effect relation. This points to 
a role of the extracellular matrix defect in muscle and peripheral nerve dysfunction in EDS
2 
This was confirmed in physiological studies in TNXB-deficient patients and tnxb knock-out 
mice.
105,106
 
Muscle involvement is probably most pronounced in kyphoscolitic EDS due to PLOD1 
mutations and musculocontractural EDS due to CHST14 mutations, and is often evident in the 
neonatal period. These conditions should be considered in the initial differential diagnosis of 
the floppy infant.
98,99,107,108
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Figure 13-3 Neuromuscular features in various Ehlers-Danlos syndrome types 
 
First row: Distal weakness and atrophy in hands of classical-like TNX-deficient type EDS. 
Limited flexion of fingers after a brachial plexus lesion after a complicated relocation of a 
shoulder dislocation, which occurred after stretching out her arm while cleaning the house. 
Second row: incomplete eye closure in patient with vascular EDS. Distal atrophy and 
weakness in a patient with musculocontractural Ehlers-Danlos syndrome due to a 
homozygous CHST14 mutation (2 pictures). 
Third row: Limited active arm abduction in a patient with kyphoscoliotic EDS, mild winging 
of scapulae, and bilateral pes planus in a patient with kyphoscoliotic EDS, respectively. 
Right image: Patient with musculocontractural Ehlers-Danlos syndrome due to a homozygous 
CHST14 mutation with distal muscle weakness and wasting. 
 
A recent case report on a patient with classical-like TNX-deficient EDS with progressive axial 
and proximal limb muscle weakness and atrophy further supported this. This patient had only 
minimal skin hyperextensibility, no joint abnormalities, and a history of easy bruising. 
Skeletal muscle biopsy disclosed strikingly weak muscle consistency at biopsy.
109
 
Furthermore, myopathic EDS is a new entry in the 2017 International EDS classification and 
represents probably the most myopathic form of EDS. As such it is generally recognized as a 
congenital myopathy which should be included in the differential diagnosis of the collagen VI 
spectrum (Bethlem myopathy/Ullrich congenital muscular dystrophy)
110
. It is featured by 
congenital muscle hypotonia and/or muscle atrophy which improves with age, and minor joint 
and skin anomalies. Motor development is delayed. Muscle biopsy shows myopathic features, 
and in a minority of patients also dystrophic changes. Myopathic EDS is apparently very rare 
and caused by heterozygous or biallelic mutations in COL12A1.
6, 111,112
 A mouse model with 
inactivation of the Col12a1 gene showed decreased grip strength and other features indicating 
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a role for a matrix-based passive force-transducing elastic element contributing to 
weakness.
111 
 
Figure 13-4 Muscle histology in EDS and the muscular connective tissue 
  
Left image: Mild myopathic changes in the muscle biopsy (lateral vastus muscle) of a 
hypermobile EDS patient due to TNXB haploinsufficiency: mildly increased variation in fibre 
diameter and increase of number of central nuclei (5%; normal: ≤3%)(arrow). Bar= 100 µm. 
Reproduced with permission of Wiley InterScience, New York.
2
 
Right image: Structure of intramuscular connective tissue. The skeletal muscle (bovine 
semitendinosus muscle) extracellular network is shown by scanning electron micrographs 
after removal of skeletal muscle fibres. A: The endomysium surrounding one individual 
skeletal muscle fibre; B: The epimysium (EP) surrounding the entire muscle; C: The 
perimysium (P), surrounding a fascicle, as well as the endomysium (E). This intrinsic network 
of connective tissue helps to understand the important role that it plays in muscle function, 
and that various EDS types are associated with mild to moderate neuromuscular symptoms 
such as muscle weakness, exercise intolerance and muscle hypotonia. Reproduced with 
permission from S. Karger AG, Basel.
131 
 
10. Neuropathy 
Brachial and/or lumbosacral plexus neuropathies and compression mononeuropathies have 
been reported in several types of EDS.
18,113-116
 Although the study of Voermans et al. focused 
primarily on muscle, signs of peripheral nerve involvement in EDS were also observed. Nerve 
conduction studies demonstrated axonal polyneuropathy in 13% of patients, mainly of 
vascular and classical-like TNXB-deficient EDS.
2
 Recently, a study on entrapment 
neuropathies and polyneuropathies in hEDS/HSDs showed a higher prevalence of neuropathic 
symptoms (paraesthesia /numbness in hands and/or feet) than of neurophysiological and 
ultrasound evidence of focal or diffuse nerve involvement. This might be due to the presence 
of radiculopathy or of small fibre neuropathy, which were not further addressed in this study. 
Additionally, a high prevalence of ulnar nerve subluxation/luxation at the elbow was detected 
on dynamic ultrasound investigation.
117
 
The pathophysiological mechanism of peripheral neuropathy in hEDS/HSDs seems related to 
joint dislocations and subluxations due to ligament and capsular laxity which may cause 
abnormal stretching of or pressure on peripheral nerves, and, thus can result in neuropathy or 
plexopathy. Increased vulnerability of peripheral nerves to stretching or pressure directly 
linked to the underlying genetic defect might also be involved. TNXB or collagen I, III or V 
A B 
C 
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deficient epi-, peri- and endoneurium (i.e. the connective tissue of peripheral nerves) might 
fail to resist increased mechanical stress.
18
 
 
11. Developmental features 
Global developmental delay in children evolving in intellectual disability is rare in EDS, apart 
from some cases of spondylodysplastic EDS.
6,112
 Given the high frequency of joint 
hypermobility in the general population as well as in disabling genetic conditions, the 
presence of a true global developmental delay should prompt the practitioner to search for 
diagnoses other than EDS. For example, an EDS-like phenotype has been described in 
association with 6q27 chromosome deletion,
118
 which may be detected by CGH-array, one of 
the first-line investigations for subjects with intellectual disability (defined as an IQ below 70 
and significant limitations in adaptive functioning). Conversely, relatively robust data support 
a tight link between joint hypermobility and reduced motor performance in children, as is also 
seen in kyphoscoliotic, dermatosparaxis, spondylodysplastic and myopathic EDS.
6
 In fact, 
while an early work failed to detect an association between joint hypermobility and 
neurodevelopmental attributes,
119
 three more recent studies demonstrated that joint 
hypermobility is more common among children with developmental coordination 
disorders.
120-122
 Complementarily, abnormal gait, clumsiness and poor coordination are 
common findings in children with a diagnosis of hEDS/HSDs.
123,124
 Such an apparently 
selective influence of congenital joint hypermobility on coordination could be the 
consequence of an impairment of proprioception in critical phases of motor development. 
This hypothesis is based on the repeated evidence of a mildly defective proprioception in 
hEDS/HSDs.
125-129
 The generalized joint hypermobility of hEDS/HSDs children explains why 
they perform well at sports, such as gymnastics, ballet and dancing, while their deficient 
motor skills often improve by exercise. The natural propensity to specific sports, which 
contrasts the poor coordination skills at school reported by many patients, is a primary feature 
of the paediatric presentation of hEDS/HSDs, as recently outlined.
4,37,39
 This 
neurodevelopmental profile seems extremely common in hEDS/HSDs and, presumably, in 
other hereditary connective tissue disorders as well.  
 
12. Principles of practice and future directions 
In this chapter a wide spectrum of neurological manifestations was illustrated in many EDS 
types. Although accumulated data is fragmented in single case reports and a few more 
relevant studies, it shows sufficiently that the nervous system is commonly involved in 
individuals with EDS. Whether neurological manifestations are primarily related to the 
underlying molecular defect or rather emerge as the consequences of peripheral dysfunctions 
eventually reflecting to the nervous system remains unclear for many of the manifestations 
presented. Given the ubiquity of many structural components of the connective tissue, 
pleiotropy (i.e. the expression of the mutated gene in many tissues, including the various 
components of the nervous system) is a promising explanation for many neurological 
manifestations of EDS. The presence of various specific structural brain and spine anomalies 
in a few patients well testifies for this theory. On the other hand, the tight link between lack of 
proprioception and joint hypermobility, and the recurrent neurodevelopmental profile in 
“double-jointed” children suggest the existence of a complex pathogenesis for other features, 
which could result from the far-reaching effects of lax joints and tissues on the development 
of motor schemas in critical phases of brain maturation.  
From a practical perspective, the emerging body of evidence indicates the utility to consider 
neurological involvement in every patient with a diagnosis of EDS. Referral to the neurologist 
with experience in EDS should be considered every time a patient describes the worsening of 
any pre-existing “neurological” symptom or in case of novel neurogenic features. In addition 
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to history gathering and physical examination, a set of investigations could be considered in 
specific conditions in order to substantiate the hypothesis of an underlying nervous system 
dysfunction/anomaly (Table 13-1). Although accumulated evidence is weak for many of 
them, their application is indicated particularly during treatment planning. In fact, the 
management of most neurological complications of EDS is still without tailored 
recommendations. Hence, their treatment lays on the experience of the single practitioner or, 
at best, of the dedicated multidisciplinary team. It is expected that, in the future, more 
attention will be offered to the reverberations of EDS on the nervous system with the aim of 
better understanding the underlying pathogenesis and, hopefully, to identify more efficacious 
treatments.  
 
13. Summary  
EDS are hereditary connective tissue disorders primarily affecting skin, joints, vessels and 
internal organs. Nevertheless, their consequences seem to span much beyond these tissues and 
also extend to central, peripheral and autonomous nervous and muscular systems. Although 
muscle cramps have been reported in EDS since the sixties of the last century, for decades, 
available data on neurological manifestations in this condition were scattered in single case 
reports and a few more relevant studies. Much attention has been put in the last five years 
particularly on neuromuscular involvement, and the emerging body of evidence indicates a 
role of nervous system involvement for prognostication and management of many EDS. 
Particular attention has been posed on dysautonomia, occipitoatlantoaxial instability and 
neuromuscular involvement, which may be considered the major contributors to neurological 
complaints and disability in the chronic patient with joint hypermobility syndrome and 
various EDS. A summary for the use of ancillary investigations in the field of neurology has 
also put forward for the practicing physician, as well as some indications for the treatment of 
the related symptoms. 
 
Addendum by the editors 
In the March 2017 issue of the American Journal of Medical Genetics Part C Seminars in 
Medical Genetics all papers were devoted to EDS, covering a new EDS nosology, new 
diagnostic criteria of the different types and also management related topics (see also chapter 
2). One of these papers is entitled “Neurological and spinal manifestations of the Ehlers-
Danlos syndromes”.
130
  
 
  
Chapter 13200
 
 
Table 13-1 Standard investigations to consider in the EDS patient  
Referring symptom/indication Possible cause Investigation 
(Proximal) muscle weakness,  Myopathy Electromyography 
Distal muscle weakness, distal 
sensory disturbances, absence of 
deep tendon reflexes, suspected 
peripheral or compression 
neuropathy 
Axonal 
polyneuropathy, 
compression 
neuropathy 
(mononeuropathy, 
plexopathy) 
Nerve conduction 
studies 
Paraesthesia, pain in hands and 
feet, reduced vital sensation (pain, 
temperature) but normal gnostic 
sensation (pressure, etc) 
Small fibre neuropathy Skin wrinkle test and/or 
quantitative sensory 
testing and/or skin 
biopsy 
Orthostatic intolerance and/or 
hypotension, chronic fatigue 
(syndrome) with recurrent 
tachycardias/palpitations/dizziness, 
or other presentations suggestive 
for dysautonomia (see box 13-1) 
Dysautonomia Head-up tilt-test 
Disabling neck pain and/or 
occipital headache, suspected 
upper cervical spine instability 
(e.g. abrupt painful limitation of 
the cervical spine, neck-tongue 
syndrome)  
Spondylosis, disc 
hernia, instability 
Static and dynamic X-
rays of the cervical 
spine and MRI of the 
cervical spine 
 
Disabling occipital/postural 
headache, seizures, pure X-linked 
dominant transmission, or 
confirmed FLNA mutation 
Brain structural 
anomaly 
Brain MRI 
Any EDS type with vascular 
fragility at first examination and, 
subsequently, in any case of focal 
symptom or thunderclap headache 
Cerebrovascular 
disease 
Brain MRA 
Disabling back pain with or 
without suspected radiculopathy, 
recurrent orthostatic/postural 
headache 
Degenerative disc 
disease, disc hernia 
Total spine MRI 
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1. Introduction 
The Ehlers-Danlos syndrome (EDS) groups a variety of heritable connective tissue disorders 
with - amongst other signs and symptoms - joint hypermobility. Recently, the two conditions 
benign joint hypermobility syndrome (BJHS) and EDS hypermobility type have been 
recognized as one and the same clinical spectrum ranging from apparently symptomatic 
generalized joint hypermobility to the most disabled individuals fitting the new diagnostic 
criteria. These new criteria are stricter than the Villefranche criteria and the Brighton criteria 
for BJHS in order to define a homogeneous phenotype for management and scientific 
purposes. Within the new EDS nosology, its name is hypermobile EDS (see chapters 2 and 5). 
EDS and other generalised joint hypermobility syndromes may have impact on the 
masticatory system. In this chapter the masticatory and oral sequels of hypermobility 
syndromes are described. The masticatory system consists of the teeth and periodontium 
(tissues around the teeth), jaws, the temporomandibular joint (TMJ), the tongue, the mucosa 
and the innervation and vascularisation of these tissues. Temporomandibular disorders 
(TMDs) is a generic term, embracing a number of clinical conditions that involve the 
masticatory muscles, the TMJ and associated structures.
1
 It is a musculoskeletal condition and 
as a consequence, TMD patients experience an increase of the known complaints when 
loading the masticatory system, e.g. by chewing. We will first briefly describe the system 
with regard to EDS; many of the mechanisms also apply other hypermobility syndromes. The 
clinical examination, assessment, diagnosis and management are part of the first section of 
this chapter. The description of the intra-oral aspects of the hypermobility syndromes such as 
the teeth and oral mucosa is part of the second section.  
 
2. The TMJ: function 
The TMJ consists of the mandibular fossa and the articular eminence, the mandibular condyle 
and the articular disc (see figure 14-1). The lining of the mandibular condyle and part of the 
temporal component of the TMJ consist of fibrous cartilage, contrary to other synovial joints. 
In between these two joint components, the articular disc divides the joint space in two joint 
compartments. The actual articular disc is neither vascularised nor innervated, contrary to its 
attachments to the condyle (especially posterior attachments), the temporal component of the 
joint and the capsule. Figure 14-2 depicts sagittal sections in a closed mouth and an open 
mouth position of a normal TMJ, and in a TMJ with disc displacement and degenerative joint 
disease. When opening the mouth, the condyle rotates and slides in anterior direction along 
the articular eminence. Throughout this movement the thin portion of the disc (the 
intermediate zone) remains located between the condyle and the eminence, serving as the 
actual contact point between the two other joint components. Note that at maximum mouth 
opening, the condyle slides beyond the crest of the articular eminence, i.e. out of the 
mandibular fossa (figure 14-2 and figure 14-3). In 89 % of a non-selected healthy population 
this happens without any clinical consequence.
2
 The maximum mouth opening is measured 
between the front teeth while opening wide. Maximum mouth opening in the general 
population ranges from 45 to 60 mm. The median maximum mouth opening in a population 
of 1011 adolescents aged 10 to 17 years was 51 mm. Ten percent of this population could 
open the mouth  ≥ 59 mm. Ten percent could open the mouth 43 mm or less.
3 
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Figure 14-1 Anatomy of the TMJ 
 
 
 
a: mandible (mandibular ramus ); b: mandibular condyle ; c: articular disk; d: mandibular 
fossa ; e: articular eminence or tubercule; f: acoustical meatus 
 
3. The TMJ: dysfunction 
The main symptoms and signs of TMDs are pain in the muscles and joints of the masticatory 
system, impairment of the mandibular movements and joint noises. In the widely used 
classification of the American Academy of Orofacial Pain, causes of TMDs are classed into 
myofascial pain, displacements of the articular disc with and without reduction, arthritis and 
osteoarthritis, as well as hypermobility of the joints (dislocations). Reduction is normalization 
of the position of the displaced intra-articular disc in between the mandibular condyle and the 
fossa/eminence when opening the mouth (figure 14-2). To arrive at one of these diagnoses, 
the clinician always needs to differentiate other diseases mimicking TMDs. This section will 
not touch upon the differential diagnoses of TMD. 
Overloading may introduce pain in the joint (pre-auricular pain) and secondary in the muscles 
of mastication (cheek and temple). In patients with EDS and other hypermobility syndromes, 
TMDs are prevalent. Since signs and symptoms of TMDs are very prevalent in the general 
population (50 % of the general population) as well, they are not a hallmark of EDS. In the 
group of individuals with TMD signs and symptoms, 5 % asks for treatment, whereas only in 
1.5% of this latter group a treatment indication exists.
4
 The risk factors for TMDs are various 
and in chronic TMD patients, often TDM is multifactorial: neuromuscular factors, 
psychosocial factors and overloading may play a role. Overloading of the articular and 
muscular structures can be the result of EDS but it can also result of other factors like trauma, 
habits like clenching and grinding, nail biting or biting on the cheek or lip. Psychological 
stress may influence mandibular behaviour and the pain system. In severe arthrogenous 
TMDs, the TMJ may be swollen (synovitis, capsulitis), leading to a disturbance of dental 
occlusion (the patient then is not able to bring in contact the back teeth of upper and lower 
jaw on the affected side). 
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Figure 14-2 Sagittal section through the TMJ
 
 
C, mandibular condyle T, articular eminence or tubercle (see also figure 14-3), fossa; G, 
acoustical meatus; MPL, attachment of the lateral pterygoid muscle to the condyle and 
articular disc: (P, posterior band, I intermediate zone, A anterior band); Bs en Bi: the 
posterior connective tissue attachments of the articular disc (Bs, superior stratum; Bi, inferior 
stratum). The double arrowheads indicate the degree of sliding of the mandibular condyle on 
opening. a), c), e), and g) closed mouth; b), d), f) and h) open mouth (not maximal). 
a) and b) represent the physiological movements, c) en d) anterior disc displacement with 
reduction; e) and f) anterior disc displacement without reduction (limiting forward sliding of 
the mandibular condyle, and thus a limited mouth opening); g) and h) osteoarthritis with 
remodelling of the disc and mandibular condyle, enabling the condyle to move anterior a bit 
further than in f) and thus increased mouth opening.  
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3.1 Disc displacement with reduction 
The most prevalent symptoms are joint noises, which may be the result of an anterior disc 
displacement. Anterior disc displacement with reduction is characterized by clicking of the 
TMJ, both when opening and closing the mouth and moving the mandible forward, and 
shifting the mandible to the contra-lateral side. The click on opening is produced when the 
disc position normalises; during closing the TMJ clicks again on the moment the disc is 
displaced again just before teeth make contact. Anterior disc displacement and the resulting 
clicking may exist without any further signs or symptoms of TMD for many years and does 
not necessarily lead to osteoarthritis. 
 
Figure 14-3 The degree of sliding of the mandibular condyle on maximum mouth opening
 
 
 
 
Sagittal section. c, mandibular condyle; t, tubercle or articular eminence; mf: mandibular 
fossa 
a: no sliding, like in closed mouth; b - d: variation of a physiological sliding depending on the 
degree of mouth opening; situation b in case of maximal opening of the mouth indicates 
limitation of sliding; e: dislocation: the mandibular condyle slides beyond the eminence and 
moved cranially, to be seen on an X-ray (panoramic, see figure 14-4). 
 
3.2 Disc displacement without reduction 
An anterior disc displacement without reduction is a mechanical obstruction in the TMJ 
(figure 14-2e and 14-2f), also known as closed lock. The condylar movement in a normal 
TMJ can be described as a combination of rotation and sliding. The anterior displaced disc 
severely limits the normal sliding in the affected joint , especially in acute cases. Rotary 
movements are still possible although painful: the mouth opening is limited to 25 – 35 mm, 
compared to 45 – 60 mm in the normal situation. In these acute situations pain from the joint 
may be caused by nociception originating in the capsule or the innervated posterior disc 
attachment which is now in between the condyle and the eminence, instead of in the 
intermediate zone. The masticatory muscles can become painful secondary due to muscle 
splinting. In chronic anterior disc displacement without reduction, the mouth opening may 
increase gradually up to 35-40 mm, still limited in comparison to the pre-existing mouth 
opening. 
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Figure 14-4 Panoramic radiograph 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Image as seen on a panoramic radiograph; the arrowheads indicate the left and right 
temporomandibular joint 
b) An example of a panoramic radiograph 
 
3.3 Myofascial pain 
Myofascial pain is chronic, mostly fluctuating local or regional pain in the face and the jaw. 
Pain may be referred to other areas such as the teeth, the head and the neck. Pressing on the 
painful areas elicits more pain. In rare cases pressing these tender or trigger points in muscles 
may refer pain to other areas nearby but anatomically not related. Toothache is one of the 
examples for which the dentist must differentiate between myofascial pain or a real toothache. 
Patients with myofascial pain experience their muscles as fatigued, stiff and tired, and less 
powerful. Movement and especially stretch of the muscle tissues causes pain. Patients tend to 
decrease their pain by continuous low level contraction of the jaw muscles, which may give 
b 
mandible 
a 
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rise to a limitation of the mouth opening. Myofascial pain may also be associated with 
hypermobility of the TMJ. 
 
3.4 Dislocation 
Dislocation of the TMJ is defined as a condition in which the mandibular condyle slides 
beyond the articular eminence and is fixed at the anterior side of this eminence of the TMJ . 
The patient is not able to close the wide open mouth (open lock of the mandible). In unilateral 
dislocations the mandible (chin) is shifted to the contralateral not-dislocated side in 
combination with the wide open mouth. The TMJ capsule is comparable to that of the 
shoulder: it is a loose capsule with only minor reinforcements by ligaments on the lateral side 
of the joint. If dislocations occur frequently, the term habitual dislocation is used. The 
repetitive overloading of the articular surfaces may induce degenerative changes, especially in 
the case the patients use heavy force to correct the condition. In habitual dislocation, patients 
are often able to close their mouth by manual manipulation. 
 
3.5 Osteoarthritis 
In chronic overloading of the TMJ surfaces, its fibrocartilage lining may decompensate: 
chondromalacia can be the result. Osteoarthritis results in friction between the joint surfaces, 
with ensuing secondary inflammatory reactions. Mostly these degenerative processes do not 
have an underlying disease cause: primary osteoarthritis. In recurrent dislocations e.g. by EDS 
or another hypermobility syndrome, secondary osteoarthritis of the TMJ’s may be the result. 
Osteoarthritis may give rise to an impaired mandibular range of movement and arthralgia 
(joint pain). The articular disc may become displaced in osteoarthritis as part of the 
pathophysiology. Finally, due to remodelling of both the articular surfaces and the articular 
disc, sliding of the mandibular condyle may gradually increase, although limited with regard 
to the original range of motion of the particular joint. The changes in other movement patterns 
will be less pronounced as well when remodelling has taken place over the months and years. 
A more gnashing sound (crepitation) can be perceived by the patient and sometimes heard by 
others. 
 
4. EDS, generalised hypermobility and TMDs 
EDS as a connective tissue disorder characterised by joint hypermobility also has an impact 
on the TMJ and masticatory muscles. Recurrent dislocations in combination with progressive 
range of motion limitation are frequently observed. In a group of 144 adult patients with EDS 
and 331 healthy controls, at physical examination the TMJ was hypermobile significantly 
more frequently in the patients than in controls, but the maximum mouth opening was 
significantly more reduced and progressively more so with age, compared to the controls.
5,6
 
Patient with EDS more often had clicking and gnashing TMJs. Chronic pain in the 
masticatory muscles was mentioned by 50% of the patients with EDS, occurring daily in one 
third of the patients. Another striking finding was the frequent use of analgesics by patients 
with EDS.
6
 
In a recent Belgian study in a population with hereditary joint hypermobility (15 hypermobile 
EDS, three classical EDS, and a control group) earlier findings indicating a positive 
correlation between joint hypermobility and TMDs,
7
 were confirmed. In 89% of the EDS 
patients myofascial pain was diagnosed, whereas in 81% bilateral disc displacement with 
reduction was observed. Bilateral arthralgia of TMJs was present in 42% of EDS patients. In 
this study the combination of myofascial pain, anterior disc displacement and arthralgia was 
present in 64%. Recurrent TMJ dislocations were reported by 100% of the EDS patients. 
Patients with a high frequency and duration of dislocations reported significantly higher pain 
scores. These patients suffered most frequently from dislocation of the TMJs when opening 
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the mouth very wide. Their mouth opening had decreased over time progressively. Chewing 
hard and on big portions of food, and yawning were the most frequently reported risk factors. 
Over 60% of the patients reported spontaneous dislocations. 
Generalized joint hypermobility and its association with signs and symptoms of TMD was 
further investigated in a general population study; generalized joint hypermobility was found 
to be associated with non-painful subtypes of TMD.
8
 A larger number of hypermobile joints 
(according to the Beighton score
9
) was associated with a larger mouth opening.
8
 However, in 
the chosen categories (no hypermobile joints, 0-3 and 4-9 hypermobile joints per subject) the 
mean differences (standard deviation) in mouth opening were clinically not relevant: 45 mm 
(7.7), 46 mm (7.3) and 47 mm (6.7), respectively
8
. The smallest detectable difference for 
mouth opening in arthrogenous TMD is 6 mm.
10
 Individuals with 4 hypermobile joints or 
more (Beighton score ≥ 4) had a higher risk for reproducible reciprocal clicking sounds 
(representing TMJ disc displacement with reduction) and concurrently lower risk for a mouth 
opening <35 mm.
8
 However, the influence of other factors such as female gender and 
generalized joint conditions other than hypermobility was stronger than that of hypermobility 
as such. No association was found between hypermobility and arthralgia or myalgia of the 
masticatory system. In a systematic review on generalized hypermobility and TMDs it was 
concluded that it is not yet clear whether generalized hypermobility is associated with TMD.
11
 
TMJ hypermobility could not be predicted on the basis of generalized hypermobility. 
Dislocation of the TMJ may occur without systemic hypermobility. In a study to test whether 
or not there is an association between generalized joint hypermobility (measured using the 
Beighton score) and temporomandibular joint disk displacement in women who had sought 
medical attention for TMDs, 66 women who were attending the clinic for TMD were 
examined for joint hypermobility, and Beighton scores were calculated. If it was suspected 
that a patient suffered arthropathic complaints, magnetic resonance imaging of both 
temporomandibular joints was performed with the mouth closed and at maximal opening. 
There was no association between generalized joint hypermobility and temporomandibular 
joint disk displacement.
12
 
One of the signs indicating hypermobility in the masticatory system is ‘Gorlin sign’: if 
positive, the individual is able to touch the tip of the nose by the tip of the tongue.
13,14
In the 
general population only 8-10% is able to do so, whereas in EDS this is 50%. The absence of 
an inferior labial of lingual frenulum is an easy to check sign of EDS, helpful in the early 
diagnosis of the disease in affected families.
15
 
 
5. Diagnostic process and physical examination 
In the diagnostic process, history taking and physical examination contribute most to the final 
diagnosis. The diagnostic process starts with the differentiation of TMD and non-TMD. Other 
conditions, causing dental pain or referred pain, such as neoplasm of the pharynx or the 
tongue may mimic signs and symptoms of TMD. A rule of thumb is that any pain in the 
masticatory system has a dental origin until proven otherwise, so a dental cause has to be 
ruled out. All other causes of TMDs need to be ruled out as well, such as neoplasms, growth 
disturbances and systemic diseases. A third diagnostic step is the differentiation between 
mainly arthrogenous and mainly myogenous TMDs (table 14-1). Provocation of the pain 
known to the patient at physical examination is essential for diagnosing TMD. TMD pain by 
definition is influenced by loading of the masticatory system like in mandibular movements 
and mandibular function such as chewing and yawning. If the mandible is locked in a 
submaximal mouth opening, it is essential to know whether the mouth cannot be opened any 
further (arthrogenous cause of limited opening: closed lock, adhesions) or whether the mouth 
cannot be fully closed (the teeth of upper and lower jaw can hardly touch each other: posterior 
disc displacement or TM joint inflammation), and at what extent of mandibular opening 
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locking occurs (at wide open indicates TMJ dislocation). The physical examination consists of 
active (by the patient) mandibular movements (opening / closing, lateral left and right side 
and protrusion), passive (by the physician) opening, and palpation of the TMJ’s and the 
masticatory muscles (temporalis and masseter muscles). Signs and symptoms to be assessed 
are provocation of the pain known to the patient, range of motion, and movement pattern. In 
patients with a history of TMJ dislocation, passive opening beyond the comfortable maximum 
mouth opening is not advised, to prevent reoccurrence. 
 
6. Imaging 
The first choice imaging technique is the panoramic radiograph (figure 14-4). This technique 
offers a broad view of the upper and lower jaw, the teeth and periodontium, the sinuses and 
the TMJs. The left and right TMJs, the length of the ascending mandibular ramus (figure 14-
1) and the mandibular base can be compared. Asymmetries, infections around the roots of the 
teeth and signs of periodontal inflammation with bony involvement, growth disturbances and 
neoplasm can be detected as well as the contours of the condyles, their lining and the 
spongeous bone. In osteoarthritis of the TMJ, osteophytes (bony spurs) are mostly located 
near the anterior part of the mandibular condyle. In case of doubt as to the findings of the 
panoramic radiograph, the clinician may consider additional imaging techniques such as CT 
or MRI. A mandibular dislocation is only very seldom an indication for imaging, since it is 
obvious from history and physical examination alone (section 5). An exception may be 
persistent dislocations in elderly persons or in post-traumatic patients. The panoramic 
radiograph may reveal such dislocations that were not expected. In such cases, the mandibular 
condyle is located anterior of the articular eminence even in the closed mouth position. 
 
7. Management of TMDs and myofascial pain 
Signs and symptoms of TMD in patients with EDS or other hypermobility syndromes are 
managed similarly as in TDM patients without these syndromes. An important first step is 
counselling, consisting of explanation of the findings, the diagnosis, the management strategy 
and prognosis, the expected management period, including the lag-time of alleviation of the 
complaints after start of therapy. Mostly reassurance as to the benign character of the 
mandibular condition as well as the responsibilities of the patient are discussed as well. In 
case of overloading of the masticatory system and myofascial pain, after explanation and 
advice as to a correct use of the masticatory system (box 14-1), the clinician may wait for 4-6 
weeks, before evaluating and deciding upon another or additional strategy.  
 
Box 14-1 Advice and instructions to avoid overloading of the TMJ and masticatory muscles 
A) Be aware of / avoid: 
• clenching jaws and grinding teeth: keep the teeth apart, lips together and the tongue 
up (the tip touching the palate right behind the incisors, like in pronouncing “ N ”) 
• nail biting, and biting on lips, cheek or tongue or other mouth behaviour 
• chewing gum and biting on pens and pencils 
• opening the mouth wide, like in yawning 
B) While chewing hard food (French bread or apple) make small pieces and use the back 
teeth. 
C) Do not take a bite with the front teeth. 
 
If pain is a main concern, medication is indicated. If inflammatory pain exists, classic non-
steroidal anti-inflammatory drugs are part of the treatment, which are contra-indicated in 
vascular EDS because these drugs increase the bleeding time, in contrast to the so-called anti-
inflammatory coxibs. In myofascial pain, low dose anti-depressants as pain modulators can 
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help to modify and alleviate the neuropathic component of pain. If counselling and advice are 
not sufficiently effective, the difference between arthrogenous and myofascial pain will guide 
the choice of a further treatment strategy. Physiotherapy can be very successful in myofascial 
pain, especially if pain is felt not only in the masticatory system but also in the neck and 
shoulder girdle. Home exercise programs consist of correction of posture (mandible, tongue, 
head), habit reversal techniques, muscle stretching, automassage, relaxation and muscle 
strengthening techniques.
16
 In clearly arthrogenous TMDs an occlusal appliance (stabilization 
splint) is used (figure 14-5). In case of missing teeth, the support of the mandible against the 
maxilla can be improved because the appliance can be used as a prosthetic device and offers 
orthopaedic stability to the mandible: similar contact between the back teeth on the left and 
right side. Bad habits unconsciously performed by the patient can be influenced as well by 
wearing the splint during parts of the day. The working mechanism of an occlusal appliance is 
still part of debate, although its influence on muscle length and change in condylar loading is 
widely accepted. As true for many other treatments, the patient-doctor relationship, 
expectations in this partnership as well as good communication are paramount for success. In 
chronic TMJ involvement, a cognitive behavioural approach may be part of the management 
strategy. Coping style and locus of control are predictive for the outcome of treatment in 
chronic TMDs.
17 
 
8. Dislocation of the mandible 
In cases of acute dislocation, the health professional will correct this by pressure in a caudal 
direction on the lower most posterior teeth in combination with a backwards directed 
pressure. The sooner this condition is addressed the easier the procedure can be executed 
because muscle spasm will develop. Provoking a gag reflex by touching the posterior part of 
the tongue is also reported to correct the dislocation. 
In patients with EDS and other hypermobility patients, it is highly probable that a dislocation 
of the mandible is based on their lax connective tissue. In these patients the dislocation is 
expected to be more recurrent than in individuals without hypermobility. The management is 
not different in both cases. Counselling, including advice as to the use and abuse of mandible 
is part of this approach (prevent yawning, biting on firm objects e.g. an apple with the front 
teeth, nail-biting). Exercises with the aim to open the mouth without the sliding of the 
mandibular condyle (figure 14-1 and 14-2) are part of the management as well. Opening of 
the mouth in this way allows for 30-35 mm interincisal distance, enough for daily activities 
without the occurrence of a dislocation. Small rubber bands between the upper and lower 
posterior teeth (through brackets attached to their buccal side) may help the patient to become 
aware of the forward thrust of the mandible on opening. If non-surgical approaches of 
dislocation have proven not to be successful, the first choice surgical procedure is the 
downsizing of articular eminence in order to facilitate the backward sliding of the mandibular 
condyle even when it has moved forward maximally.  
 
8.1 Disc dislocation in the TMJ 
In acute disc dislocation without reduction, it is worthwhile to perform a manual correction of 
the mechanical intra-articular obstruction (figure 14-2e and 14-2f) and to achieve a disc 
displacement with reduction (clicking, but not locking of the TMJ, figure 14-2c and 14-2d). If 
a disc dislocation exists for longer period of time (several weeks or months), the procedure 
becomes less feasible. This is mainly due to remodelling processes of the intra-articular 
tissues. In such cases the dislocation of the disc is accepted, while management aims at 
minimizing (over)loading of the joint (counselling, advice box 14-1) and stabilization splint). 
Unilateral disc displacement without reduction may overload the contralateral joint. Due to 
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the restrictions caused by the disc displacement, this seldom results in dislocation of the 
contralateral joint. 
 
8.2 Degenerative joint disease of the TMJ 
Degenerative joint disease of the TMJ has a favourable prognosis. The signs and symptoms 
often decrease within 2-3 years. Patients with degenerative joint disease at younger age 
cannot be differentiated from patients who did not have these complaints at younger age with 
respect to yawning, mastication and speech.
18 
Management aims at acceleration of resolution 
of pain and dysfunction and guiding the patient through the period of impairment. 
Counselling, medication (analgesics, non-steroidal anti-inflammatory drugs), exercises and 
the stabilization splint (figure 14-5) may be part of this approach. 
 
Figure 14-5 Mandibular stabilisation splint used to stabilize the mandible during sleep (not a 
regular splint)  
 
 
A: the stabilization splint for the mandible, inferior view and B: superior view. The anchors 
add to the retention of the splint. Mandibular splints are easier accepted than maxillary 
splints, leading to better compliance. C By exception, in this patient extra anchors position 
and fix the mandible against the maxilla in order to prevent locking op the TMJ during the 
night: when the chewing muscles are relaxed during sleep, the mandible cannot slide into a 
lateral position when sleeping on the side. 
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9. Oral and dental aspects of EDS 
In patients with EDS the teeth, periodontal tissues, and the oral mucosa are involved because 
of the defective connective tissue. The literature only relates to case reports, rather than 
patient groups; moreover in these reports, it is not always clear what the EDS type is. 
 
9.1 Teeth 
Various tooth abnormalities have been described in association with EDS, such as 
hypodontia, microdontia, abnormal root formation and tooth morphology. In a group of 31 
Belgian patients with EDS, 6% showed abnormal root structures.
19
 Changes of the hard 
tissues or microdontia (small teeth) have been described as well.
20,21
 Examples are high cusps, 
deep fossae and vertical clefts in enamel. In the pulp, chamber stones can be detected on X-
rays. The root of the teeth can be deformed, shorter than normal and excessive dentine 
formation may occur, making it more difficult to perform endodontic treatment. Stones in the 
pulp chamber in de molars of the primary dentition may be indicative for EDS. A smaller pulp 
chamber (94%) as well as the presence of pulp stones (78%) occur more often in patients with 
classical EDS.
19
 In patients with hypermobile EDS, pulp stones occurred in 19%, and they 
were practically absent in vascular EDS.
19
 The dentist is advised to refer the patient to the 
general medical practitioner with regard to EDS related non-dental conditions. A higher 
prevalence of decayed, missing or filled teeth could be related to an impaired hygiene as a 
result of vulnerability of the oral tissues (patients try to avoid inducing lesions of the mucosa 
and gums) and the limitation of mobility of the wrist and shoulder in some of the patients.
19
 
 
9.2 Periodontal tissues and oral mucosa 
Periodontal disease is an inflammatory condition of the supporting tissues of the teeth. Dental 
plaque causes chronic inflammation resulting in migration of attachment and pocket 
formation. Periodontal abnormalities, not related to dental plaque at an unusual young age, in 
combination with tooth loss raises suspicion of the rare periodontal EDS.
22-24
 The classical 
type and the vascular type are known regarding the vulnerability of the oral mucosa. Gingiva 
recession as a result of periodontal involvement was not a strong predictor of vascular EDS. 
The combination of increased root length, modified dental pulp shape and arthralgia had high 
sensitivity and specificity for vascular EDS in a scoring system of maximum 4 points with a 
positive score of 2 or higher.
25
 Orthodontic treatment (moving the teeth) is feasible in patients 
with EDS,
26,27
 although not without risks.
28
 Low force and a longer active treatment time than 
usual will help to respect the metabolic processes and preventing excessive resorption of the 
supporting bony tissues of the teeth. This should be especially the approach in patients with 
periodontal EDS. After finishing the treatment, fixation of the teeth in their acquired position 
is mandatory. During treatment with orthodontic appliances or brackets fixed to the teeth, the 
vulnerability of the oral tissues should be taken into account. In a recent case study, it was 
found that dental implants survived in 6 patients with classical EDS. The follow-up time was 
5.5 years (range 2-12 years), mean age at implantation 41 (range 19-68). Only mild bone loss 
(2 mm) was measured around one implant in two patients.
29
 
 
9.3 Recommendations for the dentist 
The duration of dental treatment should not challenge the ability of the patient to keep the 
mouth open without dislocation of the TMJ, or other sequels of dysfunction of the masticatory 
system. In case of longer treatment the patient should be allowed to close the mouth regularly; 
single instead of multiple treatments per session are advised. The dentist is also advised 
during the treatment of a patient with EDS or generalised hypermobility to pay extra attention 
to have the patient position the head and neck in a comfortable way at the cost of a 
compromised working posture for the dentist.  
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Anaesthesia for dental treatment may be less effective than expected.. In case of cardiac valve 
prolapse, as in individuals without hypermobility, antibiotic prophylaxis should be considered 
preceding surgical procedures. Careful manipulation in the oral cavity and the use of non-
traumatic procedures will help to prevent trauma to the tissues with a delayed healing time 
and increased bleeding tendency. 
 
10. Summary 
TMDs are highly prevalent in the general population. However, dislocations of the 
mandibular condyle are less prevalent than other TM conditions such as disc displacement, 
myofascial pain and osteoarthritis. To differentiate the non-specific TM condition from TMDs 
specific for EDS, the dentist should be informed regarding the specific criteria of EDS. In 
case of pulp stones and deviant tooth and root morphology and periodontal involvement at an 
unusual young age, the dentist may be the first health care professional to diagnose EDS. 
Referral to the general medical practitioner is advised as first step. The panoramic radiograph 
is the first choice imaging modality. Management of the sequels of EDS regarding the 
masticatory system is identical to that of non-specific TMDs in otherwise healthy individuals. 
 
11. Areas of uncertainties 
Temporomandibular joint signs and symptoms are relatively common in the general 
population. It is therefore a challenge to differentiate non-specific temporomandibular 
problems from those that are specifically related to EDS and other hypermobility syndromes. 
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Addendum by the editors 
In the March 2017 issue of the American Journal of Medical Genetics Part C Seminars in 
Medical Genetics all papers were devoted to EDS, covering a new EDS nosology, new 
diagnostic criteria of the different types and also management related topics (see also chapter 
2). One of these papers is entitled “Oral and mandibular manifestations of the Ehlers-Danlos 
syndromes”, which is recommended for further reading.
30
  
Ehlers-Danlos syndrome, generalised joint hypermobility and the masticatory system 221
 
 
Table 14-1 Characteristics of arthrogenous versus myogenous temporomandibular disorders 
 
 
 
Arthrogenous Myogenous 
Maximum mouth opening 25 - 30 mm 30 - 40 mm 
Difference between active and passive 
maximum mouth opening capacity 
0 - 2 mm > 4 mm 
Horizontal range of mandibular motion limited not limited 
Movement pattern / chin position deviation  no deviation  
Pain location TMJ cheek / temporalis 
muscle 
Pain on palpation TMJ (dorsal, lateral) cheek / temporalis 
muscle 
Auscultation clicking, crepitation no noise 
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1. Introduction 
Ehlers-Danlos syndrome (EDS) is a heterogeneous group of heritable connective tissue 
disorders (HCTD) characterized by hypermobility of joints, hyperextensibility of the skin and 
easy bruisability with formation of peculiar “cigarette paper” scars. A number of distinct 
clinical types are recognized on the basis of biochemical, genetic, and clinical findings.
1
 They 
are discussed in other chapters.  
EDS is caused by an underlying genetic defect in connective tissue. The main protein of 
connective tissue is collagen. Different types of collagen molecules exist in the eye, therefore 
EDS can, in addition to the more widely recognized phenotypic features involving the 
skeleton and skin, also have adverse structural and functional implications for the eye.
1,2
  
For most types of EDS molecular defects have been found in fibrillar collagens and collagen-
modifying enzymes. However, that EDS is not solely a disease of the collagens became clear 
by the identification of a clinically distinct, autosomal recessive classical-like EDS caused by 
deficiency of tenascin-X (TNX). Deficiency of TNX is associated with fragmentation of 
elastic fibres and reduction of collagen.
3
 
In this chapter, after a brief summary of eye anatomy, eye defects in different types of EDS 
will be described followed by ophthalmological screening / monitoring and surgery in these 
syndromes. 
Recently, the two conditions benign joint hypermobility syndrome (BJHS) and EDS 
hypermobility type have been recognized as one and the same clinical spectrum ranging from 
apparently symptomatic generalized joint hypermobility to the most disabled individuals 
fitting the new diagnostic criteria. These new criteria are more strict than the Villefranche 
criteria and the Brighton criteria for BJHS in order to define a homogeneous phenotype for 
management and scientific purposes. Within the new EDS nosology, its name is hypermobile 
EDS (see chapters 2 and 5).  
 
2. Anatomy of the eye 
In the eye, fibrillar collagen exists in the cornea, sclera and vitreous (figure 15-1). Also, 
immunoreactivity for TNX was found in the anterior one-third of the corneal stroma as thin 
fibrils and in the stroma of limbus and conjunctiva, and in blood vessels.
4
 
The cornea, the transparent front part of the fibrous tissue covering of the eye, makes it 
possible for the individual to see and for the physician to examine the inside of the eye. The 
cornea is the most important refractive medium of the eye. The diameter of the cornea is 
about 9.5-10.5 mm at birth. In the second year of life, the cornea reaches its adult size with a 
diameter of about 11.5 mm. The corneal thickness is centrally about 0.52 mm and peripherally 
about 0.67 mm.
5
 Abnormalities of the shape of the cornea can have a negative influence on 
vision. The cornea contains type I collagen and type V collagen, which accounts for 10% - 
20% of the total collagen in the cornea.
6
 Type V collagen probably plays a regulating role in 
the production of type I collagen.
2
 
The sclera is opaque; its thickness ranges from 0.3 to 1.0 mm. The sclera is thinnest just 
behind the insertions of the extraocular muscles and at the equator of the eye ball (0.3-0.4 
mm).
5
 Traumatic rupture is therefore often at these locations. The sclera also contains type I 
collagen, but here it is associated with type XII (FACIT-) collagen that probably stabilizes the 
collagen bundles and prevents shifting.
2
 
The vitreous humour is a transparent gel that keeps the eye in shape. An abnormal 
composition of the vitreous increases the risk of retinal detachment, mostly by traction at the 
retina. Vitreous contains thin type II collagen fibres associated with type XI (fibrillar) and IX 
(FACIT-) collagen. The collagen composition of the vitreous is identical with cartilage. Type 
XI collagen probably regulates the diameter of the collagen fibres. Type IX molecules 
probably stabilize the fibrous structure of collagen type II.
2
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Figure 15-1 Anatomy of the eye, interior view 
 
 
 
 
Collagen is responsible for the tremendous tensile strength of cornea and sclera, protecting 
them against perforating accidents and anchoring the eyeball in the orbit.
2
 The shape of the 
eye depends much on the intraocular pressure, since cornea and sclera poorly keep their 
shape, vitreous contributes to a considerable extent in maintaining the eye pressure.
5
 
Because EDS comprises disorders with abnormalities in collagen types I, II, III, V, XII and in 
TNX, theoretically one can expect abnormalities of the eyelids, cornea, conjunctiva, sclera 
and vitreous. Systematic ophthalmological examinations have seldom been performed in 
patients suffering from EDS, but case series are described below. 
Eye disorders can be part of all types of EDS but especially occur in kyphoscoliotic 
EDS,although only a small number of patients with symptomatic eye abnormalities is reported 
in the literature. Particularly, eyelid and conjunctiva abnormalities, keratoconus, keratoglobus 
(a global deformation of the cornea), blue sclerae, pathologic myopia, angioid streaks (breaks 
in Bruch’s membrane, a membrane under the retina), abnormal retinal vessels
7-11
 and retinal 
detachment are mentioned.
12
 Spontaneous luxation of the lens is not to be expected, because 
the fibres of the suspension apparatus of the lens do not consist of collagen, but of fibrillin.
2
 
Spontaneous luxation of the lens is one of the most characteristic ophthalmological features of 
Marfan syndrome, in which mutations are found in the FBN-1 gene, located on chromosome 
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15.
13
 The lens can, however, end up outside the eye with rupturing of the cornea or the sclera 
in EDS: a traumatic luxation.
14,15
 
 
3. Eye abnormalities in different types of EDS  
 
3.1. Classical EDS 
Considering what is known about classical EDS and the anatomy of the eye, corneal 
abnormalities could be possible, since there is a defect in the COL5A1 and the COL5A2 gene, 
coding for type V collagen. In the “Revised nosology, Villefrache 1997”, no corneal 
abnormalities were described in this type.
16
 However, Giunta and Steinmann, described 
“microcornea” in patients with 2 different point mutations (small gene abnormalities) in the 
COL5A1 gene.
17
 These mutations seem to negatively influence the maturation of the cornea.  
In 2000, 2 patients were described with a phenotype resembling classical EDS and a COL1A1 
(Arg to Cys) mutation. Both had normal white (i.e. not blue) sclerae. One of these patients 
underwent strabismus surgery uneventfully.
18
  
In 2006, Seveg et al.
7
, described thinning and steepness of the cornea in 16 eyes of 8 subjects 
form three unrelated families with classical EDS, who were heterozygous for mutations in 
either COL5A1 or COL5A2. All subjects had floppy eyelids. The corneal abnormalities did 
not affect corneal transparency and the corneal thinning did not impair vision. 
In 2013, Villani et al. examined 50 patients with classical EDS, compared to controls and 
confirmed the thinning and steeper corneas in the EDS patients, which also had increased 
irregularity of the corneal surface.
 19
 However, these changes did not cause increased 
refractive errors nor increased prevalence of keratoconus. This patient group also had 
increased symptoms and signs of tear film dysfunction. The high prevalence of dry eye in 
patients with EDS has so far been reported only in patients with hypermobile EDS.
8,20
  
 
3.2. Hypermobile EDS 
EDS hypermobility type and benign joint hypermobility syndrome (BJHS) are now 
considered as one and the same entity, named hypermobile EDS.
21
 However, in this section 
they are still discussed separately. 
In hypermobile EDS, a small subset of patients suffers from a heterozygous defect in the TNX 
gene
22
, localized on chromosome 6q21.3.
23
 Tenascin X and collagen XII act as adaptor 
molecules to interconnect collagen I-containing fibrils with each other and therefore might 
modulate the distances between fibrils. This would in turn influence the biomechanical 
properties of tissues.
24
 Veit et al. speculate on account of their studies that the restricted 
spatial co-localization of collagen XII and tenascin-X plays a role in generating specific 
mechanical properties through collagen XII acting in concert with tenascin-X as a regulator of 
fibril deposition and spacing.
24
 It is not yet clear whether this is also true for the cornea and/or 
sclera, since tenascin has only been found in cornea and collagen XII only in sclera. 
For the vast majority of patients with hypermobile EDS the gene defect is not yet known.  
In 2012, Gharbiya et al.
8
, investigated a group of 44 eyes of 22 consecutive patients with joint 
hypermobility syndrome/EDS hypermobility type (JHS/EDS-HT) and 44 controls. The ocular 
anomalies consisted of xerophthalmia, steeper corneas, pathologic myopia, vitreous 
abnormalities, and minor lens opacities. However no definite case of keratoconus and no 
significant differences in corneal thickness between patients and controls were found. These 
findings are consistent with the results of McDermott et al.
25
, who studied a cohort of 36 EDS 
patients, including 17 JHS/EDS-HT subjects, by using ultrasound pachymetry and 
topography. Similar results also were obtained by Segev et al. in classical EDS.
7
  
Mishra et al.
 
examined the eyes of 34 consecutive patients with BJHS who visited their 
rheumatology clinic. The eyelids were judged to be abnormal in 23 (68%) patients. The most 
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common abnormality, seen in 14 (41%) patients, was excess lid laxity. An additional eight 
patients (24%) had prominent horizontal folds of upper lid skin. One patient had congenital 
unilateral ptosis. No significant abnormalities of sclera, cornea or iris were found on slit-lamp 
examination. All lenses were stable with no subluxation. No abnormalities of the retina were 
found, but three patients had tilted optic discs.
26
  
Tilted optic disc is a term used to describe an optic nerve head appearance in which the 
vertical meridian of the disc is at an oblique angle or one pole of the optic disc is tilted 
anteriorly or posteriorly. Tilted discs are often associated with astigmatism and myopia.
27
 
The prevalence of tilted discs in the normal population is 1,6% and in patients with BJHS 
seems to be higher than expected. Interestingly, Forman (1979) reported on a patient with 
EDS type III (hypermobile EDS) with tilted discs.
28
 The pathobiology of tilted discs is not 
known. 
 
3.3. Vascular EDS 
The vascular EDS is caused by mutations in COL3A1, which codes for collagen type III. 
Since type III collagen is not present in the eye, no primary eye abnormalities have been 
described in vascular EDS, as would be expected. However, there can be problems with the 
eyes caused by aneurysms of brain vessels or by haemorrhage in or behind the eye.
29
 In those 
cases, proptosis (protruding of the eye), motility disturbances of the eye or redness and 
oedema of the conjunctiva may be seen.
30
 
 
3.4. Kyphoscoliotic EDS 
Kyphoscoliotic EDS is caused by a defect of lysine hydroxylation of collagen type I. It has an 
autosomal recessive inheritance. 
The kyphoscoliotic EDS is the only type of EDS in which eye problems are a key feature, but 
serious complications such as retinal detachment or rupture of the eyeball are rare.
14
 The 
estimated prevalence of this type of EDS is less than 1: 500.000.
31
 
The most frequent ocular complications are corneal and scleral abnormalities: microcornea, 
flat cornea (cornea plana), abnormal bulging of the entire cornea (keratoglobus), the central 
part of the cornea (keratoconus) or the posterior part of the central cornea ((keratoconus 
posticus) with (rare) or without spontaneous rupture
32-36
, scleromalacia (thinning of the 
sclera)
33,37
, angioid streaks
9
 and spontaneous (rare) and traumatic rupture of the sclera.
14,38
  
Cameron described 11 patients with kyphoscoliotic EDS with corneal abnormalities and blue 
sclerae. The diagnosis was, however, not proven biochemically or by molecular genetics. All 
patients had hypermobile joints and descended from consanguineous marriages. Only one 
patient also had scoliosis and skin problems. This patient had keratoglobus of both eyes and a 
spontaneous rupture of the cornea of one eye.
35
  
Symoens et al. also reported a case of a girl with a rapidly progressing kyphoscoliosis, a 
converging strabismus and retinal detachment in the right eye with type V collagen defects. 
Mutations in the type V collagen genes may cause EDS phenotypes that differ from classical 
EDS.
39
 
Retinal detachment and high myopia are also part of the kyphoscoliotic EDS, yet only a few 
patients have been described with these complications.
14,38
 Bodanowitz et al. reported on a 
kyphoscoliotic EDS patient who suffered from progressive myopia caused by change of the 
refractive power of the cornea as a consequence of progressive keratoconus. This patient also 
had scleromalacia with localized retinal detachment.
14
 The high myopia could theoretically 
also be caused by progressive lengthening of the eye because of diminished tensile strength of 
the scleral tissue. Measurements of the axial length of the eye are, however, not routinely 
performed in EDS. Retinal surgery in the reported cases was complicated by serious choroidal 
haemorrhage, retinal neovascularization with vitreous haemorrhage, recurrent retinal 
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detachment and scleral rupture.
14,40,41
 Bodanowitz therefore recommended right from the start 
to combine retinal surgery with vitrectomy to prevent these complications.
14
 Patients with 
kyphoscoliotic EDS have a marfanoid habitus, but they have no spontaneous luxation of the 
lens because the fibres of the suspension apparatus of the lens do not consist of collagen, but 
of fibrillin. 
 
3.5. Arthrochalasia EDS 
In arthrochalasia EDS, no ophthalmological abnormalities have been described. 
Abnormalities of cornea and sclera are theoretically possible, since this type involves a defect 
of the COL1A1 or COL1A2 gene
42
, and type I collagen is prevalent in the ocular structures. 
  
3.6. Dermatosparaxis EDS 
Hypertelorism and epicanthic folds are common in the dermatosparaxis EDS.
1
 
In this type, blue sclerae have also been described. Theoretically, corneal and scleral 
abnormalities can be expected because the disorder is caused by an enzyme defect in type I 
collagen metabolism
43
, but these abnormalities have not been reported to date.  
 
4. Ophthalmological Screening and Monitoring 
Based on the data in the literature, routine ophthalmological screening is necessary in patients 
with classical, hypermobile and especially in kyphoscoliotic EDS. However the thinning and 
steeper corneas described in the classical and hypermobile EDS did not cause increased 
refractive errors nor increased prevalence of keratoconus, considering that cornea thickness 
influences interpretation of ocular pressure measurements and decisions about refractive 
surgery, it seems to be likely to do an ophthalmological exam. In kyphoscoliotic EDS these 
corneal problems are symptomatic and keratoconus and keratoglobus do occur. It is important 
to detect these corneal abnormalities as well as well as high myopia or vitreous abnormalities 
as these can be risk factors for retinal detachment. After the initial ophthalmological 
examination at the time of diagnosis, the frequency of follow-up examinations depends upon 
the eye abnormalities found and has to be planned accordingly. 
 
5. Surgery 
Corneal and scleral rupture, keratoconus, keratoglobus and retinal detachment are difficult to 
treat in EDS because the sclera is so thin and fragile that stitches rip through the tissue and 
haemorrhages occur.
14
 Biglan et al. reported corneal perforations in 15 of 20 patients before 
the age of 18 years. Repair proved difficult, and many eyes needed to be eviscerated or 
enucleated.
44
 Cosar et al. reported successful revision of the repair of the corneal perforation 
with conjunctival flap
45
. Cameron and co-workers performed prophylactic epikeratoplasty 
(adding donor tissue to the corneal surface) in six patients with good tectonic results in five. 
All their patients had keratoglobus and joint hypermobility.
46
 Macsai et al. applied a novel 
surgical technique to treat a ruptured globe in a patient, successfully combining onlay 
epikeratoplasty with a delayed full-thickness corneal graft.
36
 Nakazawa and colleagues used 
preserved sclera to patch a post-traumatic scleral staphyloma in a patient with kyphoscoliotic 
EDS .
37
  
In the literature no data are found concerning the response of the eye to cataract surgery, 
glaucoma surgery and refractive surgery in patients with EDS. Repair of strabismus may be 
complicated by severe thinning of the sclera at the site of the original muscle insertion.
1
 A 
growing number of people seek aesthetic surgical treatment of the skin to look younger or 
excimer laser treatment of the cornea to get rid of glasses or contact lenses. Patients with EDS 
have to realize that surgery or laser treatment of skin, eyelids, and eyes can have serious 
Chapter 15230
 
 
complications. Ongoing research will reveal whether these complications are relevant to what 
account and in which type of EDS. 
 
6. Summary 
EDS comprises a number of HDCT, caused by defects in fibrillar collagen (type I, II, III, V) 
and other connective tissue molecules. In the eye, fibrillar collagen is present in cornea, sclera 
(type I and type V collagen) and vitreous (type II collagen). 
A number of case series of different types of EDS with eye problems are described in the 
literature, especially in kyphoscoliotic, classical and hypermobile EDS.  
Theoretically, based on knowledge of their aetiology and pathogenesis, abnormalities can be 
expected of the cornea in the classical type and of the cornea and sclera in kyphoscoliotic, 
arthrochalasis and dermatosparaxis EDS. In vascular EDS, no primary eye abnormalities are 
present, but eye symptoms caused by vascular abnormalities in brain and orbit can occur.  
Little is known of the reaction of the eyes to surgery and laser treatment. Till proven 
otherwise, it seems sensible for patients with EDS to abstain from this kind of treatment. 
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1. Introduction 
Ehlers-Danlos syndrome (EDS) is fairly unknown amongst urologists. The syndrome is only 
mentioned in a small paragraph in Campbell’s’ Urology, which counts more than 4000 pages, 
and has established its universal reputation as the “bible” of urology. EDS is a group of 
genetic connective tissue disorders that affects approximately 1 in 5,000 live births, and is 
evenly spread among males and females of all racial and ethnic groups.
1
 Although the exact 
prevalence of EDS is unknown, it is estimated to be about 1.3 million worldwide. In 10% of 
those, EDS is of the type vascular EDS(formerly type IV), which is associated with severe 
urologic complications. Worldwide there are - roughly estimated - about 75.000 practicing 
urologists. Assuming that all vascular EDS patients have urological problems, this implicates 
that every urologist should have personal contact with about 2 of these patients . In contrast 
with these numbers, EDS seems almost non-existing in international urology. This is in 
accordance with the results of an extensive urological literature search with only 20 articles 
mentioning EDS. This chapter contains some urological aspects of EDS, illustrated in 3 
patients. These illustrative cases show the importance of recognizing typical urological 
consequences of EDS for (paediatric) urologists. Thereafter we will systematically discuss the 
problems that can occur in the upper and lower urinary tract. 
 
The diagnosis of EDS is primarily based on a precise (family) history and physical 
examination. The typical history mentions recurrent (sub)luxations of joints, and 
hypermobility of joints, as defined in the Beighton and Bulbena scoring systems.
2,3
 There 
could also be problems with wound healing, abnormal bruises, voiding and defecation. 
Physical examination may also reveal hyperextensibility of the skin, widened and atrophic 
scars, facial aspects as the sign of Gorlin (point of tongue can reach the tip of the nose), 
scoliosis, and muscular hypotonia. 
Recently, the two conditions benign joint hypermobility syndrome (BJHS) and EDS 
hypermobility type have been recognized as one and the same clinical spectrum ranging from 
apparently symptomatic generalized joint hypermobility to the most disabled individuals 
fitting the new diagnostic criteria. These new criteria are more strict than the Villefranche 
criteria and the Brighton criteria for BJHS in order to define a homogeneous phenotype for 
management and scientific purposes. Within the new EDS nosology, its name is hypermobile 
EDS (see chapters 2 and 5).  
 
2. Cases 
 
2.1 Patient A 
A 27-year old woman with kyphoscoliotic EDS presented at the urology outpatient clinic. She 
has been referred by her nephrologist, who is treating her for severe hypertension. As a result 
of her EDS, she had multiple orthopaedic surgeries in childhood for spondylolisthesis. 
Eventually spondylodesis of L5 up to the sacrum had been performed. Additionally, she is 
known with a mitral valve prolapse and periodic supraventricular tachycardia. At the age of 
25 hydronephrosis on the right side was diagnosed, which was surgically treated by an 
urologist elsewhere. Indication for this surgery was a suspected ureteropelvic junction 
obstruction. Post-operatively she developed a new obstruction of the upper urinary tract, as a 
result of a radiographically invisible kidney stone in the ureter. Eventually this stone was 
surgically removed. Shortly thereafter, a renogram showed that the function of the right 
kidney was only 27% and of the left kidney 63% of the total kidney function, probably as a 
result of the previous problems.  
For urologic analysis of the upper urinary tract, a retrograde urography on the right side was 
performed. This showed a dilated pyelum and ureter with a malrotated kidney. 
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Video-urodynamic investigation showed a small capacity bladder and a bladder diverticulum. 
At voiding the diverticulum did not empty completely. Because of recurrent urinary tract 
infection an antibiotic (Nitrofurantoin) for continuous use was prescribed. 
She was also seen by her gynaecologist for pregnancy counselling. After this consult, which 
included evaluation of the risks of having a child affected with EDS, she and her partner 
decided to refrain from having their own children and to start with an adoption procedure. 
After starting with Tamsulosin, drinking 200 ml of cranberry juice twice a day and stopping 
antibiotic treatment, urinary tract infection did not recur. Her hypertension responded well on 
ACE (angiotensin converting enzyme) blockade. Ultrasonic and renographic imaging at 
follow up revealed no further functional decrease of the right kidney and ureter. She is still 
intermittently seen at the urology outpatient clinic. 
 
2.2 Patient B 
A 26-year old woman with hypermobile EDS has been visiting her urologist for more than 
three years. As a result of her EDS she became wheelchair dependent . Her medical history 
included analysis for voiding problems in another university hospital. By pressing just 
cranially of her pubic bone, she was able to empty her bladder (method of Credé), but feelings 
of residual volume remained. She never had episodes of urinary tract infections. Urodynamic 
investigation showed a bladder capacity of 800 mls without an urge to void at that volume and 
absence of normal contractions of detrusor muscle when striking the abdomen just cranially of 
the pubic bone or applying abdominal pressure. Furthermore closure pressures of bladder 
neck and urethra were too high. Based on these findings patient was taught to catheterise 
intermittently. With this procedure she could socially function well and was continent. When 
she went on vacation, she used a permanent urinary catheter. Investigation of the upper 
urinary tract showed normal kidneys without signs of hydronephrosis. Signs of an urinary 
tract infection were never found. 
 
2.3 Patient C 
A 37 year old woman with hypermobile EDS was referred by an urologist from another 
hospital because of bilateral ureteral obstruction. A CT-scan made because of abdominal pain 
and fever, showed dilatation of the left ureter. Since this problem seemed to have been 
existing for a long time, it was not considered to be the cause of the fever. Because of 
remittance of fever, a double-J catheter was placed in the left ureter. A renogram showed for 
the left kidney 31% of the total kidney function. Bilateral dilatation of the total ureter was 
seen on a repeated CT-scan. Earlier, in another hospital she underwent a diagnostic 
laparoscopy for dysmenorrhoea which revealed endometriosis and extensive adhesions 
(“frozen pelvis”). Consecutively, hysterectomy and bilateral ovariectomy was performed, 
while preoperatively another double-J catheter was placed on the right side. Postoperatively 
she developed a new episode of fever which was treated with antibiotics. As soon as the 
patient was free of fever, the double-J catheters were removed. After this procedure she had 
flank pain and retrograde urography showed a complete obstruction of the right ureter. This 
was treated by performing a right sided nephrostomy and placement of a double J-catheter on 
the left side. Antegrade urography (the contrast medium is introduced by percutaneous needle 
puncture into the renal pelvis) showed a long narrow stenosis on the right side with a minimal 
amount of contrast in the bladder. Because of this ureteral stenosis and her complicated EDS 
history she was referred to our clinic where a so-called psoas hitch re-implantation of both 
ureters was performed. Postoperative antegrade urography showed no stenosis anymore and 
no dilatation was found at follow-up ultrasound investigations of kidneys and ureters. A 
renogram showed no progressive loss of kidney function on the left side. She never had any 
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urological complaints anymore after the re-implantation and could void completely normal, 
during an evaluation time of more than 5 years. 
 
2.4 Discussion 
It could be noted that if the urologist had been aware of EDS in patient A, he would not have 
started with a surgical intervention. Even treatment of the kidney stone would preferably have 
been done via ureterorenoscopy. However, it is hard to determine if another treatment strategy 
would have prevented deterioration of the right kidney function.  
Regarding patient B, it would have been better if there had been a clinical evaluation of the 
lower urinary tract in an earlier stage. But even here it is hard to determine if this could have 
prevented worsening of the bladder function. 
The case of patient C also shows that surgical intervention should be avoided if possible, or 
should at least be discussed interdisciplinary.  
 
3. EDS and urological problems 
 
3.1 Lower urinary tract 
An association between hypermobility and poor function of the pelvic floor muscles has been 
described by paediatricians and paediatric urologists.
4
 A group of 89 paediatric patients 
without EDS, but with generalised hypermobility which partially met the criteria of Bulbena 
and Beighton, showed an abnormally high frequency of signs and symptoms caused by non-
neurogenic detrusor sphincter dyssynergia.
5 
The main complaints were urinary incontinence, 
frequent urinary tract infections, constipation and faecal soiling. This was attributed to 
insufficient supportive connective tissue in the pelvic floor due to abnormal composition of 
collagen. Especially girls are predisposed to incontinence and infections, while boys generally 
suffer from constipation and faecal soiling.
6
 Although the prevalence of urinary tract 
infections in EDS patients is unknown, it is plausible that it also occurs is higher among 
patients with EDS, but this has not yet been described in literature. Another urologic problem 
in patients with EDS, as shown in patient A, is (congenital) bladder diverticula. Some articles 
describe cases of bladder diverticula in children and adults.
7-11
 The bladder diverticulum in 
EDS is associated with other congenital malformations
12
 and
 
also malignancies.
13 
The bladder 
wall of a patient with EDS is structurally different from that of a healthy person; the same 
applies for the diverticulum.
14
 Its pathogenesis is still unknown but it is plausible that 
hyperelasticity and weakness of the bladder wall and high voiding pressure induced by 
coexistent bladder outflow obstruction play a role.
9
 The combination of these two factors is 
probably the etiological basis for bladder diverticula. These eventually hamper emptying the 
bladder properly, which leads to urinary tract infections. Dependent on the localisation of the 
diverticulum it can also cause voiding impairments by dyssynergia of the pelvic floor, bladder 
and bladder neck. If the diverticulum is located close to the ureteral orifice, reflux can ensue. 
In this case a surgical intervention is indicated,
15,16
 because persistent reflux may damage the 
kidney. Rupture of bladder diverticula is rare, occurring more frequently in boys than in girls, 
and needs to be treated conservatively.
17 
 
3.2 Upper urinary tract 
Functioning of the upper urinary tract in EDS patients has not extensively been described in 
the literature. There have been some case reports of renal cystic lesions, which have to be 
distinguished from classical renal cysts.
18
 Furthermore there is a small number of reports 
about an abnormal ureteric function, which led to an extended pyelum and ureter in these 
cases. This complication could also result from reflux caused by a diverticulum. Recently, 
bilateral kidney prolapse was described in a patient with hypermobile EDS as part of a 
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recurring and generalized visceroptosis.
19
 Renal infarction in cases with vascular EDS has 
also been reported.
20,21 
Prior to surgery, an intravenous contrast study of the upper urinary 
tract always should be performed to know the exact anatomy. If surgical intervention is 
indicated, the surgeon should be aware of the moderate quality of skin and connective tissue. 
Patients with EDS are prone to have bleeding during and after surgery, poor wound healing 
and incisional hernias.
22
 In case of urolithiasis, an endoscopic procedure by an experienced 
urologist is the treatment of choice. Extracorporeal shockwave lithotripsy (ESWL) should not 
be applied in patients with vascular EDS; a massive bleeding occurring 24 hours after ESWL 
due to a rupture of the superior mesenteric vein has been described.
23 
 
4. Conclusion 
Events affecting the function and anatomical variation of the urinary tract due to EDS have 
not comprehensively been described in the literature. Starting an urological (surgical) 
treatment of a patient who has not yet been diagnosed with EDS could lead to a non-optimal 
treatment result and possibly severe complications. It is very important that every patient with 
EDS should mention the disease to his or her urologist. The general practitioner should be 
coordinating care for the EDS patient and should inform every specialist about the diagnosis. 
 
5. Summary 
Especially in vascular EDS, urological complications may occur which need special attention. 
Unfortunately, EDS is a fairly unknown disease amongst urologists. With 3 illustrative cases 
we hope to have demonstrated the clinical impact of EDS in the urology clinic. EDS causes 
functional voiding problems by detrusor sphincter dyssynergia, bladder diverticula and loss of 
renal function due to reflux and hydronephrosis. Surgical intervention should be minimal 
because of the high complication risk. 
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1. Introduction 
In gynaecological and obstetric care, women with Ehlers-Danlos syndrome (EDS) may 
present challenging management dilemmas, which vary depending on the type and severity of 
the disease and the specific gynaecological or obstetrical situation. As expected in an 
uncommon disease with many types, data in the literature are scarce, and if present, 
classification according types is often lacking. This makes it very difficult to compare 
management schemes, especially because they are reported by different authors. 
The aim of this chapter is to highlight the most common gynaecological and obstetrical 
problems that patients and clinicians may face, and to suggest the optimal management, based 
on available literature. Because the spectrum of EDS manifestations is very broad, even for a 
given type, no strict management protocols can be established. In general, management 
should be based on the type of EDS, but individualization is mandatory and a multi-
disciplinary team approach is required. Recently, the two conditions benign joint 
hypermobility syndrome (BJHS) and EDS hypermobility type have been recognized as one 
and the same clinical spectrum ranging from apparently symptomatic generalized joint 
hypermobility to the most disabled individuals fitting the new diagnostic criteria. These new 
criteria are more strict than the Villefranche criteria and the Brighton criteria for BJHS in 
order to define a homogeneous phenotype for management and scientific purposes. Within the 
new EDS nosology, its name is hypermobile EDS (see chapters 2 and 5). The first part of this 
chapter deals with gynaecological problems and their management, while the second part 
outlines obstetrical complications and management dilemmas of pregnant EDS patients. 
 
2. Gynaecological disorders in EDS  
In patients with EDS, many medical problems may occur due to malfunctioning connective 
tissue. As outlined in the previous chapters, several types of EDS can be identified, all of 
which could have a different impact. However, no specified data regarding the impact of these 
different types on the genital tract are available in literature. Therefore, the gynaecological 
disorders discussed in this chapter are generally without differentiation in EDS types.  
The gynaecological items that are discussed in this section include preconception counseling, 
infertility, contraception, menstrual disorders, urinary incontinence and prolapse, and other 
common gynaecological disorders. Many women with EDS need intensive medical care for 
these problems. Treatment is often difficult and may lead to other complications. So, in many 
cases a multidisciplinary approach is essential. 
As the underlying defect results in abnormal connective tissue and bleeding disorders (see 
chapter 11), it may be clear that menstrual disorders, uterine or bladder prolapse, urinary 
incontinence and the surgical procedures to handle these problems, are the main points of 
concern. 
 
2.1 Preconception counselling 
Before starting a pregnancy or an infertility work-up, a couple with one partner having EDS 
should seek counseling regarding general aspects of inheritance, prenatal diagnosis, potential 
pregnancy complications and maternal and neonatal outcomes. 
The genetics of EDS, including the mode(s) of inheritance, are discussed in chapters 2 and 3. 
It is important that the diagnosis of EDS is confirmed by a clinical geneticist or another 
medical expert in the field. The specialist will counsel the couple regarding general aspects of 
EDS, possibilities for prenatal diagnostic tests, and coordinate the necessary consultations 
with other disciplines such as ophthalmology and cardiology. 
Before treatment starts, a bleeding/coagulation screening must be performed, though bleeding 
in EDS is mostly due to problems in skin, subcutis and/or vessels and not so much in 
coagulation disorders. 
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Prenatal diagnostic procedures are available in those types of EDS, in which the genetic 
defect is known in the proband and/or affected parent (see chapters 2 and 3). In case of an 
affected woman and no prenatal diagnostic tests available, the only way to assure that the 
offspring will not be affected is by in vitro fertilization (IVF) with egg-cell donation. Pre-
implantation genetic diagnostic procedures in selected cases may also be possible. If the male 
is affected, donor insemination could be a solution. Donor egg and insemination procedures 
may be obstructed by national regulations. Anonymous donor egg/embryos are available in 
some countries; in other countries most often a close family member or acquaintance is the 
only possible donor.  
Invasive diagnostic procedures may be associated with more complications in women with 
EDS. Theoretically, they may be more prone to bleeding, and if the fetus is affected, the 
chance of premature rupture of membranes is increased.
1 
Non-invasive prenatal tests are now rapidly developping and available in many countries, but 
they mostly only screen for chromosomal abnormalities.
2
 Untill now, there are no 
publications reporting the use of these non-invasive tests in EDS.  
In most countries IVF procedures have a multi-gestational rate of about 25%. In case of EDS 
this is an undesirable situation. So, if an IVF procedure is performed, single embryo transfer 
is advised. Though not enough data are available, literature suggests a very high rate of 
extreme premature delivery in twin pregnancies. In addition, other complications associated 
with multiple gestation, like postpartum haemorrhage and perineal lacerations, may occur 
more frequently in women affected by EDS.
3
 
 
2.2 Infertility 
There are no consistent data suggesting decreased fertility in women with EDS and no sperm 
abnormalities in relation to EDS have been reported, though Hurst et al. mentioned an 
infertility rate of 44,1% through a questionnaire study among members of the USA Ehlers-
Danlos National Foundation.
4 
The abortion rate is slightly increased (20-25% of 
pregnancies).
3,4
 All routine examinations should and can be performed in a couple with EDS, 
like basal temperature checks for ovulation detection, semen analysis, bloodtests, post 
coitumtest, hysterosalpingography (the conductance of the tubes is checked by filling the 
uterus and tubes with a contrast medium while making a X-ray) and laparoscopy with 
chromopertubation (the uterus and tubes are filled with dye and the conductance of the tubes 
and possible abnormalities are confirmed by direct laparoscopic inspection). 
Infertility in EDS women is mentioned by some authors and it is mainly due to anovulation 
(the ovary not releasing a ripened egg each month as part of a woman's normal cycle in her 
reproductive years), which may be as high as 41%.
5
 This high percentage could, to some 
extent, be the side effect of non-steroidal anti-inflammatory medication, which is commonly 
used for pain relief. All ovulation induction drugs are permitted in women with EDS, 
however, care must be taken to prevent twin pregnancies. Drugs that are given by injections 
(skin, muscle) may produce haematomas and no clear data are available if there is also 
abnormal absorption of the injected drugs in the subcutaneous tissue. IVF can be performed in 
all types, but in vascular EDS it may be risky, as pregnancy itself also is in patients with 
vascular EDS (see section below on obstetric care). 
  
2.3 Contraception 
Almost all contraception methods can be used in women with EDS.  
The reliability of different contraception methods is generally given by the Pearl index. This 
is the number of pregnancies that 100 women using a specific contraception method will have 
after one year. The reliability index shows at first the number of pregnancies, which would be 
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expected in theory. Secondly, the number will be shown as seen in daily practice, given the 
use of the same specific contraceptive. In table 17-1 the different numbers are summarized. 
 
2.3.1 Non-permanent methods 
Condoms, femal condoms, pessaria with sperm-killing substances can all used according to 
one’s preferences. 
Oral hormonal contraception may have the advantage of regulating menstrual bleeding 
disorders apart from birth control. 
Hormonal contraception by progesterone depots by injection (intramuscular) are often used, 
but can produce local haematomas at the site of injection. 
Other kinds of hormonal contraception. In some countries, the use of small rods of 
progesterone, which are subcutaneously inserted in the arm, is common. No data in relation to 
EDS are available, but they could migrate theoretically more easily in patients with EDS and 
their removal may be associated with more problems, secondary to poor wound healing, 
bleeding and extensive scarring. 
 
It could be disputed whether hormonal contraception may have a bad influence on blood 
lipids (cholesterol) and hypertension. These factors must be balanced against risks of 
pregnancy, bleeding disorders and general condition. In some cases individual counselling is 
appropriate. 
Two kinds of intrauterine contraceptive device (IUCD) are available: the copper IUCD and 
the IUCD with slow release of progesterone (Mirena®). The insertion of the IUCD should be 
performed with special care to avoid cervical lacerations and uterine perforations, due to the 
increased vulnerability of the tissue. Both kinds are applicable to all types of EDS. 
In general population menorrhagia (excessive menstrual bleeding) is more often reported in 
women with a copper IUCD. The IUCD with progesterone may play, apart from its 
contraceptive action, an important role in the treatment of menorrhagia; it reduces the amount 
of menstrual blood loss remarkably. These IUCD’s are a little bit more difficult to insert than 
those with copper, and extra care should be taken. 
 
2.3.2 Permanent method of contraception 
Classical laparoscopic sterilization has the disadvantage of general anaesthesia; potentially, 
more complications can be expected, as in all surgical procedures in EDS patients, but no 
clear data are available in the medical literature.  
A new kind of permanent sterilization are the recently introduced hysteroscopic sterilization 
procedures. It has the advantage that it can be performed under local anaesthesia. However, in 
±5% of cases the procedure cannot be carried out successfully, due to technical and 
anatomical factors.  
Sterilization of the (non) affected male is also an option. Care should be taken with tissue 
handling to prevent (painful) haematomas in affected males. 
 
2.4 Uterine bleeding disorders 
Uterine bleeding disorders are common in EDS affected women. In the literature, it is 
reported to be present in about 28-59% of EDS cases.
4,5,6
 The most common causes of severe 
bleeding are adenomyosis, uterine myomas, polyps, and hormonal dysfunction; sometimes no 
cause can be identified (idiopathic bleeding). Adenomyosis is a medical condition 
characterized by the presence of ectopic endometrial tissue (the inner lining of the uterus) 
within the myometrium (the thick, muscular layer of the uterus). Myoma is a benign tumour, 
which grow from the myometrium.  
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In a report by Anstey et al., 51 EDS patients were examined of which 83% had a tendency to 
bleed.
7
 
Since myomas and polyps are not found more frequently in EDS women, bleeding disorders 
could be attributed to the more frequently found menstrual disorders. Hormonal dysfunction 
and anovulation are reported in about 20-40%, however medical intervention is usually not 
indicated. 
Adenomyosis and endometriosis are reported in about 15-77%.
5,6
 As this is a diagnosis that is 
mainly made by invasive procedures (laparotomy and laparoscopy), it is difficult to evaluate 
the accuracy of these reports. In some cases endometriosis can be seen (cysts) or suspected by 
ultrasound.  
 
Options for treatment of uterine bleeding disorders include: 
- Use of oral contraconception. Continuous use, or a cycle with a 3 monthly withdrawal 
bleeding could be beneficial or acceptable 
- Tranexamic acid. This drug prevents the resolution of clots (fibrinolysis) and results 
generally in a 30% reduction of blood loss. 
- Coxibs: prostaglandin inhibitors. Usually available over the counter in drugstores. A Cox-
1 saving non-steroidal anti inflammatory drugs (NSAID) or Coxib (like etoricoxib) is 
advised in women with EDS because these drugs have no influence on the bleeding 
tendency, in contrast to classical NSAIDs. A 30 % reduction of blood loss is reported in a 
general population. The mode-of-action is the forming of a better hemostatic plug in the 
bleeding surface of the endometrium. 
- IUCD with slow release of progesterone (discussed above). This usually results in 
acceptable menstrual blood loss and less dysmenorrhea (severe painful menstrual 
periods) 
- Endometrial ablation: this is the destruction of the inner lining of the uterine cavity with 
thermal balloons or electrical loops. Results: 30 % of women have no periods at all after 
treatment, in 30 % the periods are less severe and acceptable, and in about 20% -30% the 
procedure is not felt to be successful.  
- Hysterectomy (removal of the uterus). This is the only definitive solution for the problem, 
but it may be associated with more peri-operative complications in EDS. Nevertheless, 
hysterectomy is performed more frequently in EDS patients compared to general 
population (19-44%).
6
 
 
2.5 Prolapse and urinary incontinence in women 
Since EDS are disorders of the structure and function of connective tissue, it is understandable 
that uterine and bladder prolapse and urinary incontinence occur more commonly in women 
with EDS. Although literature data are scarce and the sample sizes small, these problems are 
reported to be present in about 30-60% of EDS cases.
5,6,8 
Prolapse can be manifest as prolapse of the anterior or posterior vagina wall and/or prolapse 
of the uterus (see figure 17-1). Surgical correction is the preferred treatment in most cases. 
However, in EDS, surgery must be balanced against the possible higher surgical complication 
rate, present discomfort, recurrence rate and possible anaesthetic complications. For all these 
issues the female patient must be carefully counselled. Less invasive surgical techniques with 
slings and foreign material are developed. These techniques could be beneficial for female 
patients with EDS. However, at present no data are available concerning the effects of these 
techniques in women with EDS. Potential complications are bleeding of the vagina, due to 
insertion of the slings and abrasions for which sometimes after weeks or months removal of 
remnants is necessary. This has been described several times in non-EDS affected women and 
could be a more serious problem in EDS affected women. The same holds true for surgical 
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techniques for urinary stress incontinence. Several studies describing techniques with mesh 
have been published, but none in relation to EDS. In elderly women, who have an increased 
surgical risk, a pessarium may be used. This necessitates an examination every 3 months for 
cleaning and to check for the presence of vaginal pressure ulcers. 
 
Figure 17-1 Normal and abnormal anatomy 
 
 
 
Top left: normal anatomy 
 
Top right: vagina wall is prolapsed: 
- if the bladder is involved, it is a cystocele 
- if the rectum is involved, it is a rectocele 
- if both are involved, it is a recto-cystocele 
 
Bottom left: if the intestine prolapses between the rectum and vaginal wall, it is an enterocele 
 
Bottom right: The whole uterus is prolapsed (descensus uteri) 
(Source: merckmanuals.com) 
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Urge incontinence is usually treated with medication and the treatment is not different in 
women with EDS compared to women in the general population.  
Most pelvic floor abnormalities need a multidisciplinary approach and in most hospitals a 
team of specialists, consisting of a urologist, gynaecologist, proctologist, physiotherapist, 
psychologist, dietist and a specialized nurse physician, is present for the care of patients 
struggling with these problems.  
Recurrent prolapse or fragile tissue, noted during surgical procedures, should raise suspicion 
of EDS. 
 
2.6 Other common gynaecological disorders 
Other gynaecological disorders, which may be more frequently seen in women with EDS, 
include endometriosis (30-60%), dyspareunia (60%), atrophy of the vagina, more frequent 
need for hormonal replacement therapy (HRT) and abnormal Pap smears (19% versus 5 % in 
a normal population).
5,6
 The first four disorders could be related to one another since 
dyspareunia and sexual dysfunction may be due to prolapse, atrophy, and pain due to 
endometriosis. Castori et al. gave a comprehensive overview of gynaecological complications 
in joint hypermobility syndrome, which nowadays is considered one and the same disorder as 
EDS hypermobility type and named hypermobile EDS (see chapter 2 and 5).
9 
Atrophy of the vagina can be the result of high doses progesterone, which are often given in 
cases of endometriosis or bleeding disorders. Atrophy is as in normal population usually 
treated with locally vaginal applied estrogen. 
Endometriosis is often difficult to treat. Sometimes hormonal therapy is used, in other cases 
surgical therapy is necessary. There is no good explanation why HRT is more often used in 
women with EDS and why more Pap smears are found to be abnormal.
5,6
  
Sexual dysfunction is often a difficult problem and may need in many cases a 
multidisciplinary approach or consultation of multiple specialists such as a gynaecologist, 
psychologist and/or sexuologist. 
There are some case reports about vaginal lacerations after sexual intercourse that occurred in 
women with vascular EDS, but these events are rare and can occur in non-EDS affected 
women as well. Physically, in vascular EDS normal sexual activity is not too much a burden 
for heart and bloodvessels. 
In male patients with vascular EDS, the use of viagra is theoretically permitted, if they have 
no medical history of cerebral vascular accident or heart failure. In these cases an individual 
counseling is necessary. 
 
2.7 Conclusion regarding gynaecologic disorders 
EDS may be associated with specific gynaecological complications. Bleeding disorders, pain, 
endometriosis and prolapse are the main problems. 
This calls for special care for women with EDS, which is often intensive and involves in 
many cases several specialists. However, there still exists several areas of uncertainty: for 
example the effects of application of new surgical techniques in the treatment of incontinence 
and prolapse in EDS patients. 
 
3. Obstetric care of patients with EDS 
The second part of this chapter is on obstetric care of patients with EDS. EDS may be 
associated with numerous complications during pregnancy, ranging from mild articular 
discomfort to maternal death. The likelihood and severity of pregnancy complications appear 
to vary according to the EDS type. 
The features of EDS with the most impact on the obstetrical and associated anaesthetic 
management include, depending on type, fragile and poorly healing skin, excessive bleeding, 
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increased risk for spontaneous pneumothorax, easy joint dislocation, cardiac valvular prolapse 
and spontaneous dissections or ruptures of major vessels and viscera.
10
 Although various 
obstetric complications have been reported in patients with EDS, the vast majority of the 
published reports does not distinguish between the different types of the syndrome, thus type 
specific complication data are scarce, except for classical and vascular EDS.  
This section outlines obstetric complications in parturients (women who are about to give 
birth) with different types of EDS, based on data from current medical literature, and 
recommendations for the management of pregnancy and labour in these patients. Foetal 
complications and relevant anaesthetic considerations are summarized. 
 
3.1 Pregnancy and EDS  
Reports of complications of pregnancy in patients with EDS have appeared in literature since 
1950. These include abdominal hernias, bruising, varicose veins, antepartum and postpartum 
haemorrhage, joint subluxations, back pain, separation of the symphysis pubis, haematoma 
formation, and uterine prolapse. Early reports and even some of the later reports did not 
differentiate between the various types of EDS. Thus, it is difficult to create a complete 
database of type-specific obstetric complications in patients with EDS.  
In 1981 the first observed maternal death due to EDS had been reported. A patient developed 
spontaneous pulmonary artery rupture during the seventh month of pregnancy and died before 
arrival in the hospital.
11
 During the last three decades, additional type-specific cases of EDS 
in pregnancy were reported, and several attempts to summarize obstetric complications of this 
disorder in type-specific manner were made. They are described below. 
 
3.1.1 Classical EDS  
This type is among the most common types of EDS. Smith et al. reported on pregnancies of 
two patients with classical EDS.
12
 In one patient the delivery was complicated by a large 
vaginal laceration, and the other suffered from the dehiscence of the episiotomy, a surgical cut 
made at the opening of the vagina during childbirth, to aid a difficult delivery and prevent 
rupture of tissues. Kiilholma et al. reported two pregnancies in patients with this type of EDS: 
one resulting in premature rupture of membranes at 26 weeks, and the other resulting in a 
small-for-gestational-age (SGA) infant at 38 weeks, but no other complications were 
reported.
13
 Taylor et al. described a patient who underwent a caesarean delivery because of 
hip joint related problems.
14
 However, her delivery was uncomplicated. Georgy et al. 
described a parturient who developed a large central perineal tear after active pushing during 
the second stage of labour (period of expulsion).
15
 The increased tissue elasticity and skin 
fragility allowed the foetal head to take the pass of least tissue resistance (i.e. through the 
posterior wall and perineum, between the fourchette - a thin fold of skin at the back of the 
vulva - and anus). 
 
3.1.2 Hypermobile EDS 
Morales-Rosello et al. summarized the outcome of pregnancy in 39 women with hypermobile 
EDS.
16
 Of those 39 patients, 30 (77%) had vaginal delivery, and 26 (67%) pregnancies were 
carried to term. 32 Patients (82%) delivered liveborn infants, whereas seven subjects (18%) 
had a miscarriage. The incidence of intrapartum and postpartum haemorrhage was 10% and 
5%, respectively. No additional obstetric complications were mentioned.  
In general, during the progress of pregnancy, there may be an aggravation of symptoms, 
mainly in joints, which may neccessitate a caesarean section. Such symptoms have been 
reported to disappear after delivery.
17,18
 Some women may have an uncomplicated pregnancy 
and delivery.
16,19
 Recently, we reported on pregnancy course and outcome of a patient with 
hypermobile EDS, who had an uneventful pregnancy and delivery.
20
 To our knowledge, 
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severe complications in this type of EDS have never been reported. However, serious pelvic 
instability and symphysiolysis are reported.
9
 
 
Classical and hypermobile EDS may be associated with increased risk of premature birth 
which may be the result of cervical insufficiency and spontaneous rupture of the foetal 
membranes, both due to the intrinsic weakness of the connective tissue.
14,21,22
 In pregnancies 
in which the foetus is affected with EDS, a reduction or structural defect of the extracellular 
matrix components (collagen) may account for a general decrease in thickness of the foetal 
membranes, causing premature rupture of these membranes and premature delivery.
23
  
To date, no EDS specific data are available on the possible benefits of cervical length 
measurements to estimate the chance of preterm delivery or on fibronectin determinations in 
vaginal or cervical fluids. Nowadays, we know that if the protein fibronectin is absent in 
vaginal or cervical mucus, the chance of premature delivery is very small. However, if 
fibronectin is absent the predictive value is small too. Progesterone can be used to prevent 
premature delivery, but with regard to EDS no specific data are available and normal criteria 
can be followed: premature delivery of 34 weeks or less in history and/or a shortened cervix. 
It is questionable whether a prophylactic cerclage, a minor surgical procedure in which the 
opening to the uterus (the cervix) is closed in order to prevent a miscarriage or premature 
birth, is indicated in patients with EDS, since these patients are already predisposed to 
preterm premature rupture of membranes in case the foetus is also affected with EDS. Data 
concerning cervical cerclage in EDS patients are scarce: a patient with classical EDS, who 
underwent a prophylactic cervical cerclage and had an uneventful pregnancy, delivered at 41 
weeks’ gestation, has been described.
21 
Insufficient data are available to predict course and outcome of twin pregnancies in women 
with EDS, though case reports warned against extreme premature delivery 
Overall, in classical and hypermobile EDS, pregnancy is generally well-tolerated, with 
favourable maternal and neonatal outcome. However, maternal complications related to 
connective tissue dysfunction such as pelvic instability and obstetric problems such as 
preterm delivery, postpartum haemorrhage, complicated perineal lacerations and poor healing 
of the episiotomy wound (the surgical cut made at the opening of the vagina during delivery) 
occur more often than in general population.
24
 It may therefore be concluded that special care 
should be given to such patients to avoid perineal trauma. Furthermore, instrumental delivery 
should be avoided as much as possible.  
 
3.1.3 Vascular EDS 
This type of EDS is associated with a risk of as much as 25% maternal death, mainly due to 
rupture of the aorta or the uterus. These complications seem to be worse during labour and in 
the early postpartum period.
25
 Lurie et al. reviewed 50 pregnancies in 26 patients with well 
documented characteristics of vascular EDS.
26
 Ten of these women (38.5%) died during 
pregnancy, labour or in the immediate postpartum period: two of major vessel rupture prior to 
the onset of labour, one of uterine rupture during labour, one of uterine rupture and aorta 
rupture at delivery, five in the postpartum period after vessel rupture, and in one case, the 
cause of death was unknown. Among the 16 women who survived, five experienced 
complications such as major lacerations, haemorrhage, liver rupture, uterine rupture, and one 
woman underwent a hysterectomy after abortion. 
During delivery, women with vascular EDS are at risk for severe vaginal or perineal 
lacerations, haematoma formations, postpartum haemorrhage, wound dehiscence, or a weak 
uterine scar if caesarean delivery is performed.
25,26
 It has been estimated that vascular EDS is 
associated with a pregnancy related maternal mortality of 20% for each pregnancy and 38.5% 
for each pregnant women. The majority of deaths occurs in the peripartum period and is 
usually associated with vaginal delivery.
25
 Pepin et al. described 81 women with vascular 
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EDS, who had a total of 183 pregnancies, with 167 deliveries of live-born infants at term, 
three stillbirths, ten spontaneous abortions and three voluntary terminations.
27
 Twelve women 
(11.5%) died during the peripartum period or within two weeks after delivery (five of uterine 
rupture during labour, two of vessel rupture at delivery, and five in the postpartum period 
after vessel rupture). Based on these results, women with vascular EDS should be advised 
against pregnancy. If they do become pregnant, they should be advised against continuing the 
pregnancy.
25,26
 A more recent study showed a less dramatic outcome: 30 pregnancy related 
deaths in 565 deliveries (5,3%) of 256 women and life threatening complications in 14,5%. 
Surprisingly, there was no significant difference in survival (Kaplan-Meier curve) between 
parous and nulliparous women. They concluded that women with vascular EDS should not be 
advised against preganacy, but should be engaged in a shared decisionmaking process when 
contemplating pregnancy and pregnancy management.
28
 Elective termination of pregnancy 
before 16 weeks has been successfully accomplished without significant sequelae.
29
 However, 
it is not without risk, and an emergency hysterectomy was required in one case.
30
 If a woman 
chooses to continue the pregnancy, close follow-up is mandatory, and elective hospitalization 
is recommended during the third trimester with restriction of physical activity. Before the 
onset of labour approximately at 32 weeks, delivery should take place by planned caesarean 
section after administration of steroids to stimulate maturation of the lungs. This approach is 
recommended for the following reasons:  
(1) maternal plasma volume peaks at 32 weeks, and plasma volume might have a role in the 
severity of vascular complications,  
(2) it may minimize the fluctuations in maternal cardiac output and blood pressure associated 
with labour, a factor that may augment arterial rupture,  
(3) it may reduce the risk of significant accidental perineal trauma,  
(4) the majority of spontaneous deliveries of EDS patients occurs between 32 and 35 weeks of 
gestation. Prior to a caesarean section, the woman should be counselled about tubal ligation, a 
surgical procedure for female sterilization that involves severing and tying the fallopian tubes, 
should be offered.
18
 Caesarean delivery is associated with increased risk of perioperative 
haemorrhage.
31
 Wound healing may be impaired, and there is an increased risk of wound 
dehiscence.
32 
Whether there is a place for desmopressin in the management of bleeding is not 
yet clear.
33 
 
3.2 Foetal complications  
As a predominantly autosomal dominant disorder, EDS has a 50% risk of transmission to the 
offspring. The foetus of a woman with vascular EDS is at increased risk for prematurity 
(mainly due to premature rupture of membranes), adverse outcome associated with maternal 
vascular collapse or uterine rupture, compression of a friable umbilical cord, or 
musculoskeletal abnormalities (pes planus, talipes equinovarus, amniotic bands, etc.).
26
 The 
infants may be small-for-gestational-age, which would be favourable for their mother at 
delivery.
13,34
 Hernial defects and joint luxations may occur. A floppy infant syndrome is a 
serious complication observed in about 13% of the newborns with EDS. A high incidence of 
abnormal foetal presentations as breech delivery and face presentation was found in the 
women with EDS (12%), the highest occurrence was observed among women with 
hypermobile EDS (19%).
24 
 
3.3 Anaesthetic considerations 
The type of anaesthesia, general, epidural or spinal, and the type of EDS may have a major 
effect on the risks imposed by anaesthesia during delivery. In some types skeletal 
abnormalities of the spine may make regional anaesthesia difficult or impossible. Although 
bruising, bleeding and haematomas are common, no consistent coagulation disorder has been 
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identified in association with EDS. Nevertheless, the bleeding tendency, although not 
stemming from a coagulation disorder, can complicate arterial, peripheral, central line and/or 
neuraxial needle placement.
10
 Dolan et al. warned about increased risk of spinal haematoma in 
parturients with EDS and advised against regional anaesthesia in these patients.
35
 However, 
there are numerous reports in literature of successful use of regional techniques in parturients 
with classical and other types of EDS, both for labour analgesia and anaesthesia for a 
caesarean section.
31,32,36
 Subarachnoid block (injection of a local anaesthetic into the 
cerebrospinal fluid) with a small gauge needle (27 gauge) may minimize the risk of bleeding 
within the epidural space (the space inside the bony spinal canal but outside the membrane 
called the dura mater), but the finite duration of spinal anaesthesia may make this technique 
inappropriate as the surgery (and delivery) may be protracted because of bleeding and 
difficulty in securing haemostasis. Neuraxial techniques using epidural anaesthesia and 
combined spinal-epidural anaesthesia offer the advantage of extending the anaesthesia for the 
duration of the surgery and thus avoiding the need to switch to general anaesthesia.
31
 It has 
been observed that patients with EDS may have a reduced response to local anaesthetic 
agents, particularly in patients with hypermobile EDS.
37,38
 
General anaesthesia exposes the parturient to the risk of aspiration and difficult tracheal 
intubation. Some patients with EDS have an unstable cervical spine, which would make 
laryngoscopy and intubation hazardous. The hypertensive response to intubation may 
predispose to vessel wall damage because of the increased intraluminal pressure.
32
 If general 
anaesthesia is selected for these parturients, the airway must be gently managed in view of the 
possible presence of spine involvement, periodontal disease, propensity for gingival bleeding 
and oropharyngeal tissue fragility.
39,40
 Cardiac function should be evaluated preoperatively 
and anaesthetic implications considered. Intraoperatively, low airway pressures are needed 
because of the increased risk of pneumothorax.
37
 If possible, spontaneous ventilation is 
recommended., such as positive end expiratory pressure and pressure support ventialtion. 
 
We can conclude that if bleeding tendency is not extreme, regional anaesthesia can also be 
used. Caution, however, is necessary, since several patients experienced extension of the 
regional block beyond the intended level. Provided that general anaesthesia is carefully 
prepared and monitored, it can be applied. However, preventive measurements have to be 
taken. 
 
3.4 Conclusion regarding obstetric care 
In classical and hypermobile EDS, pregnancy is generally well tolerated, with favourable 
maternal and neonatal outcome. Women with vascular EDS should be engaged in a shared 
decisionmaking process when contemplating pregnancy and pregnancy management. Women 
with EDS are at increased risks for complications during pregnancy and delivery, such as 
pelvic instability during pregnancy, preterm delivery, postpartum haemorrhage and 
complicated perineal lacerations. 
Since a multi-organ involvement and varied presentations of the disease are noted, no uniform 
or routine obstetric and anaesthetic recommendations for peripartum care of these patients can 
be made. 
All clinical decisions should be based on knowledge of the specific EDS type. A plan of 
management should be tailored to each individual patient.  
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Table 17-1 Advantages, disadvantages and reliability (Pearl index) of different types of 
contraception 
 
 
Type of 
Contraception 
Advantages  Disadvantages  Reliability % 
(Pearl index), 
theoretically-
practically 
Condom Protects also against sexually 
acquired disease 
Discipline, lack of 
reliability
3-14 
Pessarium Protects also against sexually 
acquired disease 
Lack of reliability 6-20 
Progesterone depot Only 4 times a year an injection Takes up to a year 
before normal  
cycle resumes. 
Hematoma 
(injections)
0.3-0.3 
Progesterone implant Reliability In and out: small 
surgical procedure.  
Risk of migration.  
Scar
0.05-0.05 
Oral contraception pill Less bleeding Thrombosis risk 
slightly increased. 
Discipline
0.5-4 
IUCD ( Copper) For 5 year reliable contraception Insertion, Infection 
risk
0.6-0.8 
IUCD ( hormonal) Less bleeding 
For 5 year reliable contraception
Insertion, 
Infection risk
0.1-0.1 
Sterilization 
 
Female (laparoscopic) 
 
Female (hysteroscopic) 
 
 
 
Male 
 
 
 
Reliability 
 
Small invasive procedure (local 
anesthesia). Reliability 
 
 
Reliability 
All: ≈ irreversible 
 
Invasive procedure 
 
In ±5% procedure 
technically 
impossible 
 
Invasive procedure 
 
 
0.5-0.5 
 
0.32 
 
 
 
0.1-0.15 
 
 
Chapter 17252
 
 
References 
 1. Parry S, Strauss JS. Premature rupture of membranes. N Engl J Med 1998;338:663-70. 
 2. Allyse M, Minear MA, Berson E, et al. Non-invasive prenatal testing: a review of 
international implementation and challenges. Int J Womens Health 2015;7:113-26. 
 3. Lind J. The Marfan and Ehlers-Danlos syndromes and pregnancy. Thesis 2000. ISBN 90-
901307-3. 
 4. Hurst BS, Lange SS, Kullstam SM, et al. Obstetric and gynecologic challenges in women 
with Ehlers-Danlos syndrome. Obstet Gynecol 2014;123:506-13. 
 5. Sorokin Y, Johnson MP, Rogowski N, Richardson DA, Evans MI. Obstetric and 
gynecologic dysfunction in the Ehlers-Danlos syndrome. J Reprod Med 1994;39:281-4.  
 6. McIntosh LJ, Mallet VT, Frahm JD, Richardson DA, Evans MI. Gynecologic Disorders 
in Women wit the Ehlers-Danlos Syndrome. J Soc Gynecol Invest 1995;2:559-64.  
 7. Anstey A, Mayne K, Winter M, Van de Pette J, Pope FM. Platelet and coagulation 
studies in Ehlers-Danlos syndrome. Br J Dermatol 1991;125:155-63. 
 8. Carley ME, Schaffer J. Urinary incontinence and pelvic organ prolapse in women with 
Marfan or Ehlers-Danlos syndrome. Am J Obstet Gynecol 2000;182:1021-3. 
 9. Castori M, Morlino S, Dordoni C, et al. Gynecologic and obstetric implications of the 
joint hypermobility syndrome (a.k.a. Ehlers-Danlos syndrome hypermobility type) in 82 
Italian patients. Am J Med Genet A 2012;158A:2176-82. 
10. Krzysztof M, Kuczkowski MD. Labor analgesia for the parturient with an uncommon 
disorder: a common dilemma in the delivery suite. Obstet Gynecol Surv 2003;58:800-3. 
11. Pearl W, Spicer M. Ehlers-Danlos syndrome. South Med J 1981;74:80. 
12. Smith CV, Phelan JP.Pregnancy and the Ehler-Danlos syndrome. J Reprod Med 
1982;27:757-60. 
13. Kiilholma P, Gronroos M, Nanto V, et al. Pregnancy and delivery in Ehlers-Danlos 
syndrome. Acta Obstet Gynecol Scand 1984;63:437-9. 
14. Taylor DJ, Wilcox I, Russell JK. Ehlers–Danlos syndrome during pregnancy: a case report 
and review of the literature. Obstet Gynecol Surv 1981;36: 277–81. 
15. Georgy MS, Anwar K, Oates SE, et al. Perineal delivery in Ehlers-Danlos syndrome. Br J 
Obstet Gynaecol 1997;104:505–6. 
16. Morales-Rosello J, Hernandez-Yago J, Pope M. Type III Ehlers-Danlos syndrome and 
pregnancy. Arch Gynecol Obstet 1997;261:39-43. 
17. Atalla A, Page J. Ehler-Danlos syndrome type III in pregnancy. Obstet Gynecol 
1988;71:508-9. 
18. Golfier F, Peyrol S, Attia-Sobol J, et al. Hypermobility type of Ehler-Danlos syndrome: 
influence of pregnancies. Clin Genet 2001;60:240-1. 
19. Sakala EP, Harding MD. Ehlers–Danlos syndrome type III and pregnancy: a case report. J 
Reprod Med 1991;36:622–4. 
20. Volkov N, Nisenblat V, Ohel G, Gonen R. Ehlers-Danlos syndrome: insights on obstetric 
aspects. Obstet Gynecol Surv 2007;62:51-7. 
21. Ploeckinger B, Ulm MR, Chalubinski K. Ehlers- Danlos syndrome type II in pregnancy. 
Am J Perinatol 1997;14:99–101. 
22. De Vos M, Nuytinck L, Verellen C, et al. Preterm premature rupture of membranes in a 
patient with the hypermobility type of the Ehlers–Danlos syndrome. Fetal Diagn Ther 
1999;14:244–7. 
23. Parry S, Strauss JF III. Premature rupture of the fetal membranes. N Engl J Med 
1988;338:633-70. 
24. Lind J, Wallenburg HC. Pregnancy and the Ehlers-Danlos syndrome: a retrospective study 
in a Dutch population. Acta Obstet Gynecol Scand 2002;81:293–300. 
Gynaecological and obstetrical problems and management dilemmas in women with Ehlers-Danlos syndrome 253
 
 
25. Peaceman AM, Cruikshank DP. Ehlers- Danlos syndrome and pregnancy: association of 
type IV disease with maternal death. Obstet Gynecol 1987;69:428-31. 
26. Lurie S, Manor M, Hagay ZJ. The threat of type IV Ehlers-Danlos syndrome on maternal 
well-being during pregnancy: early delivery may make the difference. J Obstet Gynaecol 
1998;18:245-8. 
27. Pepin M, Schwarze U, Superti-Furga A et al.Clinical and genetic features of Ehler-Danlos 
syndrome type IV, the vascular type. New Engl J Med 2000;342:673-80. 
28. Murray ML, Pepin M, Peterson S, Byers PH. Pregnancy-related deaths and complications 
in women with vascular Ehlers-Danlos syndrome. Genet Med 2014;16:874-80.  
29. Klipple GL, Riordan KK. Rare inflammatory and hereditary tissue diseases. Rheum Dis 
Clin North Am 1989;15:383-98. 
30. Beighton P. Lethal complications of the Ehler-Danlos syndrome. Br Med J 1968;3:656-9. 
31. Brighouse D, Guard B. Anaesthesia for Caesarean section in a patient with Ehlers–Danlos 
syndrome type IV. Br J Anaesth 1992;69:517–9. 
32. Campbell N, Rosaeg OP. Anesthetic management of a parturient with Ehlers - Danlos 
syndrome type IV. Can J Anaesth 2002;49:493-6. 
33. Rochelson B, Caruso R, Davenport D, Kaelber A. The use of prophylactic desmopressin 
(DDAVP) in labor to prevent hemorrhage in a patient with Ehlers-Danlos syndrome. N Y 
State J Med 1991;91:268-9. 
34. Munz W, Schlembach D, Beinder E, et al. Ehlers-Danlos syndrome type I in pregnancy: a 
case report. Eur J Obstet Gynecol Reprod Biol 2001;99:126-8. 
35. Dolan P, Sisko F, Riley E. Anesthetic considerations for Ehlers–Danlos syndrome. 
Anesthesiology 1980;52:266–9. 
36. Abouleish E. Obstetric anesthesia and Ehlers–Danlos syndrome. Br J Anaesth 
1980;52:1283–6. 
37. Millar WL. Other hereditary disorders. In: Katz J, Benumof JL, Kadis LB, eds. Anesthesia 
and uncommon diseases. Philadelphia, USA: Saunders, 1990:146–9. 
38. Arendt-Nielson L, Kaalund S, Bjerring P, et al. Insufficient effect of local analgetics in 
Ehler- Danlos type III patients (connective tissue disorder). Acta Anaesthesiol Scand 
1990;34:358-61. 
39. Garahan MB, Licata A. Dermatoses. In: Gambling DR, Douglas MJ, eds. Obstetric 
anesthesia and uncommon disorders. Philadelphia, USA: Saunders, 1998:353–72. 
40. Kuczkowski KM, Benumof JL. Cesarean section and Ehlers-Danlos syndrome: choice of 
anesthesia. Int J Obstet Anesth 2002;11:222–4. 
  
Chapter 17254
 
 
Chapter 18. The child with Ehlers-Danlos syndrome 
MAJ van Rossum and A Kirby 
 
 
Marion A.J. van Rossum, MD, PhD 
Paediatric Rheumatologist/Immunologist 
Reade, Center for Rehabilitation and Rheumatology 
Department of Rheumatology, Amsterdam Rheumatology & Immunology Center 
EULAR center of excellence in rheumatology 
Dr Jan van Breemenstraat 2 
1056 AB Amsterdam, The Netherlands 
Telephone + 31 20 5896 502 
E-mail m.v.rossum@reade.nl 
 
Amanda Kirby, Professor of Developmental Disorders 
University of South Wales 
Caerleon Campus 
The Dyscovery Centre 
Felthorpe House 
Lodge Road 
Newport, NP18 3QT, UK 
Telephone +44 16 33 432330 
E-mail Amanda.kirby@southwales.ac.uk 
255
 
 
1. Introduction 
Ehlers-Danlos syndrome (EDS) is a group of inheritable disorders of connective tissue 
characterized by connective tissue laxity and fragility leading to hyperextensible skin, 
dystrophic scarring, easy bruising, and joint hypermobility (see chapter 2).
1
 Hypermobile and 
classical EDS are the most common forms of the disorder; however, they are difficult to 
diagnose at a young age. Recently, the two conditions benign joint hypermobility syndrome 
(BJHS) and EDS hypermobility type have been recognized as one and the same clinical 
spectrum ranging from apparently symptomatic generalized joint hypermobility to the most 
disabled individuals fitting the new diagnostic criteria. These new criteria are more strict than 
the Villefranche criteria and the Brighton criteria for BJHS in order to define a homogeneous 
phenotype for management and scientific purposes. Within the new EDS nosology, its name 
is hypermobile EDS (see chapters 2 and 5). Children and adolescents possess, compared to 
adults, an inherently greater range of motion in their joints that gradually decreases as they 
age. The prevalence of hypermobility in children as a phenomenon, i.e. symptomatic 
hypermobility, has been measured in a number of studies and, depending on the age or 
ethnicity of the study population or the inclusion criteria, has been reported to be between 2.3 
and 30%.
2,3,4
 Such high prevalence rates imply that hypermobility as a measured phenomenon 
in many children will most often not lead to symptoms requiring medical attention. 
However, in a significant number of children, joint hypermobility coincides with adverse 
symptoms and is associated with other health complaints, which may be harder to recognize 
and classify, particularly if the health professionals are not aware of the manifestations of the 
joint hypermobility syndromes in childhood. 
This chapter will describe the signs and symptoms of EDS and consider the diagnostic 
approaches. It will describe current understanding of intervention and supportive approaches 
at home and school for the child, and will consider future considerations for potential 
research. 
 
2. Case report 
A 5-year-old girl is referred by a general physician to the paediatric rheumatologist because of 
persisting complaints of fatigue and pain in her legs. In recent years the parents frequently 
sought medical attention for their daughter because of concern relating to her motor 
development. She learned to walk late, had a poor coordination, was reported to be clumsy 
and refused to walk longer distances as she was easily tired. She is reported now to fall 
frequently and she often has bruises. At children’s parties she is the first one who is tired and 
often has to be collected before the parties are finished. During family outings, the parents 
need to use a pushchair for her that she physically has outgrown. 
Her energy levels vary widely each day; aside weariness and lassitude she fidgets a lot and 
can show uncontrolled excessive physical activity, e.g. getting up when others are sitting such 
as at story time. At the end of a day where there may have been a lot of physical activities, she 
complains of bodily pain and has difficulties falling asleep. At school she refuses to take part 
in all class activities and requires extra rest time. She is often moody to others and tired, and 
the teachers have questioned the parents about her behaviour and bruises. Aside these signs 
and symptoms, she often complains about abdominal pain and has constipation. The child’s 
behaviour causes additional distress within the family.  
The parents and the older daughter are healthy. No other family members have joint 
complaints though her mother was supple and a good gymnast when she was young and her 
maternal grandmother had diffuse chronic joint and muscle pain and has seen multiple 
physicians for her complaints. She has been given various diagnoses including osteoarthritis 
of the hips, knees, sacro-iliac dysfunction and lumbar disk herniation for her lower-extremity 
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pain. She has had hip and knee replacements at relatively young age and suffers from severe 
osteoporosis. There were no reported sudden vascular deaths in early adulthood in the family. 
Physical examination shows a healthy, timid girl with dark shadows under her eyes. She 
walks rigidly and undresses slowly and with caution. Her physiognomy, height, weight and 
blood pressure are normal for her age. She has a smooth, supple and soft skin with several 
pretibial hematomas but no abnormal scars. On the volar surface of the distal forearm the skin 
shows some hyperextensibility. Internal physical examination does not show abnormalities. In 
standing position, joint examination shows an increased lumbar lordosis and a thoracic 
scoliosis that corrects by bending forward. She stands with hyperextended knee joints, has a 
valgus position of both ankles and flat feet. Her spontaneous muscle tension is low but during 
examination she shows normal muscle strength. Joint examination shows hypermobility in 
almost all joints of the arms and legs; the Beighton score is 6 (range 0-9; hypermobility is 
defined as a score ≥5 for both sexes) and the Bulbena score is 8 points (total range 0-10; score 
defining hypermobility is ≥4/10 in men/boys and ≥5/10 in women/girls). 
Further specialized examination by the paediatric physical therapist shows that in general, her 
motor development is in line with her age but that there is a discrepancy between her static 
and dynamic balance.  
Additional laboratory investigation is normal and radiographs of the hips, knees, ankles and 
feet show no bony abnormalities. 
Ophthalmological examination showed no abnormalities and cardiac evaluation including 
echocardiography for the evaluation of mitral valve and the aortic root was also normal. 
Based on the history, including family history, clinical symptoms and additional 
investigations the clinical diagnosis hypermobile EDS was made. 
 
3. Symptoms of children with EDS  
Signs and symptoms of children with EDS are highly variable, can become apparent at any 
age and may differ between individuals, also within a family.
5,6,7,8
 Hypermobility is frequently 
associated with intermittent pains that occur after bouts of excessive or unusual activity. 
Children between 3 and 10 years seem to be most strongly affected, because the prevalence of 
hypermobility decreases with age.
9
 Because of the genetic component of the syndromes, other 
family members are often affected too. The symptoms are complex and seem to be related to 
the severity of disease. In children with EDS almost all tissues can be involved in the disease, 
the skin and joints particularly. Among the types of EDS, classical and hypermobile EDS are 
most commonly seen. One should always be aware of the possibility of vascular EDS since 
patients with this type are prone to develop life threatening complications. Vascular EDS 
patients can be recognized by a thin translucent skin with visible underlying vessels and 
specific facial features (including a thin pinched nose, prominent eyes and lobeless ears). 
Repeated pneumothoraces or an other organ rupture can also be the initial presentation of 
vascular EDS, while joint hypermobilitity, in this type of EDS, is mostly limited to the small 
joints of the hands. The other EDS types such as kyphoscoliotic, arthrochalasia and 
dermatosparaxis EDS are extremely rare and may present at very young age with severe 
hypermobility, joint dislocations, skin hyperextensibility, easy bruising, hypotonia and gross 
motor delay.
10,11,12,13
 The symptoms of these latter EDS type patients need to be differentiated 
from patients with neuromuscular disorders who also may present as “floppy infants”. 
 
In EDS, easy bruising, especially seen at sites not prone to trauma, can be a presenting sign in 
childhood. It does occur that families of children with EDS have had contact with child 
protection agencies because of recurrent hospital visits for lacerated skin and concomitant 
bruising.
14
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The most prevalent signs of the hypermobility syndromes are described per symptom and per 
age group in respectively table 18-1 and 18-2. 
 
Children and adolescents with hypermobility often “crack” the knuckles of their fingers 
purposely to feel more comfortable. Most parents are concerned that this activity leads to joint 
damage. So far, there is no indication that this results in earlier osteoarthritis.
35 
Although hypermobility may enable a child to be a good gymnast or ballet dancer, injures 
may be more frequent in hypermobile athletes.
36
 It is described that hypermobile females 
show decreased propriocepsis of the knees leading to poorer biomechanical loading and 
microtrauma.
37
 Therefore, having a hypermobility syndrome may argue against a successful 
professional career in ballet dancing
38
 or against strenuous training such as in military 
recruits.
39
  
 
Many of the signs and symptoms associated with the hypermobility syndromes have a great 
impact on the daily life of children and adolescents, and interfere with development, family 
life, school activities, sports, social activities and peer group participation. In young children 
with EDS, the symptoms may be seen as fractious and troublesome because often these 
children are not able to clearly express their feelings of discomfort. Awareness of unusual 
behaviours as a potential sign of discomfort can help the parents, health professionals and 
school teachers to recognize symptoms and support the children to cope with their 
frustrations. In older children and adolescents, fatigue, pain, and other inconvenient symptoms 
may result in development of anxiety, depression or generalized somatic complaints. A focus 
and appropriate support for psychological symptoms and family distress are essential in the 
management of these complex diseases. 
 
4. Diagnostic evaluation 
The diagnoses of classical and hypermobile EDS are clinical diagnoses, based on the 
combination of a typical history with signs and symptoms as described above in table 18-1 
and 18-2, together with the core clinical findings: joint hypermobility (figure 18-1A, B and C) 
and soft, fragile and hyperextensible skin. Components of these two are always present but 
may vary considerably between individuals and the different types of EDS. In patients with 
vascular EDS loss of subcutaneous fat and skin symptoms are more prominent, whilst in 
kyphoscoliotic, arthrochalasia and dermatosparaxis EDS, hypotonia and motor developmental 
delay at very young age aside the cutaneous symptoms may alert physicians to start a 
diagnostic evaluation for a (inherited) connective tissue disorder. 
Musculoskeletal pain is a major problem in patients with significant hypermobility and joint 
effusions are common in those with recurrent dislocations or instability, especially of the 
ankles and knees. A family history of hypermobility is common in EDS.
1,2,3,4,5,7,8,40
 
 
In case the diagnosis EDS is suspected, additional investigations need to be done depending 
on the concomitant symptoms to exclude pathology in other organ systems, e.g. the heart. 
Children with EDS are at an increased risk for the presence of aortic dilatation or mitral valve 
prolapse.
41
 For most of the EDS types diagnostic tests are available, though not for 
hypermobile EDS and for around 10% of cases with classical EDS.
7,8
 (see chapter 2, 3 and 5) 
A comparison of the diagnostic criteria of classical and hypermobile EDS is shown in chapter 
2, 4 and 5. 
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Figure 18-1 Some features of EDS in children 
 
 
 
 
 
 
 
Hypermobility in arms, shoulders, fingers (A and B) and flat feet in a child (C) 
 
The diagnosis of generalized hypermobility is difficult to make in infants and young toddlers 
due to the general flexibility that all children possess. There are no specific tests to evaluate 
hypermobility in children or adolescents, therefore the Beighton and Bulbena scores are 
performed and rated as in adults.
26,42,43
 However, it is unclear whether these are the most 
appropriate measures and specific child based tests need to be developed. In addition to these 
A
B
C
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hypermobility tests, age specific tests are performed to evaluate motor development. At young 
age gross motor development is often delayed in the first 2 years, but normal development 
does not preclude the diagnosis. Thereafter, the results of the motor development test are 
generally normal but a discrepancy between the static (balance in stable position is normal) 
and dynamic balance (balance during activity is delayed) is often observed. In addition, 
children often perform poorly on other motor tasks such as ball skills. Poor handwriting may 
be related to pain rather than poor control. An example of a diagnostic evaluation procedure is 
provided in table 18-3. 
Recognition of the clinical signs and symptoms of EDS may prevent the burden of 
unnecessary investigations in children and adolescents. 
 
5. Management 
After taking a full history the referring professional should undertake a general physical 
examination, including assessment of movement and of the skin, and confirm the diagnosis, 
excluding differential diagnoses such as Marfan syndrome or cutis laxa syndromes.
5
 The 
pattern of difficulties, nature and severity of the problems should be established. With this 
information a treatment/educational support plan can be designed for the child and the family. 
Families, school, and if appropriate, employers need to be aware of the condition and 
appropriate emergency management. This tailored care should be based on the individual 
patients’ complaints and needs.
43
  
The first stage in treatment of children with classical and hypermobile EDS is the recognition 
that the symptoms are significant and relevant to the child, to discuss the diagnosis with the 
family, and to inform and reassure the parents and the child about the condition. The 
commonest triggers to see a doctor will be because of pain and/ or injury. A starting point is 
to explore with the family their current life style and the limitations and difficulties the 
complaints impose on the child in school and at home. This exploration also includes the 
limitation and restriction in activities the child’s fatigue imposes on the rest of the family. 
 
In order to support the family, it is necessary for them to recognise the pattern of difficulties 
in their child and to see what triggers (such as prolonged exercise, or writing and poor sitting 
position in class) additional pain for their child. Some children get into a chronic pain cycle 
and avoid movement in case of further injury.
17
 Providing a personal manual or diary for 
parents and the child to complete, allows them to map out symptoms and signs and to monitor 
their improvement or deterioration, and can allow the child to gain some control. The family 
can then see if there are triggers for injury or pain such as particular sporting activities in 
school or in the classroom. These observations can act as a focus for discussion with the 
physical therapist as well as the educational professionals in school where adjustments may 
need to be made. This can be useful also to monitor an exercise programme. 
 
In addition to above mentioned issues focus needs also to be given to specific considerations 
depending on EDS type and severity of involvement of the skin, joints and other organs. All 
patients should be aware of their skin fragility and take adequate measures to protect the skin 
and contact expert (plastic) surgeons when suturing of any wounds is needed. Surgical 
procedures must be as conservative as possible due to the complications which may arise 
when suturing of wounds is needed. In classical EDS, regular cardiology follow-up, including 
echocardiography, is recommended. In children with vascular EDS, specific information 
regarding life-threatening risks of blood vessel and organ rupture, which sometimes can occur 
already during childhood, needs to be provided. In children with kyphoscoliotic, 
arthrochalasia and dermatosparaxis EDS specific issues may arise because of the rarity of 
their disease and treatment of the symptoms of the individual patients may be complex.  
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5.1 Physical exercise 
Appropriate physical exercise can offer the child increasing confidence with his or her 
movements as well as improving motor co-ordination, core-stability and muscle strength.
43,44
 
However, some children may have given up for example ballet or gymnastics in the past 
because of increasing pain or injury; then discussion of the type of exercise they like and 
could do is needed. 
 
Discussion with the family is important to ensure that the child has opportunities to try out, 
sporting and leisure pursuits that he or she can participate in, and also to encourage social 
opportunities for integration to limit the risk of isolation. The child may be nervous of 
participating in sports in school in case of injury, but there remains a need to build muscle 
strength in order to attempt to prevent future damage. Parents may also be concerned about 
their child participating and may not encourage exercise, because of their fear of injuries. A 
psychologist may need to be involved to tease out the family dynamics, especially where for 
example both parent and child have symptoms and the child is mirroring the parent’s 
symptoms. 
 
A physiotherapist can advise the family about appropriate exercises in order to build up core 
stability in the child, muscle strength and stamina. Teaching the family how to build a gradual 
exercise programme balanced by rest and exercise is essential, whereas overuse can lead to 
complaints or injury. Specific home exercises using a ‘Swiss’ ball (a large ball that the child 
can sit and do other exercises on) at the correct size for the child can be used to improve core 
stability. Additionally, balance or wobble boards can be used. Sports such as swimming, 
yoga, Pilates, riding a bike and horse riding are also useful to improve stability and stamina. 
Taking part in sports with heavy joint strains such as contact sports, football, running and 
weight lifting needs to be discouraged because of increased chances for injuries. Care should 
be taken with contact sports, particularly when the child is hypermobile in the cervical spine 
(extension range 90º or more). Also knee injuries and finger injuries do occur more in contact 
sports and ball sports such as netball.
45,46
 Therefore individual non-contact activities are often 
recommended; however many children prefer team sports. There is evidence that where there 
is reduced exercise this may lead to reduced stamina and then this becomes a downward spiral 
leading to reducing function.
47
 
 
5.2 Feet and ankle support and propiocepsis training 
Assessment of gait is essential and where there are problems identified correction of the 
biomechanical abnormalities need to be made. Advice and guidance about footwear should be 
sought from an experienced podiatrist, and appropriate supports such as arch supports in in 
soles and heel cups should be considered where there is pes planus. Supportive footwear may 
be needed if ankles are unstable. By addressing the biomechanics, this can have a knock on 
effect on gait and position of the other joints and can reduce the hyperextension at the knees.
48
  
In children with frequent sprains, e.g. in ankles, the initial traumatic cartilage damage can lead 
to degenerative changes, especially if there is persistent or recurrent instability. Every further 
sprain has the potential to add new damage. There is reasonable evidence that immobilization 
is more effective at reducing the time taken to return to sports compared with surgery.
49,50
 The 
supports can be divided according to rigidity into elastic bandage, tape, lace-up ankle support, 
and semi-rigid ankle support. Functional treatment may involve strapping, bracing, use of an 
orthosis, tubigrips, bandages, elastic bandages, and the use of shoes fitted with support. In all 
prescribed shoe devices the fragility of the EDS skin has to be taken into account. 
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Some children with EDS show poor joint awareness and have e.g. frequent ankle sprains or 
recurrent hip or knee pain. Propiocepsis training, to enhance joint stability may reduce these 
complaints. Challenging propriocepsis by making use of unstable surfaces can lead to 
increased demands on trunk muscles, thereby improving core stability and balance.
47 
 
5.3 The school environment 
Adaptations may be required in school, especially when the child has poor handwriting or 
pain on prolonged writing or typing. Escalation of symptoms of hand or wrist pain may occur 
as the child moves through secondary school, as there is an increasing amount of handwritten 
or computer work for example. The child may be able to cope in the morning but have 
difficulties in the afternoon. Avoidance of writing and the use of alternative methods of 
written communication may need to be considered. Use of pen grips may take some of the 
pressure off, but some grips may act to further destabilise the handwriting and may not be 
very helpful. Advice from an Occupational Therapist can be beneficial to guide the teacher. 
Use of an angle board can aid support of the arm and improve positioning for the child and 
should be tried. 
 
Use of a roller ball mouse to minimise keyboard usage and a laptop or desktop computer can 
reduce the need for recording. In cases where there is continuing pain, speech to text software 
may be useful. Children may find they have increased back and neck pain if they are 
extensively working at a computer, and the table and chair are not at the correct height. 
Posture and positioning are essential to ensure that symptoms of neck and back pain are not 
exacerbated. An ergonomic assessment will consider table height, chair height, sitting depth 
and type of back and arm support. If the child is using a laptop then a laptop stand to position 
the laptop at the correct height may also be useful. 
The child’s position in the class may also be important. If the child has to turn excessively 
when copying from the board, it may be helpful if the child is facing the teacher where 
possible, so there is less rotation. 
Specific lessons may cause the student to have difficulty, such as balancing on stools in the 
science lab. Suitable seating should be considered to ensure stability. This should also be 
considered at home doing homework. 
The child travelling to and from school should only take with him or her the books needed for 
the homework, store the others in a locker and use a well-supported ‘back pack’ to carry the 
books needed at home to limit strain on any one particular joint and the back. Also the 
transportation to and from school needs attention whereas travelling can be very tiresome for 
the children thereby reducing the energy for the school activities. 
 
5.4 Psychosocial support 
Some children may have lowered self-esteem and confidence as they recognise they are 
different from their peers and they have limitations in participation in physical activities in 
school.
51
 In some cases the support from a psychologist using psycho-educational 
interventions such as cognitive-behavioural therapy can be a useful approach to limit the risk 
of depression and for the child to gain control over their pain and cope with the limitations in 
participation.
52
 Use of relaxation techniques can also help the child manage their pain.  
 
5.5 Physical support 
Local heat or cooling can have a temporary effect to reduce pain. The need to teach the child 
to pace their day and week is an important aspect of support; otherwise the child may over do 
activities one day with the consequence of not be able to do anything for several days after 
that because of fatigue and pain. Hydrotherapy can have a beneficial effect because of pain 
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relief from warm water, a safe environment to minimise risk of further trauma and can be 
used to work on multiple joints in a single session. The use of splints and braces have been 
advocated where there is pain and discomfort to provide a more functional position and to 
prevent potential further damage of joints.
53
 To avoid skin lacerations, young children with 
skin fragility can wear pads or bandages over the forehead, knees and shins to avoid skin 
tears. Older children can wear soccer pads or ski stockings with shin padding during activities 
to reduce bruises or skin problems.  
 
6. General considerations and future research  
Little work has been undertaken in educating the educators about this common condition in 
schools. Some children may have functional difficulties in school that are not addressed or 
may be mislabeled. Lack of awareness of the condition may result in less support than for 
more recognized learning difficulties such as Dyslexia or Developmental Co-ordination 
Disorder. Recognition, early diagnosis and appropriate management of the signs and 
symptoms of children with hypermobility syndromes will improve their quality of life, coping 
strategies and future perspectives.  
 
Areas of further investigation include strategies to standardize the classification and 
assessment of hypermobility syndromes such as age-specific tests. Further research into genes 
involved in tissue laxity and the impact of specific patterns of difficulties is important as well 
as the long-term follow-up outcome of musculoskeletal symptoms and associated symptoms 
in hypermobility disorders. In addition, there is a need to focus some attention on research 
into the effectiveness of therapeutic interventions in symptomatic hypermobile children and 
adolescents.  
 
7. Summary 
This chapter has highlighted the different presentations of a child with EDS and has 
demonstrated the different routes to diagnosis. Pain or injury may be a presenting symptom or 
the consequences of the physical difficulties spilling into education as difficulties in every day 
tasks such as writing or in participating in age appropriate physical activities. It also has 
shown the secondary but no less significant psychosocial consequences. Positive recognition 
and avoidance of unnecessary investigations are the first steps in the management of the 
children with hypermobility syndromes. It is important to take a holistic approach in 
supporting the child and planning to prevent injury. As the child moves into adolescence, it is 
essential that they have a good understanding of their condition and have a voice in their 
planning.   
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Table 18-1 Signs and symptoms of children with a hypermobility syndrome: classical and 
hypermobile EDS 
 
Presenting 
symptoms
3,4,
7,8,15,16,17
 
Clinical signs and 
symptoms 
Associated features and remarks 
Joint 
symptoms  
Recurrent knee, ankle 
and foot pain 
Occurs in the evening and at night, often waking 
the child from sleep, increases after unusual or 
intense activities
 Frequent falls, 
problems with gait and 
coordination 
Clumsiness, rigid movements, delay in motor 
development  
 Brief episodes of joint 
swelling 
Can occur after activities and resolve 
spontaneously within a few days 
 Clicky joints Irritating or painful clicking especially of the 
mandibular joints, hips, elbows, fingers, 
shoulders and spine
 Exercise-related pain Especially anterior knee pain. All exercise 
related pain occurs within 24 hours after 
activity. Some children experience pain directly 
after the exercise, others report pain in the late 
evening or morning thereafter. 
 Recurrent injuries 
related to sporting 
activities i.e. joint 
sprains 
Especially at the time where there is increased 
demand in training and frequency of 
competition 
 (Sub)luxation of joints Occurs most often in elbows, shoulders or hips
18
 Pain and fatigue in 
hand and wrist  
Interference with school activities such as 
handwriting
 Neck- or back pain Muscle spasm with lumbar lordosis, thoracic 
kyphosis, scoliosis or spondylolysis; acute pain 
may represent facet joint subluxation; wry neck 
or torticollis often occurs
19
 Temporomandibular 
joint dysfunction or 
abnormal dentition
20
Painful or (sub) luxation of temporomandibular 
joints. Headaches associated. 
 Pes planus In combination with valgus deformity of the 
ankles
 Joint stiffness Joint stiffness most often observed in the 
thoracolumbar region and after prolonged 
period of joint pain
Diffuse 
musculoskele
tal pain
7,8,16,21
 
Muscle pain  Sometimes development of a pain amplification 
syndrome  
 Pain at muscle 
insertion sites and 
bursa
Overuse often results in pain at the enthesis 
(continued on next page)  
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General 
symptoms 
Fatigue Unable to spend a day with activities 
appropriate for the age-group without periods of 
rest or relaxation
3,17, 22
 Sleep disturbance Difficulties getting to sleep because of pain
3,4
 Orthostatic 
intolerance, lower 
systemic blood 
pressure 
Abnormal hemodynamic response to prolonged 
supine or upright position
22,23
 
 Acrocyanosis or signs 
of vascular autonomic 
dysregulation 
Feel cold easily, light-headedness or 
discoloration of limbs related to changes in 
temperature or emotions
24,25
Skin 
symptoms
26
 
Hyperextensible and 
soft, velvety skin 
 
 Easy bruising Bruising may be thought by others to be a 
symptom of child abuse
 Slow tissue healing 
and widened atrophic 
scar formation 
 
 Pretibial varicosis and 
bruises  
 
 Molluscoid 
pseudotumors at 
pressure points 
Lumps of subcutaneous tissue at e.g. the elbows 
 Piezogenic papules on 
the heels 
Small soft tissue lumps that appear at the side of 
the heel when standing and disappear when foot 
is elevated
Cardiac 
symptoms
27
 
Aortic root dilatation  In EDS, in the absence of cardiac symptoms or a 
murmur, it is advised to measure the aortic root 
size by 5 years of age 
 Mitral or more seldom 
tricuspid valve 
prolapse 
Cardiac symptoms predominantly occur in EDS 
Gastro-
intestinal 
symptoms 
Nausea, abdominal 
pain, constipation, 
encopresis
3,28
 
Post prandial regurgitation, sphincter 
dysfunction 
Urinary tract 
symptoms 
Inguinal or umbilical 
hernia
26
 
 
 Recurrent urinary tract 
infection and enuresis
3
Sphincter dysfunction
29
 
The child with Ehlers-Danlos syndrome 265
 
 
Table 18-2 Signs and symptoms per age group in children with EDS  
 
Age group Signs and symptoms 
Newborn Congenital hip luxation or congenital hip dysplasia 
 Congenital clubfoot
30
 
 “Floppy infant syndrome” (congenital hypotonia)
10
  
 Feeding difficulties with low muscle tone  
 Hypermobility of joints (seldom apparent)  
 Skin soft and velvet-like, sometimes hyperextensible (lifelong)  
0-3 years Slight delay in development of major motor skills in the first 15 months, 
normalizing thereafter
31,32,33
  
 Pain in the legs at night 
3-6 years Recurrent pain in legs, ankles and feet, during walking and especially at 
night after a day with physical activities 
 Flat feet and pronation of the forefoot  
 Endorotation of the knees and feet with stumbling  
 Clumsiness and problems due to poor coordination 
 Reduced energy levels, inability to relate to activities of the age-group 
 Moodiness, “demanding” behaviour 
>6 years Problems with handwriting  
 Problems with school activities, sports 
> 9 years Problems with physical challenges in competition 
Adolescents Increase in back pain, increase in lumbar lordosis and thoracic kyphosis 
and scoliosis 
 Anterior knee pain 
 Pain in the hips 
 Spondylolysthesis
34
 
 Increasing difficulty coping with writing tasks 
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Table 18-3 Diagnostic evaluation form for use in clinical practice  
Milestones of motor development 
 Roll-over 
Crawl 
Stand alone  
Walk-supported 
Walk alone
5-6 Months 
6-10 Months  
9-12 Months  
10-15 Months  
10-16 Months  
Signs of generalized hypermobility syndromes 
 Hypermobility 
Hyperextensibility of the skin 
Easy bruising 
Hypertrophic skin scars 
(Sub)luxations 
Positive family history
Yes / no 
Yes / no 
Yes / no 
Yes / no 
Yes / no 
Yes / no 
Beighton hypermobility score*
26
 
Bulbena hypermobility score**
42
 
General evaluation 
 Motor development 
 
Muscle tone 
 
Muscle strength 
Delayed / according to 
age/ advanced 
Hypotonic / normotonic / 
hypertonic 
Decreased / normal / 
increased 
*  The Beighton score (see chapter 2) is used both in children and adults to assess 5 
different joint performances with a maximum score of 9. A total score of 5 is the 
minimum score defining joint generalized hypermobility. For hypermobile EDS, age and 
sex related cut-off points are used (see chapter 2, table 2-5). 
** For the Bulbena score (see chapter 2), a total score defining generalized hypermobility is 
≥ 4 in men/boys and ≥ 5 in women/girls. 
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1. Introduction 
Ethics is a branch of philosophy that involves thinking about human acts and asking questions 
about the moral rights and/or wrongs of those acts. There is no single theory of or approach to 
ethics. Ethical theories reflect the time and cultural setting in which they came into being. The 
approach one chooses has a great impact on one’s view about what is ethically right or wrong. 
In this chapter, the Ethics of Care will be the framework for reflecting on the ethical dilemmas 
related to living with generalised hypermobility or Ehlers-Danlos syndrome (EDS). Ethics of 
Care is an approach that focuses on the phenomenon of care. Care can be viewed as 
everything we do to maintain, sustain and repair our world so that we can live in it as well as 
possible.
1
 Ethics of Care focuses on the way people try to find out what is good in specific 
conditions and circumstances. It does not look for generalisation of normative standpoints, but 
focuses on the particularity of situations, is suspicious of power relationships with regard to 
dependent people, accepts vulnerability as a universal human characteristic and conceives 
human beings as inherently relational beings who need each other to be happy and to 
flourish.
2 
 
EDS confronts people with ethical problems that may be related to different life stages. In this 
chapter we will look at these dilemmas and try to find out if there are any opportunities 
related to that specific stage of life or to a specific personal character and how these can be 
found. This will empower people so that they can pursue ‘the good life, with and for others, in 
just institutions’.
3 
 
2.  Ethical dilemmas in parenthood 
The technological possibilities in our society have caused a tendency towards rationalisation. 
This is especially true for health care, which confronts people with dilemmas even before they 
give birth to their child(ren). If people want to have a child, they usually hope to give birth to 
a mentally and physically healthy child. People with EDS who wish to have children bear a 
special responsibility as the aetiology of EDS is genetic (see Box 19-1 for reproductive 
options for parents-to-be in case of a genetic disorder). They know they run a 50% risk of 
giving birth to a child with EDS, assuming the given EDS type is inherited in an autosomal 
dominant way. The child they will give birth to may (eventually) suffer from the same type of 
EDS, though the severity of the symptoms may vary. Furthermore, the child is at risk of 
losing its mother during or shortly after delivery if she suffers from vascular EDS.  

Box 19-1   Reproductive options for parents-to-be in case of a risk of having a child with a 
genetic disorder: 
- Acceptance of the risk 
- Refrain from having own children  
- Non-acceptance and prenatal diagnosis and termination of pregnancy when affected 
- Non-acceptance and pre-implantation genetic diagnosis 
- Non-acceptance and germ cell donation 
- Non-acceptance and adoption 
 
At the start of a life, people really do not want to think of this when it comes to their newborn 
child. But also if people suffer from an EDS type other than vascular EDS or from generalised 
hypermobility, the delivery of the child and taking care of it may still be problematic. People 
suffering from hypermobile EDS and generalised hypermobility usually have very mobile 
joints and ligaments. This may cause severe perinatal problems for the mother, like 
(sub)luxations. One of the problems of this EDS type is that the joint hypermobility may 
worsen due to the hormonal changes during pregnancy.
4
 This may cause more or less severe 
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problems for the mother, which may hinder her ability to take care of herself and her newborn 
child. Therefore the question may arise: why should people take those risks? Would it not be 
better for people to stop thinking about having a child if one of the parents is suffering from 
EDS? 
 
From an Ethics of Care perspective, questions like these do not make much sense. It is 
important to look at the situation from the perspective of the people involved in order to 
discover what is at stake for them.  There is a possibility parents do not even know that one 
of them has EDS. Patients are not always aware of having the syndrome, due to the wide 
variety of phenotypes and the varying degrees of severity. E.g. luxation of the shoulder joint, 
can happen to anyone. The same can be said about ligament distortion. This will only raise 
questions if it happens frequently and/or it happens also in close relatives. People may not be 
aware of the fragility of their body, especially when they do not take part in sports (very 
often), particularly if they suffer from mild EDS. Vascular EDS may be even more 
complicated: incidentally, people with vascular EDS hardly experience problems until they 
reach the age of 40. So, not infrequently, people have made their important life choices, such 
as having children, before they find out they are suffering from a type of EDS. In this case, 
the next generation will have to deal with the ethical dilemma of making a responsible choice, 
which may be a heavy burden. 
 
2.1 Motivations 
People suffering from EDS who nonetheless choose to give birth to a child, even though they 
are aware of the risks and consequences, mention a variety of reasons as to why they make 
this choice (see Box 19-2 for factors playing a role around these decisions).  
 
Box 19-2  Factors playing a role in deciding whether or not to have a child, when parents-
to-be are facing a risk of having a child with a genetic disorder: 
- Strength of their child wish 
- Magnitude of the risk 
- Severity of the genetic disorder 
- Family composition 
- Their ethical/religious norms and values 
- Acceptability of prenatal diagnosis and termination of pregnancy 
- Acceptability of pre-implantation genetic diagnosis 
- Acceptability of germ cell donation 
- Socio-economical context 
- Legal context 
 
One of these reasons is that they find themselves capable of living a meaningful life, so they 
expect their children if they also have EDS, to be able to do the same. According to them, 
thinking your child will not succeed in this, means you are raising it without hope or trust. 
According to this pessimistic point of view, no child would flourish, regardless of whether 
they have an illness or not. Parents also suppose that their knowledge of and experience with 
EDS will benefit in helping their child(ren) with EDS to create its/their own opportunities in 
life, better than non-EDS parents would be able to do. That could be one of the reasons why, 
although for most EDS types (not hypermobile EDS) prenatal diagnosis is possible, when the 
pathogenic mutations are known (see chapter 2), in our experience few parents-to-be, who are 
facing a risk of having a child with EDS, opt for prenatal diagnosis. 
They motivate their choice to become parents by pointing to the fact that all children are at 
risk of diseases and that people accept them as being unavoidable. ‘Why would I be so afraid 
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of a known risk?’ They say that they themselves, unlike most parents, are highly aware of the 
risks of starting a family, which allows them to be better prepared to handle certain 
consequences. The stories of these parents show their remarkable faith and acceptance of their 
limited abilities. 
There are also individuals with EDS who, when the woman is affected, decide that based on 
the many limitations in their daily life, pregnancy would be too much of a burden. Thus, there 
will also be parents who among others based on the magnitude of the risk to have an affected 
child, the severity of the EDS as they have or perceive it, decide to refrain from having own 
children. They still have some options (see above). Adopting a foster child is such an option, 
which of course is only available to those who are aware of their limitations and handicaps 
and have the emotional and physical strength to guide this foster child, who often has had a 
bad start in its life. Although the law does not prohibit irresponsible choices to reproduce, it 
can be difficult for EDS patients to persuade government institutions of their parental 
potential and to put parenthood into practice by becoming foster-parents. Difficult as it may 
be, it is possible and might be the best option in some situations. But there will also be parents 
who refrain from having children at all whether own or adopted based on their own situation 
and maybe other factors. 
2.2 Different norms and values 
Thus far, we have spoken of three different scenarios regarding impending parenthood. Each 
of these scenarios expresses various norms and values, which sometimes overlap. For those 
who take their own life as reference-point (the first scenario described above), equality is an 
important value. ‘Because life with its serious limitations is still valuable for me, it must be 
possible for our child to achieve the same.’ In that way, their life vision speaks of trust as an 
important value, and the fact that their child is not yet born does not make any difference to 
them. As well as equality and trust, there is in this scenario an acceptance of the vulnerability 
and imperfection of human life, which we all share to a certain extent. Being connected and 
related to one’s own child and sharing a life together is seen as being more important than 
giving birth to a perfect baby. 
For the second scenario, the parents take EDS as being one risk out of many. Equality is also 
important for them, but here this value is seen more as equality in life, understood as an 
experienced adventure, an adventure we share with every human being. In this belief system 
the awareness of the undeniable fact that life and its consequences are beyond the control of 
human beings, has been transformed in values like: ‘trust’, ‘hope’, ‘endurance’ and 
‘forbearance’. These all have to be earned along the path of life. For them, life, handicapped 
or not, is no more special than it is for other people. Also in this scenario, being connected 
and related to one’s own child and sharing a life together is seen as being more important than 
giving birth to a perfect baby. 
In the third scenario – the couple who will not give birth to a child themselves although they 
have a strong desire to have a child – the stress on rationality in autonomous decision-making 
is a central value. In this case, the values of ‘trust’ and ‘hope’ do not temper the awareness of 
their limitations. They are aware of their burdens and their reduced load capacity and make 
the decision that it would be wiser not to overload themselves by going through a 
pregnancy/delivery with all the short and long-term complications. Some of these people 
experience severe limitations in their daily life and they do not want to be responsible for 
knowingly creating the same life circumstances for their own child. Trust and hope may be 
valued by them, but these values are expressed in their opinion that their lives will be of value 
even if their wish of a child of their own is not fulfilled. They trust that they will come to a 
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point where they have overcome the grieving for their unfulfilled wish and can have a new 
life framework without a child of their own, maybe in the role of foster-parents. 
We have seen that values differ and that, even if values seem similar at first glance, they 
express different belief systems. Here we do not cling on to right or wrong along the lines of 
one specific ethical theory of human life. People make their own choices, seen in our western 
society as the expression of autonomy, a very – perhaps even the most – important value. But 
does that imply that there is nothing we can say about the three stories? Can we perhaps learn 
something from the experiences of others? 
2.3 Risks and problems 
Let us think of the risks or problems that may easily be overlooked in these stories. Our first 
group of parents experiences life as meaningful and worthwhile, irrespective of its limitations. 
Can they really think about their newborn child dispassionately? Will this child be allowed to 
be angry about living with a handicapped father or mother and will it be allowed to conceive 
life , as a worst case scenario, as unbearable and hopeless if itself is handicapped too? Will 
these parents be able to handle this reaction of their child, recognising it as a phase which they 
have already had to struggle through themselves and which their child can also overcome with 
their love and help? Or are these parents in denial of their own feelings about their limitations, 
expecting that their child will develop the same denial? Are they afraid of their own jealousy 
which is connected with life itself, and even more so if they are handicapped themselves and 
have to deal with seeing other people dancing, running and not always struggling with a lack 
of energy and with pain? If this is the case, their values would operate as a shield against their 
indigested psychological distress about their illness. It will be very difficult for them to guide 
their child through the phase of mourning, because their child might be dealing with its 
handicaps by mourning actively instead of denying its feelings like its parents do. 
Life is uncontrollable for the second group of parents, so they can set the EDS to one side. 
Although their lifestyle can foster their child’s inner powers to behave just like others and not 
to mystify a handicapped life, this child stays at risk of carrying too heavy a burden. ‘You are 
like everyone else so don’t worry and get a life’ A child in this position might not only 
compensate but take the risk of overcompensation, preferring short term gains over long term 
benefit. Children with EDS can often do the same things as other children of their age but 
they may be physically hurt easily, because their condition makes them easily tired, their 
joints are so flexible and their skin so fragile. Once hurt, they will have to rest. This rest 
reduces muscle power, which in turn heightens the risk of new lesions. So, in a short time 
they might become imprisoned in a vicious circle that can easily convert into a downwards 
spiral.  
As said earlier, people may be unaware of their own genetic problem until labour and/or after 
the birth of their affected child. Sometimes the baby is a typical ‘floppy child’. There is little 
or no muscle tone. In the worst case, the child will never start crawling. However, eventually 
most of these children will succeed in crawling and walking, although often later than other 
children of similar age. Depending on the type of EDS, parents must be aware of different 
problems. If it is EDS with skin problems, like in classical EDS, they will need to be very 
careful with everything which puts the child at risk of skin damage. Their child can do fewer 
of the things a normal healthy child would do and which will give great joy, like bumping, 
crawling, jumping and running around wildly. These active explorations will readily lead to 
first aid in a hospital, with a nasty open wound and the possibility of a need for plastic 
surgery.  
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These physical wounds are visible but, again , it is the job of the parents to choose between 
the risk of physical wounds and the risk of psychological wounds or emotional damage to the 
child. Children do not like special treatment and normally they want to play without getting 
into too much trouble, so it is up to the parents to find a balance between the pro and cons. 
A child with spontaneous joint dislocations or luxations needs a lot of guidance to optimise its 
muscle power and proprioception. Sometimes, guiding this process will demand so much of 
the parents’ energy and medical knowledge that they are forced to make a difficult choice 
between regular and special school education. Do you have to train your child as much as you 
can, while without this, it can play with children who are also limited in their play by their 
own physical problems? And do you hope that, with this stable physical and mental basis, 
your child will develop into a strong and assertive adult? Or does it work the other way 
around? Is it better to opt to treat the child as being as ‘normal’ as possible, which would 
mean letting it grow up among fully physically able children so that it can learn to survive 
from the beginning in a world that is often not well adapted and even not accessible to the 
disabled?  
There are arguments for both ways of reasoning. The most important thing, however, is not to 
idealise a certain vision or to try and find universal rules. Instead of looking at the impact of 
the illness on daily life, we have to consider carefully the possibilities and limitations of the 
specific child. A very social and outgoing child will survive more easily in an unadapted 
environment, or one with few adaptations, than a more introvert child.  
Another very important factor is how much the parents can bear. A child at regular school 
needs a lot more guidance and support, improvisation (e.g. a resting place at school and 
planning of medical visits), and explanations to teachers and other children than healthy 
pupils do. Physiotherapy and adaptation of braces and other medical equipment (like a 
wheelchair, if necessary, and so on) require visits that have to take place after school. 
Children grow quickly during their school years, so the necessary changes in medical 
equipment often seem endless, and so do the bureaucratic procedures stemming from these 
changes.  
Apart from this, the role of a parent is also burdensome for another reason. When your child is 
easily wounded or has a lot of spontaneous dislocations that require medical treatment, the 
frequent visits to the emergency department of the hospital can start to raise suspicions, not 
least about the parents themselves. And to make it worse, parents can become suspects of 
child abuse, not just in hospital but also at school. Although it will not take away the 
suspicions at the emergency department, such suspicions can make life much more difficult 
and encourage a choice for a special school. 

3. Living a (good) life with EDS 
According to an influential definition by Joan Tronto and Berenice Fischer, “caring can be 
viewed as a species activity that includes everything we do to maintain, continue and repair 
our world so that we can live in it as well as possible. That world includes our bodies, 
ourselves, and our environment, all of which we seek to interweave in a complex life-
sustaining web”.
1
 The healthier and richer people are, the less time they will be forced to 
spend on caring for themselves and the more they can get others to care for them, up to what 
Tronto has called ‘privileged irresponsibility’.
1
 People suffering from EDS are not among 
those privileged irresponsibles as we have seen in the previous section. Being confronted with 
EDS means being called to care for oneself and being responsible for those who are part of 
one’s complex life-sustaining web. 
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This life of care – for oneself and others – is an ethical enterprise through and through. Ethics 
is not an activity we only need when the course of normal life is hindered by unexpected 
problems or dilemmas. The ethical intention aims for “the good life, with and for others, in 
just institutions”.
3
 This good life is nothing other than a happy life; happiness being not just a 
feeling or sensation of wellbeing, but a flourishing of one’s capacities and possibilities. This 
search for happiness is a social activity – hence with and for others – within the context of a 
society that is built on structures that transcend and contain relationships among individuals – 
hence the “just institutions”. For instance, people with EDS can still flourish in their 
professions, experiencing their professional work as an important aspect of living a 
meaningful life, while at the same time they have to be looked after by a nurse in their daily 
lives. It all depends on the balance between the strengths and weaknesses of the patients and 
the willingness of the social system around them, whether this is possible or not. 
When we look at ethics in this way, a new perspective opens up. Underneath the moral 
dilemmas related to the choice by people suffering from EDS to have children or not, we see 
people struggling to lead a good and happy life in a society that is not ready to accept the 
vulnerability of human existence. This struggle is hallmarked by practices of caring for one’s 
fragile body and for those who are helping one to sustain a life with EDS. From this ethical 
and caring perspective, people living with EDS are entitled to ask some critical questions to 
the society they live in and about how their care is organised. 
3.1 Holistic approach 
A main critical question raised by people who live with EDS pertains to the tension between 
general and specialist medicine. Human existence has many dimensions – physical, psycho-
social and spiritual – that are intrinsically related and together form what we describe as a 
human being. Medicine, however, still focuses on diseases and syndromes rather than on 
beings.
5
 In the case of EDS, this means that patients are often treated by many different care-
givers, many of whom are specialists. Even though this division of care into specialisms may 
be understandable from the perspective of professional caregivers, from the patient’s 
perspective it leads to a reductionist approach, which is time-consuming and adds extra 
burdens to lives that are already burdened by so many inconveniencies. 
The fact that we have organised care as it is now, and the ever-increasing specialisation in 
medical science, are not facts of nature. They are the result of human action and have an 
ethical dimension. In fact, they are the result of medical power which is so accepted and self-
evident in our culture that it often hinders our capacity to look at things differently. Adopting 
a patient’s perspective would do more justice to the person who is at the centre of care: the 
person suffering from EDS who is not an object to be looked after but a human individual 
who is both being cared for and caring. A holistic approach would not only entail an approach 
in which not only the physical, psycho-social and spiritual dimensions are integrated, but also 
an approach in which the patient is co-carer and involved in shared decision making. At the 
same time it would make sense to appoint a consultant medical specialist – one who is 
familiar with EDS – as a case-manager to help streamlining the medical processes. 
3.2 Vulnerability 
EDS like any disease can confront us with the vulnerability of human existence. This 
vulnerability is one of the things our society has great problems with, since it is associated 
with an unpleasant and unhappy life. The cases we have described above show that, even in 
vulnerable positions, people often find possibilities of developing resilience and an art of 
living with fragility that will open up new horizons. Confronting EDS thus questions many 
“self-evident” suppositions. It helps us to see that life can still be worth living, even if it is 
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compromised by the prospects of increasing morbidity and fragility. Instead of fighting and/or 
hiding vulnerability, vulnerability may be accepted as a fact of life which is helpful in 
overcoming self-centeredness and isolation. It forces us to reach out to our environment and 
share our humanity. This is the very essence of the relationships and friendships that help us 
to experience life as a meaningful enterprise.  
3.3 Dependency 
People who are faced with EDS can be confronted with their own dependency. Living with 
EDS increasingly means accepting that you need other people to make (social) life possible. 
That means that people living with EDS are forced into developing a new sense of autonomy. 
The concept of liberal autonomy as a value according to which people get to lead their lives 
how they want to (related to the privileged irresponsibility mentioned above) is redefined into 
a more realistic kind of relational autonomy. It is still the individual person to whom justice 
must be done, by granting them the maximum of space and freedom. But this space and 
freedom is constituted by the relational network of people around the patient. EDS affects not 
only the life of the person suffering from the disease, but also the lives of all those people who 
are related to and sustaining that person in a web of relations. 
The need for a holistic approach, dependency and vulnerability reveal dimensions of human 
existence that are present in every life, but come to the fore more clearly in the case of EDS. 
In this way, confronting EDS is confronting aspects of life that our culture often hides or 
denies or classifies as being confined to the elderly. Patients with EDS can live like the 
elderly for a very long time – even for decades – and, because of the burden that this can 
impose, not all patients wish to live to a great age. Non-treatment decisions or a desire for 
euthanasia can materialise and must be treated with care and compassion. However, the Ethics 
of Care perspective can help reveal these aspects and encourage ethical reflection. This 
reflection is not just needed when moral dilemmas are at stake or emerge. Ethical reflection 
should begin at the very moment we start thinking about care. In this way ethical reflection 
can help to develop a richer and more diverse view on living a meaningful life. People 
suffering from EDS, their next of kin and their caregivers would benefit from such a reservoir 
of meaning. 
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1. Case: Michelle  
Michelle is 34 years of age. She was raised in a farming family and had a generally positive 
and supportive childhood. At the age of 18, she moved to the city to attend university. For the 
past ten years, she has been happily married and has 2 young daughters. She has long realized 
that she has very flexible joints, and she regularly dislocated her fingers, but she was not that 
concerned and did not consider it to be a disorder. Two years ago, however, her situation 
worsened when she dislocated her shoulder while playing tennis, and the subsequent 
operation left her with various complications. The surgeon referred her to other specialists, 
and while still in the hospital, Michelle was diagnosed with Ehlers-Danlos syndrome (EDS). 
She was mostly pleased to learn of this diagnosis, because it explained her frail joints as well 
as the pain and fatigue that had been interfering with her functioning at home and work during 
the past few years. These symptoms had been invisible, but now others could understand why 
she had not been feeling well or functioning optimally. Michelle also was thankful that the 
hospital physiotherapist helped her learn to use her joints in the appropriate way and manage 
dislocations. 
Lately, however, Michelle has become somewhat depressed and worried. She has come to 
realize that having this disease could greatly change her life. Although she has many abilities 
and loves her work, she fears that she will not be able to fulfil her high ambitions. She had 
always been able to hike in the mountains while on holiday, but this has become more 
difficult, and in the near future, she expects that she will no longer be able to walk even the 
easy trails. She needs to change so many things and is anxious that her condition will become 
dramatically worse in the future. She is also worried that her children have EDS and she needs 
to remind herself to avoid raising them too cautiously or fearfully. Although she expects that 
her optimistic nature will finally help her to deal with the consequences of EDS, a 
psychologist might help her with her current negative mood, and she is considering seeking 
cognitive-behavioural therapy. 
 
2. Introduction 
Connective tissues maintain normal bodily integrity, but when connective tissues fail in this 
role, multiple problems occur. EDS is a heterogeneous group of heritable connective tissue 
disorders characterized by articular hypermobility, skin extensibility, and tissue fragility.
1
 
This disorder is chronic, varies in severity from mild to very serious, and can be lethal. 
Hypermobility syndromes featuring joints that easily move beyond the normal range expected 
for a particular joint, are a threat to well-being and functioning. What is said about EDS in 
this chapter mostly applies to hypermobility syndromes as well.  
Recently, the two conditions benign joint hypermobility syndrome (BJHS) and EDS 
hypermobility type have been recognized as one and the same clinical spectrum ranging from 
apparently symptomatic generalized joint hypermobility to the most disabled individuals 
fitting the new diagnostic criteria. These new criteria are more strict than the Villefranche 
criteria and the Brighton criteria for BJHS in order to define a homogeneous phenotype for 
management and scientific purposes. Within the new EDS nosology, its name is hypermobile 
EDS (see chapters 2 and 5).  
 
2.1 Burden of EDS 
The psychosocial burden of EDS is substantial
2-4
, and can be summarized by the central 
theme of “living a restricted life”.
5
  
First, EDS is a relatively rare condition, which means that the diagnostic process is often 
protracted and confusing, and that healthcare providers often have insufficient knowledge of 
the medical problems and the possibilities for treatment and care. 
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Second, people with EDS have fewer opportunities in daily life than healthy people. For 
example, pain, fatigue and other symptoms hamper functioning, and people with EDS may 
fear articular dislocations or skin damage, which further limits activities.  
Third, patients may experience invalidation, or stigmatization and lack of understanding from 
family and friends, health care providers, co-workers and others in daily life.  
Finally, given the heritable nature of EDS, the pros and cons of parenthood are often 
evaluated, and decisions to refrain from childbearing can be highly disappointing.  
Psychological evaluations and interventions for patients as well as their families are vital to 
help them cope effectively with this disorder.
6
 Self-care, counselling and therapy are directed 
at both the prevention and treatment of adverse consequences. Because most bodily organs 
have connective tissue potentially affected by EDS, multiple bodily system problems can 
occur, and virtually all medical and allied disciplines play a role in education and treatment.  
 
2.2 Aim  
The aim of this chapter is to review the somatic and psychosocial consequences of EDS; that 
is, the effects of EDS on physical, psychological, and social well-being and functioning. 
Somatic problems, psychological distress, and social functioning are reviewed, and 
suggestions for coping with these problems in everyday life are given. We base our discussion 
and recommendations on the relatively few empirical articles on psychosocial functioning in 
EDS, supplemented by our knowledge of experiences of individual patients, and our 
knowledge of the somatic, emotional, and social consequences of chronic disease more 
generally. 
 
3. Somatic problems 
In a Swedish survey using the Subjective Health Complaint Inventory (SHCI), 99% of 250 
participants with EDS reported health complaints with a mean number of sixteen complaints 
for the whole sample.
7
 The somatic problems reported most often were musculoskeletal by 
246 (98%), pseudoneurological by 241 (96%), gastrointestinal by 236 (94%), allergic by 182 
(73%) and influenza-like by 144 (58%) persons. These specific somatic problems as well as 
those of vascular EDS are discussed in other chapters of the book. In the current chapter, pain, 
fatigue, joint dislocations, fragile skin, and sleeping problems are discussed. 
 
3.1 Pain 
In a questionnaire survey of 41 patients with EDS, 63% of the patients reported relatively 
elevated pain (above the scale mid-point), and only two patients reported having no pain.
8
 
Another study used structured interviews of 51 patients with EDS and found that 90% 
experienced pain for at least six months.
9
 In a larger questionnaire study among 250 patients 
(contacted through the Dutch patient association for EDS), pain during the past week was 
reported on a 0 to 100 mm visual analogue scale (VAS), 100 being the maximal level of pain: 
29% of the patients reported pain between 0 and 25, 24 % between 25 and 50, 28% between 
50 and 75, and 18% between 75 and 100.
2
 Of this sample, 41% reported chronic, widespread 
pain; that is, pain existing for more than three months in the upper and lower, left and right, 
and axial parts (i.e. spine) of the body. Of the respondents, 55% commonly used analgesics—
mostly paracetamol (acetaminophen), non-steroidal anti-inflammatory agents, and tramadol. 
One study found that pain is more prevalent and severe in hypermobile EDS than in classical 
EDS, and that pain is associated with hypermobility, joint dislocations, previous surgery, poor 
sleeping quality, and functional impairment in daily life.
10 
Thus, pain clearly is a prevalent problem in EDS, and has consequences for well-being and 
functioning. Reduced well-being and functioning, in turn, may contribute to the persistence 
and severity of pain. Education and self-management techniques likely can help to address 
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relatively low levels of pain, but more serious pain should be treated in cognitive-behavioural 
therapy (for explanation, see Box 20-1) and physical rehabilitation programmes. Such therapy 
is especially indicated if pharmacological treatment is ineffective to deal with pain and its 
consequences. 
 
Box 20-1 Cognitive-behavioural therapy 
A main premise of cognitive-behavioural therapy is that negative, dysfunctional thoughts 
have a perpetuating role in health problems, and that people need to learn skills or 
techniques to change their thoughts and feelings. Cognitive-behavioural therapy is directed 
at reduction of symptoms like depression, anxiety, pain, and physiological responses by 
changing maladaptive thoughts and actions. Examples are interventions with one specific 
aim—for example, relaxation, stress reduction or overcoming of fear-avoidance beliefs to 
support an exercise intervention and, more commonly, the incorporation of various 
methods—for example, cognitive restructuring of dysfunctional beliefs or “worry” 
thoughts, pain coping skills training, activity pacing, stress management training, relaxation 
exercises, exposure to anxious situations, thoughts and worries, and positive self-talk. 
 
3.2 Fatigue 
The survey of Dutch patients with EDS asked respondents to note the five most serious 
symptoms or problems of EDS.
2
 Fatigue (64%), pain (54%), skin fragility (33%), and 
problems with the back (29%), wrist, hand, and fingers (27%) were mentioned most 
frequently. It is striking that so many patients reported fatigue among their five most serious 
problems. This survey also compared general fatigue scores in 250 patients with EDS to those 
of healthy people from the general population using the Multidimensional Fatigue Index.
11
 
The occurrence of ‘general fatigue’ above a specified cut-off point was five times larger for 
patients with EDS than for people in the general population.
2
 A similar survey of 274 Dutch 
patients with EDS, which was conducted five years later in the same population, found that 
77% of the patients reported severe fatigue as compared to 11% and 17% in two 
predominantly female samples of the Dutch general population.
12
  
One possible way to address the elevated fatigue experienced by so many patients with EDS 
is to identify specific patient and disease characteristics that contribute to fatigue, and to 
change targeted lifestyle behaviours. For example, it has been proposed that aerobic fitness or 
strength training to deal with muscle weakness, or using weight management techniques to 
reduce obesity to treat sleeping apnoea, might be useful approaches to reduce fatigue in joint 
hypermobility syndromes.
13
 Unfortunately, the physiological origins of chronic fatigue are 
unknown, and there are no effective pharmacological treatments. Thus, although fatigue is 
indisputably an adverse consequence of EDS, it is most sensible to consider behavioural 
means, such as life-style adjustment and cognitive-behavioural, physical exercise, and sleep 
hygiene interventions.
14
  
However, the effects of such behavioural interventions have not been investigated in EDS. 
Caution is needed; for example, physical exercise programmes need to take account of 
possible joint dislocations as potential complicating factors. Moreover, to enhance their sense 
of vitality, patients will need to find a balance between physical effort and rest. Some patients 
may avoid all physical exercise to prevent pain and fatigue, but this will promote physical 
deconditioning. Other patients may persist in exercising despite pain and fatigue and stop only 
when pain or fatigue are extreme. However, this may over time result in dramatically reduced 
physical activity, as stopping exercise is stimulated because it takes away pain. Often a 
gradual build-up of the intensity of physical activity is important to prevent relapse. As in 
other chronic symptomatic conditions, activity-rest cycling can be valuable, with patients 
finding the optimal timing of activity and rest. A predetermined activity duration—rather than 
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pain or fatigue—should determine the timing of the rest-activity cycle. More generally, some 
patients will need encouragement to exercise, whereas others will need to learn to stop 
exercising in time.  
  
3.3 Joint dislocations 
In some forms of EDS, from 90 to 100% of the patients, report hypermobility of the joints
15
, 
but the severity of joint problems differs considerably among individuals and EDS types. 
Joint problems hamper work, sports, and many other important daily activities. Patients need 
to find an optimal balance between living passively to avoid joint dislocations and a more 
active - but risky - lifestyle, which can trigger joint dislocations. The challenge for patients is 
to learn to use their body without pushing their joints beyond their limits. Most patients learn 
this through trial and error. It is important that patients do not avoid physical activity, but 
instead use assistive technology, adaptations at home and at work, and aids such as braces and 
appropriate shoes to remain physically active. Fellow patients, rehabilitation physicians, and 
occupational therapists can help the patient to find adjustments that help in optimal 
functioning.  
 
3.4 Fragile skin 
Fragile skin is a problem in 40% (hypermobility EDS) to 100% (classical EDS) of the patients 
with EDS.
15
 Wound healing may be problematic, and wide, ugly scars may result. Our society 
values beautiful skin, and physical appearance is important not only for self-esteem but also 
for interpersonal communication, especially first contacts. Patients can try to prevent skin 
damage by wearing appropriate clothes and by avoiding risky situations. In case of wounds, 
appropriate care is important. In serious cases, wound care nurses, dermatologists, or plastic 
and reconstructive surgeons can be helpful.  
 
3.5 Sleeping problems 
The prevalence of sleeping problems in EDS has rarely been studied. In a small sample of 
nine patients with EDS, five reported sleeping problems, and six reported periodic limb 
movements.
16
 In contrast to this seemingly high prevalence, the Dutch survey of 250 patients 
found that only 4% reported sleeping problems as among their top five most common 
problems, but this report is likely biased by the method of requiring patients to pick a 
maximum of five major problems.
2
  
Potential sleeping problems should be assessed in patients, and if present, differential 
diagnosis of the aetiology of the problem should be pursued, because treatment for sleeping 
problems should preferably be aimed at the cause. In the differential diagnosis, sleeping 
apnoea has to be taken into consideration, because as soft tissues weaken by becoming older, 
especially in EDS patients sleeping apnoea can become an extra problem.  
Sleeping medication is generally not recommended for patients with EDS because of the 
resulting muscle relaxation and the ensuing increased risk of joint dislocations. Insomnia can 
be treated with stimulus control therapy, relaxation training, and cognitive-behavioural 
therapy.
17
 Such interventions may include techniques such as avoiding the consumption of 
coffee, alcohol, and heavy meals within several hours before sleep; making the bedroom dark, 
comfortable, and quiet; using the bed only to sleep (and for sex), thus not for reading and 
watching TV; having a regular pattern of effort and rest throughout the day as well as a fixed 
sleeping time; and - if needed - using stress-reduction, relaxation or thought-stopping 
techniques. Insomnia can also be treated with sleep restriction therapy, which reduces the 
patient’s time in bed to the total number of hours of sleep that is being obtained, and forces 
patients to be up and out of bed when not sleeping; as sleep efficiency increases, the sleep 
period can be lengthened.  
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4. Psychological well-being 
Psychological well-being is a core indicator of quality of life. The severity of one’s disease 
influences psychological well-being, but it is only one factor, and the relationship between 
disease severity and well-being is weak in most chronic diseases.
18
 Coping, resilience, 
emotional and social factors play larger roles in adaptation and well-being.  
 
4.1 Emotional consequences 
Negative emotional consequences of living with EDS are common. Interviews show that 
some people with EDS live with constant fear of skin damage, physical deterioration because 
of hypermobility, unemployment, and problematic pregnancies.
5
 Patients with joint 
hypermobility syndrome present with greater prevalence of panic disorder and 
agoraphobia.
19,20
 Parents who have children with EDS, live with the fear that authorities, 
medical personnel, or others will suspect them of bad parenting or abuse when their child 
presents with a joint dislocation or bleeding
21
, and even if no accusation are made, parents 
may still sense suspicion.
5
 Another problem mentioned in interviews is the reduced possibility 
of developing one’s abilities.
5
 The great effort needed to achieve something substantial in 
education or work is often not possible in case of EDS. This especially holds for people with 
vascular EDS who often know at a young age that, although new medication has improved the 
prognosis, their life expectancy is shortened, which has implications for important life choices 
in education, work and family planning; and can impede life satisfaction. 
A questionnaire study of 41 patients with EDS from North America found that anxiety, 
depression, anger and relationship worries were quite high.
8
 Indeed, these problems were seen 
three to four times more frequent than among the general population. Interviews of these 
patients revealed that patients attributed their emotional problems to chronic pain, impaired 
task performance, reduced social contacts, sexual problems, worries about having children, 
and frustration with the medical system. Of the 41 patients, 56% had had psychotherapy, and 
46% (had) used antidepressants or anxiolytics. These estimates of emotional difficulties in 
EDS may be relatively high, probably because this sample was recruited for a special research 
study that likely attracted very motivated or distressed patients from across the continent. 
The Dutch survey showed less emotional disturbances among people with EDS than did the 
North American study. In analyses using the RAND SF-36 questionnaire, the cut-off defining 
unhealthy functioning was set at the 10th percentile of functioning of the general population.
2
 
According to this admittedly arbitrary criterion, 10% of the general population shows poor 
functioning on a dimension of quality of life. Among patients with EDS, the percentage of 
poor functioning on emotional well-being was 18%, whereas 30% reported experiencing role 
problems secondary to emotional disturbances (figure 20-1). Overall, the risk of poor 
emotional well-being was twice as high as normal.  
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Figure 20-1 The percentage of 250 patients with Ehlers-Danlos syndrome having a low score 
on eight aspects of quality of life * 
Role limitations due to emotional problems
Emotional well-being
Energy/fatigue
Pain
General health
Role limitation due to physical health
Social functioning
Physical functioning
percentage in general population: 10 %
75 %
50 %
71 %
29 %
18 %
48 %
61 %
60 %
 
* The criterion for a low score was set at the 10th percentile of the general population. 
According to this criterion, 10% of the Dutch population obtains a low score on the RAND 
SF-36 questionnaire.
46 
 
4.1.1 Depression  
This Dutch survey also included the Zung Self-rating Depression Scale.
22
 The scores were 
compared with scores of a healthy control group (although this is not reflective of the general 
population, because patients with a chronic disease were purposely excluded). As compared 
to this healthy group, 48% of the patients with EDS were classified as having a depressive 
mood if the 10th percentile of the control group was taken as cut-off criterion. 
The approach to treating depression should depend on its severity. Antidepressant 
medications and more extensive psychological therapies, such as long-term cognitive-
behavioural therapy, are recommended to treat depression after simpler methods (e.g., guided 
self-help or exercise) have failed to produce adequate responses. Combining pharmacotherapy 
with evidence-based psychotherapy typically provides a modest increment over either 
treatment alone.
23,24
 In both severe and mild depression, mental health specialists, particularly 
clinical psychologists and psychotherapists, should provide cognitive-behavioural or 
interpersonal psychotherapy to prevent relapse or recurrence.
23,25,26 
 
4.1.2 Anxiety  
For patients with elevated anxiety, selective serotonin reuptake inhibitors (SSRIs) generally 
are the most common pharmacological treatment.
27
 Of the non-pharmacological therapies 
available, cognitive–behavioural therapy is the preferred first-line treatment for anxiety 
disorders.
28
 This approach employs a variety of techniques including cognitive restructuring, 
exposure to anxiety-generating stimuli, and behavioural experiments.
29
 The rationale behind 
cognitive restructuring is that intense, persistent negative emotions (including anxiety) and 
maladaptive coping behaviours (e.g. avoidance or safety-seeking behaviours) follow from 
how these situations and events are appraised or perceived. Accordingly, to alleviate 
emotional suffering and foster constructive coping, it is important to: (a) identify the 
maladaptive cognitions that underlie a person’s anxiety in particular situations and 
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circumstances; (b) examine the validity and utility of these cognitions; and (c) change these 
cognitions into those that are less anxiety-generating and that facilitate rather than block 
constructive action. In the treatment of panic symptoms, for example, cognitive restructuring 
is often targeted at altering catastrophic misinterpretations of benign bodily symptoms, which 
the patient otherwise appraises as dangerous. Likewise, in a person with social anxiety, 
restructuring could focus on excessively negative inferences about how one appears to 
others.
30 
 
4.2 Coping 
Chronic illnesses such as EDS are often accompanied by a helpless or passive stance by 
patients, who feel unable to influence or master their well-being. Helplessness is often 
expressed in global negative beliefs such as “because of my illness, I miss the things I like to 
do most,” “my illness controls my life,” and “my illness prevents me from doing what I really 
like to do”.
31
 These thoughts are often automatic in response to one’s illness and negative 
events. Such helplessness and avoidance of attempts to influence outcomes not only 
contribute to suffering but also increase the risk of anxiety and depression. 
In contrast, effective coping affects the impact that EDS has on psychological well-being. 
Some research of coping and related constructs with EDS has been conducted. Psychological 
well-being is increased in people who demonstrate either acceptance or a sense of 
coherence.
32
 The latter refers to having confidence that bodily reactions as well as 
environmental stressors are predictable, and that one can handle the negative consequences of 
these stimuli. In general, low helplessness and high acceptance reflect that a patient is able to 
deal with the consequences of a chronic disease.
31
  
For helplessness and negative automatic thoughts, cognitive-behavioural therapy (Box 20-1) 
can help in recognizing, discussing, and restructuring of these thoughts, setting of goals, and 
practicing steps to reach these goals. The dual-process coping model stresses the fit between 
characteristics of the situation and the specific coping strategy used.
33
 The restructuring of 
cognitions and behaviour can help to deal with situations that can be changed, whereas 
acceptance of the inevitable consequences of the disease needs to be part of patients’ coping 
repertoire to deal with situations that cannot be changed. The ideal response of a patient is to 
use both assimilative ways of coping (i.e. active attempts to alter an unsatisfactory situation in 
a way that fits personal goals and aspirations) and accommodative ways of coping (i.e. the 
adjustment of personal goals and aspirations to current situational limitations in order to 
accept the situation or interpret the given situation less negatively). Such an approach will 
help the patient to change life circumstances as needed while maintaining a satisfying life 
perspective.  
In recent years, mindfulness-based stress reduction therapy and acceptance-based therapies 
have been applied in the treatment of mental problems that may accompany chronic 
diseases.
34
 These therapies add mindfulness and acceptance to traditional cognitive-
behavioural techniques. Mindfulness meditation focuses on becoming aware and accepting all 
thoughts, feelings, and sensations instead of trying to avoid or fight them. Reviews have 
found statistically significant, small to moderate effects of mindfulness-based therapies on 
psychological distress, pain, and coping behaviour.
35-37
 Integrated mindfulness and cognitive-
behavioural therapy may enhance the treatment efficacy.
35 
Traditionally, psychologists and other mental health providers have focused on patients who 
were unable to adequately adjust to the consequences of chronic diseases. In recent years, the 
emphasis on the reasons why people fail to achieve a healthy adjustment has shifted to the 
identification of factors that help patients make that adjustment. To promote psychological 
adjustment, patients with chronic diseases are encouraged to remain active, to acknowledge 
and express their emotions in a way that allows them to take control of their lives, to engage 
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in self-management, and to focus on potential positive outcomes of their illness.
38
 Patients 
who use these strategies have the best chance of successfully adjusting to the challenges 
posed by a chronic illness like EDS. 
 
5. Social functioning  
Support from friends and family is potentially an important influence on how well people 
manage and cope with their disease. In research, this response of others has been termed 
“social support”
39
, and it has been conceptualized both structurally—that is, the size and 
composition of a person’s social network, and functionally. Functional support consists of 
actually “received” support (also called enacted support), which refers to what the others 
actually do or provide for the patient during times of need, and the “perceived” social support. 
It is the perceived support, which appears to be most closely related to health. According to 
social support theory, receiving support from others is generally beneficial to mental and 
physical health, and it may blunt the harmful impact of stressful experiences, including the 
disease itself.
40
 Empirical confirmation of this “buffering hypothesis of social support” has 
been found among patients with various rheumatic diseases.
41
 Irrespective of the disease, the 
presence of a spouse or intimate partner, having many close social relationships, being 
socially active, and perceiving others being supportive have been found to have favourable 
effects on psychological and physical functioning.
42
  
 
5.1 Social activities 
Illnesses such as EDS typically have various social consequences (Box 20-2). In a Dutch 
survey, five times as many patients with EDS reported problems with social functioning than 
did people from the general population, and the chance of experiencing problems with role 
functioning due to physical problems was seven times as large as in the general population 
(figure 20-1). Interview studies also show that impaired physical functioning in EDS hampers 
social life.
8,32 
 
Box 20-2 Possible social consequences of having a rare chronic disease 
 
- Problems with work and pursuing social activities. 
- A change of role patterns, household tasks, and leisure activities in the family; difficulty 
to decide to get offspring; difficulty deciding on the way to raise children with EDS. 
- Sexual problems. 
- Problems due to lack of knowledge of health care workers. 
- Experiencing lack of understanding and acknowledgement.  
 
5.2 Family 
Having a chronic disease affects one’s family. For example, the kind and number of leisure 
activities and roles and household tasks of family members often change as a consequence of 
illness. Yet, not all consequences are negative. A clinical consultation with a man with EDS 
revealed that he had to quit his work due to EDS, but he stayed at home and did household 
tasks, which also allowed him the privilege of seeing his children more frequently. 
Parents of children with EDS may be conflicted between protecting their children as much as 
possible, or encouraging them to face the challenges of life and not be hindered by fear of 
joint dislocations and other EDS consequences.
8
 Moreover, parents need to decide when and 
how they will inform their children about EDS, which is especially difficult for parents of 
children with vascular EDS. The decision about whether to have children in the first place and 
when so, whether or not to pursue prenatal diagnosis can be very difficult. During a 
Stretched beyond the limit: well-being and functioning in patients with Ehlers-Danlos syndrome 289
 
 
pregnancy, worry over the foetus is common. If the child does have EDS, guilt among parents 
may occur. 
  
5.3 Sexuality  
Sexuality is closely related to other dimensions of quality of life. The sexual life of patients 
with EDS may be hampered by pain, fear for damage to the vaginal tissues, and the need to 
avoid certain positions because of the risk of joint dislocation and pain.
8
 In a small and non-
representative sample, 60% of the women with EDS reported experiencing pain during sexual 
intercourse.
43
 Pain, fatigue, and depressed mood can impair the various phases of the sexual 
response cycle: desire, excitement, plateau, orgasm, and resolution. Ideally, patients and their 
partners should discuss sexual problems and mutually find behaviours and positions that 
reduce pain or risk. Such communication is difficult for many couples, however, and 
consultation from a physician or a psychologist may be helpful. 
 
5.4 Health care 
Patients with EDS may experience problems with both the lack of recognition and lack of 
knowledge of EDS by health care providers.
44
 The disease may be diagnosed only after a long 
time of fruitless contacts with physicians and other health care workers. Patients may have the 
feeling that others suspect them of hypochondria or simply that they are complaining too 
much. Patients may feel that they have to educate health care providers about EDS, rather 
than the other way around.
8
 Patients with EDS were interviewed about their health care 
experiences, and five categories of problems were identified: being ignored and belittled by 
health-care professionals, being assigned psychological or psychiatric explanations, being 
treated and considered merely as an object, being intruded in one's personal sphere when care 
is given, and being suspected of family violence.
45
 Unfortunately, the consequences of these 
experiences were that patients did not fully trust their physicians, which risked increasing 
their health problems. These authors advised health care professionals to base their actions on 
norms that protect human dignity and confirm each patient as a unique human being with 
resources and abilities to master his or her own life.  
 
5.5 Society 
These interviews of patients with EDS also revealed that they experienced a lack of 
understanding from society at large.
5
 For example, people may experience shame because 
they use a wheelchair when other people do not understand the need for it (“You can walk, 
but you use a wheelchair?”). Patients must often demonstrate great perseverance to obtain the 
accommodations or aids that they need, such as a disabled parking permit or disability status. 
Because symptoms such as pain, fatigue, and the chance of joint dislocations are not visible, it 
can be problematic to have to repeatedly explain that is difficult to perform specific tasks at 
work. Prevention of social isolation and social problems is a shared responsibility of the 
patient with EDS and the people who are in contact with the patient. Fellow-sufferers of EDS 
can be of great support.  
 
6. Conclusion 
There are few studies of psychosocial factors in EDS. Moreover, those studies that are 
available are often in small and non-representative samples. Nevertheless, the data uniformly 
suggest that reduced quality of life is common. Fatigue, pain, joint dislocations, skin 
problems, ‘weak’ vessels and organs, and sleeping disturbances threaten both psychological 
well-being and physical and social functioning. Yet, the effects of EDS on quality of life 
differ widely among individuals. Although some people with EDS have serious disease and 
poor quality of life, others are able to live a happy and satisfying life despite the serious 
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disease, and for still others the disease is milder and self-care and quality of life are good. 
Furthermore, improvements in one aspect of quality of life (i.e. symptoms, emotional well-
being, physical, or social functioning) often yield favourable consequences for other aspects 
(figure 20-2). Coping abilities and social support can buffer the adverse consequences of the 
disease. For a patient with severe EDS, a single physician as case manager should coordinate 
care. This case manager knows the medical file of the patient and can help the patient to 
decide about medical, psychological, or occupational therapies. Patients who are having 
trouble adapting successfully to their condition, should be encouraged to seek behavioural 
help, especially from someone trained in cognitive-behavioural interventions. Health care 
workers, patient associations, and people in the close environment of patients can help them 
find the appropriate education, counselling, and multidisciplinary interventions aimed at 
dealing with the adverse consequences of EDS. 
 
Figure 20-2 The consequences of a chronic disease such as Ehlers-Danlos syndrome for 
various mutually dependent aspects of well-being and functioning 
 
 
The disease process and its symptoms threaten emotional well-being and physical and social 
functioning. Yet, the effects of Ehlers-Danlos syndrome on quality of life differ widely among 
individuals. Although some people have serious disease and poor life quality, others are able 
to life a happy and satisfying life despite the serious disease, and for still others the disease is 
milder and self-care and life quality are good. Furthermore, improvement in one aspect of life 
quality (i.e., symptoms, emotional well-being, physical, or social functioning) often yield 
favourable consequences for other aspects. Coping abilities and social support can buffer the 
adverse consequences of the disease. 
 
7. Areas of uncertainty 
Studies of somatic problems, psychological distress, and social functioning in EDS are scarce, 
but quite consistent in the conclusion that quality of life is, on average, impaired in these 
domains. Our discussion and recommendation in the area of coping and therapeutic 
possibilities were almost fully based on our knowledge of experiences of individual patients, 
and our knowledge of the somatic, emotional, and social consequences of chronic disease 
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more generally. Disease-specific knowledge, especially on the effects of cognitive-
behavioural interventions, is urgently needed. 
 
8. Summary 
This chapter describes the somatic, psychological, and social impact of EDS. Research 
indicates that pain and fatigue are common problems in EDS. In addition, patients may fear 
damage to their joints, skin, and other organs; progressive disability; and even death. Other 
psychological and social dilemmas or challenges often occur, including whether or not to 
have a child, finding or keeping work that is commensurate with abilities and interests, altered 
roles in the family, a lack of understanding by others in one’s social environment, and 
obtaining appropriate health care. Yet patients vary widely with respect to the severity of the 
disease and its impact on their psychological, social, and physical functioning and well-being; 
individual assessment is needed. It is probably optimal to have one physician manage each 
patient and coordinate the many aspects of his or her care. Patients should have access to 
education, counselling, and multidisciplinary interventions aimed at reducing the adverse 
consequences of the disease. 
  
Chapter 20292
 
 
References 
1. Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ. Ehlers-Danlos 
syndromes: Revised nosology, Villefranche, 1997. Am J Med Genet seventy 998;77:31-
7. 
2. Geenen R, Baakman WBE, Boluijt H, Veenhuizen MC, Cornelissens LJM, Jacobs JWG. 
De last van lenigheid. Kwaliteit van leven bij patiënten met Ehlers-Danlos syndroom 
[Quality of life in patients with Ehlers-Danlos syndrome]. Psychol Gezondh 
2005;33:223-36. 
3. Rombaut L, Malfait F, Cools A, De Paepe A, Calders P. Musculoskeletal complaints, 
physical activity and health-related quality of life among patients with the Ehlers-Danlos 
syndrome hypermobility type. Disabil Rehabil 2010;32:1339-45. 
4. Rombaut L, Malfait F, De Paepe A, Rimbaut S, Verbruggen G, De Wandele I, et al. 
Impairment and impact of pain in female patients with Ehlers-Danlos syndrome: a 
comparative study with fibromyalgia and rheumatoid arthritis. Arthritis Rheum 
2011;63:1979-87. 
5. Berglund B, Nordstrom G, Lutzen K. Living a restricted life with Ehlers-Danlos 
Syndrome (EDS). Int J Nurs Stud 2000;37:111-8. 
6. Perdu J, Boutouyrie P, Lahlou-Laforet K, Van Kien PK, Denarie N, Mousseaux E, et al. 
Vascular Ehlers-Danlos syndrome. Presse Med 2006;35:1864-75. 
7. Maeland S, Assmus J, Berglund B. Subjective health complaints in individuals with 
Ehlers-Danlos syndrome: A questionnaire study. Int J Nurs Stud 2011;48:720-4. 
8. Lumley MA, Jordan M, Rubenstein R, Tsipouras P, Evans MI. Psychosocial functioning 
in the Ehlers-Danlos syndrome. Am J Med Genet 1994;53:149-52. 
9. Sacheti A, Szemere J, Bernstein B, Tafas T, Schechter N, Tsipouras P. Chronic pain is a 
manifestation of the Ehlers-Danlos syndrome. J Pain Symptom Manage 1997;14:88-93. 
10. Voermans NC, Knoop H, Bleijenberg G, van Engelen BG. Pain in Ehlers-Danlos 
Syndrome is common, severe, and associated with functional impairment. J Pain 
Symptom Manage 2010;40:370-8. 
11. Smets EMA, Garssen B, Bonke B, Dehaes J. The Multidimensional Fatigue Inventory 
(MFI): Psychometric qualities of an instrument to assess fatigue. J Psychosom Res 
1995;39:315-25. 
12. Voermans NC, Knoop H, van de Kamp N, Hamel BC, Bleijenberg G, van Engelen BG. 
Fatigue is a frequent and clinically relevant problem in Ehlers-Danlos syndrome. Semin 
Arthritis Rheum 2010;40:267-74. 
13. Castori M, Morlino S, Celletti C, Celli M, Morrone A, Colombi M, et al. Management of 
pain and fatigue in the joint hypermobility syndrome (a.k.a. Ehlers-Danlos syndrome, 
hypermobility type): Principles and proposal for a multidisciplinary approach. Am J Med 
Genet A 2012;158A:2055-70. 
14. Prins JB, Bleijenberg G, Bazelmans E, Elving LD, de Boo TM, Severens JL, et al. 
Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised 
controlled trial. Lancet 2001;357:841-7. 
15. Ainsworth SR, Aulicino PL. A survey of patients with Ehlers-Danlos syndrome. Clin 
Orthop Rel Res 1993:250-6. 
16. Verbraecken J, Declerck A, Van de Heyning P, De Backer W, Wouters EFM. Evaluation 
for sleep apnea in patients with Ehlers-Danlos syndrome and Marfan: a questionnaire 
study. Clin Genet 2001;60:360-5. 
17. Morgenthaler T, Kramer M, Alessi C, Friedman L, Boehlecke B, Brown T, et al. Practice 
parameters for the psychological and behavioral treatment of insomnia: An update. An 
American Academy of Sleep Medicine Report. Sleep 2006;29:1415-9. 
Stretched beyond the limit: well-being and functioning in patients with Ehlers-Danlos syndrome 293
 
 
18. Geenen R, Finset A. Psycho-social approaches in rheumatic diseases. In Bijlsma JWJ, Da 
Silva JAP, Hachulla E, et al., editors. EULAR textbook on rheumatic diseases, p. 
London: BMJ Group, 2012; 139-62. 
19. Garcia-Campayo J, Asso E, Alda M. Joint hypermobility and anxiety: The state of the art. 
Curr Psychiatry Rep 2011;13:18-25. 
20. Sanches SHB, Osorio FD, Udina M, Martin-Santos R, Crippa JAS. Anxiety and joint 
hypermobility association: a systematic review. Rev Bras Psiquiatr 2012;34:S53-S68. 
21. Wardinsky TD, Vizcarrondo FE, Cruz BK. The mistaken diagnosis of child abuse: a 
three-year USAF Medical Center analysis and literature review. Mil Med 1995;160:15-
20. 
22. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70. 
23. Hollon SD, Thase ME, Markowitz JC. Treatment and prevention of depression. Psychol 
Sci 2002:39-77. 
24. Cuijpers P, van Straten A, Schuurmans J, van Oppen P, Hollon SD, Andersson G. 
Psychotherapy for chronic major depression and dysthymia: A meta-analysis. Clin 
Psychol Rev 2010;30:51-62. 
25. Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. Evidence-
based guidelines for treating depressive disorders with antidepressants: A revision of the 
2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 
2008;22:343-96. 
26. Ebmeier KP, Donaghey C, Steele JD. Recent developments and current controversies in 
depression. Lancet 2006;367:153-67. 
27. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JRT, et al. 
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: 
recommendations from the British Association for Psychopharmacology. J 
Psychopharmacol 2005;19:567-96. 
28. Falsetti SA, Davis J. The nonpharmacologic treatment of generalized anxiety disorder. 
Psychiatr Clin North Amer 2001;24:99-117. 
29. Mitte K. Meta-analysis of cognitive-behavioral treatments for generalized anxiety 
disorder: A comparison with pharmacotherapy. Psychol Bull 2005;131:785-95. 
30. Geenen R, Newman S, Bossema ER, Vriezekolk JE, Boelen PA. Psychological 
interventions for patients with rheumatic diseases and anxiety or depression. Best Pract 
Res Clin Rheumatol 2012;26:305-19. 
31. Evers AWM, Kraaimaat FW, van Lankveld W, Jongen PJH, Jacobs JWG, Bijlsma JWJ. 
Beyond unfavorable thinking: The illness cognition questionnaire for chronic diseases. J 
Consult Clin Psychol 2001;69:1026-36. 
32. Berglund B, Mattiasson AC, Nordstrom G. Acceptance of disability and sense of 
coherence in individuals with Ehlers-Danlos syndrome. J Clin Nurs 2003;12:770-7. 
33. Brandstädter J, G. R. Tenacious goal pursuit and flexible goal adjustment: explication and 
age-related analysis of assimilative and accommodative strategies of coping. Psychol 
Aging 1990;5:58-67. 
34. Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J. Acceptance and commitment 
therapy: Model, processes and outcomes. Behav Res Ther 2006;44:1-25. 
35. Bohlmeijer E, Prenger R, Taal E, Cuijpers P. The effects of mindfulness-based stress 
reduction therapy on mental health of adults with a chronic medical disease: A meta-
analysis. J Psychosomat Res 2010;68:539-44. 
36. Merkes M. Mindfulness-based stress reduction for people with chronic diseases. Aust J 
Prim Health 2010;16:200-10. 
Chapter 20294
 
 
37. Veehof MM, Oskam MJ, Schreurs KMG, Bohlmeijer ET. Acceptance-based 
interventions for the treatment of chronic pain: A systematic review and meta-analysis. 
Pain 2011;152:533-42. 
38. De Ridder D, Geenen R, Kuijer R, van Middendorp H. Psychological adjustment to 
chronic disease. Lancet 2008;372:246-55. 
39. McNally ST, Newman S. Objective and subjective conceptualizations of social support. J 
Psychosom Res 1999;46:309-14. 
40. Cohen S, Wills TA. Stress, social support, and the buffering hypothesis. Psychol Bull 
1985;98:310-57. 
41. Montoya P, Larbig W, Braun C, Preissl H, Birbaumer N. Influence of social support and 
emotional context on pain processing and magnetic brain responses in fibromyalgia. 
Arthritis Rheum 2004;50:4035-44. 
42. Penninx B, VanTilburg T, Deeg DJH, Kriegsman DMW, Boeke AJP, VanEijk JTM. 
Direct and buffer effects of social support and personal coping resources in individuals 
with arthritis. Soc Sci Med 1997;44:393-402. 
43. Sorokin Y, Johnson MP, Rogowski N, Richardson DA, Evans MI. Obstetric and 
gynecologic dysfunction in the Ehlers-Danlos syndrome. J Reprod Med 1994;39:281-4. 
44. Baeza-Velasco C, Gely-Nargeot MC, Vilarrasa AB, Bravo JF. Joint hypermobility 
syndrome: problems that require psychological intervention. Rheumatol Int 
2011;31:1131-6. 
45. Berglund B, Anne-Cathrine M, Randers I. Dignity not fully upheld when seeking health 
care: Experiences expressed by individuals suffering from Ehlers-Danlos syndrome. 
Disabil Rehab 2010;32:1-7. 
46. van der Zee KI, Sanderman R, Heyink JW, deHaes H. Psychometric qualities of the 
RAND 36-item health survey 1.0: A multidimensional measure of general health status. 
Int J Behav Med 1996;3:104-22. 
Stretched beyond the limit: well-being and functioning in patients with Ehlers-Danlos syndrome 295
This page intentionally left blank
 
 
Chapter 21. Causes and treatment of chronic pain associated with Ehlers-
Danlos syndrome  
AJM van Wijck 
 
 
Albert J. M. van Wijck, MD 
Anaesthesiologist  
Department of Anaesthesiology 
Pain Clinic 
University Medical Center Utrecht 
PO Box 85500 
3508 GA Utrecht, Netherlands 
Telephone: +31 88 75 561 63  
E-mail A.vanWijck@umcutrecht.nl 
 
297
 
 
1. Introduction 
Patients with Ehlers-Danlos syndrome (EDS) and hypermobility syndromes have an increased 
risk of chronic pain, as shown by clinical experience and publications.
1
 This increased risk 
comes from many different sources, not only the increased risk of painful injuries and joint 
degenerations, but also from increased exposure to surgery and invasive procedures. Limited 
data link EDS to increased risk for neuropathic pain as well, due to reduced integrity of the 
connective-tissue sheaths around nerves and spinal roots. Recently, the two conditions benign 
joint hypermobility syndrome (BJHS) and EDS hypermobility type have been recognized as 
one and the same clinical spectrum ranging from apparently symptomatic generalized joint 
hypermobility to the most disabled individuals fitting the new diagnostic criteria. These new 
criteria are more strict than the Villefranche criteria and the Brighton criteria for BJHS in 
order to define a homogeneous phenotype for management and scientific purposes. Within the 
new EDS nosology, its name is hypermobile EDS (see chapters 2 and 5).  
This chapter considers the pain suffered by EDS patients from a multidisciplinary perspective. 
In the first section we discuss the theory and pathophysiology of pain. Then we discuss 
specific chronic pain syndromes that have increased prevalence in EDS. We then discuss 
drugs, nerve stimulation, and the psychological approach as possible forms of treatment. 
 
2. Theory of pain 
 
2.1 Definition 
Pain is an unpleasant, sensory and emotional experience which accompanies actual or 
potential tissue damage or is described in terms of such damage. This definition was 
formulated by the International Association for the Study of Pain (IASP). The first part of the 
definition touches upon the function of pain. In the event of imminent damage to the tissues, 
pain ensures that a person limits the damage. An example of this is a hand placed on a hot 
stove. The pain ensures that the hand is withdrawn before it is burnt. In the case of existing 
damage, for example a broken leg, pain has an important function that makes recovery 
possible: pain forces a person to take rest. The second part of the definition has been added 
because tissue damage cannot always be demonstrated. This is often the case for chronic pain. 
For chronic pain the relationship with tissue damage is far less clear than in the case of acute 
pain. Resting or reducing the burden on the painful body part is then no longer an adequate 
response. Prolonged rest leads to atrophy and the load tolerance is reduced. Minimal exertion 
then soon gives rise to overloading, which in turn can lead to damage. Pain is referred to as 
chronic when it exists for longer than 3 months after any possible tissue damage is considered 
healed. Pain cannot be measured objectively. The degree of nociception can sometimes be 
estimated if the source of the pain is known. A physician often knows from experience how 
much pain a given condition causes, but experimental studies show considerable variability in 
the perception of pain, which has been found to be genetically influenced.
2,3
 A limitation on 
clinical care and pain research is the difficulty quantitating pain severity. Most commonly, 
pain experienced is measured by asking the patient about the severity of the pain, for example, 
using a Likert scale of 0 to 10, where 0 represents no pain and 10 the worst pain that someone 
can imagine. 
 
2.2 Nociceptive and neuropathic pain 
Existing and imminent tissue damage stimulates free nerve endings of pain cells, the 
nociceptors. This stimulus can be mechanical or chemical through mediators that are released 
during inflammation such as histamine and prostaglandins. This process of stimulating the 
nociceptors is termed nociception and the pain that is felt as a result of this is called 
nociceptive pain. If a nociceptor is stimulated over a prolonged period of time, the stimulation 
Chapter 21298
 
 
threshold can be lowered as a result of which hyperalgesia, an increased sensitivity for pain 
stimuli, arises.
4
 This phenomenon is referred to as sensitisation.  
Damage to the nervous system (neuropathy) can also give rise to pain: neuropathic pain. In 
this case pathological connections develop in the posterior horn of the spinal cord to such an 
extent that tactile stimuli are felt as pain stimuli. This phenomenon is called allodynia. An 
example of neuropathic pain is phantom limb pain, a pain sensation in a body part that is no 
longer there, for example, because it has been amputated. 
It is important to draw a distinction between nociceptive pain and neuropathic pain because of 
the difference in treatment. In general, neuropathic pain responds poorly to traditional 
painkillers. An “electrical” or burning character of the pain and the occurrence of sensory 
disorders such as hypaesthesia (reduced tactile sensitivity) and allodynia are indicative for 
neuropathy. In our and other’s experience neuropathy often plays an important but 
underestimated role in the case of EDS.
5
 
 
2.3 Multidimensionality of pain 
After a nociceptor has been activated, the signal is transmitted via the sensory A-delta and C 
nerve fibres (pain nerves), the spinal cord and the thalamus to the cerebral cortex, where the 
sensation of pain arises. The interpretation of this signal is partly dependent on the context, 
such as psychological constitution, distraction and previous experiences. The experience of 
pain and the suffering from pain are therefore not linearly related to the severity of the 
nociception. Pain behaviour is what someone else can see. The well-known “circles of 
Loeser” provide a picture of the relationships between nociception, pain sensation, pain 
experienced and pain behaviour (figure 21-1). 
 
Figure 21-1 Circles of Loeser 
 
 
 
 
 
 
 
 
 
 
 
 
The interpretation of pain is partly dependent on the context, such as psychological 
constitution, distraction and previous experiences. The experience of pain and the suffering 
from pain are therefore not linearly related to the severity of the nociception. Pain behaviour 
is what someone else can see. These well-known “circles of Loeser” provide a picture of the 
relationships between nociception, pain sensation, pain experienced and pain behaviour  
  
behaviour 
suffering 
pain 
nociception 
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2.4 Pain model 
For the treatment of chronic pain it is helpful to mention its different aspects in a model, see 
figure 21-2. A disease can lead to complaints and consequences. As soon as the disease has 
healed, the complaints disappear and mostly the consequences as well. However, the disease 
cannot always be found and some diseases such as EDS cannot be cured. If the complaint 
persists, symptomatic treatment is indicated. Options for the symptomatic treatment of pain 
are painkillers (analgesics), nerve blockages and nerve stimulation. However, the treatment of 
chronic pain does not always give satisfactory results. Then the patient continues to 
experience pain and the consequences of this pain. The consequences can be thoughts (‘I have 
a severe illness’), feelings (anger or depression) and behaviour (resting, groaning). The 
behaviour of others also plays a role. In the case of acute injury the patient's network is 
helpful and understanding, but in the case of chronic pain this can change into 
incomprehension and irritation. Sometimes partners strengthen inadequate pain behaviour. 
 
Figure 21-2 Model of consequences of a chronic disease 
 
For the treatment of chronic pain it is helpful to realise that the suffering from a chronic 
disease leads to several psychological and social consequences for the patient and the 
patient’s personal environment. 
 
 
3. Medical treatment of nociceptive pain 
 
3.1 Paracetamol/Acetaminophen 
Acetaminophen or paracetamol is often a first choice for acute and chronic pain. However, 
there is increasing awareness of the principal side effect; liver damage; this drug is a common 
cause of acute liver failure.
6
 A major problem is the inclusion of acetaminophen in many 
other combination medications so most patients do not even know what their daily total 
consumption is. This includes non-prescription medications, for instance for colds, menstrual 
pain, and sinusitis, but the major concern for chronic-pain patients is the combination of 
acetaminophen and opioid analgesics. Patients who become opioid tolerant and are prescribed 
or chose to take high doses to relieve severe pain risk unintentional acetaminophen toxicity. In 
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2009, a Joint Advisory Committee recommended to the U.S. Food and Drug Administration 
(FDA) that combination pain relievers containing acetaminophen be removed from the U.S. 
market, the recommended maximum total daily dose of acetaminophen be lowered below its 
current 4 g per day and that the maximum single adult non-prescription dose of 
acetaminophen be lowered.
7
 If the combination products are eliminated, the acetaminophen 
and the other ingredients could be prescribed separately. Patients would take two pills instead 
of one, and be more aware of the acetaminophen they are consuming. This is particularly 
important to consider in treating chronic pain of neuropathic origin, where the acetaminophen 
consumed in combination pain-relievers may not even be effective. Patients with underlying 
hepatic dysfunction or risk factors, for instance from hepatitis C, should limit consumption 
and use acetaminophen and acetaminophen-containing medications only under medical 
supervision. 
 
3.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 
The NSAIDs are a group of anti-inflammatory drugs that do not contain corticosteroids. 
Besides their anti-inflammatory effect, NSAIDs also have analgesic and antifebrile (fever-
reducing) effects. They work by inhibiting the enzyme cyclo-oxygenase (COX) that is 
involved in the synthesis of prostaglandins from the parent substance arachidonic acid. 
Prostaglandins play a role in disease and tissue damage and in numerous physical processes. 
There are at least two forms of cyclo-oxygenase that are referred to as COX-1 and COX-2. 
Broadly speaking it is supposed that COX-1 is responsible for the prostaglandin synthesis in 
physiological processes and COX-2 for pathological processes. Not just the therapeutic effect 
but also the side effects of NSAIDs can be traced back to the inhibition of the prostaglandin 
synthesis: 
 
1. Acute and chronic renal impairment. People with heart failure, the elderly and people 
suffering from dehydration are particularly prone to this risk. 
2. Side effects in the stomach or intestines such as heartburn and ulcers can lead to 
haemorrhages and perforations. 
3. A blood-pressure increasing effect in hypertensive patients and reduction of the blood-
pressure lowering effect of drugs against high blood pressure. 
4. Inhibition of the coagulation of blood platelets with increased tendency to bleed. 
5. Reduction in the blood-thinning effect of acetyl salicylic acid that is prescribed to 
patients who have experienced a heart or brain infarct. The blood thinning effect is less, 
for example, after ibuprofen, nabumetone and indomethacin, but not after diclofenac.
8
 
 
To reduce the side effects of the classic NSAIDs that act upon both COX-1 and COX-2, drugs 
have been developed that selectively inhibit COX-2 and spare COX-1, like celecoxib and 
etoricoxib. They cause less stomach ulcers or complications thereof, but reduction of the risk 
of stomach damage can also be achieved by the combination of a non-COX-2 selective 
NSAID with a drug that protects the stomach mucous membrane or a gastric acid inhibitor 
(like a proton pump inhibitor).
9
 The risk of kidney damage is just as big for selective COX-2 
inhibitors as for traditional NSAIDs, and COX-2 selective NSAID increase the risk of 
cardiovascular complications by increased clot formation of the blood.
10
  
If acetaminophen provides insufficient relief then for EDS a NSAID can be tried. If there is 
not an increased risk for gastrointestinal complications a traditional NSAID is the treatment of 
choice. In the case of an increased risk for gastrointestinal complications and no increased risk 
of cardiovascular complications, a COX-2 inhibitor can be used instead. In case of also 
increased risk of cardiovascular complications, a traditional NSAID combined with a proton 
pump inhibitory drug can be used. For vascular EDS, all NSAIDs and especially classic 
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(COX-1 inhibiting) NSAIDs are contraindicated as these patients already have an increased 
risk of haemorrhages, which is a major problem if stomach ulcers would develop. 
 
3.3 Opioids 
These powerful analgesics are mainly indicated for acute severe nociceptive pain (for 
example after an operation) and for chronic severe pain as a consequence of cancer. 
Various morphine preparations with a slow release are available, in strengths varying from 10 
to 200 mg; oxycodone with slow release, in strengths varying from 5 to 80 mg and plasters 
with fentanyl that release 25 to 100 micrograms per hour. The side effects are constipation, 
nausea, sedation, urine retention, dependency (addiction) and at excessively high doses 
depressed breathing. The patient is started on a low dosage that is increased according to the 
effect. Opioids should always be given in combination with a laxative. In view of the 
indication and the side effects, these preparations will scarcely play a role in the treatment of 
pain associated with EDS. 
An exception should perhaps be made for tramadol and tapentadol, both opioids, which also 
have other effects on pain-modulating nerve fibres. Tramadol is therefore sometimes used in 
the case of neuropathic pain. The dosage administered ranges from 50 to 400 mg per day if 
necessary. The side effects are the same as for the strong opioids but occur less frequently. 
However, several hours after intake, many people suffer from drowsiness. It is assumed that 
this is not particularly related to the dosage but to the changes of the concentration of the drug 
in the blood. If 'slow release' tablets are used, which release the drug gradually, fewer changes 
in the blood concentrations occur and there are less side effects. In clinical practice, the 
experience is that the drowsiness initially present almost completely disappears after a few 
days, despite continued use of the medication. 
 
4. Medical treatment of neuropathic pain 
Neuropathic pain can be a component of pain associated with EDS. This is possibly because 
damage to the nerves can also occur as a consequence of the nature of the disease. Neuropathy 
is difficult to treat. Drugs used against neuropathic pain have generally not been developed as 
a painkiller, but for another disease such as depression or epilepsy. The medical treatment of 
neuropathic pain is in practice a matter of trial and error.  
 
4.1 Tricyclic antidepressants 
While this group of drugs was first approved and marketed for treating depression, older trials 
showed independent efficacy in relieving neuropathic pain.
11
 Besides inhibiting the 
transmission of pain stimuli, their major mode of action in control of neuropathic pain is 
based on enhancing the amount of substances in the pain-modulating neural tracts that 
descend to the spinal cord from the higher nuclei in the brain stem. A body of experience has 
been gained with amitriptyline and imipramine, but a recent review found little evidence to 
support the use of imipramine to treat neuropathic pain.
11
 The usual dosage of both drugs for 
this application is 25-50 mg per day; sometimes this is increased to 75 mg and even to 150 mg 
per day. The principle side effects are dry mouth, constipation, blurred vision, difficulty with 
urinating and decreased blood pressure upon getting up from a sitting position. 
 
4.2 Anti-epileptics 
This group of drugs are primarily used for the treatment of epilepsy. They owe their effect to 
the inhibition of the transmission of stimuli in the brain. Carbamazepine, pregabalin and 
gabapentin are most frequently used for the control of pain.
11
  
The effectiveness of carbamazepine is best documented for facial pain and diabetic 
neuropathy, which is neural damage as a consequence of diabetes that can be associated with 
Chapter 21302
 
 
severe pain. The initial dosage of carbamazepine is 200-400 mg per day; if necessary this can 
gradually be increased to 600-800 mg per day; maximum 1200 mg per day. During the first 
14 days of the treatment in particular, side effects on the central nervous system (CNS) can 
occur such as dizziness, difficulty with coordinated movement and speech, drowsiness and 
tiredness. Due to the chance of a reduced production of white blood cells and liver 
impairments, the blood must be monitored on a regular basis.  
The mode of action of gabapentin has not been precisely determined. The effectiveness has 
mainly been described for postherpetic neuralgia (pain that arises after experiencing shingles) 
and for diabetic neuropathy. The initial dose is 300 mg per day, which can be increased in 
steps to a maximum of 3600 mg per day. The side effects are relatively mild and transient in 
nature and mainly affect the CNS: sleepiness, dizziness and difficulty with coordinated 
movement and speech. 
 
4.3 Cannabis preparations
12-14
 
Cannabis is the dried female inflorescence of the plant Cannabis sativa; its active ingredients 
are termed cannabinoids. More than 60 have been demonstrated, of which the principle 
ingredient is delta-9-tetrahydrocannabinol (THC or dronabinol). In theory, cannabinoids can 
inhibit pain transmission at various locations in the CNS.
13
 However, the clinical usefulness 
and the risk/benefit ratio is debatable.
11
 
Oral use is possible by making tea from the preparation. The quantities of active substances 
that end up in the blood after absorption though the gastrointestinal tract are minimal, partly 
because large quantities are broken down during the passage through the liver. If inhaled, 
uptake is via the lungs which leads to a quicker effect and a higher bioavailability. Inhalers 
can be obtained which heat the cannabis to a temperature of about 200
o 
C. The advantage of 
inhaling (volatilisation) compared to smoking (smouldering) is that no cancerous substances 
are released. The maximum effect is only noticeable after 1 to 2 weeks. If necessary, the 
dosage can be increased after 2 weeks. 
If conventional therapies provide insufficient effect, a cannabis preparation can be tried as a 
supplementary treatment in the dosages given. Starting with cannabis tea is the most practical 
approach. If this provides no relief after two weeks then administration via an inhaler can be 
tried. If no noticeable effect has occurred with this after 2 weeks then cannabis clearly does 
not help and its use can be stopped. 
 
5. Nerve blocks 
Nerve blockage focuses on blocking the transmission of pain from the nociceptor to the 
central nervous system. In general, this blockage can take place in four different ways: 
 
• Injection of a local anaesthetic. Local anaesthetics block the transmission of pain by a 
nerve, as a result of which local anaesthesia occurs. The effect lasts for several hours but 
due to the breaching of the sensitisation it can sometimes be a long time before the pain 
returns (several months). A problem in the case of EDS,  however, is that the sensitivity 
for local anaesthetics may be reduced.
15-17
 
• Cryocoagulation of a nerve. Freezing damages the nerve so that it no longer transmits 
stimuli for a period of 3 months or longer. 
• Radiofrequency treatment of a nerve or ganglion. A high frequency alternating electrical 
current is used to change the structure of the nervous tissue as a result of which fewer 
signals can be transmitted. The effect lasts for several years. However, if the treatment is 
too extensive then neuropathic pain or loss of strength can occur. By using normothermic 
pulsed radiofrequency, the risk of nerve damage is negligible. 
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• Injection of neurolytic substances such as alcohol or phenol. The duration of 
effectiveness is unpredictable. A risk is the occurrence of neuropathic pain. Therefore to 
date this technique has only been used on the autonomous nervous system (“sympathetic 
blockage”), where the chance of neuropathic pain is very small. 
Literature data on nerve blocks in patients with EDS are lacking.  
 
5.1 Trigger point infiltration 
A trigger point is a painful spasm of several muscle fibres. It can occur in virtually every 
muscle. Stress appears to play a role in its development. A typical radiation pattern of pain 
can exist, which can lie outside of the muscle. During a physical examination a trigger point 
can sometimes be felt as a painful lump in a muscle. The treatment consists of injecting 
several millimetres of lidocaine into the trigger point followed by stretching exercises. 
 
5.2 Peripheral nerve blocks 
If a peripheral nerve is infiltrated at some point along its pathway with a local anaesthetic, a 
temporary interruption to the pain sensation occurs. This is particularly worthwhile if 
sensitisation plays an important role. Examples are headache originating from the neck 
(occipital nerve) and shoulder pain (suprascapularis nerve). 
 
5.3 Sympathetic blocks 
The autonomous nervous system controls a wide range of physical functions such as 
peristalsis (bowel movements), sweat secretion and blood pressure, without us even being 
aware of it. It consists of two parts, the sympathetic and parasympathetic nervous systems. 
The sympathetic nervous system plays a role in the modulation of pain. As a result of chronic 
pain, the sympathetic nervous system becomes sensitised, which leads amongst other things to 
vasoconstriction and an increase in the pain. The limb concerned becomes cold and pale. The 
aim of sympathetic blockage is to improve the blood flow and to reduce the chronic pain.  
 
5.4 Epidural injection 
The dura is the outermost spinal cord and cerebral membrane. Around this membrane is the 
epidural space that is filled with blood vessels and fat. The incoming and outgoing nerve roots 
pass though this space. Anaesthesia can be achieved by injecting a local anaesthetic. 
Considerable experience has been gained with this technique in anaesthesia for operations. By 
using less strong concentrations of local anaesthetic, less intensive blockages are produced so 
that the motor function remains intact. By adding other drugs such as morphine, 
glucocorticoids or clonidine the analgesic effect in terms of duration or intensity can be 
increased. Epidural injections can be administered throughout the vertebral column. The 
volume injected determines the number of treated spinal cord segments. In the case of EDS, 
the administration of an epidural injection is associated with an increased risk of 
complications due to the possibly weaker dura.
18
 Consequently, the dura can be 
unintentionally perforated and, in the case of vascular EDS, there is an increased chance of 
haemorrhages due to the damage of an epidural blood vessel. 
 
6. Nerve stimulation
19 
 
Electrical nerve stimulation can contribute to pain alleviation. The presumed mode of action 
is the ‘gate theory’, which proposes that in the spinal cord, stimuli via the thick nerve fibres 
can inhibit the propagation of the other stimuli (for example, pain stimuli) like a gate that is 
being closed. The gate can be closed by activating thick nerve fibres and opened by activating 
thin nerve fibres. If a small current is administered via the skin then the thick nerve fibres are 
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mainly activated. According to this theory, the nociceptive and neuropathic pain would be 
suppressed. 
Another explanation is that in response to electrical stimulation of skin nerves, endogenous 
endorphins (substances similar to morphine) are released in the central nervous system. A 
third theory states that certain electrical stimuli increase the production of the substance ATP 
(adenosine triphosphate, the energy source in cells), which increases wound healing and 
general well-being. 
The best-known form of electro-analgesia is transcutaneous electrical neurostimulation 
(TENS), a method to inhibit pain by electrically stimulating painful areas via electrodes on the 
skin. Recently developed TENS applications are the Burst mode, modulated rate TENS, point 
TENS and APS (action potential simulation). None of the transcutaneous forms of electro-
analgesia have been proven to be effective in patients with chronic pain, as well-designed 
studies have scarcely been performed. Nevertheless, TENS is used regularly, partly because 
this therapy is not invasive and is relatively safe.  
Besides the transcutaneous form of electro-analgesia there is also an implantable form. Here 
an electrode is placed in the epidural space and is attached to a subcutaneous pulse generator. 
This treatment has been proven to be effective for certain forms of neuropathic pain such as 
peripheral nerve damage and sympathetic reflex dystrophy. The safety and effectiveness in 
the case of pain associated with EDS is, however, completely unknown. 
 
7. Psychological approach 
Pain has consequences for feelings, thoughts and behaviour. In turn these consequences can 
play a role in perpetuating pain. In the case of less serious psychological consequences, 
educational programmes and self-help books can help. Serious consequences of chronic pain 
are treated with reactivating rehabilitation programmes and cognitive-behavioural therapy. 
 
7.1 Feelings 
Patients with chronic pain sometimes report that the pain is greater if they are angry or tense. 
This is not just a matter of perception but is also related to the physiological changes that then 
take place. The perception of pain involves many structures and processes in the central 
nervous system. One of these substances is the stress hormone noradrenaline that can increase 
the pain in patients with a chronic pain syndrome. Noradrenaline is mostly released if a 
person is angry or tense and this can clarify the increase in pain. 
Noradrenaline is also released during movement. Moreover, the physiological perception of a 
change in the position of the limbs (proprioception) can be experienced as pain. This can form 
the basis for kinesiophobia, anxiety for movement and anxiety for injury. In the case of EDS, 
the anxiety for certain movements that can result in (partial) dislocations, is real. This 
becomes problematic if anxiety results in unnecessary severe immobility and subsequent pain, 
fatigue and muscle weakness,
20
 as a result of which the chance of dislocations can increase. 
Prolonged pain can trigger depression. Depression reduces the chance of successful 
treatments and should be diagnosed and treated as quickly as possible. 
If anger, tension, gloominess and anxiety occur then it is worthwhile devoting attention to 
these during therapy so that the quality of life can be improved. Relaxation training, 
cognitive-behavioural therapy and stress management can be deployed for this purpose. The 
psychologist is the therapist indicated for coping with stress. Sometimes stress management 
forms part of the courses offered in hospitals and rehabilitation centres for coping with pain. 
There are also many possibilities outside of the psychological circuit for participating in 
relaxation training.  
 
 
Causes and treatment of chronic pain associated with Ehlers-Danlos syndrome 305
 
 
7.2 Thoughts 
Convictions that the patient holds onto, have consequences for the choice of therapy and 
therapy compliance. A patient who thinks that pain is solely the consequence of tissue damage 
will not be open towards a behavioural intervention. Someone who is convinced that rest is 
good and that physical exertion leads to damage in the body, will be difficult to motivate to 
exercise more. Some patients have catastrophizing, negative thoughts. They think that nothing 
helps, that the pain will always be there and will never subside, that the pain is intolerable and 
will become worse upon the slightest exertion and that the worst possible outcome will result 
from any behaviour. Individual psychotherapy or group therapy can be considered for patients 
who are helpless and say that they have tried everything, who are convinced that nothing 
helps, who have a marginal expectation of a positive outcome of therapy and who have a lack 
of self-effectiveness. Self-effectiveness is the conviction that one can achieve a certain 
objective and that one is capable of effecting and persisting in a behaviour that is necessary to 
achieve that objective.  
The therapist will first of all have to estimate to what extent the patient's thoughts are realistic. 
If unrealistic thoughts are present then these will have to be addressed first in the treatment. A 
psychotherapist can help a patient to recognise inhibitory and negative thoughts after which 
these thoughts can be discussed and be replaced by realistic thoughts such as if I keep moving 
then perhaps things will go better for me; that I experience pain does not mean that my body 
is being damaged; I can still cycle if I use an adapted bike. Only after this phase has been 
completed will the patient be open to stress management and can realistic objectives that 
facilitate the patient’s functioning and quality of life be chosen and practised.  
 
7.3 Cognitive-Behavioural Therapy 
Although one does not chose to have chronic pain, and often one cannot make it go away, 
patients can choose and control their own methods for coping with pain. Clinical experience 
shows tremendous variety in coping styles; some patients are completely disabled by 
moderate amounts of chronic pain whereas others carry on heroically in the face of severe 
chronic pain. Some methods for coping with pain are more favourable than others.
21,22
 
Ignoring the pain, concentrating on something else and seeking diversion are helpful not only 
for coping with acute pain, but can also work for chronic pain as well. One of the fundamental 
characteristics of chronic neuropathic pain is that it is often worse at night when patients lie in 
bed without distraction. Many patients report that their chronic pain fades into the background 
when they engage in their favourite activities. Considerable pain research demonstrates the 
negative effects of “catastrophizing”, magnifying the significance of chronic pain.
20
 
Negative thoughts are associated with psychological suffering, a greater use of painkillers and 
reduced possibilities for performing activities of daily living. Coping styles such as ‘praying 
and hoping’, wishful thinking and optimism are associated with improved functional 
possibilities. They probably encourage the patient to adopt an active role in dealing with the 
pain. Pain can lead to passiveness. Numerous experiments have demonstrated that an animal 
or person who has no control over a situation can become passive and helpless. An animal 
that can avoid an annoying stimulus, such as a pain stimulus, by pressing a button will 
actively do so. An animal that receives as many stimuli but has no control over these will 
become passive and will eventually stop taking any more action. This type of experiment 
reflects the term 'learned helplessness’. In people, it is assumed that this occurs as a 
consequence of powerlessness under uncontrollable pain. It is expressed, for example, in the 
form of depression and catastrophizing, negative thoughts. Whereas some patients become 
passive, other patients tend instead to overexert themselves. If people attempt, come what 
may, to carry out a certain activity then the relative overexertion can lead to them being 
confronted in the following days with an extreme increase in the pain, which prompts them to 
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take a lot of rest. Such a yo-yo pattern that alternates between too much and too little exertion 
can better give way to a more uniform pattern of movements. 
Cognitive-behavioural therapy focuses on teaching patients how to identify better strategies 
for coping with and managing their chronic pain. Where the focus should lie depends on the 
individual patient's problem. After the patient and therapist have jointly determined some 
realistic treatment objectives, cognitive-behavioural therapy usually involves three phases. 
The first phase consists of education and mapping negative thoughts, detrimental behaviour 
and the patient's possibilities and realistic goals. In the second phase new thoughts and coping 
skills are learned and practised. Techniques that can be deployed include stress management, 
relaxation training, an improved planning of activities, instructions for improving the posture 
and using medical devices, working with exercises and a gradual increase of the physical 
condition (‘graded exercise’) or help in setting realistic goals with respect to the quality of 
life. The third concluding phase is focused on internalising the behaviour learned and not 
relapsing into negative thought patterns.  
 
8. Areas of uncertainties 
For many of the treatment modalities described above, the specific effects in EDS patients are 
not known; the reduced sensitivity for local anaesthetics in EDS patients indicates that this 
may be more than only a theoretical issue.  
 
9. Summary 
Other than the observation that pain is highly prevalent in the case of EDS, too little is known 
about the specifics of this problem. Treatment predominantly takes place according to general 
principles that are not specific for EDS. These treatment modalities were reviewed here. 
 
Addendum by the editors 
In the March 2017 issue of the American Journal of Medical Genetics Part C Seminars in 
Medical Genetics all papers were devoted to EDS, covering a new EDS nosology, new 
diagnostic criteria of the different types and also management related topics (see also chapter 
2). One of these papers entitled “Pain management in Ehlers-Danlos syndrome”, is 
recommended for further reading.
23 
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1. Introduction 
In the last decade, scientific research in the area of hypermobility related disorders has grown 
exponentially. Despite the accumulation of scientific knowledge, these categories of patients 
remain challenging for most clinicians due to many issues surrounding aetiology, disease 
classification, diagnostics and treatment. Even for experienced physicians it remains hard to 
correctly identify patients and to determine which factors should be modified in order to get 
positive treatment outcomes. Historically, the diagnoses Benign Joint Hypermobility 
Syndrome (BJHS) and Ehlers Danlos Syndrome; hypermobility type (EDS-HT) were viewed 
as separate entities, however over the years it became clear that the diagnostic criteria had 
considerable overlap and were often found to be clinically indistinguishable. With the 
accumulation of scientific knowledge on both BJHS and EDS-HT, it became apparent that a 
revision of the diagnostic criteria was necessary in order to improve clinical care and 
scientific advances. In 2017, the diagnoses BJHS/EDS-HT were replaced by new diagnostic 
entities in terms of Hypermobility Spectrum Disorders (HSD) and Hypermobile Ehlers-
Danlos Syndrome (hEDS; for diagnostic criteria see chapter 2, table 2-5).
1,2
 Although 
scientific research on populations diagnosed according to the new theoretical framework and 
nosology is limited, the current chapter provides a theoretical framework which will aid 
clinicians in creating a personalized treatment strategy. The authors recognize that the 
evidence used within this chapter is based on scientific observations gathered on the old 
diagnostic criteria and that further research with the new diagnostic criteria is crucial in order 
to provide the most optimal care. Therefore the current theoretical framework should be 
viewed as conceptual and only serves as a starting point for clinical care. 
The objective of this chapter is to provide clinicians with a clinical model of hEDS and HSD 
for which treatment can be optimized to the needs of the individual patient. Due to the 
complexity of the symptom profiles of HSD/hEDS, the international classification of 
functioning (ICF) will be adopted as a central framework. The ICF is a multidimensional 
model of functioning with activities and participation as the key construct. This model 
provides a framework to describe limitations associated with an individual’s functioning and 
identifies influencing environmental factors. On this framework a clinical profile and 
treatment strategy can be based. 
 
2. Clinical profiles 
 
2.1 Clinical profiling 
Traditionally individuals with BJHS/EDS-HT are characterized by the presence of connective 
tissue laxity, in terms of Generalised Joint Hypermobility (GJH), hyperextensible skin and 
arthralgia. However over the years, it became clear that the nature of these disorders is far 
more complex and can be viewed as a unique pathological entity within the field of 
rheumatology.
3,4
 This is now recognized within the new diagnostic criteria of HSD/hEDS.
1
 In 
order to ensure maximum treatment efficiency, it is essential to have an accurate individual 
patient’s clinical profile that enables the health care provider to target the specific factors that 
will enhance functional recovery. The clinical profile is based on four clinical components 
(figure 22-1): (1) Connective tissue laxity, (2) Musculoskeletal dysfunction, (3) Multi-
systemic involvement and (4) Psychological dysfunction. 
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Figure 22-1  Phenotype of hyermobile EDS and hypermobility related disorders: symptom 
profile  
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2.1.1 Component 1: Connective tissue laxity 
It is assumed that GJH is an expression of generalized connective tissue laxity, in which joint 
capsules, ligaments, tendons and muscle structures are hyperextensible.
5-7
 Therefore, in 
HSD/hEDS the presence of GJH according to the Beighton criteria is a clinical feature. The 
Beighton score is considered as the gold standard from infancy to old age, and has been the 
most used instrument to classify GJH. Originally, the Beighton score was developed for use in 
research and not designed for clinical use (personal communication of Beighton). Although 
several studies confirmed good reliability and face validity, a considerable variation in test 
procedures has been described. This concerns not only the practical instruction of how to 
perform the various tests, but maybe more importantly, also variations in the cut-off level for 
a positive test and in the definition of GJH.
3
 It remains unclear which cut-off level is the most 
appropriate. In the previous classifications a score of ≥4 (EDS-HT ≥5) is considered to be the 
minimum level for GJH, independent of age, gender and ethnicity.
8
 Other cut-offs of ≥5, ≥6, 
≥7 have also been suggested, but the validity of these cut-off values can be debated. Recent 
studies have shown that a Beighton score of ≥6 at the age of 10 is a predictor for pain 
recurrence and persistence at 14 years,
9-11
 and a Beighton score of ≥6 at the age of 14 is a 
predictor for general pain at 18 years of age.
12
 This would suggest that scores ≥5 would be 
more appropriate. However with increasing age, joint laxity decreases, which may imply that 
a cut-off level of ≥4 eventually may be more appropriate.
13
 In addition, gender and ethnicity 
specific effects on joint laxity have been documented and should also be incorporated in the 
classification of GJH (see chapter 2 for age and sex related cut-off values for the Beighton 
score, used in the new criteria of hEDS). The Beighton score requires information on 
hypermobility in 4 joints (thumb, little finger, elbow and knee) and spine, whereas no 
information is required on other joints, e.g. shoulder and hip joint. Within the current 
diagnostic criteria, no such distinction is made. Furthermore, there is little knowledge on the 
natural course of GJH with increasing age, which also complicates clinical diagnostic 
procedures.
14,15
 
Skin features are the second most distinguishing clinical characteristic that is related to 
connective tissue laxity. Hyperelasticity, scarring, bruising, smooth and velvety skin have 
been incorporated into the diagnostic criteria;
16
 however the methods of assessment have not 
been specified in either Villefranche nor Brighton criteria sets (see chapter 2 for criteria for 
skin hyperextensibility).
3
 
Recent research (figure 22-2: blue connections) has shown that the presence and grade of GJH 
are clinical findings that are directly associated with disability.
17,18
 They have also been 
demonstrated to be associated with pain, fatigue, muscle weakness, dysautonomia and 
anxiety.
5,17-20
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Figure 22-2 Suspected interactions and relations of symptoms in the context of the 
International Classification of Functioning, Disability and Health (ICF) 
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2.1.2 Component 2: Musculoskeletal dysfunction 
The presence of chronic pain is a frequent clinical feature that is present in many patients 
diagnosed with HSD/hEDS and a major diagnostic criteria in the BJHS and EDS-HT 
diagnoses. Pain is often characterized from mild to severe, affecting multiple joints which 
may vary over time and may occur episodically but sometimes persists and becomes chronic. 
In a selected group of patients with musculoskeletal pain seeking specialized care, GJH is 
prevalent in 9%-57%,
12,18,21,22
 exceeding the anticipated prevalence scores of 10-20% in the 
general population.
23
 Although this increased prevalence for GJH in chronic pain patients is 
striking, a minority of persons with GJH will probably develop a chronic pain syndrome, 
which negatively impacts daily life, interferes with work and leisure time activities (figure 22-
2: red connections).
12,18,21,22
 Pain can also directly modify muscle strength and proprioception 
dependent modalities, which may cause additional deconditioning and loss of motor control 
through reflex inhibition.
24
 The second dominant symptom is fatigue.
25
 Fatigue is highly 
prevalent amongst individuals with GJH
26
, HSD/BJHS, and is considered by patients to be 
one of the most disabling symptoms. Recent literature shows that in 75% of all included 
patients with EDS-HT/BJHS severe chronic fatigue was present.
25
 In patients who were more 
severely fatigued, higher levels of impairment and psychological distress were present (figure 
22-2: red connections).
26
 
It is assumed that deconditioning occurs as a consequence of (in)activity related overuse 
which results in under-activity in order to recover.
27
 Consequently, there is a downward spiral 
of less activity due to fear and more pain with less provocation, leading to deconditioning.
27
 
Reduced exercise capacity and muscle weakness have been extensively documented in 
BJHS/EDS-HT patients, and have also been shown in high-level athletes with GJH and 
healthy individuals with GJH in the absence of chronic pain. The presence of muscle 
weakness and reduced exercise tolerance in asymptomatic GJH may imply that 
deconditioning also directly (i.e. not via under-activity) is associated with connective tissue 
laxity.
17,18,28
 Scientific literature shows that muscle weakness is an important clinical finding 
that is not only associated with disability (figure 22-2: yellow connections), but has also been 
found to be strongly associated with pain and fatigue (figure 22-2: red connection). 
In the last decades, evidence has accumulated on the existence in the symptom profile of 
BJHS/EDS-HT of a neurological pathway, in which proprioception (peripheral nervous 
system) and generalized hyperalgesia (central nervous system) are implicated in the 
development of pain. Proprioception is a specialized sensory modality that provides 
information about position, movement and sense of resistance which is transmitted by a 
variety of sensory receptors in the periphery.
30
 In theory, proprioceptive deficits may disrupt 
motor control and cause joint instability which in turn may lead to micro-fractures on joint 
surfaces. Literature to date only reports the incidence of proprioceptive deficits, with no 
evidence on the clinical relevance of these findings nor on their role in the development of 
complaints in subjects with GJH.
18,29
  
The presence of generalized hyperalgesia in adult patients with EDS-HT has been described.
30
 
Subjects with EDS-HT had considerably lower pain pressure thresholds in symptomatic and 
asymptomatic areas, compared to healthy controls. It was hypothesized that central orientated 
upregulating processes are present within the central nervous system. Due to centralized 
sensitization, subjects with BJHS/EDS-HT may be more susceptible to pain and fatigue. 
Recently these neurological features have also been described in children and were found to 
be discriminative between BJHS/EDS-HT, GJH and healthy controls.
31
  
 
2.1.3 Component 3: Multi-systemic involvement 
Although EDS-HT/BJHS is traditionally viewed as a disease with primary locomotor 
complaints, in some patients multi-systemic symptoms dominate the symptom profile. Multi-
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systemic complaints like gastro-intestinal issues, incontinence as well as dysautonomia have 
been documented.
4,14,18-21,32,33
 Regarding sympathic regulation, patients tend to have 
abnormalities within both sympathetic resting activity and sympathetic reactivity.
23,24
 
Dysautonomia manifesting in erratic heart rate (heart rate variability), as well as reactions on 
sudden changes of external stimuli, such as blood pressure fall during Valsalva manoeuvre, 
orthostatic intolerance and postural tachycardia, have also been shown as an integral part of 
the phenotype of JHS/hEDS.
19,20
 
Multi-systemic signs and symptoms have been found to be directly associated with disability 
in terms of decreased quality of life (figure 22-2: green connections).
19,20
 In addition, a 
positive association with connective tissue laxity, pain and deconditioning has been shown, 
indicating that with increasing severity of multi-systemic symptoms, the severity of perceived 
pain and deconditioning increases.
19,20
 In children with BJHS/EDS-HT, it has been 
demonstrated that the presence of multi-systemic features like postural orthostatic 
tachycardia, skin scarring, bowel issues and chronic diarrhoea were found to be predictive for 
escalating pain, fatigue, muscle weakness and progressive disability.
34
 The importance of 
multi-systemic features have only been established in children and are not yet established in 
adults, however it is assumed that multi-systemic features are also an important clinical 
feature in adults as well.  
 
2.1.4 Component 4: Psychological dysfunction 
The impact of BJHS/EDS-HT on daily life seems not to be solely explained by a person’s 
level of hypermobility.
35
 High Beighton scores alone do not account for more impairments in 
daily life. It seems that besides biomedical factors, psychosocial factors also contribute to a 
person’s level of disability. In the chronic pain literature, a fear-avoidance model has been 
introduced to explain the disabling role of pain-related fear,
36
 which has been confirmed by 
numerous studies.
36-38
 It states that highly fearful persons who tend to catastrophize, will 
avoid activities they perceive as harmful or pain provoking. In the long term, this avoidance 
behaviour can result in disability, deconditioning and depression, further fuelling the vicious 
circle of disabling musculoskeletal pain. 
It could be that pain related fear will have an accumulating disabling effect in hypermobile 
persons with pain. In the case of a new onset of musculoskeletal pain, fear of pain will trigger 
avoidance of painful muscle contractions, leading to subnormal muscle performance. For 
persons with joint hypermobility, it is hypothesized that subnormal muscle performance will 
possibly have the immediate negative consequence that the muscles’ compensation 
mechanism, essential for joint stability, will fail. Functional consequences, such as impaired 
balance ability and reduced balance confidence, will further fuel fear of movement and 
catastrophizing thoughts about pain and vice versa. In fearful hypermobile patients, a painful 
stimulus can thus, even in the short term, lead to a high level of disability, depression and 
disuse.
39
 
The high prevalence of both anxiety and joint hypermobility in patients with musculoskeletal 
pain, could indicate that this hypothesized mechanism may explain disability in a substantial 
subgroup of patients.
35
 A finding that seems to support a common pathway for hypermobility 
and anxiety, is an increased prevalence score for joint hypermobility in patient populations 
with other anxiety related problems: 62% of patients with a panic disorder appeared to be 
hypermobile.
40
  
 
2.2 Clinical profile assessment 
When considering the highly heterogeneous clinical presentation of EDS-HT/BJHS or 
HSD/hEDS patients, simply classifying each individual on the basis of criteria will not suffice 
and may even lead to an unsuccessful treatment.
18,21,32
 Therefore, it is essential that each 
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patient is profiled on all aspects of the ICF model to enable the creation of an individualized 
tailored treatment regime.
41
 Currently no international consensus exists on which outcomes 
are the most clinically relevant and by which measures these should be assessed.
6,14,18,21,27,32
 
The recommendations presented in this paragraph for the clinical profile assessment should be 
merely viewed as recommendations and should be adjusted to the individual context of each 
health professional (e.g. available equipment, time constraints, training) and patient (e.g. 
cognitive level, physical issues that render the patient unfit to be tested). The suggested 
clinical profile will consist of the previously mentioned components: disability, connective 
tissue laxity, musculoskeletal dysfunction, multi-systemic involvement and psychological 
dysfunction. It should be pointed out that when engaging in a diagnostic assessment of a 
HSD/hEDS patient, multi-disciplinary cooperation is vital and may even be considered as a 
necessity. The presented examples of outcome measures are derived from literature and 
personal experience of the authors. 
 
2.2.1 Disability 
Disability is a multi-dimensional concept defined as a patient-oriented health outcome which 
contains aspects of individual daily functioning, including physical, psychological and social 
factors.
42
 Reducing disability is often used as a primary outcome in a variety of study designs, 
whereas an operational definition is frequently lacking.
43
 It can, however, be operationalized 
in both capacity and performance measures, where capacity refers to what a patient can do in 
a standardized environment, and performance to what a person does in daily life.
44,45
 
Regarding capacity qualifiers, it can be advised that standardized tests on functional outcomes 
like walking, transfers and activities of daily living are incorporated. A functional assessment 
based on the specific needs of the patient would form an integral part of the assessment which 
should be complemented by standardized testing. Standardized tests like the 6 minute walk 
test,
46,47
 and chair rise test
47
 would be suitable and are frequently used in clinical practice. In 
addition, for these measures there are normal values available as an aid in the assessment of 
the grade of disability. Currently, more modern measures of disability are available in terms 
of continuous activity monitoring. Although these measures are more costly and not often 
used in clinical practice, it could be recommended that when a more detailed assessment of 
activity patterns is indicated, these type of outcome measures are applied, especially in 
children.
48
 Measures of disability performance are often assessed during medical history 
taking and should be complimented by questionnaires. Assessors should choose the most 
appropriate set of questionnaires, based on age, goal and patient preference. Generic 
questionnaires like the Health Assessment Questionnaire
49
 and the Child Health Assessment 
Questionnaire
50
 are recommended as they have been validated, have normal values, account 
for the use of assistive devices, and are available in multiple languages. 
 
2.2.2 Connective tissue laxity 
It is recommended that connective tissue laxity is assessed when joints and skin are relaxed, 
by observation and testing. A general view on the grade of laxity may be informative on the 
status of connective tissue; however no evidence is available that shows that disease severity 
is associated with increasing connective tissue laxity.
5
 The presence of GJH according to the 
Beighton score is traditionally scored within the diagnostic criteria, but should also be 
monitored over time. When using the Beighton score it is crucial that it is performed 
according to a standardized protocol and more importantly, assessors should be well 
experienced when using the Beighton score.
8
 Despite the simple appearance of the Beighton 
score and its applicability, it should not be underestimated and intensive training / inter-
assessor consensus is essential.
8
 The protocol by Smits et al., which makes use of a 
goniometer in order to increase precision, can be recommended for the standardisation of the 
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Beighton score.
51
 GJH is classified if a score of ≥5 is obtained, when using the Villefranche 
criteria, irrespective of age, gender and ethnicity. Despite the central role of GJH in the 
diagnostic criteria, much discussion exists on the cut-off value for GJH.
3
 Therefore, it is 
recommended that other measures of joint mobility are incorporated in the assessment of 
connective tissue laxity like goniometry and skin laxity. Goniometry with proper training can 
be a valuable tool for assessing individual joints,
52
 especially when comparing measurements 
with normal values. Skin assessment should be performed by visual inspection on the 
appearance of the skin (bruising, scarring) and palpation (smooth, velvety feel). A general 
inspection of the whole body is recommended. Regarding skin laxity, manual testing at the 
volar aspect of the forearm is frequently applied and is sufficient in order to identify 
hyperextensibility (yes/no). More advanced measures of skin extensibility are available; 
however, their clinical relevance has not yet been established. 
 
2.2.3 Musculoskeletal dysfunction 
Regarding pain, it is important to not only document its location but also its severity and 
duration. Traditional measures like the visual analogue scale (VAS) or numeric rating scale 
(NRS) are often included in the clinical assessment. It is important to quantify pain as a 
general measure but also to assess the pain intensity for each individual location.
53
 Pain body 
schemes like the Pain Manakin not only provide information on the location of pain but can 
also be converted into a percentage of painful body surface, which informs on the spread of 
pain.
54
 Also pain sensitivity measurement may be a useful addition to the clinical profile, by 
assessing pain pressure thresholds, which inform on the sensitivity for pain.
30
 Fatigue can be 
assessed in a similar way as pain severity by VAS or NRS; however, chronic fatigue may also 
be viewed as a state in which biological fatigue is hard to discriminate from mental fatigue. 
Questionnaires like the Checklist Individual Strength
26
 in adults and the Multi-dimensional 
Fatigue Scale in children
55
 are examples of questionnaires which assess the full scope of 
fatigue related problems.  
Muscle weakness can be assessed by the use of handheld dynamometers,
56
 which can 
accurately quantify the extent of muscle force and can be related to age and gender related 
normal values. However, these measures do not necessary represent functional muscle 
strength. Therefore, it is recommended that functional strength measures are incorporated, 
such as repeated functional tasks (e.g. squatting, lifting), sit to stand, walking stairs, one leg 
stand, and jump tests (single leg hop, sidehop test).
18,45
 Manual muscle strength tests are not 
advised as they are only informative on muscle strength symmetry and are not suited to 
quantify and compare muscle force between patients.
56
 Cardiovascular exercise tolerance 
testing may also be indicated.
57
 Both bike (e.g. steep ramp protocol) and walk tests (e.g. 
Bruce treadmill exercise test) can be applied, depending on the available equipment. 
However, when engaging in maximal exercise testing, safety issues should be addressed and 
constant monitoring should be applied as a risk of cardiac complications is present. Field 
based tests like the shuttle walk test or stair climb test may serve as less intensive measures 
that can also estimate exercise capacity.
58
 Muscle weakness may also be caused by other 
medical conditions, e.g. neurological diseases; therefore differential diagnostics remains 
important. 
Proprioceptive deficits are mentioned frequently in medical literature and are often implicated 
as a potential cause for the development of pain. However, measures of proprioception are 
quite sophisticated and often not applicable in clinical practice. Standing balance (e.g. 
Romberg test, stork test) or functional observations on motor control/clumsiness may be more 
feasible.
59
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2.2.4 Multi-systemic involvement 
Multi-systemic involvement can present itself in numerous ways and is often missed by 
clinicians. Medical history assessment should involve specific questions regarding gastro-
intestinal complaints (organ dysfunction: abdominal pains, diarrhoea, constipation, 
incontinence), fainting (dysautonomia: syncope and presyncope), perceived heart beat 
irregularities (dysautonomia: palpitations) and issues of thermo-regulation after exercise 
(dysautonomia: like elevated body temperature). As the spectrum of these types of signs and 
symptoms is quite broad, the use of a standardized questionnaire is advised. Examples of such 
questionnaires are the Autonomic Symptom Profile
20
 and the Somatic Complaint List.
60
 
Measures specifically focused on dysautonomia, like the tilt test, are not advised as they 
involve specialized protocols and strict medical supervision. 
 
2.2.5 Psychological dysfunction  
Psychological dysfunction should be screened for in every patient and may prove to be 
invaluable during the treatment process. If psychological dysfunction is present, the expertise 
of a psychologist is indicated and should be incorporated in the treatment procedures. 
Screening for this dysfunction can be viewed as essential and needs to be performed on each 
patient. As time and disease symptoms progress, the odds of developing psychological 
dysfunction increase. At medical history assessment, clinicians should be aware of potential 
signs of depression (fatigue, mood, loss of initiative and appetite), anxiety and pain avoidance 
(anxiety associated with specific activities and or pain). Questionnaires for adults like the 
Hospital Anxiety and Depression Scale (HADS), a short questionnaire,
18
 and the Symptom 
Checklist (SCL-90),
61
 a more extensive questionnaire are useful generic measures of 
psychological dysfunction and are recommended. In children, the Revised Child Anxiety and 
Depression Scale, a short questionnaire,
62
 or the Child Behaviour Checklist,
63
 a more 
extensive questionnaire, are recommended. 
 
3. Tailored intervention 
Based on the clinical symptom profile, a tailored intervention may be constructed. Recently a 
consensus was reached by the Ehlers-Danlos Consortium on the rationality of treatment for 
HSD/hEDS patients. The current paragraph is based on this consensus statement, however it 
should be viewed as a summary. For a more detailed description of the available evidence for 
treatment as well as the background of the rationality for treatment we would like to refer to 
Engelbert et al 2017.
39
 The presented recommendations are based on current knowledge 
available and personal experience and should be adapted to the nature of the clinical profile, 
patient preference and context. An overview of all included studies on children
18,64,65
 and 
adults
12,66-70
 is shown in table 22-1. The best treatment strategy for highly disabled people 
with hypermobility is likely to be multidisciplinary. In this way, both physical (hypermobility 
and related deconditioning) and psychosocial (fear, depression, inadequate coping) 
components associated with pain can be addressed. During this treatment, patients will be 
guided in how to develop pain management skills and to change unhelpful coping strategies 
into helpful ones, in order to decrease disability. Based on systematic evaluation, positive 
effects of multidisciplinary behavioural treatment for patients with chronic pain syndromes 
have been confirmed.
71
 Whether multidisciplinary treatment specifically targeting 
pain/disability-related problems in hypermobile people is effective or whether it needs further 
adaptation to this specific group is currently unclear. As Keer and Simmonds mentioned in 
their review concerning joint protection and rehabilitation in the adult with a hypermobility 
syndrome,
72
 it is not yet known which form the optimal physical rehabilitation programme 
should adopt. As long as scientific data on optimal treatment is lacking, recommendations can 
only be made based on ‘best opinion’ (practice-based).
72,73
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In general, all treatment modalities that aim at enhancing physical fitness, in terms of muscle 
strength and exercise tolerance, have beneficial effects on pain.
12,18
 It is crucial when applying 
a physical training programme that a physiological baseline is established, which will prevent 
the occurrence of over or undertraining. Due to the unstable nature of the condition, training 
intensity should be adjusted to physical and psychological changes over time. It should be 
noted that the retention time of the accomplished treatment effects is limited. Therefore, 
maintaining adequate physical activity patterns is vital and should be recognised as a priority. 
The addition of cognitive therapy can also aid in preserving the achieved treatment effects and 
functional recovery. Although current research indicates that physical training in combination 
with a cognitive intervention is effective in pain management, effects on disability have not 
been shown. The addition of proprioceptive and postural control exercises (closed chain) have 
also been demonstrated as being effective on pain in children and adults. This combination of 
exercises will not only have effects on muscle power, but also on motor control.
12,65,69 
In recent years it has become clear that treatment intensity is very important. Exercise should 
be treated just as medicine, in which side effects may occur and the doses should be graded. 
In the initial phase (clinical profiling) relevant treatment variables are identified; individual 
goal setting should be the main focus. In the second phase physical training in combination 
with cognitive interventions (patient education or individualized psychological intervention) 
should be initiated in a graded fashion. Initially, the primary focus should be on the cognitive 
aspects and later on, it should be more on the physical aspects with increasing exposure to 
higher training intensity. During the whole treatment period, cognitive intervention should be 
part of the treatment regime (depending on the patient profile and his or her progression). In 
the final phase the focus should be more on education as well as on continuing adequate 
physical activity with adequate responses to recurrence of injury. In this phase, frequency and 
duration of patient-therapist contacts should be reduced and the patient should be enabled to 
be more independent and in control of his/her condition. After treatment has ended, patients 
are able to manage re-injury and are advised to contact the multidisciplinary treatment team 
only if required. Assistive devices are often prescribed in order to reduce disability and pain, 
however the use of such interventions is also controversial. Currently no evidence is available 
on the effectiveness of supportive devices and walking aids for this category of patients.
39
 As 
conserving and expanding the habitual activity should be a top priority in any intervention for 
HSD/hEDS
18,34,74
, the usage may be beneficial in certain cases however it may also cause 
further deconditioning and subsequent disability. Therefore, in line with the evidence 
statement, judicious use of assistive devices and walking aids is advised and should be made 
on an individual bases.
39
  
 
4. Areas of uncertainty 
As mentioned previously, the evidence presented in this chapter is based on patients 
diagnosed with BJHS/EDS-HT and it remains unclear if these findings are also applicable to 
patients diagnosed according to the newly adopted diagnostic criteria (HSD/hEDS). Although 
the new criteria are more specific, which would cause a shift in patient characteristics, it is 
expected that the basic principles as described in this chapter and in the evidence statement 
are similar. Recent knowledge on the natural course of disability is now available, in which 
the importance of multi-systemic issues have been demonstrated, still the pathological 
mechanisms underlying HSD/hEDS remain obscure. 
Future scientific exploration should focus more on longitudinal study designs in order to 
create (predictive) clinical models of HSD/hEDS from which risk profiles can be derived, 
with which patient trajectories and multidisciplinary treatment can be optimized. Until that 
time, clinicians should treat the recommendations in this chapter as guiding principles, which 
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should be constantly adjusted to the individual patient and his/her environment as well as to 
the individual context of the healthcare provider. 
 
5. Summary 
The diversity in signs and symptoms and the large heterogeneity of clinical presentation 
among patients with HSD/hEDS often pose a complex problem for healthcare providers in 
terms of diagnosis, assessment and treatment. The clinical presentation of the phenotype of 
HSD/hEDS can be described by four components: 1) Connective tissue laxity, 2) 
Musculoskeletal dysfunction, 3) Multi-systemic involvement, and 4) Psychological 
dysfunction. On the basis of these components a clinical profile can be derived from which a 
tailored intervention may be constructed. Although it remains unclear which treatment 
modalities (or combinations thereof) are best suited for HSD/hEDS, treatment should be 
tailored to the clinical profile of the patient and be applied in a graded fashion in order to 
ensure maximum effectiveness. 
 
Addendum by the editors 
In the March 2017 issue of the American Journal of Medical Genetics Part C Seminars in 
Medical Genetics all papers were devoted to EDS, covering a new EDS nosology, new 
diagnostic criteria of the different types and also management related topics (see also chapter 
2). One of these papers is entitled “The evidence-based rationale for physical therapy 
treatment of children, adolescents, and adults diagnosed with joint hypermobility 
syndrome/hypermobile Ehlers-Danlos syndrome”.
39 
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Table 22-1 Scientific literature regarding treatment modalities of BJHS/EDS-HT  
 
Author 
(year), 
individuals 
Type of 
intervention
Brief description of 
treatment modality 
Treatment 
specifics 
Evaluation 
points 
Author conclusion 
Bathen et al 
68
 
(2013) 
 
Adults 
Physical and 
cognitive 
rehabilitation 
 
Multi-disciplinary treatment: 
Medical, 
physical/occupational 
therapy, social worker 
Clinical admission: 
combination of physical 
treatment aiming at 
enhancing physical fitness 
(68% of all sessions, n=17), 
and cognitive intervention on 
pain management and 
lifestyle (42% of all sessions, 
N=8) 
Home exercise: physical 
exercise and monitoring by 
telephone 
Total duration: 
13.5 weeks  
Clinical 
admission:2.5 
weeks  
Home 
exercise: 12 
weeks 
Frequency: 4 
sessions a 
week 
Intensity: (?) 
Baseline at 
start of 
treatment; 
Re-admission 
and 
assessment at 
13 weeks (end 
of treatment) 
-Significant changes 
in perceived 
performance of daily 
activities and 
participation 
-Significant reduction 
of kinesiophobia.  
-Smaller changes in 
self-perceived pain.  
 
Rahman et 
al 
70
 
(2014) 
 
Adults 
Cognitive 
oriented 
approach 
 
Multi-disciplinary: Medical, 
psychology, physical therapy
Cognitive intervention on 
illness beliefs, pain 
management, relaxation and 
lifestyle advice 
Total duration: 
6 weeks 
Frequency: 1 
to 2 sessions 
a week 
Intensity: 7 
hours a week 
Baseline at 
start of 
treatment; 
10 weeks after 
baseline (T1: 
end of 
treatment) 
Follow-up: at 
26 weeks after 
baseline
-Significantly 
decreased disability 
and pain at T1. 
-at follow-up, the gain 
in disability regressed 
to baseline level, but 
the changes in pain 
perception were 
retained 
Ferrell et al 
69
 
(2004) 
 
Adults 
Physical 
rehabilitation  
Mono-disciplinary: physical 
therapy 
Home based physical 
exercise (open and closed 
chain exercises), aimed at 
enhancing proprioception, 
muscle strength and 
balance. 
Total duration: 
8 weeks 
Frequency: 2 
times a week 
Intensity: 
increasing 
number of sets 
and 
repetitions.
Baseline at 
start of 
treatment; 
End of 
treatment at 8 
weeks  
-Disability was 
significantly decreased 
after 8 weeks of 
treatment 
-Improvements in pain 
intensity: lower scores 
on VAS at 8 weeks 
 
(Continued on next page)  
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Sahin et al 
71
 
(2008) 
 
Adults 
Physical 
rehabilitation 
Mono-disciplinary: physical 
therapy 
Clinic based proprioceptive 
and balance exercises 
Total duration: 
8 weeks 
Frequency: 3 
times a week 
Intensity: (?) 
Baseline at 
start of 
treatment; 
End of 
treatment at  
8 weeks 
-Significantly decreased 
disability at 8 weeks  
-Improvements in pain 
intensity: lower scores 
on VAS at 8 weeks 
Barton et al 
67
 
(1996) 
 
Adults 
Physical 
rehabilitation 
Mono-disciplinary: physical 
therapy 
Clinic based joint stabilizing 
exercises  
Total duration: 
6 weeks 
Frequency: 3 
times a week 
Intensity: 
repetitions 
tailored to 
individual 
capabilities.  
No criteria 
specified 
Baseline at 
start of 
treatment; 
At 6 weeks 
after baseline 
(end of 
treatment) 
At 12 weeks 
after baseline 
(Follow-up) 
-Significant 
improvements in 
disability and pain at 
both time points 
Pacey et al 
65
 
(2013) 
 
Children 
Physical 
rehabilitation 
Mono-disciplinary: physical 
therapy 
Clinic based joint stabilizing 
exercises performed within 
hypermobile range versus 
neutral range 
Total duration: 
8 weeks 
Frequency: 
weekly 
sessions 
Intensity: 30-
60 minutes 
Baseline at 
start of 
treatment; 
At 8 weeks 
after baseline 
end of 
treatment); 
At 12 weeks 
after baseline 
(Follow-up)
-Significant 
improvements in 
disability and pain at 
both time points in both 
groups 
Kemp et al 
66
 
(2009) 
 
Children 
Physical 
rehabilitation 
Mono-disciplinary 
Clinic based proprioceptive 
and balance exercises 
versus physical training 
alone 
Total duration: 
6 weeks 
Frequency: 
once a week 
Intensity: 
physical 
training: 30 
seconds 
intervals. 
Proprioceptive 
exercises: No 
criteria 
specified
Baseline at 
start of 
treatment; 
At 6 weeks 
after baseline 
(midterm of 
treatment); 
At 12 weeks 
after baseline 
(end of 
treatment) 
Both interventions 
demonstrated significant 
pain reduction, but no 
between- groups 
difference. 
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1. Introduction 
At admission to a hospital, a patient usually knows less about his or her illness than the 
department nurse. However, this is often not the case for patients with the Ehlers-Danlos 
syndrome (EDS). There are two reasons for this. First, these syndromes are so uncommon that 
a nurse will probably never have had to deal with it before and will therefore neither 
recognize the syndrome nor the symptoms. Second, for many patients being diagnosed with 
EDS has been such a long, difficult process that, during this time, they will have studied their 
own symptoms and have discovered the collagen disorder for themselves.
1 
More than many other illnesses, EDS are disorders that are different for each patient. The 
specific nature of these disorders requires great dedication of both the nurse or nursing staff 
and the patient. The nurse must listen professionally and critically to the patient if they are to 
work together well. The patient must take the time to explain what EDS is to the nurse and 
must in particular explain its specific consequences for him/her as a patient. 
This chapter’s goal is to clarify the nursing procedures required for these disorders and to 
explain how a nurse can best deal with a patient with EDS, who is admitted to hospital. 
Throughout the text the term EDS may indicate EDS. 
 
2. Types of EDS 
The 2017 International classification distinguishes 13 types of EDS (see chapter 2). These 
types share a number of symptoms. Only three of the most common types will be discussed in 
this chapter: the classical, hypermobile and vascular EDS, which together account for 90% of 
the prevailing EDS cases. Recently, the two conditions benign joint hypermobility syndrome 
(BJHS) and EDS hypermobility type have been recognized as one and the same clinical 
spectrum ranging from apparently symptomatic generalized joint hypermobility to the most 
disabled individuals fitting the new diagnostic criteria. These new criteria are more strict than 
the Villefranche criteria and the Brighton criteria for BJHS in order to define a homogeneous 
phenotype for management and scientific purposes. Within the new EDS nosology, its name 
is hypermobile EDS (see chapters 2 and 5). However, to a greater or lesser degree 
hypermobile joints, highly elastic skin and bruising are common to all types. Table 23-1 
shows the extent to which these 3 problems occur among six of the 13 types of EDS. 
 
3. The medical history taking 
A number of problems and issues relating to the syndrome require attention when admitting 
an EDS patient to hospital for a procedure or operation. These play a role in addition to the 
indication for admission and should be included in the history taking of the nurse. To a greater 
or lesser degree, there are four prominent chronic problems.
1 
 
1. hypermobile joints, possibly with (sub)luxation or dislocation as a result; 
2. highly elastic, fragile skin (where serious injury can result from limited trauma); 
3. skin which bruises easily (haematoma) because the connective tissue around the blood 
vessels is less strong. 
4. in vascular EDS, the connective tissue within the blood vessel walls and the hollow organs 
(intestines, heart, etc.) is weak, resulting in a high risk of bleeding and ruptures. In the 
other EDS types, the connective tissue around the blood vessel walls is less tight, resulting 
in an increased risk of haematomas (see chapter 6). 
 
For this complex disorder in which many organs and organ systems may be involved, a 
thorough medical history taking from each individual with EDS is of the utmost importance. 
Thereafter, a specific nursing plan can be drawn up. For a patient with EDS, the areas which 
initially require nursing care will emerge from the medical history. 
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During the history taking, the nurse will integrate the 11 health patterns (box 23-1) with EDS-
specific issues and individual specific problems. 
 
Box 23-1 Classification of 11 functional health patterns
2 
 
 
1. Health perception – health management pattern 
2. Nutritional - metabolic pattern 
3. Elimination pattern 
4. Activity - exercise pattern 
5. Sleep - rest pattern 
6. Cognitive – perceptual pattern 
7. Self-perception pattern 
8. Role relationship pattern 
9. Sexuality - reproductive pattern 
10. Coping - stress intolerance pattern 
11. Values – belief pattern 
 
When designing a specific nursing plan, basic assumptions are the following.  
Each patient experiences medical problems differently and each one tries to maintain mental 
and physical health in his or her own way.
3
 A deteriorating condition such as EDS can 
severely impair mental well-being and physical functioning. 
Activity patterns are partially determined by the degree of pain and fatigue experienced. 
Although thinking about symptoms and the effect of exercise has changed greatly in recent 
years – for many disorders, symptoms are reduced by exercise – it is very important for EDS 
patients to carefully alternate rest and exertion. The patients themselves generally know their 
individual ‘instructions for use’ well.
2
 
Regarding dietary and metabolic patterns, factors such as diet, stomach and intestinal pain, 
constipation or complications such as a rectum prolapse will influence how a patient deals 
with the problems. Each patient experiences, accepts and deals with the burden of a chronic 
disorder differently. 
When nursing a patient with EDS, it is important to determine the nature and seriousness of 
the symptoms. This applies both to the symptom-related problems as well as to the problems 
leading to hospitalization. It is also important to bear in mind that the patient’s condition may 
vary greatly each day or even throughout the day. It is not unusual for a patient to be able to 
perform all the normal daily activities independently in the morning and to need help and 
assistance to change clothing in the evening. 
 
Case study 
A 45-year-old woman checks in at the gynaecology department in order to be admitted for 
removal of the uterus via the abdominal wall (abdominal uterus extirpation). When the 
patient is greeted upon arrival, the nurse shaking the patient’s hand notices that it feels 
‘strange’, like a velvet flannel with bones. The patient has classical EDS. The skin of 
patients with this type of EDS feels velvety soft and doughy.  
Notably, the patient has taken along her own mattress and pillow since she is unable to lie 
on hard hospital beds because of neck and back pain resulting from hypermobile joints. She 
explains that for her hypermobile EDS, primarily of the smaller joints such as those of 
fingers, ribs and the wrists, plays an important role. She is chronically constipated and 
frequently has intestinal complaints. 
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To ensure that the operation, hospitalization, discharge and convalescence of an EDS patient 
are as successful as possible, it is important that a thorough medical history is taken.  
Below is described how the process of admission, pre-operative screening, pre-, per- and post-
operative support, convalescence and discharge can optimally be controlled. 
 
3.1 Admission 
The issues requiring extra attention during medical history taking are: 
• use of medicine 
In many cases, the patient will be using various medicines, some on demand, such as pain 
killers. Will the patient be also responsible for managing these at the ward? Make sure there 
are clear arrangements about this particularly in relation to the department’s prevailing policy 
on pain control. If a patient is already using pain killers, the department’s policy may need to 
be adapted to this to prevent the patient either from becoming overdosed or from having to 
change to a medication cited in the formulary. 
• allergies 
Besides any allergies, most EDS patients are hypersensitive to plasters. In addition, 
sometimes when sticky plaster is removed, part or all of the epidermis is torn. In such cases, 
other solutions for affixing bandages must be sought, such as elastic bandages or compresses. 
• eating habits 
It is not unusual for a patient to have an adapted diet because of sensitivity or intolerance of 
the intestines or a hypotonic gastrointestinal tract (see chapter 10). There is higher risk of 
constipation as a result of lengthy bed rest. You and the patient should keep an eye on this; if 
necessary, ask a dietician to set up a diet enriched with fibre and with plenty of liquids. 
Many EDS patients suffer from a motility disorder in the gastrointestinal tract and use 
medication for this. Narcotics and bed rest can increase these problems. You and the patient 
should keep an eye on this and take timely action, for instance by taking measures such as the 
use of lactulose and a micro enema and avoidance of medication known to aggravate these 
problems.
3 
 
3.2 Pre-operative screening 
The following issues are of importance:  
• Does the patient have problems with moving his or her head or opening his or her 
mouth, predicting problems at intubation? 
When anaesthetizing such patients, a number of precautions should be kept in mind. When a 
patient is under anaesthesia, the muscles relax; in EDS patients these muscles help to stabilize 
the hypermobile joints. Thus, there is an increased risk of joint (sub)luxation. The patient 
must therefore be moved with the utmost care. The anaesthesiologist should also carefully 
monitor the patient’s maxillary joints while inserting a tube into his or her throat. Also these 
joints can get luxated easily. The risk of a headache after the operation is reduced by 
repositioning of the jaws and removing the tube as quickly as possible if this occurs.
4 
• Does inserting a needle to draw blood or fasten a drip prove to be problematic? 
The nurse or doctor should be aware of the fact that the patient's vessels are fragile and tend to 
roll away from the tip of the needle. The vessels do not contract well either or the collagen 
around the vessels is less tight, increasing the chances of serious haematomas. Huge bruises 
can result from a misplaced injection or needle insertion because the tissue around the vessels 
is less firm. It is advisable to ask someone with a great deal of experience with injections or 
needle insertion to perform this task, to prevent extra pain and injury. 
• In some patients with EDS local anaesthetics are not as effective as expected. So, 
when local anaesthesia is planned, this should be taken into account. 
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3.3 Pre-, per- and postoperative support 
• In addition to the acute pain brought on by the operation, EDS patients also may 
experience chronic pain in various places in the body. This is the result of hypermobile 
and sometimes damaged joints, joint capsules and muscles. It is advisable to discuss 
the possibilities of pharmacological pain management before surgery and to call a 
physiotherapist early on after surgery for support during the often slow 
convalescence.
5
 
• There is a higher risk of postoperative sleeplessness as a result of the pain caused by 
the operation in addition to the already existing chronic pain symptoms caused by 
EDS. The patient and nurse should discuss how best to deal with this problem. Lying 
in bed for long periods often leads to back pain. The patient may require more exercise 
that the standard operation protocol dictates. However, if the patient suffers from 
complaints of the back and pelvis resulting from lying on a hard operation table, it 
may not be possible to follow the mobilization protocol because a few days of bed rest 
are needed before mobilization can be initiated.
6
  
• Due to the patient's highly fragile skin, there is an increased risk of decubitus ulcers 
(bedsores, pressure ulcers). On medical grounds, the EDS itself calls for an anti-
decubitus mattress. In the case above, the patient took her own pillow along 
(remember the risk of sub-luxation of the maxillary joints) to enhance her comfort 
when lying down and sleeping. If the patient is bed bound, a dietician can prescribe a 
diet high in protein. Bedsores can be prevented by changing positions, through 
massage and by mobilizing the patient as early and much as is possible. 
• It is important to monitor bleeding at the incision site. Due to poor quality of vessel 
walls, poor vessel contraction and possibly bleeding disorders (see chapter 11), the 
risk of continued bleeding after the operation is higher. 
• Total floppiness (hypotonia) of the organ walls is an important issue to watch for. In 
cases of an abdominal injury, a spica elastic bandage can be applied to prevent further 
bleeding. 
 
Among patients with vascular EDS vessel and organ problems will be prominent far more 
often than normal. Upon meeting patients with this vascular EDS, one will notice the thin 
transparent skin. Sometimes (certainly not always) people with this type of EDS have 
characteristic facial features such as a pointed noise, hollow eyes, missing ear lobes and 
down-slanting eyelids; more often they have an aged aspect of the hands (acrogeria). The risk 
of the vessel and organ walls tearing is greatly increased among patients with vascular EDS. 
Because of the close contact between the nurse and patient at the ward, the nurse will be the 
first to notice the symptoms of these complications; she or he should take action immediately. 
Although it is generally wise to have an intensive care bed available for EDS patients, for 
surgery upon patients with the vascular type, it is prerequisite. 
 
3.4 Convalescence and discharge 
In part due to issues involved in each individual patient, it is difficult to make any generalized 
judgment about the extent and intensity of an EDS patient’s convalescence or what help may 
be required at home after discharge. The individual need for further care will have to do with 
factors such as the number of days which have elapsed since the surgery took place, the 
patient’s condition and ability to manage independently prior to the operation and the extent 
of pain and disability.  
A slow recovery and extended convalescence period often have consequences for the duration 
of the hospitalization. In order not to extend this time longer than needed , it is important to 
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give timely attention to the issue of whether homecare and possible other resources have to be 
provided or not. 
 
4. Summary 
The relatively rare EDS is an unknown disorder for many nurses. Although there are 
differences in symptoms and degrees of seriousness, three problems occur among patients to a 
greater or lesser degree: 1) hypermobile joints, 2) highly elastic, fragile skin and 3) easy 
bruising. A nurse who has to take care of a patient with EDS will have to have to gain some 
knowledge of the symptoms and can, through the nursing diagnosis, determine the range of 
problems as well as the related contributory factors and consequences. By doing so, he or she 
can prevent a number of complications and also reduce their seriousness. 
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Table 23-1 Impact of the three main problems associated with six of the 13 types of EDS*# 
 
 
Types of EDS 
Highly elastic 
skin 
Hypermobile 
joints 
Frailty of 
vessels and 
organs 
Classical EDS +++ + + 
Hypermobile EDS + +++ + 
Vascular EDS + + +++ 
Kyphoscoliotic EDS + ++ + 
Arthrochalasia EDS ++ +++ ++ 
Dermatosparaxis EDS ++ +++ + 
 
* + limited ; ++ moderate ; +++ severe impact 
# see chapter 2 for the 2017 EDS nosology  
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1. Introduction 
Occupational therapy does not focus on a particular disease, disorder, or the treatment of 
symptoms, but rather on performing daily activities. Together with the patient, occupational 
therapists try to ensure that, as far as possible, patients are able to do what they want to do 
despite their limitations. Unlike in the past, the emphasis these days is not so much on 
independence, but on being able to carry out ‘meaningful’ tasks; in other words making it 
possible for the patient to do the things that are particularly important in his or her life. This 
principle means that patients with Ehlers-Danlos syndrome (EDS) have to make choices, such 
as deciding how they want to spend the limited energy they have. It is important that patients 
are aware of their limited physical capacity.  
Therefore, setting priorities in this way is an important aspect of occupational therapy. The 
reasons for a patient’s limited ability to participate in certain activities can be determined by 
analysing their situation. In collaboration with the patient, whilst taking their individual 
situation into account, occupational therapists can set realistic objectives and try to find 
solutions by adapting those activities and making use of various assistive devices. Whether 
such a device is suitable depends not only on the patient’s physical limitations, but also on the 
assistive device used and the way in which the patient and his/her social environment deals 
with their illness. 
In general, occupational therapy can only be successful once a patient has accepted his/her 
limitations, at least to a certain degree. Only then, the patient will be able to focus on adapting 
his/her lifestyle, applying the rules of daily living and finding practical solutions. 
Occupational therapists not only offer advice regarding assistive devices or adaptive 
measures, but also examine the ways in which activities are carried out. Particularly, muscle 
and joint problems can result in functional limitations in hypermobile patients. The use of 
joint protective measures is therefore an important aspect of the therapy, the starting point of 
which is being able to find a balance between physical load and capacity. Occupational 
therapists can also advise patients with skin disorders on skin protective measures. 
This chapter deals with problem analysis and treatment in patients with EDS from an 
occupational therapy point of view. In addition to joint and skin protective measures, this 
chapter also includes information on the use of assistive devices, adaptive measures, orthotics 
and other aids. It is appropriate to note that recently the two conditions benign joint 
hypermobility syndrome (BJHS) and EDS hypermobility type have been recognized as one 
and the same clinical spectrum ranging from apparently symptomatic generalized joint 
hypermobility to the most disabled individuals fitting the new diagnostic criteria. These new 
criteria are more strict than the Villefranche criteria and the Brighton criteria for BJHS in 
order to define a homogeneous phenotype for management and scientific purposes. Within the 
new EDS nosology, its name is hypermobile EDS (see chapters 2 and 5). 
 
 
2. Problem analysis in occupational therapy 
 
2.1 Method of approach, issues and objectives 
Occupational therapists take a holistic and system-oriented approach, in other words they 
regard the patient as a whole and in relation to his/her environment. This approach is 
particularly important when patients have to readjust their lives, set new goals and rediscover 
balance in various areas of their lives.  
 
Occupational therapy focuses primarily on the functional limitations experienced by the 
patient. Problem analysis may yield that a patient with EDS has difficulty performing many 
basic skills such as sitting, or sitting for a longer duration, walking, standing, getting up, 
bending, stretching, raising limbs, lifting and holding on to things. This can result in 
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limitations with regard to all manner of activities; these activities can be divided into the 
following categories: mobility (walking, climbing stairs, using a wheelchair), personal care 
and housework (washing, combing hair, fastening clothing, cooking, cleaning), 
work/schoolwork and leisure activities. 
Functional limitations can have significant social and emotional consequences. Occupational 
therapists therefore focus not only on independence, but also on issues such as meaningful 
daily living or satisfying social contacts: in short on the patient’s quality of life. Occupational 
therapists help patients to resume these activities in cases where the patient would regard the 
inability to perform them as a handicap. If this is not a realistic target, the occupational 
therapist will try, together with the patient, to find suitable alternatives.  
 
2.2 Complicating factors: many concurrent problems and limited duration  
Limitations experienced by hypermobile patients are primarily due to muscle and joint pain, 
fatigue and joint dislocation/subluxation, including the risk of these. Patients usually suffer 
complaints in several joints at once, and in EDS these are often accompanied by other 
problems, such as skin disorders. When using assistive devices or splints, it is important to 
take into account the potential negative local effect on the skin, and the fact that stress 
reduction in one joint or body part may lead to excess physical strain on another. 
Occupational therapy should also take into account that patients with EDS can only carry out 
certain activities for a limited duration. Many activities are painful, yet not impossible to 
perform. Although total avoidance of pain and movement leads to further physical decline, 
this also applies for excess physical strain and suppression of the pain. It is therefore 
important, albeit extremely difficult, to achieve the right balance between physical load and 
capacity. A daily and weekly programme, including both sufficient activity and rest, is 
essential. It can keep fatigue within acceptable levels, which some patients find a greater 
obstacle than the pain. It is also important that patients learn to deal with pain. A general rule 
of thumb is that a particular activity is not damaging if the pain subsides relatively quickly 
once the activity is stopped. However, an activity may be regarded as causing excess physical 
strain if the pain and fatigue generally last longer than two days.  
 
3. Adapting activities, applying the rules of daily living  
 
3.1 Joint protective measures  
Occupational therapists try to ensure that patients learn to perform activities in such a way 
that these cause a minimum of strain, yet are carried out to the best of the patient’s ability. 
This may involve adapting the way in which an object is held, adapting the patient’s posture 
or carrying out the sub-tasks involved in the activity in a different order so that, for example, 
the patient can walk a longer total distance than before. For patients with generalised 
hypermobility, adaptations usually call for the use of measures that help protect the joints. 
These joint protective measures are described below as rules of daily living, which have been 
adapted from those used in the treatment of rheumatoid arthritis. It is essential that the patient 
has knowledge of his/her own abilities and limitations in order to apply the rules of daily 
living correctly, by means such as, but not limited to: 
 
a) Maintaining optimal physical condition.  
This includes getting a good night rest (a good mattress, pillow and an armchair for resting 
during the day), maintaining muscle strength and movement, maintaining a healthy diet and 
body weight, wearing adequate footwear and avoiding cold and damp environments. Excess 
physical and mental stress should be avoided whenever possible.  
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b) Alternating periods of activity with rest and stick to a balanced programme of daily and 
weekly activities. 
It may be advisable to plan periods of rest and to divide tasks into smaller sub-tasks. Many 
people with hypermobility syndromes plan extra rest periods and only light tasks or no tasks 
at all towards the end of the day, when they often experience an increase in symptoms. For 
others, it is important to begin the day slowly and not to plan many tasks straight away. 
Productive days can also be planned, but these should generally be alternated with less busy 
days. 
 
c) Using alternate methods for performing various activities.  
It may help to perform certain activities while sitting in order to save energy and reduce the 
physical stress caused by those activities, such as showering, getting dressed, making 
sandwiches, cooking, ironing, and enjoying hobbies. Applying ergonomic principles can 
make it easier to perform certain tasks. Placing appliances such as refrigerators, dishwashers 
or washing machines at a suitable height can avoid unnecessary bending. Furthermore, 
stretching can be avoided by arranging cupboards in such a manner that commonly used items 
are within easy reach. Long periods of standing or sitting in one position are best avoided, as 
are repetitive activities. Physical load should be divided over several joints where possible, for 
example, by using two hands rather than one to lift objects such as pans or mugs. Since some 
patients suffer from reduced proprioception (the sense of relative position and movement), 
visual control of movement can provide good support when performing certain activities. 
 
d) Using suitable products, equipment and assistive devices.  
There are many ways to help patients move objects more easily (e.g. using a trolley bag, 
serving trolley or walking frame). Extra long handles (to increase leverage) and the use of 
thick handgrips can serve to lighten some tasks. Sharp knives, lightweight pans and ready-
meals can all help to make the task of cooking a lot easier. Easy-care or non-iron garments, 
that can be put on and taken off easily, can also help patients to save their energy.  
 
e) Finding suitable means of transport and using assistance when needed. For example, 
someone to help with the housework, heavy work in particular, can help prevent excess 
physical strain. Moreover, this allows generalised hypermobility patients to save their limited 
energy resources for other activities. 
 
3.2 Skin protective measures  
Occupational therapists can help with the prevention of skin damage in EDS patients with 
serious skin problems. Therapy is necessary because relatively small injuries can worsen 
easily into large wounds, which do not heal well and can result in unsightly scarring. Some 
examples of skin protective measures are taking care with home furnishings by avoiding 
furniture with sharp points, being careful when walking on slippery floors or loose rugs, 
wearing protective clothing for certain activities, making sure that pressure ulcers do not 
develop when lying or sitting in the same position for long periods, and taking extra care 
when using splints or support socks/stockings as the skin can tear easily. 
 
4. Assistive devices, adaptive measures and services/facilities  
Physicians and patients are often afraid that the use of assistive devices and adaptive measures 
will result in physical decline, assuming that the muscle and joint conditions will deteriorate 
as the assistive devices take over normal tasks. This assumption, however, does not hold if the 
right assistive devices are used for the right applications. The aim of occupational therapy is 
to increase the patient’s functional potential; assistive devices and adaptive measures 
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therefore serve to make the patient more active and independent, rather than increase 
passivity. It is true that shower stools, special work/office chairs and wheelchairs result in 
patients standing and walking less. However, this does not mean that these devices actually 
promote physical decline, but rather that they are used in order to prevent incorrect physical 
load or excess physical strain. The object is indeed to find a balance between physical load 
and capacity and so prevent both excess, incorrect load and too little physical load. It is 
important to bear in mind that the use of splints does involve the risk of physical decline. 
Therefore we will pay special attention to this subject below.  
 
Studies have shown that a large percentage of assistive devices and adaptive measures are 
purchased at too high a price, are not used, or are used incorrectly and thus fail to meet the 
patient’s needs. This can happen when people try to find hasty solutions without performing 
adequate problem analysis beforehand. Moreover, problems can also occur when the right 
type of device or facility is used, but in the wrong size or version. There is a huge number of 
types and brands of assistive devices on the market, and choosing the right one depends very 
much on the individual situation for which it is intended. Furthermore, some assistive devices 
are complicated to use and therefore impractical. The degree of difficulty involved in 
choosing the right equipment is therefore high; practical training and instruction is essential, 
and it can be helpful if the occupational therapist visits the patient at home. It may be useful to 
plan a follow-up visit after the treatment has ended, to check whether the device is being used 
correctly and is providing adequate support.  
 
4.1 Use of assistive devices and adaptive measures in everyday life  
Below is a review of the use of assistive devices for four categories, namely mobility, 
personal care and housework, home modifications, and work/school/leisure. 
 
4.1.1 Assistive devices and adaptive measures for mobility  
Wheelchair use can vary from occasional/recreational to total dependence. Many patients are 
unable to propel themselves manually in a wheelchair as this creates too great a strain on their 
arms. Electric wheels/wheelchairs and mobility scooters can provide a solution. Electric 
wheelchairs and mobility scooters that can be folded or dismantled to fit in a car are available 
in an increasing number. These devices can significantly increase a person’s mobility, 
provided the support and seat comfort are sufficient to allow the patient to sit for reasonably 
long periods. The choice between an electric wheelchair and a mobility scooter for outdoor 
use, depends on the patient’s ability and the vehicle’s ease of operation. It is essential that the 
transport device has good suspension, that the seat, arms and backrest of the chair provide 
good support, and that the seat position can be changed (reclining backrest). Walking frames 
or walking aids usually place too much stress on the hands, arms and shoulders, although they 
are sometimes used for short distances. A walking frame also allows a patient to carry objects 
over short distances. 
 
Automatic transmission, power steering and power brakes are usually essential for patients 
who wish to drive a car, but there are also many car modifications available such as a lift to 
raise a wheelchair into the back of a car. A disabled parking permit allows patients to park 
closer to their destination and limits the need to walk long distances. A modified bicycle can 
also provide a solution for some patients. The vehicle of choice is usually the ‘comfort cycle’, 
in which the positions of the handlebars, saddle and pedals have been adjusted to reduce strain 
on the knees, hands, arms and neck. These bicycles can also be fitted with an electric motor 
when required. Finally, patients can opt to make use of collective transport services such as 
taxi buses, which are now provided by the government in many countries.  
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4.1.2 Assistive devices and adaptive measures for personal care, housework and other 
everyday activities 
It may be important for some people to have clothing fitted with alternative fastenings (e.g. 
Velcro, elastic shoelaces), and thermal underwear can help to protect against the cold. A range 
of devices is available which makes it easier to get in and out of the bathtub. Shower stools 
can be useful, as can brushes and sponges with long handles, which help to make washing less 
painful. Eating and drinking are made easier by using lightweight and/or modified cutlery (see 
figure 24-1). There are also many assistive household devices for sale, and solutions can 
usually be found for carrying out everyday activities more easily. Some patients benefit from 
having a special work/office chair or saddle stool, which can allow household tasks to be 
carried out whilst sitting. In some cases, every day life can be made easier with the assistance 
of a service dog. 
 
Figure 24-1 Adapted cutlery: knife, cheese plane and spoon 
 
 
 
 
Recently, more attention has been given to the subject of sexuality. Pain or other problems 
during sexual activity can have a negative effect on a patient’s relationship and personal 
happiness. Although occupational therapists are not always inclined to deal with sexual 
issues, they might sometimes be able to suggest possible solutions such as assistive devices 
like the support of special cushions and/or position. 
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4.1.3 Home modifications 
It may sometimes be necessary to modify the home in order to make it wheelchair accessible. 
A stair lift can be installed if climbing the stairs is a problem. A shaft lift may provide a better 
alternative if using a stair lift is too much of a burden for the patient. Kitchens can also be 
adapted using pull-out worktops, ceramic cooking plate for sliding rather than lifting pans 
onto, or a ‘hob tap’ from which pans can be filled with water at the cooking plate. 
Furthermore, shower chairs that allow patients to shower whilst sitting and bathroom 
handgrips, that increase safety and stability, are often very useful. Finally, even small 
modifications in the home can be extremely useful, such as cord-operated switches, large 
switch cover plates, lever-operated taps and radiator fittings, or large rounded doorknobs that 
put less strain on finger joints. 
 
4.1.4 Assistive devices and adaptive measures for work, school and leisure 
An occupational therapist can examine a patient’s workstation and provide advice on 
ergonomic layout. Computers allow people to work from home and therefore keep flexible 
working hours. There are many types of pens available that make writing easier; users find 
that fountain or gel pens, for example, glide across the surface of paper easily. Laptops can 
offer a good alternative to writing and are therefore regularly used in schools. It is also 
important that children are provided with good furniture at school; it may also be necessary to 
provide facilities that allow the child to rest between lessons. At secondary school, changing 
classrooms each period can present problems, as can carrying books to and from school and 
lessons. With a little creativity, solutions to these problems can usually be found, and 
occupational therapists will sometimes visit the child’s school in order to assess the situation. 
For leisure, there is also a wide range of modified materials on the market, such as garden 
tools and musical instruments. Also, patients can be provided with extra cushions for bar 
stools, outdoor café chairs or church pews, and cushions with a back support. Beach 
wheelchairs can also be hired at many seaside resorts. 
 
4.2 Splints  
Splints can be divided into three types: mobilisation splints, immobilisation splints and 
restrictive splints. The first allows joints to increase the range of movement, the second 
prevents movement in joints, and the last limits a joint’s range of movement (see figure 24-2). 
Caution is recommended when considering splints particularly for patients with EDS: splints 
can injure the skin locally, they can be too heavy for the surrounding joints, long-term use can 
cause the condition of muscles, ligaments and tendons to deteriorate. Furthermore, patients 
often consider splints undesirable from a cosmetic point of view. Nevertheless, splints can be 
useful in many cases. ‘Finger splints’, which are used to prevent overstretching of small 
finger joints, or splints that are only worn for specific activities or for a limited period, can 
significantly increase the range of activities a patient is able to perform, and may reduce pain. 
Sometimes there is no alternative but to wear a splint, for example, when pain and recurrent 
dislocations affect the patient’s quality of life adversely. Appropriate preventive and safety 
measures must be taken when using splints for patients with generalised hypermobility. 
Health care providers or patients themselves should regularly check the skin under a splint 
carefully: checking under newly applied splints several times at maximum intervals of 30 
minutes. The splint must be lightweight, but also as large as possible, so that the pressure on 
the skin is spread over as large an area as possible. Patients should be instructed to remove the 
splint if it becomes uncomfortable, and then contact their health care specialist. 
 
In some cases, people may choose to use assistive devices or adaptive measures that do 
indeed promote physical decline, but which at the same time help to increase their quality of 
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life. It is important that the occupational therapist and the patient first carefully discuss the 
pros and cons involved.  
 
Figure 24-2 Restrictive and immobilisation splints  
 
 
Images above: 'silver rings', preventing hyperextension of proximal interphalangeal joints of 
fingers (blue arrow heads) and of the interphalangeal joint of the thumb (yellow arrow head): 
restrictive splints. 
Images below: a short and long wrist splint, immobilising the wrist: immobilisation splints.  
 
5. Financial reimbursement  
Reimbursement of the costs incurred for many assistive devices, aids and adaptive measures 
is available from sources such as the government or insurance companies. Legislation and 
regulations on financial reimbursement vary from one country to another and are subject to 
regular change; the subject of reimbursement is therefore not dealt with in detail here. 
 
6. Conclusion  
The use of occupational therapy for syndromes such as EDS is based on comprehensive 
problem analysis, in which the occupational therapist sets realistic objectives together with the 
patient. Treatment focuses on increasing the range of activities that can be performed by the 
patient. In order to achieve this, occupational therapists teach patients alternative methods of 
performing certain activities by adapting certain rules of daily life; such as taking measures to 
protect joints, whilst also helping patients to select and use assistive devices, adaptive 
measures and services/facilities. 
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Addendum. Considerations, precautions and measures in case of surgery in 
patients with Ehlers-Danlos syndrome 
 
 
These are just general recommendations; depending on the clinical situation or condition of an 
individual patient, other or additional measures may be necessary. 
 
Before surgery 
1. Most important, especially in patients with classical Ehlers-Danlos syndrome (EDS), 
vascular EDS or kyphoscoliotic EDS, is to weigh the potential benefits of surgery and 
possible complications of surgery and of required diagnostic investigations, before 
they are planned. Consider all non-surgical alternatives 
2. Choose, if possible and clinically indicated, minimal and non-invasive diagnostic 
procedures, such as computer tomography (CT), magnetic resonance imaging (MRI) 
and ultrasonography; avoid in patients with vascular EDS or kyphoscoliotic EDS 
punctures, arteriography, endoscopy, clyster and colonic irrigation 
3. In case of planned intubation, X-rays of the cervical spine in several positions of the 
head may be indicated to diagnose hypermobility of the upper cervical vertebrae and 
malformations of vertebrae 
4. Preoperative examination by a cardiologist is indicated if at adequate preoperative 
screening cardiac problems are found 
5. Routine screening for clotting and bleeding disorders is not indicated; screen only if 
clinically indicated; in case of prolonged bleeding time, testing whether DDAVP can 
diminish the bleeding time may be indicated 
6. Because of increased risk of bleeding during and after surgery (in vascular and 
kyphoscoliotic EDS caused by defective connective tissue within vessels and in other 
EDS types caused by lax connective tissue around vessels), carbasalate calcium and 
acetylsalicylic acid should be discontinued for 7-10 days if possible and other non-
steroidal anti-inflammatory drugs for 5-7 days 
7. In vascular EDS, blood pressure should be checked several times and be controlled 
before surgery, if too high 
8. Especially for a patient with vascular or kyphoscoliotic EDS, it should be checked 
before the actual day of surgery and at that day whether there is enough blood 
available of the patient’s blood type  
 
During surgery 
1. In case of local or regional anaesthesia: keep in mind that patients with EDS may 
experience insufficient aesthetic effect 
2. Beware of (sub)luxation of the mandibular joints at intubation; then rapid 
repositioning is indicated  
3. Beware of an increased risk of (sub)luxation of joints because of muscle relaxing 
anaesthesia, especially when repositioning a patient or performing surgery of the 
upper extremity 
4. For incisions of the skin, follow Langer's lines of the skin, corresponding to the 
alignment of collagen fibres within the dermis, resulting in minimal cleavage of these 
fibres 
5. Avoid pressure or tension on skin, vessels and organs by using atraumatic surgery 
equipment and haemoclips, instead of stiches. Beware of tension on the skin when 
closing the wound, especially in a patient with classical EDS. Much experience is 
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required for surgery in patients with EDS, especially vascular, classical or 
kyphoscoliotic EDS. It could be wise to have another experienced surgeon stand-by 
for emergencies 
6. Avoid the use of probes 
7. In case of bowel ruptures in vascular EDS it is generally better to place a stoma than 
trying to suture the rupture 
8. Beware of an increased risk of pneumothorax at mechanical ventilation; a lower peak-
flow volume may be indicated 
 
After surgery 
1. Again beware of an increased risk of pneumothorax at mechanical ventilation; a lower 
peak-flow volume may be indicated  
2. Beware of increased risk of anastomotic leakage and its complications, such as 
bleeding and infection 
3. Avoid rectal body temperature assessments and punctures of arteries (e.g. for blood 
gases measurements); limit number of vena punctures 
4. In patients with vascular EDS: again regularly check and control blood pressure and 
prescribe a proton pump inhibitor because of the risk of a major bleeding in case of a 
stress ulcer 
5. Apply special techniques for bandaging of wounds to prevent wound herniation 
6. The revalidation period may be longer than normal; start revalidation early, under 
supervision of a physiotherapist 
  
Addendum350
 
 
Index 
 
 
adaptations and devices ............................................................................................ 70, 135, 342 
aesthetic surgery ......................................................................................................... see surgery 
arterial tortuosity syndrome ..................................................................................................... 86 
arthrochalasia EDS ............................................................................................................... 9, 22 
(chapter) ............................................................................................................................... 97 
clinical findings .................................................................................................................. 110 
clinical findings & hip dislocation (figure) ........................................................................ 111 
criteria ................................................................................................................................. 109 
differential diagnosis .......................................................................................................... 116 
eye ...................................................................................................................................... 230 
gel electrophoresis of collagens (figure) ............................................................................ 113 
hip dislocation (figure) ....................................................................................................... 112 
history ................................................................................................................................. 110 
inheritance .......................................................................................................................... 114 
management ....................................................................................................................... 117 
structural defect .......................................................................................................... 112, 114 
ultrastructural appearance of collagen fibrils (figure) ........................................................ 115 
Beighton score ........................................................................................................ 7, 21, 49, 314 
(table) ................................................................................................................................... 18 
adapted ................................................................................................................................. 52 
cut-off values ...................................................................................................................... 314 
bleeding tendency in EDS 
(chapter) ............................................................................................................................. 167 
clotting cascade .................................................................................................................. 168 
DDAVP .............................................................................................................................. 172 
haemostasis ......................................................................................................................... 168 
measures ............................................................................................................................. 171 
platelets ............................................................................................................................... 170 
recombinant factor VIIa ..................................................................................................... 173 
uterine bleeds ...................................................................................................................... 244 
work-up .............................................................................................................................. 170 
brain and spine structural anomalies in EDS ......................................................................... 192 
brittle cornea syndrome .............................................................................................. 10, 23, 108 
Bulbena score ..................................................................................................................... 7, 257 
(table) ................................................................................................................................... 19 
cardiac abnormalities in EDS 
(chapter) ............................................................................................................................. 177 
cardiovascular dysautonomia ............................................................................................. 190 
mitral valve prolapse (figure) ............................................................................................. 179 
cardiac-valvular EDS ........................................................................................................... 8, 20 
Chiari malformation ............................................................................................................... 193 
(figure) ................................................................................................................................ 193 
children ................................................................................................................................... 289 
consideration for parents with EDS to have a child (table) ................................................ 273 
ethics in parenthood ........................................................................................................... 272 
reproductive options for parents with EDS (table) ............................................................. 272 
 
 351
 
 
with EDS (chapter) ............................................................................................................. 255 
with EDS, case ................................................................................................................... 256 
with EDS, diagnostic evaluation ........................................................................................ 258 
with EDS, management ...................................................................................................... 260 
with EDS, signs and symptoms .......................................................................................... 257 
classical EDS ........................................................................................................................ 7, 85 
(chapter) ............................................................................................................................... 47 
cardiac abnormalities .......................................................................................................... 178 
eye ...................................................................................................................................... 228 
gastrointestinal manifestations ........................................................................................... 148 
gastrointestinal manifestations (table) ................................................................................ 156 
classical-like EDS ................................................................................................................ 8, 20 
classification of EDS .................................................................................................................. 6 
genetically (table) ................................................................................................................. 17 
historically (table) ................................................................................................................ 15 
main problems (table) ......................................................................................................... 337 
cognitive-behavioural therapy ................................................................................ 284, 306, 307 
collagen 
(figure) .................................................................................................................................. 37 
abnormalities (table) ........................................................................................... 15, 17, 20, 43 
cross-linking ....................................................................................................................... 105 
gel electrophoresis in arthrochalasia EDS (figure) ............................................................ 113 
structure in dermatosparaxis EDS (figure) ......................................................................... 116 
ultrastructural appearance in arthrochalasia EDS (figure) .................................................. 115 
coping with EDS .................................................................................................................... 288 
dental issues in EDS ............................................................................................................... 220 
dermatosparaxis EDS ........................................................................................................... 9, 22 
(chapter) ............................................................................................................................... 97 
clinical findings .................................................................................................................. 119 
criteria ................................................................................................................................. 118 
differential diagnosis .......................................................................................................... 120 
eye ...................................................................................................................................... 230 
genetic defect ...................................................................................................................... 119 
structure of collagen versus normal collagen (figure) ........................................................ 116 
diagnosis of EDS ...................................................................................................................... 11 
differential diagnosis ............................................................................................................ 12 
differential diagnosis (table) ........................................................................................... 20, 72 
differential diagnosis of vascular EDS ................................................................................. 85 
history taking ........................................................................................................................ 11 
physical examination ............................................................................................................ 12 
signs (table) .......................................................................................................................... 20 
education .................................................................................................................................. 70 
epilepsy ................................................................................................................................... 195 
ethics 
(chapter) ............................................................................................................................. 271 
consideration for parents with EDS to have a child (table) ................................................ 273 
living a (good) life with EDS ............................................................................................. 276 
parenthood .......................................................................................................................... 272 
reproductive options for parents with EDS (table) ............................................................. 272 
 
Index352
 
 
eye 
(chapter) ............................................................................................................................. 225 
anotomy .............................................................................................................................. 226 
anotomy (figure) ................................................................................................................. 227 
screening and monitoring ................................................................................................... 230 
surgery ................................................................................................................................ 230 
fatigue ............................................................................................................................. 189, 284 
(figure) .................................................................................................................................. 65 
gastrointestinal manifestations 
(chapter) ............................................................................................................................. 145 
impact ................................................................................................................................. 151 
in classical EDS (table) ...................................................................................................... 156 
in hypermobile EDS (table) ........................................................................................ 154, 155 
in hypermobility (table) ...................................................................................................... 158 
in hypermobility spectrum disorders (table) .............................................................. 154, 155 
in unclassified EDS ............................................................................................................ 149 
management ....................................................................................................................... 151 
pathogenesis ....................................................................................................................... 150 
genetics 
(chapters) .......................................................................................................................... 5, 33 
counselling ........................................................................................................................... 13 
DNA ..................................................................................................................................... 34 
DNA to protein (figure) ........................................................................................................ 35 
genes (table) ............................................................................................................. 15, 17, 43 
glossary ................................................................................................................................. 27 
with clinical signs (table) ..................................................................................................... 43 
gynaecological issues .......................................................................... see also pregnancy issues 
(chapter) ............................................................................................................................. 241 
consideration for parents with EDS to have a child (table) ................................................ 273 
contraception ...................................................................................................................... 243 
contraception methods (table) ............................................................................................ 252 
infertility ............................................................................................................................. 243 
normal and abnormal anatomy (figure) .............................................................................. 246 
other disorders .................................................................................................................... 247 
prolapse & urinary incontinence ........................................................................................ 245 
reproductive options for parents with EDS (table) ............................................................. 272 
sexuality ............................................................................................................................. 290 
uterine bleeding .................................................................................................................. 244 
history of EDS ........................................................................................................................ 129 
hypermobile EDS ................................................................................................................. 9, 21 
cardiac abnormalities .......................................................................................................... 178 
cardiovascular exercise tolerance testing ........................................................................... 319 
disability ............................................................................................................................. 318 
dysfunctions (figure) .......................................................................................................... 313 
eye ...................................................................................................................................... 228 
gastrointestinal manifestations ........................................................................................... 147 
gastrointestinal manifestations (table) ........................................................................ 154, 155 
history ..................................................................................................................................... 1 
interactions of dysfunctions and symptoms (figure) .................................................... 65, 313 
 
Index 353
 
 
management ................................................................................................................. 70, 320 
management (chapter) ........................................................................................................ 311 
management (table) ............................................................................................................ 323 
multi-systemic involvement ....................................................................................... 316, 320 
muscle weakness ................................................................................................................ 319 
musculoskeletal dysfunction ...................................................................................... 316, 319 
psychological dysfunction .......................................................................................... 317, 320 
hypermobility 
(chapter) ............................................................................................................................... 61 
autonomic dysfunction ......................................................................................................... 66 
bone mass ............................................................................................................................. 66 
classification ......................................................................................................................... 66 
classification (table) ............................................................................................................. 72 
epidemiology ........................................................................................................................ 62 
fatigue ................................................................................................................................... 64 
fatigue (figure) ...................................................................................................................... 65 
gastrointestinal manifestations ........................................................................................... 148 
gastrointestinal manifestations (table) ................................................................................ 158 
history ..................................................................................................................................... 1 
International Classification of Functioning, Disability and Health (figure) ...................... 315 
management ......................................................................................................................... 70 
pain ....................................................................................................................................... 64 
pain (figure) .......................................................................................................................... 65 
prevalence ............................................................................................................................. 63 
terminology .................................................................................................................... 62, 67 
hypermobility spectrum disorders .................................................................................... 63, 146 
dysfunctions (figure) .......................................................................................................... 313 
features (table) .................................................................................................................... 154 
gastrointestinal manifestations (chapter) ............................................................................ 145 
gastrointestinal manifestations (table) ................................................................................ 155 
interactions of dysfunctions and symptoms (figure) .......................................................... 313 
management (chapter) ........................................................................................................ 311 
management (table) ............................................................................................................ 323 
neurological manifestations (chapter) ................................................................................ 187 
kyphoscoliotic EDS ........................................................................................................ 9, 23, 85 
(chapter) ............................................................................................................................... 97 
clinical findings .................................................................................................................... 99 
clinical findings in kEDS-FKBP14 (figure) ....................................................................... 104 
criteria ................................................................................................................................... 98 
diagnostic tests ................................................................................................................... 106 
differential diagnosis .......................................................................................................... 107 
eye ...................................................................................................................................... 229 
genetic defect ...................................................................................................................... 105 
history ................................................................................................................................... 99 
inheritance .......................................................................................................................... 106 
lysyl hydroxylase ................................................................................................................ 106 
management ....................................................................................................................... 109 
mutations of FKBP14 gene (figure) ................................................................................... 100 
mutations of PLOD1 gene (figure) ..................................................................................... 100 
prenatal testing ................................................................................................................... 107 
Index354
 
 
prevalence ........................................................................................................................... 105 
skeletal deformities (figure) ............................................................................................... 102 
Larsen syndrome .................................................................................................................... 116 
life style advice ....................................................................................................................... 341 
Loeys-Dietz syndrome ............................................................................................... 69, 86, 193 
Marfan syndrome ....................................................................................................... 69, 86, 193 
losartan ....................................................................................................................... 1, 69, 70 
mindfulness ............................................................................................................................ 288 
mitral valve prolapse .............................................................. see cardiac abnormalities in EDS 
musculocontractural EDS ........................................................................................... 10, 25, 108 
neck (figure) ....................................................................................................................... 195 
myopathic EDS .................................................................................................................. 10, 25 
neurological manifestations .................................................................................................... 196 
(chapter) ............................................................................................................................. 187 
(figure) ................................................................................................................................ 197 
developmental delay ........................................................................................................... 199 
headache ............................................................................................................................. 189 
investigations (table) .......................................................................................................... 201 
management ....................................................................................................................... 199 
muscle histology (figure) ................................................................................................... 198 
neuropathy .......................................................................................................................... 198 
Nevo syndrome ...................................................................................................................... 108 
nursing care 
(chapter) ............................................................................................................................. 331 
11 functional health patterns (box) ..................................................................................... 333 
at admission ........................................................................................................................ 334 
medical history taking ........................................................................................................ 332 
occupational therapy .............................................................................................................. 134 
(chapter) ............................................................................................................................. 339 
adaptations and devices .............................................................................. 342, 343, 344, 345 
devices (figure) ................................................................................................................... 344 
home modifications ............................................................................................................ 345 
problem analysis ................................................................................................................. 340 
splints ................................................................................................................................. 345 
splints (figure) .................................................................................................................... 346 
orthopaedic issues in EDS 
(chapter) ............................................................................................................................. 127 
case ..................................................................................................................................... 128 
management ....................................................................................................................... 133 
origin .................................................................................................................................. 130 
orthopaedic shoes ............................................................................................................... 135 
osteoarthritis ......................................................................................................................... 66 
shoulder arthrodesis (figure) .............................................................................................. 129 
signs and symptoms ........................................................................................................... 131 
sugery of scoliosis (figure) ................................................................................................. 132 
surgery ................................................................................................................................ 135 
pain ........................................................................................................................... 64, 188, 283 
(chapter) ............................................................................................................................. 297 
epidural injections .............................................................................................................. 304 
insufficient effect of local analgesics ........................... 64, 140, 188, 251, 303, 307, 334, 349 
Index 355
 
 
Loeser circles (figure) ........................................................................................................ 299 
nerve blocks ........................................................................................................................ 303 
nerve stimulation ................................................................................................................ 304 
nociceptive and neuropathic ............................................................................................... 298 
pain killers .......................................................................................................................... 300 
psychological approach ...................................................................................................... 305 
sympathetic blocks ............................................................................................................. 304 
periodontal EDS ........................................................................................................... 10, 25, 85 
physical therapy ..................................................................................................................... 133 
and exercises (figure) ........................................................................................................... 65 
exercises at home ................................................................................................................. 70 
in children with EDS .......................................................................................................... 261 
in temporomandibular disorders ......................................................................................... 218 
pregnancy issues .......................................................................... see also gynaecological issues 
(chapter) ............................................................................................................................. 241 
anaesthesia during delivery ................................................................................................ 250 
contraception ...................................................................................................................... 243 
foetal complications ........................................................................................................... 250 
in classical EDS .................................................................................................................. 248 
in hypermobile EDS ........................................................................................................... 248 
in vascular EDS ............................................................................................................ 89, 249 
infertility ............................................................................................................................. 243 
preconception counselling .................................................................................................. 242 
pseudoxanthoma elasticum ...................................................................................................... 86 
quality of life 
(chapter) ............................................................................................................................. 281 
aspects of well-being and functioning (figure) .................................................................. 291 
case ..................................................................................................................................... 282 
consequences of a chronic disease ..................................................................................... 300 
coping ................................................................................................................................. 288 
living a (good) life with EDS ............................................................................................. 276 
problems (figure) ................................................................................................................ 287 
psychological dysfunction .................................................................................................. 320 
psychological issues ........................................................................................................... 286 
sexuality ............................................................................................................................. 290 
sleeping problems ............................................................................................................... 285 
social consequences of having a rare chronic disease ........................................................ 289 
social functioning ............................................................................................................... 289 
skin ......................................................................................................................................... 285 
anatomy (figure) ................................................................................................................... 48 
biopsy ................................................................................................................................... 39 
cigarette paper aspect (figure) .............................................................................................. 50 
in classical EDS .................................................................................................................... 49 
in hypermobile EDS ................................................................................................... 314, 318 
manifestations ......................................................................................................................... 7 
molluscoid pseudotumors ............................................................................................. 51, 141 
molluscoid pseudotumors (figure) ....................................................................................... 51 
piezogenic papules ............................................................................................................... 52 
piezogenic papules (figure) .................................................................................................. 52 
protective measures ............................................................................................................ 342 
Index356
 
 
testing ..................................................................................................................................... 6 
sleeping problems ................................................................................................................... 285 
social functioning ................................................................................................................... 289 
spondylodysplastic EDS ............................................................................................. 10, 24, 108 
Stickler syndrome ..................................................................................................................... 69 
manifestations (table) ........................................................................................................... 73 
surgery 
aesthetic corrections ........................................................................................................... 141 
plastic surgery (chapter) ..................................................................................................... 139 
precautions and measures (addendum) .............................................................................. 349 
temporomandibular disorders 
(chapter) ............................................................................................................................. 209 
anatomy of the temporomandibular joint (figure) .............................................................. 211 
arthrogenous versus myogenous (table) ............................................................................. 222 
diagnostic process .............................................................................................................. 216 
dysfunctions of the temporomandibular joint (figure) ....................................................... 212 
luxation of the jaw .............................................................................................................. 218 
luxation of the jaw (figure) ................................................................................................. 213 
management ....................................................................................................................... 217 
mechanisms ........................................................................................................................ 210 
oral splint (figure) ............................................................................................................... 219 
osteoarthritis of the jaw .............................................................................................. 215, 219 
panoramic radiograph (figure) ........................................................................................... 214 
physical therapy .................................................................................................................. 218 
prevalence in EDS and hypermobility ............................................................................... 215 
urological complications 
(chapter) ............................................................................................................................. 235 
cases ................................................................................................................................... 236 
lower urinary tract .............................................................................................................. 238 
upper urinary tract .............................................................................................................. 238 
vascular EDS .................................................................................................. 8, 40, 68, 180, 181 
(chapter) ............................................................................................................................... 79 
acrogeria (figure) .................................................................................................................. 68 
advices (table) .................................................................................................................... 182 
biochemical and molecular diagnosis .................................................................................. 83 
bleeding .............................................................................................................................. 168 
bleeding therapy ................................................................................................................. 171 
celiprolol ....................................................................................... 1, 69, 70, 88, 173, 182, 192 
cerebrovascular manifestations .......................................................................................... 191 
clinical findings .................................................................................................................... 80 
differential diagnosis ............................................................................................................ 85 
dilated aortic root (figure) .................................................................................................. 180 
eye ...................................................................................................................................... 229 
gastrointestinal manifestations ........................................................................................... 146 
genetics ................................................................................................................................. 84 
history ................................................................................................................................... 80 
management ......................................................................................................................... 87 
pregnancy ..................................................................................................................... 89, 249 
prevalence ............................................................................................................................. 80 
vascular fragility ................................................................................................................... 81 
Index 357
This page intentionally left blank
This page intentionally left blank
This page intentionally left blank
